@DRUG$: Concomitant cholestyramine administration decreased the mean AUC of total @DRUG$ approximately 55%. DDI-false
Cholestyramine: Concomitant @DRUG$ administration decreased the mean AUC of total @DRUG$ approximately 55%. DDI-false
The incremental LDL-C reduction due to adding @DRUG$ to @DRUG$ may be reduced by this interaction. DDI-mechanism
Patients who take both @DRUG$ and @DRUG$ should be carefully monitored. DDI-effect
Carcinogenesis, Mutagenesis, Impairment of Fertility A 104-week dietary carcinogenicity study with @DRUG$ was conducted in rats at doses up to 1500 mg/kg/day (males) and 500 mg/kg/day (females) (~20 times the human exposure at 10 mg daily based on AUC0-24hr for total @DRUG$). DDI-advise
A 104-week dietary carcinogenicity study with @DRUG$ was also conducted in mice at doses up to 500 mg/kg/day (>150 times the human exposure at 10 mg daily based on AUC0-24hr for total @DRUG$). DDI-false
In oral (gavage) fertility studies of @DRUG$ conducted in rats, there was no evidence of reproductive toxicity at doses up to 1000 mg/kg/day in male or female rats (~7 times the human exposure at 10 mg daily based on AUC0-24hr for total @DRUG$). DDI-false
@DRUG$: The safety and effectiveness of @DRUG$ administered with fibrates have not been established. DDI-false
@DRUG$: The safety and effectiveness of ezetimibe administered with @DRUG$ have not been established. DDI-false
Fibrates: The safety and effectiveness of @DRUG$ administered with @DRUG$ have not been established. DDI-false
In rabbits treated with @DRUG$, an increased incidence of extra thoracic ribs was observed at 1000 mg/kg/day (150 times the human exposure at 10 mg daily based on AUC0-24hr for total @DRUG$). DDI-false
Multiple dose studies of @DRUG$ given in combination with @DRUG$ (statins) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures. DDI-false
Multiple dose studies of @DRUG$ given in combination with HMG-CoA reductase inhibitors (@DRUG$) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures. DDI-mechanism
Multiple dose studies of @DRUG$ given in combination with HMG-CoA reductase inhibitors (statins) in rats and rabbits during organogenesis result in higher @DRUG$ and statin exposures. DDI-mechanism
Multiple dose studies of ezetimibe given in combination with @DRUG$ (@DRUG$) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures. DDI-false
Multiple dose studies of ezetimibe given in combination with @DRUG$ (statins) in rats and rabbits during organogenesis result in higher @DRUG$ and statin exposures. DDI-false
Multiple dose studies of ezetimibe given in combination with HMG-CoA reductase inhibitors (@DRUG$) in rats and rabbits during organogenesis result in higher @DRUG$ and statin exposures. DDI-false
When @DRUG$ is administered with an @DRUG$ in a woman of childbearing potential, refer to the pregnancy category and package labeling for the HMG-CoA reductase inhibitor. DDI-false
When @DRUG$ is administered with an HMG-CoA reductase inhibitor in a woman of childbearing potential, refer to the pregnancy category and package labeling for the @DRUG$. DDI-advise
When ZETIA is administered with an @DRUG$ in a woman of childbearing potential, refer to the pregnancy category and package labeling for the @DRUG$. DDI-false
Co-administration of @DRUG$ with @DRUG$ is not recommended until use in patients is studied. DDI-false
@DRUG$: In a pharmacokinetic study, concomitant @DRUG$ administration increased total ezetimibe concentrations approximately 1.5-fold. DDI-advise
@DRUG$: In a pharmacokinetic study, concomitant fenofibrate administration increased total @DRUG$ concentrations approximately 1.5-fold. DDI-false
Fenofibrate: In a pharmacokinetic study, concomitant @DRUG$ administration increased total @DRUG$ concentrations approximately 1.5-fold. DDI-false
@DRUG$: In a pharmacokinetic study, concomitant @DRUG$ administration increased total ezetimibe concentrations approximately 1.7-fold. DDI-mechanism
@DRUG$: In a pharmacokinetic study, concomitant gemfibrozil administration increased total @DRUG$ concentrations approximately 1.7-fold. DDI-false
Gemfibrozil: In a pharmacokinetic study, concomitant @DRUG$ administration increased total @DRUG$ concentrations approximately 1.7-fold. DDI-false
@DRUG$: No clinically significant pharmacokinetic interactions were seen when @DRUG$ was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. DDI-mechanism
@DRUG$: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with @DRUG$, simvastatin, pravastatin, lovastatin, or fluvastatin. DDI-false
@DRUG$: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, @DRUG$, pravastatin, lovastatin, or fluvastatin. DDI-false
@DRUG$: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, @DRUG$, lovastatin, or fluvastatin. DDI-false
@DRUG$: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, @DRUG$, or fluvastatin. DDI-false
@DRUG$: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or @DRUG$. DDI-false
HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when @DRUG$ was co-administered with @DRUG$, simvastatin, pravastatin, lovastatin, or fluvastatin. DDI-false
HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when @DRUG$ was co-administered with atorvastatin, @DRUG$, pravastatin, lovastatin, or fluvastatin. DDI-false
HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when @DRUG$ was co-administered with atorvastatin, simvastatin, @DRUG$, lovastatin, or fluvastatin. DDI-false
HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when @DRUG$ was co-administered with atorvastatin, simvastatin, pravastatin, @DRUG$, or fluvastatin. DDI-false
HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when @DRUG$ was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or @DRUG$. DDI-false
HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with @DRUG$, @DRUG$, pravastatin, lovastatin, or fluvastatin. DDI-false
HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with @DRUG$, simvastatin, @DRUG$, lovastatin, or fluvastatin. DDI-false
HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with @DRUG$, simvastatin, pravastatin, @DRUG$, or fluvastatin. DDI-false
HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with @DRUG$, simvastatin, pravastatin, lovastatin, or @DRUG$. DDI-false
HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, @DRUG$, @DRUG$, lovastatin, or fluvastatin. DDI-false
HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, @DRUG$, pravastatin, @DRUG$, or fluvastatin. DDI-false
HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, @DRUG$, pravastatin, lovastatin, or @DRUG$. DDI-false
HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, @DRUG$, @DRUG$, or fluvastatin. DDI-false
HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, @DRUG$, lovastatin, or @DRUG$. DDI-false
HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, @DRUG$, or @DRUG$. DDI-false
@DRUG$: The total @DRUG$ level increased 12-fold in one renal transplant patient receiving multiple medications, including cyclosporine. DDI-false
@DRUG$: The total ezetimibe level increased 12-fold in one renal transplant patient receiving multiple medications, including @DRUG$. DDI-false
Cyclosporine: The total @DRUG$ level increased 12-fold in one renal transplant patient receiving multiple medications, including @DRUG$. DDI-false
Interaction with @DRUG$: Although @DRUG$ does not itself cause orthostatic hypotension, its administration to patients already receiving guanethidine can result in profound orthostatic effects. DDI-mechanism
Interaction with @DRUG$: Although minoxidil does not itself cause orthostatic hypotension, its administration to patients already receiving @DRUG$ can result in profound orthostatic effects. DDI-false
Interaction with Guanethidine: Although @DRUG$ does not itself cause orthostatic hypotension, its administration to patients already receiving @DRUG$ can result in profound orthostatic effects. DDI-false
If at all possible @DRUG$ should be discontinued well before @DRUG$ is begun. DDI-effect
In a study in which 34 different drugs were tested, therapeutically relevant concentrations of @DRUG$, @DRUG$ and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent. DDI-advise
In a study in which 34 different drugs were tested, therapeutically relevant concentrations of @DRUG$, sodium salicylate and @DRUG$ displaced protein-bound teniposide in fresh human serum to a small but significant extent. DDI-false
In a study in which 34 different drugs were tested, therapeutically relevant concentrations of @DRUG$, sodium salicylate and sulfamethizole displaced protein-bound @DRUG$ in fresh human serum to a small but significant extent. DDI-false
In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, @DRUG$ and @DRUG$ displaced protein-bound teniposide in fresh human serum to a small but significant extent. DDI-mechanism
In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, @DRUG$ and sulfamethizole displaced protein-bound @DRUG$ in fresh human serum to a small but significant extent. DDI-false
In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and @DRUG$ displaced protein-bound @DRUG$ in fresh human serum to a small but significant extent. DDI-false
Therefore, caution should be used in administering @DRUG$ (@DRUG$ injection) to patients receiving these other agents. DDI-mechanism
There was no change in the plasma kinetics of @DRUG$ when coadministered with @DRUG$. DDI-false
An increase in intracellular levels of @DRUG$ was observed in vitro in the presence of @DRUG$. DDI-false
@DRUG$ AND OTHER @DRUG$ WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS. DDI-mechanism
@DRUG$ AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO @DRUG$ AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS. DDI-false
@DRUG$ AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF @DRUG$ TO TOXIC LEVELS. DDI-false
ASPIRIN AND OTHER @DRUG$ WILL BE ADDITIVE TO @DRUG$ AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS. DDI-false
ASPIRIN AND OTHER @DRUG$ WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF @DRUG$ TO TOXIC LEVELS. DDI-false
ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO @DRUG$ AND MAY INCREASE PLASMA CONCENTRATIONS OF @DRUG$ TO TOXIC LEVELS. DDI-false
@DRUG$ given concomitantly with @DRUG$ may predispose to systemic bleeding. DDI-false
@DRUG$ may enhance the hypoglycemic effect of oral @DRUG$ of the sulfonylurea class. DDI-effect
@DRUG$ competes with a number of drugs for protein binding sites, notably @DRUG$, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. DDI-effect
@DRUG$ competes with a number of drugs for protein binding sites, notably penicillin, @DRUG$, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. DDI-int
@DRUG$ competes with a number of drugs for protein binding sites, notably penicillin, thiopental, @DRUG$, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. DDI-mechanism
@DRUG$ competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, @DRUG$, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. DDI-int
@DRUG$ competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, @DRUG$, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. DDI-int
@DRUG$ competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, @DRUG$, naproxen, warfarin, methotrexate, and possibly corticosteroids. DDI-int
@DRUG$ competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, @DRUG$, warfarin, methotrexate, and possibly corticosteroids. DDI-int
@DRUG$ competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, @DRUG$, methotrexate, and possibly corticosteroids. DDI-int
@DRUG$ competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, @DRUG$, and possibly corticosteroids. DDI-int
@DRUG$ competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly @DRUG$. DDI-int
Salicylate competes with a number of drugs for protein binding sites, notably @DRUG$, @DRUG$, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. DDI-int
Salicylate competes with a number of drugs for protein binding sites, notably @DRUG$, thiopental, @DRUG$, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. DDI-false
Salicylate competes with a number of drugs for protein binding sites, notably @DRUG$, thiopental, thyroxine, @DRUG$, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. DDI-false
Salicylate competes with a number of drugs for protein binding sites, notably @DRUG$, thiopental, thyroxine, triiodothyronine, @DRUG$, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. DDI-false
Salicylate competes with a number of drugs for protein binding sites, notably @DRUG$, thiopental, thyroxine, triiodothyronine, phenytoin, @DRUG$, naproxen, warfarin, methotrexate, and possibly corticosteroids. DDI-false
Salicylate competes with a number of drugs for protein binding sites, notably @DRUG$, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, @DRUG$, warfarin, methotrexate, and possibly corticosteroids. DDI-false
Salicylate competes with a number of drugs for protein binding sites, notably @DRUG$, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, @DRUG$, methotrexate, and possibly corticosteroids. DDI-false
Salicylate competes with a number of drugs for protein binding sites, notably @DRUG$, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, @DRUG$, and possibly corticosteroids. DDI-false
Salicylate competes with a number of drugs for protein binding sites, notably @DRUG$, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly @DRUG$. DDI-false
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, @DRUG$, @DRUG$, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. DDI-false
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, @DRUG$, thyroxine, @DRUG$, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. DDI-false
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, @DRUG$, thyroxine, triiodothyronine, @DRUG$, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. DDI-false
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, @DRUG$, thyroxine, triiodothyronine, phenytoin, @DRUG$, naproxen, warfarin, methotrexate, and possibly corticosteroids. DDI-false
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, @DRUG$, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, @DRUG$, warfarin, methotrexate, and possibly corticosteroids. DDI-false
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, @DRUG$, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, @DRUG$, methotrexate, and possibly corticosteroids. DDI-false
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, @DRUG$, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, @DRUG$, and possibly corticosteroids. DDI-false
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, @DRUG$, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly @DRUG$. DDI-false
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, @DRUG$, @DRUG$, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. DDI-false
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, @DRUG$, triiodothyronine, @DRUG$, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. DDI-false
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, @DRUG$, triiodothyronine, phenytoin, @DRUG$, naproxen, warfarin, methotrexate, and possibly corticosteroids. DDI-false
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, @DRUG$, triiodothyronine, phenytoin, sulfinpyrazone, @DRUG$, warfarin, methotrexate, and possibly corticosteroids. DDI-false
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, @DRUG$, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, @DRUG$, methotrexate, and possibly corticosteroids. DDI-false
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, @DRUG$, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, @DRUG$, and possibly corticosteroids. DDI-false
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, @DRUG$, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly @DRUG$. DDI-false
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, @DRUG$, @DRUG$, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. DDI-false
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, @DRUG$, phenytoin, @DRUG$, naproxen, warfarin, methotrexate, and possibly corticosteroids. DDI-false
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, @DRUG$, phenytoin, sulfinpyrazone, @DRUG$, warfarin, methotrexate, and possibly corticosteroids. DDI-false
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, @DRUG$, phenytoin, sulfinpyrazone, naproxen, @DRUG$, methotrexate, and possibly corticosteroids. DDI-false
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, @DRUG$, phenytoin, sulfinpyrazone, naproxen, warfarin, @DRUG$, and possibly corticosteroids. DDI-false
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, @DRUG$, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly @DRUG$. DDI-false
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, @DRUG$, @DRUG$, naproxen, warfarin, methotrexate, and possibly corticosteroids. DDI-false
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, @DRUG$, sulfinpyrazone, @DRUG$, warfarin, methotrexate, and possibly corticosteroids. DDI-false
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, @DRUG$, sulfinpyrazone, naproxen, @DRUG$, methotrexate, and possibly corticosteroids. DDI-false
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, @DRUG$, sulfinpyrazone, naproxen, warfarin, @DRUG$, and possibly corticosteroids. DDI-false
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, @DRUG$, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly @DRUG$. DDI-false
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, @DRUG$, @DRUG$, warfarin, methotrexate, and possibly corticosteroids. DDI-false
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, @DRUG$, naproxen, @DRUG$, methotrexate, and possibly corticosteroids. DDI-false
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, @DRUG$, naproxen, warfarin, @DRUG$, and possibly corticosteroids. DDI-false
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, @DRUG$, naproxen, warfarin, methotrexate, and possibly @DRUG$. DDI-false
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, @DRUG$, @DRUG$, methotrexate, and possibly corticosteroids. DDI-false
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, @DRUG$, warfarin, @DRUG$, and possibly corticosteroids. DDI-false
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, @DRUG$, warfarin, methotrexate, and possibly @DRUG$. DDI-false
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, @DRUG$, @DRUG$, and possibly corticosteroids. DDI-false
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, @DRUG$, methotrexate, and possibly @DRUG$. DDI-false
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, @DRUG$, and possibly @DRUG$. DDI-false
In elderly patients concurrently receiving certain @DRUG$, primarily @DRUG$, an increased incidence of thrombopenia with purpura has been reported. DDI-false
It has been reported that @DRUG$ may prolong the prothrombin time in patients who are receiving the @DRUG$ warfarin. DDI-false
It has been reported that @DRUG$ may prolong the prothrombin time in patients who are receiving the anticoagulant @DRUG$. DDI-false
It has been reported that sulfamethoxazole may prolong the prothrombin time in patients who are receiving the @DRUG$ @DRUG$. DDI-effect
@DRUG$ may inhibit the hepatic metabolism of @DRUG$. DDI-false
At a 1.6-g dose, @DRUG$ produced a slight but significant increase in the half-life of @DRUG$ but did not produce a corresponding decrease in the metabolic clearance rate. DDI-mechanism
@DRUG$ can also displace @DRUG$ from plasma protein-binding sites, thus increasing free methotrexate concentrations. DDI-mechanism
@DRUG$ can also displace methotrexate from plasma protein-binding sites, thus increasing free @DRUG$ concentrations. DDI-mechanism
Sulfonamides can also displace @DRUG$ from plasma protein-binding sites, thus increasing free @DRUG$ concentrations. DDI-false
Mutual inhibition of metabolism occurs with concurrent use of @DRUG$ and @DRUG$; DDI-false
The effect of @DRUG$ on oral @DRUG$ is variable. DDI-mechanism
There are reports of enhanced as well as diminished effects of @DRUG$ when given concurrently with @DRUG$. DDI-false
convulsions have been reported with concurrent use of @DRUG$ and @DRUG$. DDI-effect
Drugs that induce hepatic enzymes such as @DRUG$, @DRUG$, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. DDI-effect
Drugs that induce hepatic enzymes such as @DRUG$, phenytoin, and @DRUG$ may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. DDI-false
Drugs that induce hepatic enzymes such as @DRUG$, phenytoin, and rifampin may increase the clearance of @DRUG$ and may require increased in methylprednisolone dose to achieve the desired response. DDI-false
Drugs that induce hepatic enzymes such as @DRUG$, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in @DRUG$ dose to achieve the desired response. DDI-mechanism
Drugs that induce hepatic enzymes such as phenobarbital, @DRUG$, and @DRUG$ may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. DDI-false
Drugs that induce hepatic enzymes such as phenobarbital, @DRUG$, and rifampin may increase the clearance of @DRUG$ and may require increased in methylprednisolone dose to achieve the desired response. DDI-false
Drugs that induce hepatic enzymes such as phenobarbital, @DRUG$, and rifampin may increase the clearance of methylprednisolone and may require increased in @DRUG$ dose to achieve the desired response. DDI-mechanism
Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and @DRUG$ may increase the clearance of @DRUG$ and may require increased in methylprednisolone dose to achieve the desired response. DDI-false
Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and @DRUG$ may increase the clearance of methylprednisolone and may require increased in @DRUG$ dose to achieve the desired response. DDI-mechanism
Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of @DRUG$ and may require increased in @DRUG$ dose to achieve the desired response. DDI-false
Drugs such as @DRUG$ and @DRUG$ may inhibit the metabolism of methylprednisolone and thus decrease its clearance. DDI-false
Drugs such as @DRUG$ and ketoconazole may inhibit the metabolism of @DRUG$ and thus decrease its clearance. DDI-false
Drugs such as troleandomycin and @DRUG$ may inhibit the metabolism of @DRUG$ and thus decrease its clearance. DDI-mechanism
@DRUG$ may increase the clearance of chronic high dose @DRUG$. DDI-mechanism
This could lead to decreased @DRUG$ serum levels or increase the risk of @DRUG$ toxicity when methylprednisolone is withdrawn. DDI-effect
This could lead to decreased @DRUG$ serum levels or increase the risk of salicylate toxicity when @DRUG$ is withdrawn. DDI-false
This could lead to decreased salicylate serum levels or increase the risk of @DRUG$ toxicity when @DRUG$ is withdrawn. DDI-false
@DRUG$ should be used cautiously in conjunction with @DRUG$ in patients suffering from hypoprothrombinemia. DDI-effect
Patients receiving @DRUG$ and @DRUG$ generally should not be treated with ganglion blockers. DDI-advise
Patients receiving @DRUG$ and sulfonamides generally should not be treated with @DRUG$. DDI-false
Patients receiving antibiotics and @DRUG$ generally should not be treated with @DRUG$. DDI-advise
The action of @DRUG$ may be potentiated by anesthesia, other @DRUG$ and alcohol. DDI-advise
The action of @DRUG$ may be potentiated by anesthesia, other antihypertensive drugs and @DRUG$. DDI-effect
The action of Mecamylamine may be potentiated by anesthesia, other @DRUG$ and @DRUG$. DDI-effect
However, @DRUG$, a potent inhibitor of cytochrome P450 3A4, may increase plasma levels of @DRUG$ during concomitant dosing. DDI-false
patients receiving @DRUG$ and @DRUG$ should have more frequent monitoring of neutrophil counts. DDI-mechanism
@DRUG$ @DRUG$ may increase sensitivity to oral anticoagulants. DDI-advise
@DRUG$ Anabolic steroids may increase sensitivity to oral @DRUG$. DDI-false
Anticoagulants @DRUG$ may increase sensitivity to oral @DRUG$. DDI-false
@DRUG$ or @DRUG$ In patients with edema, concomitant administration with adrenal cortical steroids or ACTH may increase the edema. DDI-false
@DRUG$ or ACTH In patients with edema, concomitant administration with @DRUG$ or ACTH may increase the edema. DDI-false
@DRUG$ or ACTH In patients with edema, concomitant administration with adrenal cortical steroids or @DRUG$ may increase the edema. DDI-false
Adrenal steroids or @DRUG$ In patients with edema, concomitant administration with @DRUG$ or ACTH may increase the edema. DDI-false
Adrenal steroids or @DRUG$ In patients with edema, concomitant administration with adrenal cortical steroids or @DRUG$ may increase the edema. DDI-false
Adrenal steroids or ACTH In patients with edema, concomitant administration with @DRUG$ or @DRUG$ may increase the edema. DDI-false
@DRUG$: A multidose study of @DRUG$, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected. DDI-false
@DRUG$: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with @DRUG$, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected. DDI-false
@DRUG$: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in @DRUG$ half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected. DDI-false
@DRUG$: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in @DRUG$ half-life and AUC were also detected. DDI-false
Warfarin: A multidose study of @DRUG$, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with @DRUG$, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected. DDI-false
Warfarin: A multidose study of @DRUG$, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in @DRUG$ half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected. DDI-mechanism
Warfarin: A multidose study of @DRUG$, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in @DRUG$ half-life and AUC were also detected. DDI-false
Warfarin: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with @DRUG$, resulted in a mean increase in @DRUG$ half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected. DDI-false
Warfarin: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with @DRUG$, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in @DRUG$ half-life and AUC were also detected. DDI-false
Warfarin: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in @DRUG$ half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in @DRUG$ half-life and AUC were also detected. DDI-false
A 5.5-fold decrease in the mean @DRUG$ dose from 6.13 mg/day to 1.13 mg/day (approximately 80-85% reduction of @DRUG$ dose), was necessary to maintain a target INR of 1.5. DDI-false
When @DRUG$ therapy is initiated in a patient already receiving treatment with @DRUG$, the INR or prothrombin time (PT) should be monitored closely and the dose of warfarin adjusted as necessary until a stable target INR or PT has been achieved. DDI-false
When @DRUG$ therapy is initiated in a patient already receiving treatment with warfarin, the INR or prothrombin time (PT) should be monitored closely and the dose of @DRUG$ adjusted as necessary until a stable target INR or PT has been achieved. DDI-advise
When oxandrolone therapy is initiated in a patient already receiving treatment with @DRUG$, the INR or prothrombin time (PT) should be monitored closely and the dose of @DRUG$ adjusted as necessary until a stable target INR or PT has been achieved. DDI-false
Furthermore, in patients receiving both drugs, careful monitoring of the INR or PT, and adjustment of the @DRUG$ dosage if indicated are recommended when the @DRUG$ dose is changed or discontinued. DDI-false
Oral @DRUG$ @DRUG$ may inhibit the metabolism of oral hypoglycemic agents. DDI-advise
Oral @DRUG$ Oxandrolone may inhibit the metabolism of oral @DRUG$. DDI-false
Oral hypoglycemic agents @DRUG$ may inhibit the metabolism of oral @DRUG$. DDI-false
The following agents may increase certain actions or side effects of @DRUG$: @DRUG$, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-mechanism
The following agents may increase certain actions or side effects of @DRUG$: amantadine, @DRUG$ (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of @DRUG$: amantadine, antiarrhythmic agents of class I (e.g., @DRUG$), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of @DRUG$: amantadine, antiarrhythmic agents of class I (e.g., quinidine), @DRUG$, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of @DRUG$: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, @DRUG$ (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of @DRUG$: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., @DRUG$), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of @DRUG$: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), @DRUG$, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of @DRUG$: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, @DRUG$, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of @DRUG$: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, @DRUG$ (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of @DRUG$: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., @DRUG$), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of @DRUG$: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), @DRUG$ and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of @DRUG$: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and @DRUG$, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of @DRUG$: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, @DRUG$, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of @DRUG$: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, @DRUG$, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: @DRUG$, @DRUG$ (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: @DRUG$, antiarrhythmic agents of class I (e.g., @DRUG$), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: @DRUG$, antiarrhythmic agents of class I (e.g., quinidine), @DRUG$, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: @DRUG$, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, @DRUG$ (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: @DRUG$, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., @DRUG$), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: @DRUG$, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), @DRUG$, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: @DRUG$, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, @DRUG$, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: @DRUG$, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, @DRUG$ (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: @DRUG$, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., @DRUG$), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: @DRUG$, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), @DRUG$ and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: @DRUG$, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and @DRUG$, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: @DRUG$, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, @DRUG$, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: @DRUG$, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, @DRUG$, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, @DRUG$ (e.g., @DRUG$), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, @DRUG$ (e.g., quinidine), @DRUG$, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, @DRUG$ (e.g., quinidine), antihistamines, @DRUG$ (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, @DRUG$ (e.g., quinidine), antihistamines, antipsychotic agents (e.g., @DRUG$), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, @DRUG$ (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), @DRUG$, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, @DRUG$ (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, @DRUG$, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, @DRUG$ (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, @DRUG$ (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, @DRUG$ (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., @DRUG$), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, @DRUG$ (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), @DRUG$ and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, @DRUG$ (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and @DRUG$, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, @DRUG$ (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, @DRUG$, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, @DRUG$ (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, @DRUG$, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., @DRUG$), @DRUG$, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., @DRUG$), antihistamines, @DRUG$ (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., @DRUG$), antihistamines, antipsychotic agents (e.g., @DRUG$), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., @DRUG$), antihistamines, antipsychotic agents (e.g., phenothiazines), @DRUG$, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., @DRUG$), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, @DRUG$, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., @DRUG$), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, @DRUG$ (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., @DRUG$), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., @DRUG$), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., @DRUG$), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), @DRUG$ and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., @DRUG$), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and @DRUG$, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., @DRUG$), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, @DRUG$, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., @DRUG$), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, @DRUG$, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), @DRUG$, @DRUG$ (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), @DRUG$, antipsychotic agents (e.g., @DRUG$), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), @DRUG$, antipsychotic agents (e.g., phenothiazines), @DRUG$, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), @DRUG$, antipsychotic agents (e.g., phenothiazines), benzodiazepines, @DRUG$, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), @DRUG$, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, @DRUG$ (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), @DRUG$, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., @DRUG$), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), @DRUG$, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), @DRUG$ and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), @DRUG$, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and @DRUG$, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), @DRUG$, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, @DRUG$, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), @DRUG$, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, @DRUG$, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, @DRUG$ (e.g., @DRUG$), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, @DRUG$ (e.g., phenothiazines), @DRUG$, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, @DRUG$ (e.g., phenothiazines), benzodiazepines, @DRUG$, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, @DRUG$ (e.g., phenothiazines), benzodiazepines, MAO inhibitors, @DRUG$ (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, @DRUG$ (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., @DRUG$), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, @DRUG$ (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), @DRUG$ and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, @DRUG$ (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and @DRUG$, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, @DRUG$ (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, @DRUG$, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, @DRUG$ (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, @DRUG$, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., @DRUG$), @DRUG$, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., @DRUG$), benzodiazepines, @DRUG$, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., @DRUG$), benzodiazepines, MAO inhibitors, @DRUG$ (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., @DRUG$), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., @DRUG$), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., @DRUG$), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), @DRUG$ and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., @DRUG$), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and @DRUG$, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., @DRUG$), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, @DRUG$, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., @DRUG$), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, @DRUG$, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), @DRUG$, @DRUG$, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), @DRUG$, MAO inhibitors, @DRUG$ (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), @DRUG$, MAO inhibitors, narcotic analgesics (e.g., @DRUG$), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), @DRUG$, MAO inhibitors, narcotic analgesics (e.g., meperidine), @DRUG$ and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), @DRUG$, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and @DRUG$, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), @DRUG$, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, @DRUG$, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), @DRUG$, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, @DRUG$, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, @DRUG$, @DRUG$ (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, @DRUG$, narcotic analgesics (e.g., @DRUG$), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, @DRUG$, narcotic analgesics (e.g., meperidine), @DRUG$ and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, @DRUG$, narcotic analgesics (e.g., meperidine), nitrates and @DRUG$, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, @DRUG$, narcotic analgesics (e.g., meperidine), nitrates and nitrites, @DRUG$, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, @DRUG$, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, @DRUG$, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, @DRUG$ (e.g., @DRUG$), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, @DRUG$ (e.g., meperidine), @DRUG$ and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, @DRUG$ (e.g., meperidine), nitrates and @DRUG$, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, @DRUG$ (e.g., meperidine), nitrates and nitrites, @DRUG$, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, @DRUG$ (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, @DRUG$, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., @DRUG$), @DRUG$ and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., @DRUG$), nitrates and @DRUG$, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., @DRUG$), nitrates and nitrites, @DRUG$, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., @DRUG$), nitrates and nitrites, sympathomimetic agents, @DRUG$, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), @DRUG$ and @DRUG$, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), @DRUG$ and nitrites, @DRUG$, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), @DRUG$ and nitrites, sympathomimetic agents, @DRUG$, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and @DRUG$, @DRUG$, tricyclic antidepressants, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and @DRUG$, sympathomimetic agents, @DRUG$, and other drugs having anticholinergic activity. DDI-false
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, @DRUG$, @DRUG$, and other drugs having anticholinergic activity. DDI-false
@DRUG$ antagonize the effects of @DRUG$. DDI-false
@DRUG$ in the presence of increased intraocular pressure may be hazardous when taken concurrently with agents such as @DRUG$. DDI-false
@DRUG$ may affect gastrointestinal absorption of various drugs, such as slowly dissolving dosage forms of @DRUG$; DDI-effect
@DRUG$ may antagonize the effects of drugs that alter gastrointestinal motility, such as @DRUG$. DDI-mechanism
Because @DRUG$ may interfere with the absorption of @DRUG$, simultaneous use of these drugs should be avoided. DDI-mechanism
Since @DRUG$ (@DRUG$) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital). DDI-mechanism
Since @DRUG$ (methsuximide) may interact with concurrently administered @DRUG$, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital). DDI-false
Since @DRUG$ (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg @DRUG$ may increase the plasma concentrations of phenytoin and phenobarbital). DDI-int
Since @DRUG$ (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of @DRUG$ and phenobarbital). DDI-false
Since @DRUG$ (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and @DRUG$). DDI-false
Since Celontin (@DRUG$) may interact with concurrently administered @DRUG$, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital). DDI-false
Since Celontin (@DRUG$) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg @DRUG$ may increase the plasma concentrations of phenytoin and phenobarbital). DDI-int
Since Celontin (@DRUG$) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of @DRUG$ and phenobarbital). DDI-false
Since Celontin (@DRUG$) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and @DRUG$). DDI-false
Since Celontin (methsuximide) may interact with concurrently administered @DRUG$, periodic serum level determinations of these drugs may be necessary (eg @DRUG$ may increase the plasma concentrations of phenytoin and phenobarbital). DDI-false
Since Celontin (methsuximide) may interact with concurrently administered @DRUG$, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of @DRUG$ and phenobarbital). DDI-false
Since Celontin (methsuximide) may interact with concurrently administered @DRUG$, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and @DRUG$). DDI-false
Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg @DRUG$ may increase the plasma concentrations of @DRUG$ and phenobarbital). DDI-false
Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg @DRUG$ may increase the plasma concentrations of phenytoin and @DRUG$). DDI-false
Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of @DRUG$ and @DRUG$). DDI-false
@DRUG$: @DRUG$ and probably other loop diuretics given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes. DDI-false
@DRUG$: Furosemide and probably other @DRUG$ given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes. DDI-false
@DRUG$: Furosemide and probably other loop diuretics given concomitantly with @DRUG$ can cause unusually large or prolonged losses of fluid and electrolytes. DDI-false
Diuretics: @DRUG$ and probably other @DRUG$ given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes. DDI-false
Diuretics: @DRUG$ and probably other loop diuretics given concomitantly with @DRUG$ can cause unusually large or prolonged losses of fluid and electrolytes. DDI-false
Diuretics: Furosemide and probably other @DRUG$ given concomitantly with @DRUG$ can cause unusually large or prolonged losses of fluid and electrolytes. DDI-effect
Other @DRUG$: When @DRUG$ Tablets are used with other antihypertensive drugs, care must be taken, especially during initial therapy. DDI-effect
Other @DRUG$: When MYKROX Tablets are used with other @DRUG$, care must be taken, especially during initial therapy. DDI-false
Other Antihypertensives: When @DRUG$ Tablets are used with other @DRUG$, care must be taken, especially during initial therapy. DDI-false
@DRUG$ and Other @DRUG$: May decrease the antihypertensive effects of MYKROX Tablets. DDI-advise
@DRUG$ and Other Non-Steroidal Anti-Inflammatory Drugs: May decrease the antihypertensive effects of @DRUG$ Tablets. DDI-false
Salicylates and Other @DRUG$: May decrease the antihypertensive effects of @DRUG$ Tablets. DDI-effect
@DRUG$: @DRUG$ may decrease arterial responsiveness to norepinephrine, but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use. DDI-effect
@DRUG$: Metolazone may decrease arterial responsiveness to @DRUG$, but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use. DDI-false
Sympathomimetics: @DRUG$ may decrease arterial responsiveness to @DRUG$, but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use. DDI-false
@DRUG$: Efficacy may be decreased due to urinary alkalizing effect of @DRUG$. DDI-effect
@DRUG$: @DRUG$, as well as other thiazide-like diuretics, may affect the hypoprothrombinemic response to anticoagulants; DDI-false
@DRUG$: Metolazone, as well as other @DRUG$, may affect the hypoprothrombinemic response to anticoagulants; DDI-false
@DRUG$: Metolazone, as well as other thiazide-like diuretics, may affect the hypoprothrombinemic response to @DRUG$; DDI-false
Anticoagulants: @DRUG$, as well as other @DRUG$, may affect the hypoprothrombinemic response to anticoagulants; DDI-false
Anticoagulants: @DRUG$, as well as other thiazide-like diuretics, may affect the hypoprothrombinemic response to @DRUG$; DDI-false
Anticoagulants: Metolazone, as well as other @DRUG$, may affect the hypoprothrombinemic response to @DRUG$; DDI-effect
@DRUG$, @DRUG$, and Narcotics: The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy. DDI-false
@DRUG$, Barbiturates, and @DRUG$: The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy. DDI-false
@DRUG$, Barbiturates, and Narcotics: The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with @DRUG$ therapy. DDI-false
Alcohol, @DRUG$, and @DRUG$: The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy. DDI-false
Alcohol, @DRUG$, and Narcotics: The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with @DRUG$ therapy. DDI-false
Alcohol, Barbiturates, and @DRUG$: The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with @DRUG$ therapy. DDI-false
@DRUG$: @DRUG$-induced hypokalemia can increase the sensitivity of the myocardium to digitalis. DDI-false
@DRUG$: Diuretic-induced hypokalemia can increase the sensitivity of the myocardium to @DRUG$. DDI-false
Digitalis Glycosides: @DRUG$-induced hypokalemia can increase the sensitivity of the myocardium to @DRUG$. DDI-false
@DRUG$ or @DRUG$: May increase the risk of hypokalemia and increase salt and water retention. DDI-effect
@DRUG$: Serum @DRUG$ levels may increase. DDI-false
@DRUG$: @DRUG$-induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs (such as tubocurarine) the most serious effect would be respiratory depression which could proceed to apnea. DDI-false
@DRUG$: Diuretic-induced hypokalemia may enhance neuromuscular blocking effects of @DRUG$ (such as tubocurarine) the most serious effect would be respiratory depression which could proceed to apnea. DDI-false
@DRUG$: Diuretic-induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs (such as @DRUG$) the most serious effect would be respiratory depression which could proceed to apnea. DDI-false
Curariform Drugs: @DRUG$-induced hypokalemia may enhance neuromuscular blocking effects of @DRUG$ (such as tubocurarine) the most serious effect would be respiratory depression which could proceed to apnea. DDI-false
Curariform Drugs: @DRUG$-induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs (such as @DRUG$) the most serious effect would be respiratory depression which could proceed to apnea. DDI-effect
Curariform Drugs: Diuretic-induced hypokalemia may enhance neuromuscular blocking effects of @DRUG$ (such as @DRUG$) the most serious effect would be respiratory depression which could proceed to apnea. DDI-effect
Coadministration of @DRUG$ with @DRUG$ resulted in increased plasma ranitidine concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14- hydroxy- clarithromycin plasma concentrations (31%). DDI-false
Coadministration of @DRUG$ with clarithromycin resulted in increased plasma @DRUG$ concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14- hydroxy- clarithromycin plasma concentrations (31%). DDI-mechanism
Coadministration of @DRUG$ with clarithromycin resulted in increased plasma ranitidine concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased @DRUG$ plasma concentrations (31%). DDI-false
Coadministration of TRITEC with @DRUG$ resulted in increased plasma @DRUG$ concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14- hydroxy- clarithromycin plasma concentrations (31%). DDI-false
Coadministration of TRITEC with @DRUG$ resulted in increased plasma ranitidine concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased @DRUG$ plasma concentrations (31%). DDI-false
Coadministration of TRITEC with clarithromycin resulted in increased plasma @DRUG$ concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased @DRUG$ plasma concentrations (31%). DDI-false
Coadministration with @DRUG$ results in a slight decrease in the rate of @DRUG$ absorption that is clinically unimportant. DDI-false
Coadministration with a high dose of @DRUG$ (170 mEq) results in a 28% decrease in plasma concentrations of @DRUG$ and may decrease plasma concentrations of bismuth from TRITEC. DDI-false
Coadministration with a high dose of @DRUG$ (170 mEq) results in a 28% decrease in plasma concentrations of ranitidine and may decrease plasma concentrations of bismuth from @DRUG$. DDI-mechanism
Coadministration with a high dose of antacid (170 mEq) results in a 28% decrease in plasma concentrations of @DRUG$ and may decrease plasma concentrations of bismuth from @DRUG$. DDI-false
For information on drug interactions associated with @DRUG$, refer to the @DRUG$     package insert. DDI-false
@DRUG$ should be used with caution in patients receiving other local @DRUG$ or agents structurally related to amide-type local anesthetics, since the toxic effects of these drugs are additive. DDI-false
@DRUG$ should be used with caution in patients receiving other local anesthetics or agents structurally related to @DRUG$, since the toxic effects of these drugs are additive. DDI-advise
Ropivacaine should be used with caution in patients receiving other local @DRUG$ or agents structurally related to @DRUG$, since the toxic effects of these drugs are additive. DDI-advise
In vivo, the plasma clearance of @DRUG$ was reduced by 70% during coadministration of @DRUG$ (25 mg bid for 2 days), a selective and potent CYP1A2 inhibitor. DDI-false
Thus strong inhibitors of cytochrome P4501A2, such as @DRUG$, given concomitantly during administration of @DRUG$, can interact with Ropivacaine leading to increased ropivacaine plasma levels. DDI-mechanism
Thus strong inhibitors of cytochrome P4501A2, such as @DRUG$, given concomitantly during administration of Ropivacaine, can interact with @DRUG$ leading to increased ropivacaine plasma levels. DDI-mechanism
Thus strong inhibitors of cytochrome P4501A2, such as @DRUG$, given concomitantly during administration of Ropivacaine, can interact with Ropivacaine leading to increased @DRUG$ plasma levels. DDI-false
Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of @DRUG$, can interact with @DRUG$ leading to increased ropivacaine plasma levels. DDI-false
Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of @DRUG$, can interact with Ropivacaine leading to increased @DRUG$ plasma levels. DDI-mechanism
Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of Ropivacaine, can interact with @DRUG$ leading to increased @DRUG$ plasma levels. DDI-false
Possible interactions with drugs known to be metabolized by CYP1A2 via competitive inhibition such as @DRUG$ and @DRUG$ may also occur. DDI-false
Coadministration of a selective and potent inhibitor of CYP3A4, @DRUG$ (100 mg bid for 2 days with @DRUG$ infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of ropivacaine. DDI-false
Coadministration of a selective and potent inhibitor of CYP3A4, @DRUG$ (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after @DRUG$) caused a 15% reduction in in-vivo plasma clearance of ropivacaine. DDI-mechanism
Coadministration of a selective and potent inhibitor of CYP3A4, @DRUG$ (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of @DRUG$. DDI-mechanism
Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with @DRUG$ infusion administered 1 hour after @DRUG$) caused a 15% reduction in in-vivo plasma clearance of ropivacaine. DDI-mechanism
Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with @DRUG$ infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of @DRUG$. DDI-false
Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after @DRUG$) caused a 15% reduction in in-vivo plasma clearance of @DRUG$. DDI-false
@DRUG$ and @DRUG$ are incompatible with sodium bicarbonate solution. DDI-false
@DRUG$ and dobutamine are incompatible with @DRUG$ solution. DDI-false
norepinephrine and @DRUG$ are incompatible with @DRUG$ solution. DDI-false
The addition of @DRUG$ to parenteral solutions containing @DRUG$ should be avoided, except where compatibility has been previously established. DDI-false
Drug-Drug Interactions Effect of @DRUG$    (@DRUG$) on the Metabolism of Other Drugs: Rivastigmine is primarily metabolized through hydrolysis by esterases. DDI-advise
Drug-Drug Interactions Effect of @DRUG$    (rivastigmine tartrate) on the Metabolism of Other Drugs: @DRUG$ is primarily metabolized through hydrolysis by esterases. DDI-false
Drug-Drug Interactions Effect of Exelon    (@DRUG$) on the Metabolism of Other Drugs: @DRUG$ is primarily metabolized through hydrolysis by esterases. DDI-false
No pharmacokinetic interaction was observed between @DRUG$ and @DRUG$, warfarin, diazepam, or fluoxetine in studies in healthy volunteers. DDI-false
No pharmacokinetic interaction was observed between @DRUG$ and digoxin, @DRUG$, diazepam, or fluoxetine in studies in healthy volunteers. DDI-false
No pharmacokinetic interaction was observed between @DRUG$ and digoxin, warfarin, @DRUG$, or fluoxetine in studies in healthy volunteers. DDI-false
No pharmacokinetic interaction was observed between @DRUG$ and digoxin, warfarin, diazepam, or @DRUG$ in studies in healthy volunteers. DDI-false
No pharmacokinetic interaction was observed between rivastigmine and @DRUG$, @DRUG$, diazepam, or fluoxetine in studies in healthy volunteers. DDI-false
No pharmacokinetic interaction was observed between rivastigmine and @DRUG$, warfarin, @DRUG$, or fluoxetine in studies in healthy volunteers. DDI-false
No pharmacokinetic interaction was observed between rivastigmine and @DRUG$, warfarin, diazepam, or @DRUG$ in studies in healthy volunteers. DDI-false
No pharmacokinetic interaction was observed between rivastigmine and digoxin, @DRUG$, @DRUG$, or fluoxetine in studies in healthy volunteers. DDI-false
No pharmacokinetic interaction was observed between rivastigmine and digoxin, @DRUG$, diazepam, or @DRUG$ in studies in healthy volunteers. DDI-false
No pharmacokinetic interaction was observed between rivastigmine and digoxin, warfarin, @DRUG$, or @DRUG$ in studies in healthy volunteers. DDI-false
The elevation of prothrombin time induced by @DRUG$ is not affected by administration of @DRUG$. DDI-false
Effect of Other Drugs on the Metabolism of @DRUG$: Drugs that induce or inhibit CYP450 metabolism are not expected to alter the metabolism of @DRUG$. DDI-false
Single dose pharmacokinetic studies demonstrated that the metabolism of @DRUG$ is not significantly affected by concurrent administration of @DRUG$, warfarin, diazepam, or fluoxetine. DDI-false
Single dose pharmacokinetic studies demonstrated that the metabolism of @DRUG$ is not significantly affected by concurrent administration of digoxin, @DRUG$, diazepam, or fluoxetine. DDI-false
Single dose pharmacokinetic studies demonstrated that the metabolism of @DRUG$ is not significantly affected by concurrent administration of digoxin, warfarin, @DRUG$, or fluoxetine. DDI-false
Single dose pharmacokinetic studies demonstrated that the metabolism of @DRUG$ is not significantly affected by concurrent administration of digoxin, warfarin, diazepam, or @DRUG$. DDI-false
Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of @DRUG$, @DRUG$, diazepam, or fluoxetine. DDI-false
Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of @DRUG$, warfarin, @DRUG$, or fluoxetine. DDI-false
Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of @DRUG$, warfarin, diazepam, or @DRUG$. DDI-false
Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, @DRUG$, @DRUG$, or fluoxetine. DDI-false
Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, @DRUG$, diazepam, or @DRUG$. DDI-false
Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, warfarin, @DRUG$, or @DRUG$. DDI-false
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of @DRUG$ were not influenced by commonly prescribed medications such as @DRUG$ (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). DDI-false
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of @DRUG$ were not influenced by commonly prescribed medications such as antacids (n=77), @DRUG$ (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). DDI-false
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of @DRUG$ were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), @DRUG$ (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). DDI-false
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of @DRUG$ were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), @DRUG$ (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). DDI-false
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of @DRUG$ were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), @DRUG$ (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). DDI-false
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of @DRUG$ were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), @DRUG$ (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). DDI-false
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of @DRUG$ were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), @DRUG$ (n=177), antianginals (n=35), and antihistamines (n=15). DDI-false
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of @DRUG$ were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), @DRUG$ (n=35), and antihistamines (n=15). DDI-false
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of @DRUG$ were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and @DRUG$ (n=15). DDI-false
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as @DRUG$ (n=77), @DRUG$ (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). DDI-false
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as @DRUG$ (n=77), antihypertensives (n=72), @DRUG$ (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). DDI-false
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as @DRUG$ (n=77), antihypertensives (n=72), calcium channel blockers (n=75), @DRUG$ (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). DDI-false
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as @DRUG$ (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), @DRUG$ (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). DDI-false
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as @DRUG$ (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), @DRUG$ (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). DDI-false
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as @DRUG$ (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), @DRUG$ (n=177), antianginals (n=35), and antihistamines (n=15). DDI-false
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as @DRUG$ (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), @DRUG$ (n=35), and antihistamines (n=15). DDI-false
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as @DRUG$ (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and @DRUG$ (n=15). DDI-false
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), @DRUG$ (n=72), @DRUG$ (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). DDI-false
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), @DRUG$ (n=72), calcium channel blockers (n=75), @DRUG$ (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). DDI-false
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), @DRUG$ (n=72), calcium channel blockers (n=75), antidiabetics (n=21), @DRUG$ (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). DDI-false
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), @DRUG$ (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), @DRUG$ (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). DDI-false
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), @DRUG$ (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), @DRUG$ (n=177), antianginals (n=35), and antihistamines (n=15). DDI-false
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), @DRUG$ (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), @DRUG$ (n=35), and antihistamines (n=15). DDI-false
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), @DRUG$ (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and @DRUG$ (n=15). DDI-false
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), @DRUG$ (n=75), @DRUG$ (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). DDI-false
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), @DRUG$ (n=75), antidiabetics (n=21), @DRUG$ (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). DDI-false
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), @DRUG$ (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), @DRUG$ (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). DDI-false
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), @DRUG$ (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), @DRUG$ (n=177), antianginals (n=35), and antihistamines (n=15). DDI-false
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), @DRUG$ (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), @DRUG$ (n=35), and antihistamines (n=15). DDI-false
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), @DRUG$ (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and @DRUG$ (n=15). DDI-false
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), @DRUG$ (n=21), @DRUG$ (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). DDI-false
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), @DRUG$ (n=21), nonsteroidal anti-inflammatory drugs (n=79), @DRUG$ (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). DDI-false
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), @DRUG$ (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), @DRUG$ (n=177), antianginals (n=35), and antihistamines (n=15). DDI-false
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), @DRUG$ (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), @DRUG$ (n=35), and antihistamines (n=15). DDI-false
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), @DRUG$ (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and @DRUG$ (n=15). DDI-false
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), @DRUG$ (n=79), @DRUG$ (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). DDI-false
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), @DRUG$ (n=79), estrogens (n=70), @DRUG$ (n=177), antianginals (n=35), and antihistamines (n=15). DDI-false
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), @DRUG$ (n=79), estrogens (n=70), salicylate analgesics (n=177), @DRUG$ (n=35), and antihistamines (n=15). DDI-false
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), @DRUG$ (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and @DRUG$ (n=15). DDI-false
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), @DRUG$ (n=70), @DRUG$ (n=177), antianginals (n=35), and antihistamines (n=15). DDI-false
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), @DRUG$ (n=70), salicylate analgesics (n=177), @DRUG$ (n=35), and antihistamines (n=15). DDI-false
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), @DRUG$ (n=70), salicylate analgesics (n=177), antianginals (n=35), and @DRUG$ (n=15). DDI-false
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), @DRUG$ (n=177), @DRUG$ (n=35), and antihistamines (n=15). DDI-false
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), @DRUG$ (n=177), antianginals (n=35), and @DRUG$ (n=15). DDI-false
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), @DRUG$ (n=35), and @DRUG$ (n=15). DDI-false
Use with @DRUG$: Because of their mechanism of action, @DRUG$ have the potential to interfere with the activity of anticholinergic medications. DDI-false
Use with @DRUG$: Because of their mechanism of action, cholinesterase inhibitors have the potential to interfere with the activity of @DRUG$. DDI-false
Use with Anticholinergics: Because of their mechanism of action, @DRUG$ have the potential to interfere with the activity of @DRUG$. DDI-false
Use with @DRUG$ and Other @DRUG$: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol. DDI-effect
Use with @DRUG$ and Other Cholinesterase Inhibitors: A synergistic effect may be expected when @DRUG$ are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol. DDI-false
Use with @DRUG$ and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with @DRUG$, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol. DDI-false
Use with @DRUG$ and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar @DRUG$ or cholinergic agonists such as bethanechol. DDI-false
Use with @DRUG$ and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or @DRUG$ such as bethanechol. DDI-false
Use with @DRUG$ and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as @DRUG$. DDI-false
Use with Cholinomimetics and Other @DRUG$: A synergistic effect may be expected when @DRUG$ are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol. DDI-false
Use with Cholinomimetics and Other @DRUG$: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with @DRUG$, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol. DDI-false
Use with Cholinomimetics and Other @DRUG$: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar @DRUG$ or cholinergic agonists such as bethanechol. DDI-false
Use with Cholinomimetics and Other @DRUG$: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or @DRUG$ such as bethanechol. DDI-false
Use with Cholinomimetics and Other @DRUG$: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as @DRUG$. DDI-false
Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when @DRUG$ are given concurrently with @DRUG$, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol. DDI-false
Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when @DRUG$ are given concurrently with succinylcholine, similar @DRUG$ or cholinergic agonists such as bethanechol. DDI-effect
Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when @DRUG$ are given concurrently with succinylcholine, similar neuromuscular blocking agents or @DRUG$ such as bethanechol. DDI-effect
Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when @DRUG$ are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as @DRUG$. DDI-effect
Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with @DRUG$, similar @DRUG$ or cholinergic agonists such as bethanechol. DDI-effect
Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with @DRUG$, similar neuromuscular blocking agents or @DRUG$ such as bethanechol. DDI-false
Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with @DRUG$, similar neuromuscular blocking agents or cholinergic agonists such as @DRUG$. DDI-false
Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar @DRUG$ or @DRUG$ such as bethanechol. DDI-false
Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar @DRUG$ or cholinergic agonists such as @DRUG$. DDI-false
Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or @DRUG$ such as @DRUG$. DDI-false
@DRUG$ Reports suggest that @DRUG$ may diminish the antihypertensive effect of angiotensin-converting enzyme (ACE) inhibitors. DDI-false
@DRUG$ Reports suggest that NSAIDs may diminish the antihypertensive effect of @DRUG$. DDI-false
ACE inhibitors Reports suggest that @DRUG$ may diminish the antihypertensive effect of @DRUG$. DDI-false
This interaction should be given consideration in patients taking @DRUG$ concomitantly with @DRUG$. DDI-effect
@DRUG$: Concomitant administration of 200 mg @DRUG$ QID did not alter the single-dose pharmacokinetics of 30 mg meloxicam. DDI-advise
@DRUG$: Concomitant administration of 200 mg cimetidine QID did not alter the single-dose pharmacokinetics of 30 mg @DRUG$. DDI-false
Cimetidine: Concomitant administration of 200 mg @DRUG$ QID did not alter the single-dose pharmacokinetics of 30 mg @DRUG$. DDI-false
@DRUG$: @DRUG$ 15 mg once daily for 7 days did not alter the plasma concentration profile of digoxin after b-acetyldigoxin administration for 7 days at clinical doses. DDI-false
@DRUG$: Meloxicam 15 mg once daily for 7 days did not alter the plasma concentration profile of @DRUG$ after b-acetyldigoxin administration for 7 days at clinical doses. DDI-false
Digoxin: @DRUG$ 15 mg once daily for 7 days did not alter the plasma concentration profile of @DRUG$ after b-acetyldigoxin administration for 7 days at clinical doses. DDI-false
In vitro testing found no protein binding drug interaction between @DRUG$ and @DRUG$. DDI-false
@DRUG$: Clinical studies, as well as post-marketing observations, have shown that @DRUG$ can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients. DDI-false
@DRUG$: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of @DRUG$ and thiazide diuretics in some patients. DDI-false
@DRUG$: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and @DRUG$ in some patients. DDI-false
Furosemide: Clinical studies, as well as post-marketing observations, have shown that @DRUG$ can reduce the natriuretic effect of @DRUG$ and thiazide diuretics in some patients. DDI-false
Furosemide: Clinical studies, as well as post-marketing observations, have shown that @DRUG$ can reduce the natriuretic effect of furosemide and @DRUG$ in some patients. DDI-effect
Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of @DRUG$ and @DRUG$ in some patients. DDI-effect
Studies with @DRUG$ agents and @DRUG$ have not demonstrated a reduction in natriuretic effect. DDI-false
@DRUG$: single and multiple dose pharmacodynamics and pharmacokinetics are not affected by multiple doses of @DRUG$. DDI-false
Nevertheless, during concomitant therapy with @DRUG$ and @DRUG$, patients should be observed closely for signs of declining renal function, as well as to assure diuretic efficacy. DDI-false
@DRUG$: In clinical trials, @DRUG$ have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. DDI-advise
@DRUG$: In clinical trials, NSAIDs have produced an elevation of plasma @DRUG$ levels and a reduction in renal lithium clearance. DDI-false
@DRUG$: In clinical trials, NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal @DRUG$ clearance. DDI-false
Lithium: In clinical trials, @DRUG$ have produced an elevation of plasma @DRUG$ levels and a reduction in renal lithium clearance. DDI-false
Lithium: In clinical trials, @DRUG$ have produced an elevation of plasma lithium levels and a reduction in renal @DRUG$ clearance. DDI-mechanism
Lithium: In clinical trials, NSAIDs have produced an elevation of plasma @DRUG$ levels and a reduction in renal @DRUG$ clearance. DDI-false
@DRUG$: Concomitant administration of @DRUG$ (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of meloxicam. DDI-false
@DRUG$: Concomitant administration of aspirin (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of @DRUG$. DDI-false
Aspirin: Concomitant administration of @DRUG$ (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of @DRUG$. DDI-false
In a study conducted in healthy subjects, mean pre-dose @DRUG$ concentration and AUC were increased by 21% in subjects receiving @DRUG$ doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving lithium alone. DDI-mechanism
In a study conducted in healthy subjects, mean pre-dose @DRUG$ concentration and AUC were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg BID with @DRUG$ 15 mg QD as compared to subjects receiving lithium alone. DDI-false
In a study conducted in healthy subjects, mean pre-dose @DRUG$ concentration and AUC were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving @DRUG$ alone. DDI-false
In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving @DRUG$ doses ranging from 804 to 1072 mg BID with @DRUG$ 15 mg QD as compared to subjects receiving lithium alone. DDI-false
In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving @DRUG$ doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving @DRUG$ alone. DDI-mechanism
In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg BID with @DRUG$ 15 mg QD as compared to subjects receiving @DRUG$ alone. DDI-false
Patients on @DRUG$ treatment should be closely monitored when @DRUG$ is introduced or withdrawn. DDI-false
@DRUG$: A study in 13 rheumatoid arthritis (RA) patients evaluated the effects of multiple doses of @DRUG$ on the pharmacokinetics of methotrexate taken once weekly. DDI-advise
@DRUG$: A study in 13 rheumatoid arthritis (RA) patients evaluated the effects of multiple doses of meloxicam on the pharmacokinetics of @DRUG$ taken once weekly. DDI-false
Methotrexate: A study in 13 rheumatoid arthritis (RA) patients evaluated the effects of multiple doses of @DRUG$ on the pharmacokinetics of @DRUG$ taken once weekly. DDI-false
@DRUG$ did not have a significant effect on the pharmacokinetics of single doses of @DRUG$. DDI-false
In vitro, @DRUG$ did not displace @DRUG$ from its human serum binding sites. DDI-false
@DRUG$: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing @DRUG$ therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding. DDI-false
@DRUG$: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing MOBIC therapy in patients receiving @DRUG$ or similar agents, since these patients are at an increased risk of bleeding. DDI-false
Warfarin: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing @DRUG$ therapy in patients receiving @DRUG$ or similar agents, since these patients are at an increased risk of bleeding. DDI-false
The effect of @DRUG$ on the anticoagulant effect of @DRUG$ was studied in a group of healthy subjects receiving daily doses of warfarin that produced an INR (International Normalized Ratio) between 1.2 and 1.8. DDI-advise
The effect of @DRUG$ on the anticoagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of @DRUG$ that produced an INR (International Normalized Ratio) between 1.2 and 1.8. DDI-false
The effect of meloxicam on the anticoagulant effect of @DRUG$ was studied in a group of healthy subjects receiving daily doses of @DRUG$ that produced an INR (International Normalized Ratio) between 1.2 and 1.8. DDI-false
In these subjects, @DRUG$ did not alter @DRUG$ pharmacokinetics and the average anticoagulant effect of warfarin as determined by prothrombin time. DDI-false
In these subjects, @DRUG$ did not alter warfarin pharmacokinetics and the average anticoagulant effect of @DRUG$ as determined by prothrombin time. DDI-false
In these subjects, meloxicam did not alter @DRUG$ pharmacokinetics and the average anticoagulant effect of @DRUG$ as determined by prothrombin time. DDI-false
Caution should be used when administering @DRUG$ with @DRUG$ since patients on warfarin may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced. DDI-false
Caution should be used when administering @DRUG$ with warfarin since patients on @DRUG$ may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced. DDI-advise
Caution should be used when administering MOBIC with @DRUG$ since patients on @DRUG$ may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced. DDI-false
however, as with other @DRUG$, concomitant administration of @DRUG$ and aspirin is not generally recommended because of the potential for increased adverse effects. DDI-false
however, as with other @DRUG$, concomitant administration of meloxicam and @DRUG$ is not generally recommended because of the potential for increased adverse effects. DDI-false
however, as with other NSAIDs, concomitant administration of @DRUG$ and @DRUG$ is not generally recommended because of the potential for increased adverse effects. DDI-advise
Concomitant administration of low-dose @DRUG$ with @DRUG$ may result in an increased rate of GI ulceration or other complications, compared to use of MOBIC alone. DDI-advise
Concomitant administration of low-dose @DRUG$ with MOBIC may result in an increased rate of GI ulceration or other complications, compared to use of @DRUG$ alone. DDI-effect
Concomitant administration of low-dose aspirin with @DRUG$ may result in an increased rate of GI ulceration or other complications, compared to use of @DRUG$ alone. DDI-false
@DRUG$ is not a substitute for @DRUG$ for cardiovascular prophylaxis. DDI-false
@DRUG$: Pretreatment for four days with @DRUG$ significantly increased the clearance of meloxicam by 50%. DDI-false
@DRUG$: Pretreatment for four days with cholestyramine significantly increased the clearance of @DRUG$ by 50%. DDI-false
Cholestyramine: Pretreatment for four days with @DRUG$ significantly increased the clearance of @DRUG$ by 50%. DDI-false
@DRUG$ may inhibit the hepatic metabolism of @DRUG$. DDI-mechanism
@DRUG$, given at a common clinical dosage, increased the @DRUG$ half-life by 51% and decreased the phenytoin metabolic clearance rate by 30%. DDI-mechanism
@DRUG$, given at a common clinical dosage, increased the phenytoin half-life by 51% and decreased the @DRUG$ metabolic clearance rate by 30%. DDI-mechanism
Trimethoprim, given at a common clinical dosage, increased the @DRUG$ half-life by 51% and decreased the @DRUG$ metabolic clearance rate by 30%. DDI-mechanism
If @DRUG$ replacement is required, the @DRUG$ dose should be carefully adjusted. DDI-false
Limited published data indicate that @DRUG$ treatment increases cytochrome P450 (CP450) mediated @DRUG$ clearance in man. DDI-false
These data suggest that @DRUG$ administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., @DRUG$, sex steroids, anticonvulsants, cyclosporin). DDI-mechanism
These data suggest that @DRUG$ administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, @DRUG$, anticonvulsants, cyclosporin). DDI-mechanism
These data suggest that @DRUG$ administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, @DRUG$, cyclosporin). DDI-mechanism
These data suggest that @DRUG$ administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, @DRUG$). DDI-mechanism
These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., @DRUG$, @DRUG$, anticonvulsants, cyclosporin). DDI-mechanism
These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., @DRUG$, sex steroids, @DRUG$, cyclosporin). DDI-false
These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., @DRUG$, sex steroids, anticonvulsants, @DRUG$). DDI-false
These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, @DRUG$, @DRUG$, cyclosporin). DDI-false
These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, @DRUG$, anticonvulsants, @DRUG$). DDI-false
These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, @DRUG$, @DRUG$). DDI-false
Concurrent use of @DRUG$ and other @DRUG$ may increase the CNS depressant effects of methyprylon or these other medications. DDI-false
Concurrent use of @DRUG$ and other CNS depression-producing drugs may increase the CNS depressant effects of @DRUG$ or these other medications. DDI-effect
Concurrent use of alcohol and other @DRUG$ may increase the CNS depressant effects of @DRUG$ or these other medications. DDI-false
@DRUG$ may decrease the effectiveness of oral @DRUG$, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers. DDI-false
@DRUG$ may decrease the effectiveness of oral contraceptives, certain @DRUG$, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers. DDI-effect
@DRUG$ may decrease the effectiveness of oral contraceptives, certain antibiotics, @DRUG$, theophylline, corticosteroids, anticoagulants, and beta blockers. DDI-effect
@DRUG$ may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, @DRUG$, corticosteroids, anticoagulants, and beta blockers. DDI-effect
@DRUG$ may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, @DRUG$, anticoagulants, and beta blockers. DDI-effect
@DRUG$ may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, @DRUG$, and beta blockers. DDI-effect
@DRUG$ may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and @DRUG$. DDI-effect
Barbiturates may decrease the effectiveness of oral @DRUG$, certain @DRUG$, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers. DDI-effect
Barbiturates may decrease the effectiveness of oral @DRUG$, certain antibiotics, @DRUG$, theophylline, corticosteroids, anticoagulants, and beta blockers. DDI-false
Barbiturates may decrease the effectiveness of oral @DRUG$, certain antibiotics, quinidine, @DRUG$, corticosteroids, anticoagulants, and beta blockers. DDI-false
Barbiturates may decrease the effectiveness of oral @DRUG$, certain antibiotics, quinidine, theophylline, @DRUG$, anticoagulants, and beta blockers. DDI-false
Barbiturates may decrease the effectiveness of oral @DRUG$, certain antibiotics, quinidine, theophylline, corticosteroids, @DRUG$, and beta blockers. DDI-false
Barbiturates may decrease the effectiveness of oral @DRUG$, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and @DRUG$. DDI-false
Barbiturates may decrease the effectiveness of oral contraceptives, certain @DRUG$, @DRUG$, theophylline, corticosteroids, anticoagulants, and beta blockers. DDI-false
Barbiturates may decrease the effectiveness of oral contraceptives, certain @DRUG$, quinidine, @DRUG$, corticosteroids, anticoagulants, and beta blockers. DDI-false
Barbiturates may decrease the effectiveness of oral contraceptives, certain @DRUG$, quinidine, theophylline, @DRUG$, anticoagulants, and beta blockers. DDI-false
Barbiturates may decrease the effectiveness of oral contraceptives, certain @DRUG$, quinidine, theophylline, corticosteroids, @DRUG$, and beta blockers. DDI-false
Barbiturates may decrease the effectiveness of oral contraceptives, certain @DRUG$, quinidine, theophylline, corticosteroids, anticoagulants, and @DRUG$. DDI-false
Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, @DRUG$, @DRUG$, corticosteroids, anticoagulants, and beta blockers. DDI-false
Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, @DRUG$, theophylline, @DRUG$, anticoagulants, and beta blockers. DDI-false
Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, @DRUG$, theophylline, corticosteroids, @DRUG$, and beta blockers. DDI-false
Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, @DRUG$, theophylline, corticosteroids, anticoagulants, and @DRUG$. DDI-false
Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, @DRUG$, @DRUG$, anticoagulants, and beta blockers. DDI-false
Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, @DRUG$, corticosteroids, @DRUG$, and beta blockers. DDI-false
Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, @DRUG$, corticosteroids, anticoagulants, and @DRUG$. DDI-false
Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, @DRUG$, @DRUG$, and beta blockers. DDI-false
Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, @DRUG$, anticoagulants, and @DRUG$. DDI-false
Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, @DRUG$, and @DRUG$. DDI-false
Caution is recommended when administering @DRUG$ with compounds that are metabolized/eliminated predominantly by the UGT1A1 pathway (e.g. @DRUG$). DDI-false
Concomitant treatment with @DRUG$ resulted in a 21% increase in the AUC of @DRUG$. DDI-advise
Caution is recommended when administering @DRUG$ with @DRUG$. DDI-mechanism
When administered concomitantly with @DRUG$   , @DRUG$ may enhance or precipitate bradycardia, A.V. DDI-advise
The use of drugs that stimulate alpha-adrenergic receptors (e.g., @DRUG$, @DRUG$, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. DDI-effect
The use of drugs that stimulate alpha-adrenergic receptors (e.g., @DRUG$, pseudoephedrine, @DRUG$, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. DDI-false
The use of drugs that stimulate alpha-adrenergic receptors (e.g., @DRUG$, pseudoephedrine, ephedrine, @DRUG$ or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. DDI-false
The use of drugs that stimulate alpha-adrenergic receptors (e.g., @DRUG$, pseudoephedrine, ephedrine, phenylpropanolamine or @DRUG$) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. DDI-false
The use of drugs that stimulate alpha-adrenergic receptors (e.g., @DRUG$, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of @DRUG$   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. DDI-false
The use of drugs that stimulate alpha-adrenergic receptors (e.g., @DRUG$, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when @DRUG$    is administered concomitantly with agents that cause vasoconstriction. DDI-effect
The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, @DRUG$, @DRUG$, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. DDI-false
The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, @DRUG$, ephedrine, @DRUG$ or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. DDI-false
The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, @DRUG$, ephedrine, phenylpropanolamine or @DRUG$) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. DDI-false
The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, @DRUG$, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of @DRUG$   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. DDI-false
The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, @DRUG$, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when @DRUG$    is administered concomitantly with agents that cause vasoconstriction. DDI-effect
The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, @DRUG$, @DRUG$ or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. DDI-false
The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, @DRUG$, phenylpropanolamine or @DRUG$) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. DDI-false
The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, @DRUG$, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of @DRUG$   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. DDI-false
The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, @DRUG$, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when @DRUG$    is administered concomitantly with agents that cause vasoconstriction. DDI-effect
The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, @DRUG$ or @DRUG$) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. DDI-false
The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, @DRUG$ or dihydroergotamine) may enhance or potentiate the pressor effects of @DRUG$   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. DDI-false
The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, @DRUG$ or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when @DRUG$    is administered concomitantly with agents that cause vasoconstriction. DDI-effect
The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or @DRUG$) may enhance or potentiate the pressor effects of @DRUG$   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. DDI-false
The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or @DRUG$) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when @DRUG$    is administered concomitantly with agents that cause vasoconstriction. DDI-effect
The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of @DRUG$   . Therefore, caution should be used when @DRUG$    is administered concomitantly with agents that cause vasoconstriction. DDI-false
@DRUG$    has been used in patients concomitantly treated with salt-retaining steroid therapy (i.e., @DRUG$), with or without salt supplementation. DDI-false
@DRUG$. @DRUG$, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. DDI-false
@DRUG$. Alpha-adrenergic blocking agents, such as @DRUG$, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. DDI-false
@DRUG$. Alpha-adrenergic blocking agents, such as prazosin, @DRUG$, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. DDI-false
@DRUG$. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and @DRUG$, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. DDI-false
@DRUG$. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of @DRUG$. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. DDI-false
@DRUG$. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of @DRUG$ (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. DDI-false
@DRUG$. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as @DRUG$, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. DDI-false
@DRUG$. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, @DRUG$, ranitidine, procainamide, triamterene, flecainide, and quinidine. DDI-false
@DRUG$. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, @DRUG$, procainamide, triamterene, flecainide, and quinidine. DDI-false
@DRUG$. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, @DRUG$, triamterene, flecainide, and quinidine. DDI-false
@DRUG$. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, @DRUG$, flecainide, and quinidine. DDI-false
@DRUG$. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, @DRUG$, and quinidine. DDI-false
@DRUG$. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and @DRUG$. DDI-false
ProAmatine. @DRUG$, such as @DRUG$, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. DDI-false
ProAmatine. @DRUG$, such as prazosin, @DRUG$, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. DDI-false
ProAmatine. @DRUG$, such as prazosin, terazosin, and @DRUG$, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. DDI-false
ProAmatine. @DRUG$, such as prazosin, terazosin, and doxazosin, can antagonize the effects of @DRUG$. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. DDI-false
ProAmatine. @DRUG$, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of @DRUG$ (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. DDI-effect
ProAmatine. @DRUG$, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as @DRUG$, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. DDI-false
ProAmatine. @DRUG$, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, @DRUG$, ranitidine, procainamide, triamterene, flecainide, and quinidine. DDI-false
ProAmatine. @DRUG$, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, @DRUG$, procainamide, triamterene, flecainide, and quinidine. DDI-false
ProAmatine. @DRUG$, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, @DRUG$, triamterene, flecainide, and quinidine. DDI-false
ProAmatine. @DRUG$, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, @DRUG$, flecainide, and quinidine. DDI-false
ProAmatine. @DRUG$, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, @DRUG$, and quinidine. DDI-false
ProAmatine. @DRUG$, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and @DRUG$. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as @DRUG$, @DRUG$, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as @DRUG$, terazosin, and @DRUG$, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as @DRUG$, terazosin, and doxazosin, can antagonize the effects of @DRUG$. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as @DRUG$, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of @DRUG$ (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. DDI-effect
ProAmatine. Alpha-adrenergic blocking agents, such as @DRUG$, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as @DRUG$, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as @DRUG$, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, @DRUG$, ranitidine, procainamide, triamterene, flecainide, and quinidine. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as @DRUG$, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, @DRUG$, procainamide, triamterene, flecainide, and quinidine. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as @DRUG$, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, @DRUG$, triamterene, flecainide, and quinidine. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as @DRUG$, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, @DRUG$, flecainide, and quinidine. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as @DRUG$, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, @DRUG$, and quinidine. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as @DRUG$, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and @DRUG$. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, @DRUG$, and @DRUG$, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, @DRUG$, and doxazosin, can antagonize the effects of @DRUG$. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, @DRUG$, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of @DRUG$ (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. DDI-effect
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, @DRUG$, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as @DRUG$, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, @DRUG$, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, @DRUG$, ranitidine, procainamide, triamterene, flecainide, and quinidine. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, @DRUG$, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, @DRUG$, procainamide, triamterene, flecainide, and quinidine. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, @DRUG$, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, @DRUG$, triamterene, flecainide, and quinidine. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, @DRUG$, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, @DRUG$, flecainide, and quinidine. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, @DRUG$, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, @DRUG$, and quinidine. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, @DRUG$, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and @DRUG$. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and @DRUG$, can antagonize the effects of @DRUG$. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and @DRUG$, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of @DRUG$ (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. DDI-effect
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and @DRUG$, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as @DRUG$, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and @DRUG$, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, @DRUG$, ranitidine, procainamide, triamterene, flecainide, and quinidine. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and @DRUG$, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, @DRUG$, procainamide, triamterene, flecainide, and quinidine. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and @DRUG$, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, @DRUG$, triamterene, flecainide, and quinidine. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and @DRUG$, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, @DRUG$, flecainide, and quinidine. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and @DRUG$, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, @DRUG$, and quinidine. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and @DRUG$, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and @DRUG$. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of @DRUG$. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of @DRUG$ (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of @DRUG$. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as @DRUG$, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of @DRUG$. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, @DRUG$, ranitidine, procainamide, triamterene, flecainide, and quinidine. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of @DRUG$. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, @DRUG$, procainamide, triamterene, flecainide, and quinidine. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of @DRUG$. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, @DRUG$, triamterene, flecainide, and quinidine. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of @DRUG$. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, @DRUG$, flecainide, and quinidine. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of @DRUG$. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, @DRUG$, and quinidine. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of @DRUG$. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and @DRUG$. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of @DRUG$ (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as @DRUG$, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of @DRUG$ (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, @DRUG$, ranitidine, procainamide, triamterene, flecainide, and quinidine. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of @DRUG$ (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, @DRUG$, procainamide, triamterene, flecainide, and quinidine. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of @DRUG$ (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, @DRUG$, triamterene, flecainide, and quinidine. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of @DRUG$ (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, @DRUG$, flecainide, and quinidine. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of @DRUG$ (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, @DRUG$, and quinidine. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of @DRUG$ (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and @DRUG$. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as @DRUG$, @DRUG$, ranitidine, procainamide, triamterene, flecainide, and quinidine. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as @DRUG$, cimetidine, @DRUG$, procainamide, triamterene, flecainide, and quinidine. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as @DRUG$, cimetidine, ranitidine, @DRUG$, triamterene, flecainide, and quinidine. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as @DRUG$, cimetidine, ranitidine, procainamide, @DRUG$, flecainide, and quinidine. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as @DRUG$, cimetidine, ranitidine, procainamide, triamterene, @DRUG$, and quinidine. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as @DRUG$, cimetidine, ranitidine, procainamide, triamterene, flecainide, and @DRUG$. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, @DRUG$, @DRUG$, procainamide, triamterene, flecainide, and quinidine. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, @DRUG$, ranitidine, @DRUG$, triamterene, flecainide, and quinidine. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, @DRUG$, ranitidine, procainamide, @DRUG$, flecainide, and quinidine. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, @DRUG$, ranitidine, procainamide, triamterene, @DRUG$, and quinidine. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, @DRUG$, ranitidine, procainamide, triamterene, flecainide, and @DRUG$. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, @DRUG$, @DRUG$, triamterene, flecainide, and quinidine. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, @DRUG$, procainamide, @DRUG$, flecainide, and quinidine. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, @DRUG$, procainamide, triamterene, @DRUG$, and quinidine. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, @DRUG$, procainamide, triamterene, flecainide, and @DRUG$. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, @DRUG$, @DRUG$, flecainide, and quinidine. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, @DRUG$, triamterene, @DRUG$, and quinidine. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, @DRUG$, triamterene, flecainide, and @DRUG$. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, @DRUG$, @DRUG$, and quinidine. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, @DRUG$, flecainide, and @DRUG$. DDI-false
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, @DRUG$, and @DRUG$. DDI-false
@DRUG$ has been reported to enhance the sedative activity of @DRUG$, alcohol, chlorpromazine, and reserpine. DDI-false
@DRUG$ has been reported to enhance the sedative activity of barbiturates, @DRUG$, chlorpromazine, and reserpine. DDI-effect
@DRUG$ has been reported to enhance the sedative activity of barbiturates, alcohol, @DRUG$, and reserpine. DDI-effect
@DRUG$ has been reported to enhance the sedative activity of barbiturates, alcohol, chlorpromazine, and @DRUG$. DDI-effect
Thalidomide has been reported to enhance the sedative activity of @DRUG$, @DRUG$, chlorpromazine, and reserpine. DDI-effect
Thalidomide has been reported to enhance the sedative activity of @DRUG$, alcohol, @DRUG$, and reserpine. DDI-false
Thalidomide has been reported to enhance the sedative activity of @DRUG$, alcohol, chlorpromazine, and @DRUG$. DDI-false
Thalidomide has been reported to enhance the sedative activity of barbiturates, @DRUG$, @DRUG$, and reserpine. DDI-false
Thalidomide has been reported to enhance the sedative activity of barbiturates, @DRUG$, chlorpromazine, and @DRUG$. DDI-false
Thalidomide has been reported to enhance the sedative activity of barbiturates, alcohol, @DRUG$, and @DRUG$. DDI-false
Oral @DRUG$: In 10 healthy women, the pharmacokinetic profiles of @DRUG$ and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied. DDI-false
Oral @DRUG$: In 10 healthy women, the pharmacokinetic profiles of norethindrone and @DRUG$ following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied. DDI-false
Oral @DRUG$: In 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of @DRUG$ and 75    g of ethinyl estradiol were studied. DDI-false
Oral @DRUG$: In 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of @DRUG$ were studied. DDI-false
Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of @DRUG$ and @DRUG$ following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied. DDI-false
Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of @DRUG$ and ethinyl estradiol following administration of a single dose containing 1.0 mg of @DRUG$ and 75    g of ethinyl estradiol were studied. DDI-false
Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of @DRUG$ and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of @DRUG$ were studied. DDI-false
Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of norethindrone and @DRUG$ following administration of a single dose containing 1.0 mg of @DRUG$ and 75    g of ethinyl estradiol were studied. DDI-false
Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of norethindrone and @DRUG$ following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of @DRUG$ were studied. DDI-false
Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of @DRUG$ and 75    g of @DRUG$ were studied. DDI-false
Important Non-@DRUG$ Drug Interactions Drugs That Interfere with @DRUG$: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. DDI-false
Important Non-@DRUG$ Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of @DRUG$, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. DDI-false
Important Non-@DRUG$ Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, @DRUG$, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. DDI-false
Important Non-@DRUG$ Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, @DRUG$, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. DDI-false
Important Non-@DRUG$ Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, @DRUG$, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. DDI-false
Important Non-@DRUG$ Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, @DRUG$, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. DDI-false
Important Non-@DRUG$ Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, @DRUG$, phenytoin, carbamazepine, or certain herbal supplements such as St. DDI-false
Important Non-@DRUG$ Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, @DRUG$, carbamazepine, or certain herbal supplements such as St. DDI-false
Important Non-@DRUG$ Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, @DRUG$, or certain herbal supplements such as St. DDI-false
Important Non-Thalidomide Drug Interactions Drugs That Interfere with @DRUG$: Concomitant use of @DRUG$, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. DDI-false
Important Non-Thalidomide Drug Interactions Drugs That Interfere with @DRUG$: Concomitant use of HIV-protease inhibitors, @DRUG$, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. DDI-false
Important Non-Thalidomide Drug Interactions Drugs That Interfere with @DRUG$: Concomitant use of HIV-protease inhibitors, griseofulvin, @DRUG$, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. DDI-false
Important Non-Thalidomide Drug Interactions Drugs That Interfere with @DRUG$: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, @DRUG$, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. DDI-false
Important Non-Thalidomide Drug Interactions Drugs That Interfere with @DRUG$: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, @DRUG$, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. DDI-false
Important Non-Thalidomide Drug Interactions Drugs That Interfere with @DRUG$: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, @DRUG$, phenytoin, carbamazepine, or certain herbal supplements such as St. DDI-false
Important Non-Thalidomide Drug Interactions Drugs That Interfere with @DRUG$: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, @DRUG$, carbamazepine, or certain herbal supplements such as St. DDI-false
Important Non-Thalidomide Drug Interactions Drugs That Interfere with @DRUG$: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, @DRUG$, or certain herbal supplements such as St. DDI-false
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of @DRUG$, @DRUG$, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. DDI-false
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of @DRUG$, griseofulvin, @DRUG$, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. DDI-false
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of @DRUG$, griseofulvin, modafinil, @DRUG$, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. DDI-false
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of @DRUG$, griseofulvin, modafinil, penicillins, @DRUG$, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. DDI-false
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of @DRUG$, griseofulvin, modafinil, penicillins, rifampin, @DRUG$, phenytoin, carbamazepine, or certain herbal supplements such as St. DDI-false
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of @DRUG$, griseofulvin, modafinil, penicillins, rifampin, rifabutin, @DRUG$, carbamazepine, or certain herbal supplements such as St. DDI-false
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of @DRUG$, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, @DRUG$, or certain herbal supplements such as St. DDI-false
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, @DRUG$, @DRUG$, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. DDI-false
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, @DRUG$, modafinil, @DRUG$, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. DDI-false
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, @DRUG$, modafinil, penicillins, @DRUG$, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. DDI-false
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, @DRUG$, modafinil, penicillins, rifampin, @DRUG$, phenytoin, carbamazepine, or certain herbal supplements such as St. DDI-false
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, @DRUG$, modafinil, penicillins, rifampin, rifabutin, @DRUG$, carbamazepine, or certain herbal supplements such as St. DDI-false
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, @DRUG$, modafinil, penicillins, rifampin, rifabutin, phenytoin, @DRUG$, or certain herbal supplements such as St. DDI-false
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, @DRUG$, @DRUG$, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. DDI-false
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, @DRUG$, penicillins, @DRUG$, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. DDI-false
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, @DRUG$, penicillins, rifampin, @DRUG$, phenytoin, carbamazepine, or certain herbal supplements such as St. DDI-false
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, @DRUG$, penicillins, rifampin, rifabutin, @DRUG$, carbamazepine, or certain herbal supplements such as St. DDI-false
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, @DRUG$, penicillins, rifampin, rifabutin, phenytoin, @DRUG$, or certain herbal supplements such as St. DDI-false
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, @DRUG$, @DRUG$, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. DDI-false
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, @DRUG$, rifampin, @DRUG$, phenytoin, carbamazepine, or certain herbal supplements such as St. DDI-false
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, @DRUG$, rifampin, rifabutin, @DRUG$, carbamazepine, or certain herbal supplements such as St. DDI-false
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, @DRUG$, rifampin, rifabutin, phenytoin, @DRUG$, or certain herbal supplements such as St. DDI-false
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, @DRUG$, @DRUG$, phenytoin, carbamazepine, or certain herbal supplements such as St. DDI-false
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, @DRUG$, rifabutin, @DRUG$, carbamazepine, or certain herbal supplements such as St. DDI-false
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, @DRUG$, rifabutin, phenytoin, @DRUG$, or certain herbal supplements such as St. DDI-false
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, @DRUG$, @DRUG$, carbamazepine, or certain herbal supplements such as St. DDI-false
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, @DRUG$, phenytoin, @DRUG$, or certain herbal supplements such as St. DDI-false
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, @DRUG$, @DRUG$, or certain herbal supplements such as St. DDI-false
@DRUG$ with @DRUG$ may reduce the effectiveness of the contraception and up to one month after discontinuation of these concomitant therapies. DDI-false
@DRUG$ may enhance the effects of @DRUG$, barbiturates and other CNS depressants. DDI-effect
@DRUG$ may enhance the effects of alcohol, @DRUG$ and other CNS depressants. DDI-effect
@DRUG$ may enhance the effects of alcohol, barbiturates and other @DRUG$. DDI-effect
SKELAXIN may enhance the effects of @DRUG$, @DRUG$ and other CNS depressants. DDI-effect
SKELAXIN may enhance the effects of @DRUG$, barbiturates and other @DRUG$. DDI-false
SKELAXIN may enhance the effects of alcohol, @DRUG$ and other @DRUG$. DDI-false
@DRUG$ and @DRUG$ increase the effects of pseudoephedrine. DDI-false
@DRUG$ and beta adrenergic blockers increase the effects of @DRUG$. DDI-false
MAO inhibitors and @DRUG$ increase the effects of @DRUG$. DDI-effect
@DRUG$ may reduce the antihypertensive effects of @DRUG$, mecamylamine, reserpine and veratrum alkaloids. DDI-effect
@DRUG$ may reduce the antihypertensive effects of methyldopa, @DRUG$, reserpine and veratrum alkaloids. DDI-effect
@DRUG$ may reduce the antihypertensive effects of methyldopa, mecamylamine, @DRUG$ and veratrum alkaloids. DDI-effect
@DRUG$ may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and @DRUG$. DDI-effect
Sympathomimetics may reduce the antihypertensive effects of @DRUG$, @DRUG$, reserpine and veratrum alkaloids. DDI-effect
Sympathomimetics may reduce the antihypertensive effects of @DRUG$, mecamylamine, @DRUG$ and veratrum alkaloids. DDI-false
Sympathomimetics may reduce the antihypertensive effects of @DRUG$, mecamylamine, reserpine and @DRUG$. DDI-false
Sympathomimetics may reduce the antihypertensive effects of methyldopa, @DRUG$, @DRUG$ and veratrum alkaloids. DDI-false
Sympathomimetics may reduce the antihypertensive effects of methyldopa, @DRUG$, reserpine and @DRUG$. DDI-false
Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, @DRUG$ and @DRUG$. DDI-false
Drugs which may potentiate the myeloproliferative effects of @DRUG$, such as @DRUG$ and corticosteroids, should be used with caution. DDI-false
Drugs which may potentiate the myeloproliferative effects of @DRUG$, such as lithium and @DRUG$, should be used with caution. DDI-false
Drugs which may potentiate the myeloproliferative effects of Leukine, such as @DRUG$ and @DRUG$, should be used with caution. DDI-false
The in vitro binding of @DRUG$ to human plasma proteins is unaffected by @DRUG$, and tolmetin does not alter the prothrombin time of normal volunteers. DDI-false
The in vitro binding of @DRUG$ to human plasma proteins is unaffected by tolmetin, and @DRUG$ does not alter the prothrombin time of normal volunteers. DDI-false
The in vitro binding of warfarin to human plasma proteins is unaffected by @DRUG$, and @DRUG$ does not alter the prothrombin time of normal volunteers. DDI-false
However, increased prothrombin time and bleeding have been reported in patients on concomitant @DRUG$ and @DRUG$ therapy. DDI-false
Therefore, caution should be exercised when administering @DRUG$ to patients on @DRUG$. DDI-effect
In adult diabetic patients under treatment with either @DRUG$ or @DRUG$ there is no change in the clinical effects of either TOLECTIN or the hypoglycemic agents. DDI-advise
In adult diabetic patients under treatment with either @DRUG$ or insulin there is no change in the clinical effects of either @DRUG$ or the hypoglycemic agents. DDI-false
In adult diabetic patients under treatment with either @DRUG$ or insulin there is no change in the clinical effects of either TOLECTIN or the @DRUG$. DDI-false
In adult diabetic patients under treatment with either sulfonylureas or @DRUG$ there is no change in the clinical effects of either @DRUG$ or the hypoglycemic agents. DDI-false
In adult diabetic patients under treatment with either sulfonylureas or @DRUG$ there is no change in the clinical effects of either TOLECTIN or the @DRUG$. DDI-false
In adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either @DRUG$ or the @DRUG$. DDI-false
Caution should be used if @DRUG$ is administered concomitantly with @DRUG$. DDI-false
@DRUG$ and other @DRUG$ have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of methotrexate. DDI-advise
@DRUG$ and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of @DRUG$ in an animal model, possibly enhancing the toxicity of methotrexate. DDI-false
@DRUG$ and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of @DRUG$. DDI-mechanism
TOLECTIN and other @DRUG$ have been reported to reduce the tubular secretion of @DRUG$ in an animal model, possibly enhancing the toxicity of methotrexate. DDI-false
TOLECTIN and other @DRUG$ have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of @DRUG$. DDI-mechanism
TOLECTIN and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of @DRUG$ in an animal model, possibly enhancing the toxicity of @DRUG$. DDI-false
An inhibitor of CYP2C8 (such as @DRUG$) may increase the AUC of @DRUG$ and an inducer of CYP2C8 (such as rifampin) may decrease the AUC of rosiglitazone. DDI-false
An inhibitor of CYP2C8 (such as @DRUG$) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (such as @DRUG$) may decrease the AUC of rosiglitazone. DDI-mechanism
An inhibitor of CYP2C8 (such as @DRUG$) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (such as rifampin) may decrease the AUC of @DRUG$. DDI-false
An inhibitor of CYP2C8 (such as gemfibrozil) may increase the AUC of @DRUG$ and an inducer of CYP2C8 (such as @DRUG$) may decrease the AUC of rosiglitazone. DDI-false
An inhibitor of CYP2C8 (such as gemfibrozil) may increase the AUC of @DRUG$ and an inducer of CYP2C8 (such as rifampin) may decrease the AUC of @DRUG$. DDI-false
An inhibitor of CYP2C8 (such as gemfibrozil) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (such as @DRUG$) may decrease the AUC of @DRUG$. DDI-false
Pharmacokinetic properties of @DRUG$ were not altered by the addition of either @DRUG$ or zidovudine or the combination of lamivudine and zidovudine. DDI-mechanism
Pharmacokinetic properties of @DRUG$ were not altered by the addition of either lamivudine or @DRUG$ or the combination of lamivudine and zidovudine. DDI-false
Pharmacokinetic properties of @DRUG$ were not altered by the addition of either lamivudine or zidovudine or the combination of @DRUG$ and zidovudine. DDI-false
Pharmacokinetic properties of @DRUG$ were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and @DRUG$. DDI-false
Pharmacokinetic properties of abacavir were not altered by the addition of either @DRUG$ or @DRUG$ or the combination of lamivudine and zidovudine. DDI-false
Pharmacokinetic properties of abacavir were not altered by the addition of either @DRUG$ or zidovudine or the combination of @DRUG$ and zidovudine. DDI-false
Pharmacokinetic properties of abacavir were not altered by the addition of either @DRUG$ or zidovudine or the combination of lamivudine and @DRUG$. DDI-false
Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or @DRUG$ or the combination of @DRUG$ and zidovudine. DDI-false
Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or @DRUG$ or the combination of lamivudine and @DRUG$. DDI-false
Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of @DRUG$ and @DRUG$. DDI-false
No clinically significant changes to @DRUG$ or @DRUG$ pharmacokinetics were observed following concomitant administration of abacavir. DDI-false
No clinically significant changes to @DRUG$ or zidovudine pharmacokinetics were observed following concomitant administration of @DRUG$. DDI-false
No clinically significant changes to lamivudine or @DRUG$ pharmacokinetics were observed following concomitant administration of @DRUG$. DDI-false
@DRUG$ has no effect on the pharmacokinetic properties of @DRUG$. DDI-false
@DRUG$ decreases the elimination of @DRUG$ causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir. DDI-false
@DRUG$ decreases the elimination of abacavir causing an increase in overall exposure . The addition of @DRUG$ has no clinically significant effect on the pharmacokinetic properties of abacavir. DDI-mechanism
@DRUG$ decreases the elimination of abacavir causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of @DRUG$. DDI-false
Ethanol decreases the elimination of @DRUG$ causing an increase in overall exposure . The addition of @DRUG$ has no clinically significant effect on the pharmacokinetic properties of abacavir. DDI-false
Ethanol decreases the elimination of @DRUG$ causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of @DRUG$. DDI-false
Ethanol decreases the elimination of abacavir causing an increase in overall exposure . The addition of @DRUG$ has no clinically significant effect on the pharmacokinetic properties of @DRUG$. DDI-false
In a study of 11 HIV-infected patients receiving @DRUG$-maintenance therapy (40 mg and 90 mg daily) with 600 mg of @DRUG$ twice daily (twice the currently recommended dose), oral methadone clearance increased 22% (90% CI 6% to 42%). DDI-false
In a study of 11 HIV-infected patients receiving @DRUG$-maintenance therapy (40 mg and 90 mg daily) with 600 mg of ZIAGEN twice daily (twice the currently recommended dose), oral @DRUG$ clearance increased 22% (90% CI 6% to 42%). DDI-mechanism
In a study of 11 HIV-infected patients receiving methadone-maintenance therapy (40 mg and 90 mg daily) with 600 mg of @DRUG$ twice daily (twice the currently recommended dose), oral @DRUG$ clearance increased 22% (90% CI 6% to 42%). DDI-false
Other @DRUG$ should not be used concomitantly with @DRUG$    (metaproterenol sulfate USP) because they may have additive effects. DDI-false
Other @DRUG$ should not be used concomitantly with Alupent    (@DRUG$ USP) because they may have additive effects. DDI-advise
Other beta adrenergic aerosol bronchodilators should not be used concomitantly with @DRUG$    (@DRUG$ USP) because they may have additive effects. DDI-advise
@DRUG$ should be administered with caution to patients being treated with @DRUG$ or tricyclic antidepressants, since the action of beta adrenergic agonists on the vascular system may be potentiated. DDI-false
@DRUG$ should be administered with caution to patients being treated with monoamine oxidase inhibitors or @DRUG$, since the action of beta adrenergic agonists on the vascular system may be potentiated. DDI-advise
@DRUG$ should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, since the action of @DRUG$ on the vascular system may be potentiated. DDI-advise
Beta adrenergic agonists should be administered with caution to patients being treated with @DRUG$ or @DRUG$, since the action of beta adrenergic agonists on the vascular system may be potentiated. DDI-false
Beta adrenergic agonists should be administered with caution to patients being treated with @DRUG$ or tricyclic antidepressants, since the action of @DRUG$ on the vascular system may be potentiated. DDI-false
Beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or @DRUG$, since the action of @DRUG$ on the vascular system may be potentiated. DDI-false
A study published in 2002 found that @DRUG$ causes a statistically significant increase in plasma clearance of @DRUG$. DDI-false
In 1984, Drs Rimmer and Richens at the University of Wales reported that administering @DRUG$ with @DRUG$ lowered the serum phenytoin concentration in patients with treatment-resistant epilepsy. DDI-mechanism
In 1984, Drs Rimmer and Richens at the University of Wales reported that administering @DRUG$ with phenytoin lowered the serum @DRUG$ concentration in patients with treatment-resistant epilepsy. DDI-mechanism
In 1984, Drs Rimmer and Richens at the University of Wales reported that administering vigabatrin with @DRUG$ lowered the serum @DRUG$ concentration in patients with treatment-resistant epilepsy. DDI-false
@DRUG$ may enhance the sedative effects of @DRUG$ including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. DDI-false
@DRUG$ may enhance the sedative effects of central nervous system depressants including @DRUG$, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. DDI-effect
@DRUG$ may enhance the sedative effects of central nervous system depressants including alcohol, @DRUG$, hypnotics, narcotic analgesics, sedatives, and tranquillisers. DDI-effect
@DRUG$ may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, @DRUG$, narcotic analgesics, sedatives, and tranquillisers. DDI-effect
@DRUG$ may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, @DRUG$, sedatives, and tranquillisers. DDI-effect
@DRUG$ may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, @DRUG$, and tranquillisers. DDI-effect
@DRUG$ may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and @DRUG$. DDI-effect
Triprolidine may enhance the sedative effects of @DRUG$ including @DRUG$, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. DDI-effect
Triprolidine may enhance the sedative effects of @DRUG$ including alcohol, @DRUG$, hypnotics, narcotic analgesics, sedatives, and tranquillisers. DDI-false
Triprolidine may enhance the sedative effects of @DRUG$ including alcohol, barbiturates, @DRUG$, narcotic analgesics, sedatives, and tranquillisers. DDI-false
Triprolidine may enhance the sedative effects of @DRUG$ including alcohol, barbiturates, hypnotics, @DRUG$, sedatives, and tranquillisers. DDI-false
Triprolidine may enhance the sedative effects of @DRUG$ including alcohol, barbiturates, hypnotics, narcotic analgesics, @DRUG$, and tranquillisers. DDI-false
Triprolidine may enhance the sedative effects of @DRUG$ including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and @DRUG$. DDI-false
Triprolidine may enhance the sedative effects of central nervous system depressants including @DRUG$, @DRUG$, hypnotics, narcotic analgesics, sedatives, and tranquillisers. DDI-false
Triprolidine may enhance the sedative effects of central nervous system depressants including @DRUG$, barbiturates, @DRUG$, narcotic analgesics, sedatives, and tranquillisers. DDI-false
Triprolidine may enhance the sedative effects of central nervous system depressants including @DRUG$, barbiturates, hypnotics, @DRUG$, sedatives, and tranquillisers. DDI-false
Triprolidine may enhance the sedative effects of central nervous system depressants including @DRUG$, barbiturates, hypnotics, narcotic analgesics, @DRUG$, and tranquillisers. DDI-false
Triprolidine may enhance the sedative effects of central nervous system depressants including @DRUG$, barbiturates, hypnotics, narcotic analgesics, sedatives, and @DRUG$. DDI-false
Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, @DRUG$, @DRUG$, narcotic analgesics, sedatives, and tranquillisers. DDI-false
Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, @DRUG$, hypnotics, @DRUG$, sedatives, and tranquillisers. DDI-false
Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, @DRUG$, hypnotics, narcotic analgesics, @DRUG$, and tranquillisers. DDI-false
Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, @DRUG$, hypnotics, narcotic analgesics, sedatives, and @DRUG$. DDI-false
Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, @DRUG$, @DRUG$, sedatives, and tranquillisers. DDI-false
Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, @DRUG$, narcotic analgesics, @DRUG$, and tranquillisers. DDI-false
Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, @DRUG$, narcotic analgesics, sedatives, and @DRUG$. DDI-false
Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, @DRUG$, @DRUG$, and tranquillisers. DDI-false
Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, @DRUG$, sedatives, and @DRUG$. DDI-false
Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, @DRUG$, and @DRUG$. DDI-false
The effects of @DRUG$, such as @DRUG$ and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine. DDI-false
The effects of @DRUG$, such as atropine and @DRUG$ may be enhanced by the concomitant administration of triprolidine. DDI-false
The effects of @DRUG$, such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of @DRUG$. DDI-false
The effects of anticholinergic drugs, such as @DRUG$ and @DRUG$ may be enhanced by the concomitant administration of triprolidine. DDI-effect
The effects of anticholinergic drugs, such as @DRUG$ and tricyclic antidepressants may be enhanced by the concomitant administration of @DRUG$. DDI-false
The effects of anticholinergic drugs, such as atropine and @DRUG$ may be enhanced by the concomitant administration of @DRUG$. DDI-effect
Caution should be exercised when administering @DRUG$ therapy in combination with other @DRUG$. DDI-effect
In addition to bleeding associated with @DRUG$ and @DRUG$, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy. DDI-advise
In addition to bleeding associated with @DRUG$ and vitamin K antagonists, drugs that alter platelet function (such as @DRUG$, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy. DDI-false
In addition to bleeding associated with @DRUG$ and vitamin K antagonists, drugs that alter platelet function (such as aspirin, @DRUG$, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy. DDI-false
In addition to bleeding associated with @DRUG$ and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and @DRUG$) may increase the risk of bleeding if administered prior to or after Retavase    therapy. DDI-false
In addition to bleeding associated with @DRUG$ and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after @DRUG$    therapy. DDI-false
In addition to bleeding associated with heparin and @DRUG$, drugs that alter platelet function (such as @DRUG$, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy. DDI-effect
In addition to bleeding associated with heparin and @DRUG$, drugs that alter platelet function (such as aspirin, @DRUG$, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy. DDI-false
In addition to bleeding associated with heparin and @DRUG$, drugs that alter platelet function (such as aspirin, dipyridamole, and @DRUG$) may increase the risk of bleeding if administered prior to or after Retavase    therapy. DDI-false
In addition to bleeding associated with heparin and @DRUG$, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after @DRUG$    therapy. DDI-false
In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as @DRUG$, @DRUG$, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy. DDI-effect
In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as @DRUG$, dipyridamole, and @DRUG$) may increase the risk of bleeding if administered prior to or after Retavase    therapy. DDI-false
In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as @DRUG$, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after @DRUG$    therapy. DDI-false
In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, @DRUG$, and @DRUG$) may increase the risk of bleeding if administered prior to or after Retavase    therapy. DDI-effect
In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, @DRUG$, and abciximab) may increase the risk of bleeding if administered prior to or after @DRUG$    therapy. DDI-false
In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and @DRUG$) may increase the risk of bleeding if administered prior to or after @DRUG$    therapy. DDI-effect
The occurrence of stupor, muscular rigidity, severe agitation, and elevated temperature has been reported in some patients receiving the combination of @DRUG$ and @DRUG$. DDI-effect
This is typical of the interaction of @DRUG$ and @DRUG$. DDI-effect
Severe toxicity has also been reported in patients receiving the combination of @DRUG$ and @DRUG$ and selective serotonin reuptake inhibitors and ELDEPRYL. DDI-int
Severe toxicity has also been reported in patients receiving the combination of @DRUG$ and ELDEPRYL and @DRUG$ and ELDEPRYL. DDI-false
Severe toxicity has also been reported in patients receiving the combination of @DRUG$ and ELDEPRYL and selective serotonin reuptake inhibitors and @DRUG$. DDI-effect
Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and @DRUG$ and @DRUG$ and ELDEPRYL. DDI-effect
Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and @DRUG$ and selective serotonin reuptake inhibitors and @DRUG$. DDI-false
Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and ELDEPRYL and @DRUG$ and @DRUG$. DDI-false
One case of hypertensive crisis has been reported in a patient taking the recommended doses of @DRUG$ and a @DRUG$ (ephedrine). DDI-false
One case of hypertensive crisis has been reported in a patient taking the recommended doses of @DRUG$ and a sympathomimetic medication (@DRUG$). DDI-effect
One case of hypertensive crisis has been reported in a patient taking the recommended doses of selegiline and a @DRUG$ (@DRUG$). DDI-effect
When @DRUG$ and @DRUG$ are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when atropine is used alone. DDI-false
When @DRUG$ and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when @DRUG$ is used alone. DDI-effect
When atropine and @DRUG$ are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when @DRUG$ is used alone. DDI-false
This is especially true if the total dose of @DRUG$ has been large and the administration of @DRUG$ has been delayed. DDI-false
2 - 4 The following precautions should be kept in mind in the treatment of anticholinesterase poisoning, although they do not bear directly on the use of @DRUG$: since @DRUG$ are potentiated by the anticholinesterases, they should be used cautiously in the treatment of convulsions; DDI-false
2 - 4 The following precautions should be kept in mind in the treatment of anticholinesterase poisoning, although they do not bear directly on the use of @DRUG$: since barbiturates are potentiated by the @DRUG$, they should be used cautiously in the treatment of convulsions; DDI-false
2 - 4 The following precautions should be kept in mind in the treatment of anticholinesterase poisoning, although they do not bear directly on the use of pralidoxime: since @DRUG$ are potentiated by the @DRUG$, they should be used cautiously in the treatment of convulsions; DDI-false
@DRUG$, @DRUG$, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning. DDI-advise
@DRUG$, theophylline, @DRUG$, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning. DDI-false
@DRUG$, theophylline, aminophylline, @DRUG$, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning. DDI-false
@DRUG$, theophylline, aminophylline, succinylcholine, @DRUG$, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning. DDI-false
@DRUG$, theophylline, aminophylline, succinylcholine, reserpine, and @DRUG$ should be avoided in patients with organophosphate poisoning. DDI-false
morphine, @DRUG$, @DRUG$, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning. DDI-false
morphine, @DRUG$, aminophylline, @DRUG$, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning. DDI-false
morphine, @DRUG$, aminophylline, succinylcholine, @DRUG$, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning. DDI-false
morphine, @DRUG$, aminophylline, succinylcholine, reserpine, and @DRUG$ should be avoided in patients with organophosphate poisoning. DDI-false
morphine, theophylline, @DRUG$, @DRUG$, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning. DDI-false
morphine, theophylline, @DRUG$, succinylcholine, @DRUG$, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning. DDI-false
morphine, theophylline, @DRUG$, succinylcholine, reserpine, and @DRUG$ should be avoided in patients with organophosphate poisoning. DDI-false
morphine, theophylline, aminophylline, @DRUG$, @DRUG$, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning. DDI-false
morphine, theophylline, aminophylline, @DRUG$, reserpine, and @DRUG$ should be avoided in patients with organophosphate poisoning. DDI-false
morphine, theophylline, aminophylline, succinylcholine, @DRUG$, and @DRUG$ should be avoided in patients with organophosphate poisoning. DDI-false
@DRUG$ administered concomitantly with @DRUG$ may significantly decrease the serum concentrations of MPA. DDI-false
@DRUG$ administered concomitantly with depo-subQ provera 104 may significantly decrease the serum concentrations of @DRUG$. DDI-mechanism
Aminoglutethimide administered concomitantly with @DRUG$ may significantly decrease the serum concentrations of @DRUG$. DDI-false
In clinical studies of @DRUG$, patients taking @DRUG$ concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. DDI-false
In clinical studies of @DRUG$, patients taking TOBI concomitantly with @DRUG$ (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. DDI-false
In clinical studies of @DRUG$, patients taking TOBI concomitantly with dornase alfa (@DRUG$   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. DDI-false
In clinical studies of @DRUG$, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), @DRUG$, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. DDI-false
In clinical studies of @DRUG$, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled @DRUG$, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. DDI-false
In clinical studies of @DRUG$, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other @DRUG$, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. DDI-false
In clinical studies of @DRUG$, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral @DRUG$ demonstrated adverse experience profiles similar to the study population as a whole. DDI-false
In clinical studies of TOBI, patients taking @DRUG$ concomitantly with @DRUG$ (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. DDI-false
In clinical studies of TOBI, patients taking @DRUG$ concomitantly with dornase alfa (@DRUG$   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. DDI-false
In clinical studies of TOBI, patients taking @DRUG$ concomitantly with dornase alfa (PULMOZYME   , Genentech), @DRUG$, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. DDI-false
In clinical studies of TOBI, patients taking @DRUG$ concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled @DRUG$, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. DDI-false
In clinical studies of TOBI, patients taking @DRUG$ concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other @DRUG$, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. DDI-false
In clinical studies of TOBI, patients taking @DRUG$ concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral @DRUG$ demonstrated adverse experience profiles similar to the study population as a whole. DDI-false
In clinical studies of TOBI, patients taking TOBI concomitantly with @DRUG$ (@DRUG$   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. DDI-false
In clinical studies of TOBI, patients taking TOBI concomitantly with @DRUG$ (PULMOZYME   , Genentech), @DRUG$, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. DDI-false
In clinical studies of TOBI, patients taking TOBI concomitantly with @DRUG$ (PULMOZYME   , Genentech), (beta)-agonists, inhaled @DRUG$, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. DDI-false
In clinical studies of TOBI, patients taking TOBI concomitantly with @DRUG$ (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other @DRUG$, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. DDI-false
In clinical studies of TOBI, patients taking TOBI concomitantly with @DRUG$ (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral @DRUG$ demonstrated adverse experience profiles similar to the study population as a whole. DDI-false
In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (@DRUG$   , Genentech), @DRUG$, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. DDI-false
In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (@DRUG$   , Genentech), (beta)-agonists, inhaled @DRUG$, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. DDI-false
In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (@DRUG$   , Genentech), (beta)-agonists, inhaled corticosteroids, other @DRUG$, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. DDI-false
In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (@DRUG$   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral @DRUG$ demonstrated adverse experience profiles similar to the study population as a whole. DDI-false
In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), @DRUG$, inhaled @DRUG$, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. DDI-false
In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), @DRUG$, inhaled corticosteroids, other @DRUG$, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. DDI-false
In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), @DRUG$, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral @DRUG$ demonstrated adverse experience profiles similar to the study population as a whole. DDI-false
In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled @DRUG$, other @DRUG$, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. DDI-false
In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled @DRUG$, other anti-pseudomonal antibiotics, or parenteral @DRUG$ demonstrated adverse experience profiles similar to the study population as a whole. DDI-false
In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other @DRUG$, or parenteral @DRUG$ demonstrated adverse experience profiles similar to the study population as a whole. DDI-false
Some @DRUG$ can enhance @DRUG$ toxicity by altering antibiotic concentrations in serum and tissue. DDI-false
Some @DRUG$ can enhance aminoglycoside toxicity by altering @DRUG$ concentrations in serum and tissue. DDI-effect
Some diuretics can enhance @DRUG$ toxicity by altering @DRUG$ concentrations in serum and tissue. DDI-false
@DRUG$ should not be administered concomitantly with @DRUG$, furosemide, urea, or mannitol. DDI-false
@DRUG$ should not be administered concomitantly with ethacrynic acid, @DRUG$, urea, or mannitol. DDI-advise
@DRUG$ should not be administered concomitantly with ethacrynic acid, furosemide, @DRUG$, or mannitol. DDI-advise
@DRUG$ should not be administered concomitantly with ethacrynic acid, furosemide, urea, or @DRUG$. DDI-advise
TOBI should not be administered concomitantly with @DRUG$, @DRUG$, urea, or mannitol. DDI-advise
TOBI should not be administered concomitantly with @DRUG$, furosemide, @DRUG$, or mannitol. DDI-false
TOBI should not be administered concomitantly with @DRUG$, furosemide, urea, or @DRUG$. DDI-false
TOBI should not be administered concomitantly with ethacrynic acid, @DRUG$, @DRUG$, or mannitol. DDI-false
TOBI should not be administered concomitantly with ethacrynic acid, @DRUG$, urea, or @DRUG$. DDI-false
TOBI should not be administered concomitantly with ethacrynic acid, furosemide, @DRUG$, or @DRUG$. DDI-false
DRUG INTERACTIONS  There are no known drug/drug interactions with oral @DRUG$  Vaccinations with @DRUG$ are not recommended in immunocompromised individuals  Nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis. DDI-false
DRUG INTERACTIONS  There are no known drug/drug interactions with oral @DRUG$  Vaccinations with live organism vaccines are not recommended in immunocompromised individuals  @DRUG$ together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis. DDI-false
DRUG INTERACTIONS  There are no known drug/drug interactions with oral @DRUG$  Vaccinations with live organism vaccines are not recommended in immunocompromised individuals  Nalidixic acid together with high-dose intravenous @DRUG$ has caused deaths in children due to haemorrhagic enterocolitis. DDI-false
DRUG INTERACTIONS  There are no known drug/drug interactions with oral ALKERAN  Vaccinations with @DRUG$ are not recommended in immunocompromised individuals  @DRUG$ together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis. DDI-false
DRUG INTERACTIONS  There are no known drug/drug interactions with oral ALKERAN  Vaccinations with @DRUG$ are not recommended in immunocompromised individuals  Nalidixic acid together with high-dose intravenous @DRUG$ has caused deaths in children due to haemorrhagic enterocolitis. DDI-false
DRUG INTERACTIONS  There are no known drug/drug interactions with oral ALKERAN  Vaccinations with live organism vaccines are not recommended in immunocompromised individuals  @DRUG$ together with high-dose intravenous @DRUG$ has caused deaths in children due to haemorrhagic enterocolitis. DDI-false
Impaired renal function has been described in bone marrow transplant patients who were conditioned with high-dose intravenous @DRUG$ and who subsequently received @DRUG$ to prevent graft-versus-host disease DDI-false
@DRUG$ should be administered with caution to patients taking @DRUG$ because of the possibility of conduction disturbances. DDI-false
These effects should be considered when anticholinergic properties may be contributing to the therapeutic effect of concomitant medication (e.g., @DRUG$, inhaled @DRUG$). DDI-advise
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: @DRUG$, artificial tears, @DRUG$, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: @DRUG$, artificial tears, calcium, @DRUG$, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: @DRUG$, artificial tears, calcium, conjugated estrogens, @DRUG$, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: @DRUG$, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, @DRUG$, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: @DRUG$, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, @DRUG$, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: @DRUG$, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, @DRUG$, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: @DRUG$, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, @DRUG$, multivitamins, naproxen, omeprazole, paracetamol, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: @DRUG$, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, @DRUG$, naproxen, omeprazole, paracetamol, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: @DRUG$, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, @DRUG$, omeprazole, paracetamol, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: @DRUG$, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, @DRUG$, paracetamol, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: @DRUG$, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, @DRUG$, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: @DRUG$, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and @DRUG$. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, @DRUG$, @DRUG$, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, @DRUG$, conjugated estrogens, @DRUG$, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, @DRUG$, conjugated estrogens, hydroxychloroquine sulfate, @DRUG$, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, @DRUG$, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, @DRUG$, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, @DRUG$, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, @DRUG$, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, @DRUG$, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, @DRUG$, multivitamins, naproxen, omeprazole, paracetamol, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, @DRUG$, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, @DRUG$, naproxen, omeprazole, paracetamol, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, @DRUG$, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, @DRUG$, omeprazole, paracetamol, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, @DRUG$, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, @DRUG$, paracetamol, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, @DRUG$, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, @DRUG$, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, @DRUG$, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and @DRUG$. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, @DRUG$, @DRUG$, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, @DRUG$, hydroxychloroquine sulfate, @DRUG$, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, @DRUG$, hydroxychloroquine sulfate, ibuprofen, @DRUG$, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, @DRUG$, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, @DRUG$, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, @DRUG$, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, @DRUG$, multivitamins, naproxen, omeprazole, paracetamol, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, @DRUG$, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, @DRUG$, naproxen, omeprazole, paracetamol, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, @DRUG$, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, @DRUG$, omeprazole, paracetamol, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, @DRUG$, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, @DRUG$, paracetamol, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, @DRUG$, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, @DRUG$, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, @DRUG$, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and @DRUG$. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, @DRUG$, @DRUG$, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, @DRUG$, ibuprofen, @DRUG$, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, @DRUG$, ibuprofen, levothyroxine sodium, @DRUG$, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, @DRUG$, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, @DRUG$, multivitamins, naproxen, omeprazole, paracetamol, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, @DRUG$, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, @DRUG$, naproxen, omeprazole, paracetamol, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, @DRUG$, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, @DRUG$, omeprazole, paracetamol, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, @DRUG$, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, @DRUG$, paracetamol, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, @DRUG$, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, @DRUG$, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, @DRUG$, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and @DRUG$. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, @DRUG$, @DRUG$, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, @DRUG$, levothyroxine sodium, @DRUG$, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, @DRUG$, levothyroxine sodium, medroxyprogesterone acetate, @DRUG$, multivitamins, naproxen, omeprazole, paracetamol, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, @DRUG$, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, @DRUG$, naproxen, omeprazole, paracetamol, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, @DRUG$, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, @DRUG$, omeprazole, paracetamol, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, @DRUG$, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, @DRUG$, paracetamol, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, @DRUG$, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, @DRUG$, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, @DRUG$, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and @DRUG$. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, @DRUG$, @DRUG$, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, @DRUG$, medroxyprogesterone acetate, @DRUG$, multivitamins, naproxen, omeprazole, paracetamol, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, @DRUG$, medroxyprogesterone acetate, methotrexate, @DRUG$, naproxen, omeprazole, paracetamol, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, @DRUG$, medroxyprogesterone acetate, methotrexate, multivitamins, @DRUG$, omeprazole, paracetamol, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, @DRUG$, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, @DRUG$, paracetamol, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, @DRUG$, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, @DRUG$, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, @DRUG$, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and @DRUG$. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, @DRUG$, @DRUG$, multivitamins, naproxen, omeprazole, paracetamol, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, @DRUG$, methotrexate, @DRUG$, naproxen, omeprazole, paracetamol, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, @DRUG$, methotrexate, multivitamins, @DRUG$, omeprazole, paracetamol, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, @DRUG$, methotrexate, multivitamins, naproxen, @DRUG$, paracetamol, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, @DRUG$, methotrexate, multivitamins, naproxen, omeprazole, @DRUG$, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, @DRUG$, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and @DRUG$. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, @DRUG$, @DRUG$, naproxen, omeprazole, paracetamol, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, @DRUG$, multivitamins, @DRUG$, omeprazole, paracetamol, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, @DRUG$, multivitamins, naproxen, @DRUG$, paracetamol, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, @DRUG$, multivitamins, naproxen, omeprazole, @DRUG$, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, @DRUG$, multivitamins, naproxen, omeprazole, paracetamol, and @DRUG$. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, @DRUG$, @DRUG$, omeprazole, paracetamol, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, @DRUG$, naproxen, @DRUG$, paracetamol, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, @DRUG$, naproxen, omeprazole, @DRUG$, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, @DRUG$, naproxen, omeprazole, paracetamol, and @DRUG$. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, @DRUG$, @DRUG$, paracetamol, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, @DRUG$, omeprazole, @DRUG$, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, @DRUG$, omeprazole, paracetamol, and @DRUG$. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, @DRUG$, @DRUG$, and prednisone. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, @DRUG$, paracetamol, and @DRUG$. DDI-false
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, @DRUG$, and @DRUG$. DDI-false
The induction dose requirements of @DRUG$ Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with @DRUG$ (eg, morphine, meperidine, and fentanyl, etc.) DDI-false
The induction dose requirements of @DRUG$ Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, @DRUG$, meperidine, and fentanyl, etc.) DDI-false
The induction dose requirements of @DRUG$ Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, @DRUG$, and fentanyl, etc.) DDI-false
The induction dose requirements of @DRUG$ Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and @DRUG$, etc.) DDI-false
The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with @DRUG$ (eg, @DRUG$, meperidine, and fentanyl, etc.) DDI-false
The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with @DRUG$ (eg, morphine, @DRUG$, and fentanyl, etc.) DDI-false
The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with @DRUG$ (eg, morphine, meperidine, and @DRUG$, etc.) DDI-false
The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, @DRUG$, @DRUG$, and fentanyl, etc.) DDI-false
The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, @DRUG$, meperidine, and @DRUG$, etc.) DDI-false
The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, @DRUG$, and @DRUG$, etc.) DDI-false
and combinations of @DRUG$ and @DRUG$ (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). DDI-false
and combinations of @DRUG$ and sedatives (eg, @DRUG$, barbiturates, chloral hydrate, droperidol, etc.). DDI-false
and combinations of @DRUG$ and sedatives (eg, benzodiazepines, @DRUG$, chloral hydrate, droperidol, etc.). DDI-false
and combinations of @DRUG$ and sedatives (eg, benzodiazepines, barbiturates, @DRUG$, droperidol, etc.). DDI-false
and combinations of @DRUG$ and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, @DRUG$, etc.). DDI-false
and combinations of opioids and @DRUG$ (eg, @DRUG$, barbiturates, chloral hydrate, droperidol, etc.). DDI-false
and combinations of opioids and @DRUG$ (eg, benzodiazepines, @DRUG$, chloral hydrate, droperidol, etc.). DDI-false
and combinations of opioids and @DRUG$ (eg, benzodiazepines, barbiturates, @DRUG$, droperidol, etc.). DDI-false
and combinations of opioids and @DRUG$ (eg, benzodiazepines, barbiturates, chloral hydrate, @DRUG$, etc.). DDI-false
and combinations of opioids and sedatives (eg, @DRUG$, @DRUG$, chloral hydrate, droperidol, etc.). DDI-false
and combinations of opioids and sedatives (eg, @DRUG$, barbiturates, @DRUG$, droperidol, etc.). DDI-false
and combinations of opioids and sedatives (eg, @DRUG$, barbiturates, chloral hydrate, @DRUG$, etc.). DDI-false
and combinations of opioids and sedatives (eg, benzodiazepines, @DRUG$, @DRUG$, droperidol, etc.). DDI-false
and combinations of opioids and sedatives (eg, benzodiazepines, @DRUG$, chloral hydrate, @DRUG$, etc.). DDI-false
and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, @DRUG$, @DRUG$, etc.). DDI-false
During maintenance of anesthesia or sedation, the rate of @DRUG$ Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental @DRUG$ (eg, nitrous oxide or opioids). DDI-false
During maintenance of anesthesia or sedation, the rate of @DRUG$ Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, @DRUG$ or opioids). DDI-false
During maintenance of anesthesia or sedation, the rate of @DRUG$ Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, nitrous oxide or @DRUG$). DDI-false
During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental @DRUG$ (eg, @DRUG$ or opioids). DDI-false
During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental @DRUG$ (eg, nitrous oxide or @DRUG$). DDI-false
During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, @DRUG$ or @DRUG$). DDI-false
The concurrent administration of potent inhalational agents (eg, @DRUG$, @DRUG$, and halothane) during maintenance with DIPRIVAN Injectable Emulsion has not been extensively evaluated. DDI-false
The concurrent administration of potent inhalational agents (eg, @DRUG$, enflurane, and @DRUG$) during maintenance with DIPRIVAN Injectable Emulsion has not been extensively evaluated. DDI-false
The concurrent administration of potent inhalational agents (eg, @DRUG$, enflurane, and halothane) during maintenance with @DRUG$ Injectable Emulsion has not been extensively evaluated. DDI-false
The concurrent administration of potent inhalational agents (eg, isoflurane, @DRUG$, and @DRUG$) during maintenance with DIPRIVAN Injectable Emulsion has not been extensively evaluated. DDI-false
The concurrent administration of potent inhalational agents (eg, isoflurane, @DRUG$, and halothane) during maintenance with @DRUG$ Injectable Emulsion has not been extensively evaluated. DDI-false
The concurrent administration of potent inhalational agents (eg, isoflurane, enflurane, and @DRUG$) during maintenance with @DRUG$ Injectable Emulsion has not been extensively evaluated. DDI-false
@DRUG$ Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used @DRUG$ (eg, succinylcholine and nondepolarizing muscle relaxants). DDI-false
@DRUG$ Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used neuromuscular blocking agents (eg, @DRUG$ and nondepolarizing muscle relaxants). DDI-false
@DRUG$ Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used neuromuscular blocking agents (eg, succinylcholine and @DRUG$). DDI-false
DIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used @DRUG$ (eg, @DRUG$ and nondepolarizing muscle relaxants). DDI-false
DIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used @DRUG$ (eg, succinylcholine and @DRUG$). DDI-false
DIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used neuromuscular blocking agents (eg, @DRUG$ and @DRUG$). DDI-false
No significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation (including a range of @DRUG$, inhalational agents, @DRUG$, and local anesthetic agents) have been observed. DDI-false
No significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation (including a range of @DRUG$, inhalational agents, analgesic agents, and local @DRUG$) have been observed. DDI-false
No significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation (including a range of muscle relaxants, inhalational agents, @DRUG$, and local @DRUG$) have been observed. DDI-false
Oral @DRUG$ has been reported to potentiate the anticoagulant effect of @DRUG$ and warfarin, resulting in a prolongation of prothrombin time. DDI-false
Oral @DRUG$ has been reported to potentiate the anticoagulant effect of coumarin and @DRUG$, resulting in a prolongation of prothrombin time. DDI-effect
Oral metronidazole has been reported to potentiate the anticoagulant effect of @DRUG$ and @DRUG$, resulting in a prolongation of prothrombin time. DDI-effect
Drug interactions should be kept in mind when @DRUG$ (@DRUG$ gel), 1% is prescribed for patients who are receiving anticoagulant treatment, although they are less likely to occur with topical metronidazole administration because of low absorption. DDI-false
Drug interactions should be kept in mind when @DRUG$ (metronidazole gel), 1% is prescribed for patients who are receiving anticoagulant treatment, although they are less likely to occur with topical @DRUG$ administration because of low absorption. DDI-false
Drug interactions should be kept in mind when METROGEL (@DRUG$ gel), 1% is prescribed for patients who are receiving anticoagulant treatment, although they are less likely to occur with topical @DRUG$ administration because of low absorption. DDI-false
Caution is advised for patients receiving high-dose @DRUG$ and @DRUG$ concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors. DDI-false
Caution is advised for patients receiving high-dose @DRUG$ and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose @DRUG$ and carbonic anhydrase inhibitors. DDI-advise
Caution is advised for patients receiving high-dose @DRUG$ and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and @DRUG$. DDI-false
Caution is advised for patients receiving high-dose aspirin and @DRUG$ concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose @DRUG$ and carbonic anhydrase inhibitors. DDI-false
Caution is advised for patients receiving high-dose aspirin and @DRUG$ concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and @DRUG$. DDI-false
Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose @DRUG$ and @DRUG$. DDI-false
@DRUG$ may be used with @DRUG$, quinine and other antimalarials, and with other antibiotics. DDI-false
@DRUG$ may be used with sulfonamides, @DRUG$ and other antimalarials, and with other antibiotics. DDI-false
@DRUG$ may be used with sulfonamides, quinine and other @DRUG$, and with other antibiotics. DDI-false
@DRUG$ may be used with sulfonamides, quinine and other antimalarials, and with other @DRUG$. DDI-false
Pyrimethamine may be used with @DRUG$, @DRUG$ and other antimalarials, and with other antibiotics. DDI-false
Pyrimethamine may be used with @DRUG$, quinine and other @DRUG$, and with other antibiotics. DDI-false
Pyrimethamine may be used with @DRUG$, quinine and other antimalarials, and with other @DRUG$. DDI-false
Pyrimethamine may be used with sulfonamides, @DRUG$ and other @DRUG$, and with other antibiotics. DDI-false
Pyrimethamine may be used with sulfonamides, @DRUG$ and other antimalarials, and with other @DRUG$. DDI-false
Pyrimethamine may be used with sulfonamides, quinine and other @DRUG$, and with other @DRUG$. DDI-false
@DRUG$ (@DRUG$) should be administered until normal hematopoiesis is restored. DDI-false
Mild hepatotoxicity has been reported in some patients when @DRUG$ and @DRUG$ were administered concomitantly. DDI-false
Due to its effects on gastric emptying, @DRUG$ therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., @DRUG$ such as atropine) and agents that slow the intestinal absorption of nutrients (e.g., alpha glucosidase inhibitors). DDI-effect
Due to its effects on gastric emptying, @DRUG$ therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., anticholinergic agents such as @DRUG$) and agents that slow the intestinal absorption of nutrients (e.g., alpha glucosidase inhibitors). DDI-advise
Due to its effects on gastric emptying, @DRUG$ therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., anticholinergic agents such as atropine) and agents that slow the intestinal absorption of nutrients (e.g., @DRUG$). DDI-advise
Due to its effects on gastric emptying, SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., @DRUG$ such as @DRUG$) and agents that slow the intestinal absorption of nutrients (e.g., alpha glucosidase inhibitors). DDI-advise
Due to its effects on gastric emptying, SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., @DRUG$ such as atropine) and agents that slow the intestinal absorption of nutrients (e.g., @DRUG$). DDI-false
Due to its effects on gastric emptying, SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., anticholinergic agents such as @DRUG$) and agents that slow the intestinal absorption of nutrients (e.g., @DRUG$). DDI-false
When the rapid onset of a concomitant orally administered agent is a critical determinant of effectiveness (such as @DRUG$), the agent should be administered at least 1 hour prior to or 2 hours after @DRUG$ injection. DDI-false
In clinical trials, the concomitant use of @DRUG$ or @DRUG$ did not alter the adverse event profile of SYMLIN. DDI-advise
In clinical trials, the concomitant use of @DRUG$ or biguanides did not alter the adverse event profile of @DRUG$. DDI-false
In clinical trials, the concomitant use of sulfonylureas or @DRUG$ did not alter the adverse event profile of @DRUG$. DDI-false
No formal interaction studies have been performed to assess the effect of @DRUG$ on the kinetics of oral @DRUG$. DDI-false
Mixing @DRUG$ and @DRUG$ The pharmacokinetic parameters of SYMLIN were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant human insulin immediately prior to injection. DDI-false
Mixing @DRUG$ and Insulin The pharmacokinetic parameters of @DRUG$ were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant human insulin immediately prior to injection. DDI-false
Mixing @DRUG$ and Insulin The pharmacokinetic parameters of SYMLIN were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant @DRUG$ immediately prior to injection. DDI-false
Mixing SYMLIN and @DRUG$ The pharmacokinetic parameters of @DRUG$ were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant human insulin immediately prior to injection. DDI-false
Mixing SYMLIN and @DRUG$ The pharmacokinetic parameters of SYMLIN were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant @DRUG$ immediately prior to injection. DDI-false
Mixing SYMLIN and Insulin The pharmacokinetic parameters of @DRUG$ were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant @DRUG$ immediately prior to injection. DDI-false
Thus, @DRUG$ and @DRUG$ should not be mixed and must be administered separately. DDI-false
Since @DRUG$ is a substrate for the metabolic pathways involving CYP2D6 and CYP1A2 enzymes, inhibition or induction of either of these enzymes would be expected to alter @DRUG$ plasma concentrations. DDI-advise
In a formal, single-dose interaction study (n = 6 males) the clearance of @DRUG$ was decreased by 38% following the coadministration of @DRUG$, an inhibitor of CYP1A2. DDI-false
In a formal study, @DRUG$ were shown not to affect @DRUG$    plasma concentrations. DDI-mechanism
ECG intervals (PR, QRS, and QT) were not affected by concurrent @DRUG$    and @DRUG$, diuretics, or propranolol. DDI-false
ECG intervals (PR, QRS, and QT) were not affected by concurrent @DRUG$    and digoxin, @DRUG$, or propranolol. DDI-false
ECG intervals (PR, QRS, and QT) were not affected by concurrent @DRUG$    and digoxin, diuretics, or @DRUG$. DDI-false
ECG intervals (PR, QRS, and QT) were not affected by concurrent Mexitil    and @DRUG$, @DRUG$, or propranolol. DDI-false
ECG intervals (PR, QRS, and QT) were not affected by concurrent Mexitil    and @DRUG$, diuretics, or @DRUG$. DDI-false
ECG intervals (PR, QRS, and QT) were not affected by concurrent Mexitil    and digoxin, @DRUG$, or @DRUG$. DDI-false
Concurrent administration of @DRUG$ and @DRUG$    has been reported to increase, decrease, or leave unchanged Mexitil    plasma levels; DDI-false
Concurrent administration of @DRUG$ and Mexitil    has been reported to increase, decrease, or leave unchanged @DRUG$    plasma levels; DDI-mechanism
Concurrent administration of cimetidine and @DRUG$    has been reported to increase, decrease, or leave unchanged @DRUG$    plasma levels; DDI-false
@DRUG$    does not alter serum @DRUG$ levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum digoxin levels. DDI-false
@DRUG$    does not alter serum digoxin levels but @DRUG$, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum digoxin levels. DDI-false
@DRUG$    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to @DRUG$   , has been reported to lower serum digoxin levels. DDI-false
@DRUG$    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum @DRUG$ levels. DDI-false
Mexitil    does not alter serum @DRUG$ levels but @DRUG$, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum digoxin levels. DDI-false
Mexitil    does not alter serum @DRUG$ levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to @DRUG$   , has been reported to lower serum digoxin levels. DDI-false
Mexitil    does not alter serum @DRUG$ levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum @DRUG$ levels. DDI-false
Mexitil    does not alter serum digoxin levels but @DRUG$, when used to treat gastrointestinal symptoms due to @DRUG$   , has been reported to lower serum digoxin levels. DDI-false
Mexitil    does not alter serum digoxin levels but @DRUG$, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum @DRUG$ levels. DDI-effect
Mexitil    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to @DRUG$   , has been reported to lower serum @DRUG$ levels. DDI-false
Concurrent use of @DRUG$    and @DRUG$ may lead to increased plasma theophylline levels. DDI-false
Concurrent use of @DRUG$    and theophylline may lead to increased plasma @DRUG$ levels. DDI-effect
Concurrent use of Mexitil    and @DRUG$ may lead to increased plasma @DRUG$ levels. DDI-false
This increase was observed at the first test point which was the second day after starting @DRUG$   . @DRUG$ plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. DDI-false
This increase was observed at the first test point which was the second day after starting @DRUG$   . Theophylline plasma levels returned to pre-@DRUG$    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. DDI-false
This increase was observed at the first test point which was the second day after starting @DRUG$   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing @DRUG$   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. DDI-false
This increase was observed at the first test point which was the second day after starting @DRUG$   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If @DRUG$ and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. DDI-false
This increase was observed at the first test point which was the second day after starting @DRUG$   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and @DRUG$ are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. DDI-false
This increase was observed at the first test point which was the second day after starting @DRUG$   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, @DRUG$ blood levels should be monitored, particularly when the Mexitil    dose is changed. DDI-false
This increase was observed at the first test point which was the second day after starting @DRUG$   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the @DRUG$    dose is changed. DDI-false
This increase was observed at the first test point which was the second day after starting Mexitil   . @DRUG$ plasma levels returned to pre-@DRUG$    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. DDI-false
This increase was observed at the first test point which was the second day after starting Mexitil   . @DRUG$ plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing @DRUG$   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. DDI-false
This increase was observed at the first test point which was the second day after starting Mexitil   . @DRUG$ plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If @DRUG$ and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. DDI-false
This increase was observed at the first test point which was the second day after starting Mexitil   . @DRUG$ plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and @DRUG$ are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. DDI-false
This increase was observed at the first test point which was the second day after starting Mexitil   . @DRUG$ plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, @DRUG$ blood levels should be monitored, particularly when the Mexitil    dose is changed. DDI-false
This increase was observed at the first test point which was the second day after starting Mexitil   . @DRUG$ plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the @DRUG$    dose is changed. DDI-false
This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-@DRUG$    values within 48 hours after discontinuing @DRUG$   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. DDI-false
This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-@DRUG$    values within 48 hours after discontinuing Mexitil   . If @DRUG$ and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. DDI-false
This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-@DRUG$    values within 48 hours after discontinuing Mexitil   . If Mexitil and @DRUG$ are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. DDI-false
This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-@DRUG$    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, @DRUG$ blood levels should be monitored, particularly when the Mexitil    dose is changed. DDI-false
This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-@DRUG$    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the @DRUG$    dose is changed. DDI-false
This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing @DRUG$   . If @DRUG$ and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. DDI-false
This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing @DRUG$   . If Mexitil and @DRUG$ are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. DDI-false
This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing @DRUG$   . If Mexitil and theophylline are to be used concurrently, @DRUG$ blood levels should be monitored, particularly when the Mexitil    dose is changed. DDI-false
This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing @DRUG$   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the @DRUG$    dose is changed. DDI-false
This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If @DRUG$ and @DRUG$ are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. DDI-false
This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If @DRUG$ and theophylline are to be used concurrently, @DRUG$ blood levels should be monitored, particularly when the Mexitil    dose is changed. DDI-advise
This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If @DRUG$ and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the @DRUG$    dose is changed. DDI-false
This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and @DRUG$ are to be used concurrently, @DRUG$ blood levels should be monitored, particularly when the Mexitil    dose is changed. DDI-false
This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and @DRUG$ are to be used concurrently, theophylline blood levels should be monitored, particularly when the @DRUG$    dose is changed. DDI-false
This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, @DRUG$ blood levels should be monitored, particularly when the @DRUG$    dose is changed. DDI-false
In another formal study (n = 8 extensive and n = 7 poor metabolizers of CYP2D6), coadministration of @DRUG$ did not alter the kinetics of @DRUG$ in the poor CYP2D6 metabolizer group. DDI-false
Additionally, in one controlled study in five normal subjects and seven patients, the clearance of @DRUG$ was decreased 50% following the administration of @DRUG$   . DDI-false
In this crossover steady state study, the pharmacokinetics of @DRUG$ were unaffected in either phenotype by the coadministration of @DRUG$. DDI-mechanism
Addition of @DRUG$ to @DRUG$ did not lead to further electrocardiographic parameters changes of QRS, QTc, RR, and PR intervals than propafenone alone. DDI-false
Addition of @DRUG$ to propafenone did not lead to further electrocardiographic parameters changes of QRS, QTc, RR, and PR intervals than @DRUG$ alone. DDI-false
Addition of mexiletine to @DRUG$ did not lead to further electrocardiographic parameters changes of QRS, QTc, RR, and PR intervals than @DRUG$ alone. DDI-false
When concomitant administration of either of these two drugs with @DRUG$ is initiated, the dose of @DRUG$ should be slowly titrated to desired effect. DDI-false
In a large compassionate use program @DRUG$    has been used concurrently with commonly employed antianginal, @DRUG$, and anticoagulant drugs without observed interactions. DDI-false
In a large compassionate use program @DRUG$    has been used concurrently with commonly employed antianginal, antihypertensive, and @DRUG$ without observed interactions. DDI-false
In a large compassionate use program Mexitil    has been used concurrently with commonly employed antianginal, @DRUG$, and @DRUG$ without observed interactions. DDI-false
A variety of @DRUG$ such as @DRUG$ or propranolol were also added, sometimes with improved control of ventricular ectopy. DDI-false
A variety of @DRUG$ such as quinidine or @DRUG$ were also added, sometimes with improved control of ventricular ectopy. DDI-false
A variety of antiarrhythmics such as @DRUG$ or @DRUG$ were also added, sometimes with improved control of ventricular ectopy. DDI-false
When @DRUG$ or other hepatic enzyme inducers such as @DRUG$ and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. DDI-false
When @DRUG$ or other hepatic enzyme inducers such as rifampin and @DRUG$ have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. DDI-false
When @DRUG$ or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with @DRUG$   , lowered Mexitil    plasma levels have been reported. DDI-false
When @DRUG$ or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered @DRUG$    plasma levels have been reported. DDI-mechanism
When phenytoin or other hepatic enzyme inducers such as @DRUG$ and @DRUG$ have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. DDI-false
When phenytoin or other hepatic enzyme inducers such as @DRUG$ and phenobarbital have been taken concurrently with @DRUG$   , lowered Mexitil    plasma levels have been reported. DDI-false
When phenytoin or other hepatic enzyme inducers such as @DRUG$ and phenobarbital have been taken concurrently with Mexitil   , lowered @DRUG$    plasma levels have been reported. DDI-mechanism
When phenytoin or other hepatic enzyme inducers such as rifampin and @DRUG$ have been taken concurrently with @DRUG$   , lowered Mexitil    plasma levels have been reported. DDI-false
When phenytoin or other hepatic enzyme inducers such as rifampin and @DRUG$ have been taken concurrently with Mexitil   , lowered @DRUG$    plasma levels have been reported. DDI-mechanism
When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with @DRUG$   , lowered @DRUG$    plasma levels have been reported. DDI-false
@DRUG$ (oral): The activity of oral @DRUG$ may be potentiated by anti-vitamin-K activity attributed to methimazole. DDI-false
@DRUG$ (oral): The activity of oral anticoagulants may be potentiated by anti-vitamin-K activity attributed to @DRUG$. DDI-false
Anticoagulants (oral): The activity of oral @DRUG$ may be potentiated by anti-vitamin-K activity attributed to @DRUG$. DDI-false
@DRUG$: Serum digitalis levels may be increased when hyperthyroid patients on a stable @DRUG$ regimen become euthyroid; DDI-effect
@DRUG$: @DRUG$ clearance may decrease when hyperthyroid patients on a stable theophylline regimen become euthyroid; DDI-false
@DRUG$: Theophylline clearance may decrease when hyperthyroid patients on a stable @DRUG$ regimen become euthyroid; DDI-false
Theophylline: @DRUG$ clearance may decrease when hyperthyroid patients on a stable @DRUG$ regimen become euthyroid; DDI-false
Other @DRUG$ should not be used concomitantly with @DRUG$ because they may have additive effects. DDI-false
Some @DRUG$ may interact with @DRUG$. DDI-advise
Those @DRUG$ include @DRUG$, valproic acid, and phenobarbital. DDI-int
Those @DRUG$ include divalproex sodium, @DRUG$, and phenobarbital. DDI-false
Those @DRUG$ include divalproex sodium, valproic acid, and @DRUG$. DDI-false
Those anticonvulsants include @DRUG$, @DRUG$, and phenobarbital. DDI-false
Those anticonvulsants include @DRUG$, valproic acid, and @DRUG$. DDI-false
Those anticonvulsants include divalproex sodium, @DRUG$, and @DRUG$. DDI-false
@DRUG$ may also affect the effects of other drugs, which include some @DRUG$, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here. DDI-false
@DRUG$ may also affect the effects of other drugs, which include some steroid medications, @DRUG$, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here. DDI-int
@DRUG$ may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, @DRUG$, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here. DDI-effect
@DRUG$ may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, @DRUG$ and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here. DDI-int
@DRUG$ may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and @DRUG$ Please note that Mephenytoin may interact with other drugs that are not listed here. DDI-int
@DRUG$ may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that @DRUG$ may interact with other drugs that are not listed here. DDI-false
Mephenytoin may also affect the effects of other drugs, which include some @DRUG$, @DRUG$, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here. DDI-false
Mephenytoin may also affect the effects of other drugs, which include some @DRUG$, warfarin, certain heart medicines, birth control pills, @DRUG$, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here. DDI-false
Mephenytoin may also affect the effects of other drugs, which include some @DRUG$, warfarin, certain heart medicines, birth control pills, anti-infective medicines, @DRUG$ and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here. DDI-false
Mephenytoin may also affect the effects of other drugs, which include some @DRUG$, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and @DRUG$ Please note that Mephenytoin may interact with other drugs that are not listed here. DDI-false
Mephenytoin may also affect the effects of other drugs, which include some @DRUG$, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that @DRUG$ may interact with other drugs that are not listed here. DDI-false
Mephenytoin may also affect the effects of other drugs, which include some steroid medications, @DRUG$, certain heart medicines, birth control pills, @DRUG$, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here. DDI-false
Mephenytoin may also affect the effects of other drugs, which include some steroid medications, @DRUG$, certain heart medicines, birth control pills, anti-infective medicines, @DRUG$ and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here. DDI-false
Mephenytoin may also affect the effects of other drugs, which include some steroid medications, @DRUG$, certain heart medicines, birth control pills, anti-infective medicines, furosemide and @DRUG$ Please note that Mephenytoin may interact with other drugs that are not listed here. DDI-false
Mephenytoin may also affect the effects of other drugs, which include some steroid medications, @DRUG$, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that @DRUG$ may interact with other drugs that are not listed here. DDI-false
Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, @DRUG$, @DRUG$ and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here. DDI-false
Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, @DRUG$, furosemide and @DRUG$ Please note that Mephenytoin may interact with other drugs that are not listed here. DDI-false
Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, @DRUG$, furosemide and theophylline Please note that @DRUG$ may interact with other drugs that are not listed here. DDI-false
Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, @DRUG$ and @DRUG$ Please note that Mephenytoin may interact with other drugs that are not listed here. DDI-false
Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, @DRUG$ and theophylline Please note that @DRUG$ may interact with other drugs that are not listed here. DDI-false
Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and @DRUG$ Please note that @DRUG$ may interact with other drugs that are not listed here. DDI-false
Use with Other @DRUG$: The depressant effects of @DRUG$ are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. DDI-false
Use with Other @DRUG$: The depressant effects of morphine are potentiated by the presence of other @DRUG$ such as alcohol, sedatives, antihistaminics, or psychotropic drugs. DDI-false
Use with Other @DRUG$: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as @DRUG$, sedatives, antihistaminics, or psychotropic drugs. DDI-false
Use with Other @DRUG$: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, @DRUG$, antihistaminics, or psychotropic drugs. DDI-false
Use with Other @DRUG$: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, @DRUG$, or psychotropic drugs. DDI-false
Use with Other @DRUG$: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or @DRUG$. DDI-false
Use with Other Central Nervous System Depressants: The depressant effects of @DRUG$ are potentiated by the presence of other @DRUG$ such as alcohol, sedatives, antihistaminics, or psychotropic drugs. DDI-false
Use with Other Central Nervous System Depressants: The depressant effects of @DRUG$ are potentiated by the presence of other CNS depressants such as @DRUG$, sedatives, antihistaminics, or psychotropic drugs. DDI-effect
Use with Other Central Nervous System Depressants: The depressant effects of @DRUG$ are potentiated by the presence of other CNS depressants such as alcohol, @DRUG$, antihistaminics, or psychotropic drugs. DDI-effect
Use with Other Central Nervous System Depressants: The depressant effects of @DRUG$ are potentiated by the presence of other CNS depressants such as alcohol, sedatives, @DRUG$, or psychotropic drugs. DDI-effect
Use with Other Central Nervous System Depressants: The depressant effects of @DRUG$ are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or @DRUG$. DDI-effect
Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other @DRUG$ such as @DRUG$, sedatives, antihistaminics, or psychotropic drugs. DDI-effect
Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other @DRUG$ such as alcohol, @DRUG$, antihistaminics, or psychotropic drugs. DDI-false
Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other @DRUG$ such as alcohol, sedatives, @DRUG$, or psychotropic drugs. DDI-false
Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other @DRUG$ such as alcohol, sedatives, antihistaminics, or @DRUG$. DDI-false
Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as @DRUG$, @DRUG$, antihistaminics, or psychotropic drugs. DDI-false
Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as @DRUG$, sedatives, @DRUG$, or psychotropic drugs. DDI-false
Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as @DRUG$, sedatives, antihistaminics, or @DRUG$. DDI-false
Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, @DRUG$, @DRUG$, or psychotropic drugs. DDI-false
Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, @DRUG$, antihistaminics, or @DRUG$. DDI-false
Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, @DRUG$, or @DRUG$. DDI-false
Use of @DRUG$ in conjunction with oral @DRUG$ may increase the risk of respiratory depression, hypotension and profound sedation or coma. DDI-false
Interaction with @DRUG$: @DRUG$ (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. DDI-effect
Interaction with @DRUG$: Agonist/antagonist analgesics (i.e., @DRUG$, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. DDI-false
Interaction with @DRUG$: Agonist/antagonist analgesics (i.e., pentazocine, @DRUG$, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. DDI-false
Interaction with @DRUG$: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, @DRUG$, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. DDI-false
Interaction with @DRUG$: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or @DRUG$) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. DDI-false
Interaction with @DRUG$: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof @DRUG$. DDI-false
Interaction with Mixed Agonist/Antagonist Opioid Analgesics: @DRUG$ (i.e., @DRUG$, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. DDI-false
Interaction with Mixed Agonist/Antagonist Opioid Analgesics: @DRUG$ (i.e., pentazocine, @DRUG$, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. DDI-false
Interaction with Mixed Agonist/Antagonist Opioid Analgesics: @DRUG$ (i.e., pentazocine, nalbuphine, @DRUG$, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. DDI-false
Interaction with Mixed Agonist/Antagonist Opioid Analgesics: @DRUG$ (i.e., pentazocine, nalbuphine, butorphanol, or @DRUG$) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. DDI-false
Interaction with Mixed Agonist/Antagonist Opioid Analgesics: @DRUG$ (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof @DRUG$. DDI-false
Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., @DRUG$, @DRUG$, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. DDI-false
Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., @DRUG$, nalbuphine, @DRUG$, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. DDI-false
Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., @DRUG$, nalbuphine, butorphanol, or @DRUG$) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. DDI-false
Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., @DRUG$, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof @DRUG$. DDI-false
Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, @DRUG$, @DRUG$, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. DDI-false
Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, @DRUG$, butorphanol, or @DRUG$) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. DDI-false
Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, @DRUG$, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof @DRUG$. DDI-false
Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, @DRUG$, or @DRUG$) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. DDI-false
Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, @DRUG$, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof @DRUG$. DDI-false
Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or @DRUG$) should NOT be administered to patients who have received or are receiving a course of therapy with a proof @DRUG$. DDI-false
@DRUG$ may decrease the hypotensive effect of @DRUG$. DDI-advise
Human pharmacologic studies have shown that @DRUG$ may inhibit the metabolism of @DRUG$, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). DDI-effect
Human pharmacologic studies have shown that @DRUG$ may inhibit the metabolism of coumarin anticoagulants, @DRUG$ (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). DDI-mechanism
Human pharmacologic studies have shown that @DRUG$ may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (@DRUG$, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). DDI-mechanism
Human pharmacologic studies have shown that @DRUG$ may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, @DRUG$, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). DDI-mechanism
Human pharmacologic studies have shown that @DRUG$ may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, @DRUG$), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). DDI-mechanism
Human pharmacologic studies have shown that @DRUG$ may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), @DRUG$, and tricyclic drugs (imipramine, clomipramine, desipramine). DDI-mechanism
Human pharmacologic studies have shown that @DRUG$ may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and @DRUG$ (imipramine, clomipramine, desipramine). DDI-mechanism
Human pharmacologic studies have shown that @DRUG$ may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (@DRUG$, clomipramine, desipramine). DDI-mechanism
Human pharmacologic studies have shown that @DRUG$ may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, @DRUG$, desipramine). DDI-mechanism
Human pharmacologic studies have shown that @DRUG$ may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, @DRUG$). DDI-mechanism
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of @DRUG$, @DRUG$ (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). DDI-mechanism
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of @DRUG$, anticonvulsants (@DRUG$, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). DDI-false
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of @DRUG$, anticonvulsants (phenobarbital, @DRUG$, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). DDI-false
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of @DRUG$, anticonvulsants (phenobarbital, diphenylhydantoin, @DRUG$), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). DDI-false
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of @DRUG$, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), @DRUG$, and tricyclic drugs (imipramine, clomipramine, desipramine). DDI-false
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of @DRUG$, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and @DRUG$ (imipramine, clomipramine, desipramine). DDI-false
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of @DRUG$, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (@DRUG$, clomipramine, desipramine). DDI-false
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of @DRUG$, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, @DRUG$, desipramine). DDI-false
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of @DRUG$, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, @DRUG$). DDI-false
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, @DRUG$ (@DRUG$, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). DDI-false
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, @DRUG$ (phenobarbital, @DRUG$, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). DDI-false
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, @DRUG$ (phenobarbital, diphenylhydantoin, @DRUG$), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). DDI-false
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, @DRUG$ (phenobarbital, diphenylhydantoin, primidone), @DRUG$, and tricyclic drugs (imipramine, clomipramine, desipramine). DDI-false
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, @DRUG$ (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and @DRUG$ (imipramine, clomipramine, desipramine). DDI-false
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, @DRUG$ (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (@DRUG$, clomipramine, desipramine). DDI-false
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, @DRUG$ (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, @DRUG$, desipramine). DDI-false
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, @DRUG$ (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, @DRUG$). DDI-false
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (@DRUG$, @DRUG$, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). DDI-false
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (@DRUG$, diphenylhydantoin, @DRUG$), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). DDI-false
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (@DRUG$, diphenylhydantoin, primidone), @DRUG$, and tricyclic drugs (imipramine, clomipramine, desipramine). DDI-false
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (@DRUG$, diphenylhydantoin, primidone), phenylbutazone, and @DRUG$ (imipramine, clomipramine, desipramine). DDI-false
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (@DRUG$, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (@DRUG$, clomipramine, desipramine). DDI-false
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (@DRUG$, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, @DRUG$, desipramine). DDI-false
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (@DRUG$, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, @DRUG$). DDI-false
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, @DRUG$, @DRUG$), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). DDI-false
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, @DRUG$, primidone), @DRUG$, and tricyclic drugs (imipramine, clomipramine, desipramine). DDI-false
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, @DRUG$, primidone), phenylbutazone, and @DRUG$ (imipramine, clomipramine, desipramine). DDI-false
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, @DRUG$, primidone), phenylbutazone, and tricyclic drugs (@DRUG$, clomipramine, desipramine). DDI-false
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, @DRUG$, primidone), phenylbutazone, and tricyclic drugs (imipramine, @DRUG$, desipramine). DDI-false
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, @DRUG$, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, @DRUG$). DDI-false
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, @DRUG$), @DRUG$, and tricyclic drugs (imipramine, clomipramine, desipramine). DDI-false
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, @DRUG$), phenylbutazone, and @DRUG$ (imipramine, clomipramine, desipramine). DDI-false
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, @DRUG$), phenylbutazone, and tricyclic drugs (@DRUG$, clomipramine, desipramine). DDI-false
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, @DRUG$), phenylbutazone, and tricyclic drugs (imipramine, @DRUG$, desipramine). DDI-false
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, @DRUG$), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, @DRUG$). DDI-false
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), @DRUG$, and @DRUG$ (imipramine, clomipramine, desipramine). DDI-false
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), @DRUG$, and tricyclic drugs (@DRUG$, clomipramine, desipramine). DDI-false
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), @DRUG$, and tricyclic drugs (imipramine, @DRUG$, desipramine). DDI-false
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), @DRUG$, and tricyclic drugs (imipramine, clomipramine, @DRUG$). DDI-false
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and @DRUG$ (@DRUG$, clomipramine, desipramine). DDI-false
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and @DRUG$ (imipramine, @DRUG$, desipramine). DDI-false
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and @DRUG$ (imipramine, clomipramine, @DRUG$). DDI-false
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (@DRUG$, @DRUG$, desipramine). DDI-false
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (@DRUG$, clomipramine, @DRUG$). DDI-false
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, @DRUG$, @DRUG$). DDI-false
The safety of using @DRUG$ in combination with @DRUG$ or other centrally acting alpha-2 agonists has not been systemically evaluated. DDI-false
The safety of using @DRUG$ in combination with clonidine or other centrally acting @DRUG$ has not been systemically evaluated. DDI-false
The safety of using methylphenidate in combination with @DRUG$ or other centrally acting @DRUG$ has not been systemically evaluated. DDI-false
Co-administration of @DRUG$ with strong inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. DDI-false
Co-administration of @DRUG$ with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. DDI-mechanism
Co-administration of @DRUG$ with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, @DRUG$, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. DDI-mechanism
Co-administration of @DRUG$ with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, @DRUG$, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. DDI-mechanism
Co-administration of @DRUG$ with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, @DRUG$, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. DDI-mechanism
Co-administration of @DRUG$ with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, @DRUG$, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. DDI-mechanism
Co-administration of @DRUG$ with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, @DRUG$, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. DDI-mechanism
Co-administration of @DRUG$ with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, @DRUG$, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. DDI-mechanism
Co-administration of @DRUG$ with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, @DRUG$, telithromycin, voriconizole) may increases sunitinib concentrations. DDI-mechanism
Co-administration of @DRUG$ with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, @DRUG$, voriconizole) may increases sunitinib concentrations. DDI-mechanism
Co-administration of @DRUG$ with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, @DRUG$) may increases sunitinib concentrations. DDI-mechanism
Co-administration of @DRUG$ with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases @DRUG$ concentrations. DDI-mechanism
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., @DRUG$, @DRUG$, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. DDI-mechanism
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, @DRUG$, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, clarithromycin, @DRUG$, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, clarithromycin, atazanavir, @DRUG$, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, clarithromycin, atazanavir, indinavir, @DRUG$, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, @DRUG$, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, @DRUG$, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, @DRUG$, telithromycin, voriconizole) may increases sunitinib concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, @DRUG$, voriconizole) may increases sunitinib concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, @DRUG$) may increases sunitinib concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases @DRUG$ concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, @DRUG$, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, clarithromycin, @DRUG$, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, clarithromycin, atazanavir, @DRUG$, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, clarithromycin, atazanavir, indinavir, @DRUG$, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, clarithromycin, atazanavir, indinavir, nefazodone, @DRUG$, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, @DRUG$, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, @DRUG$, telithromycin, voriconizole) may increases sunitinib concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, @DRUG$, voriconizole) may increases sunitinib concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, @DRUG$) may increases sunitinib concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases @DRUG$ concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, @DRUG$, @DRUG$, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, @DRUG$, atazanavir, @DRUG$, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, @DRUG$, atazanavir, indinavir, @DRUG$, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, @DRUG$, atazanavir, indinavir, nefazodone, @DRUG$, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, @DRUG$, atazanavir, indinavir, nefazodone, nelfinavir, @DRUG$, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, @DRUG$, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, @DRUG$, telithromycin, voriconizole) may increases sunitinib concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, @DRUG$, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, @DRUG$, voriconizole) may increases sunitinib concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, @DRUG$, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, @DRUG$) may increases sunitinib concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, @DRUG$, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases @DRUG$ concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, @DRUG$, @DRUG$, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, @DRUG$, indinavir, @DRUG$, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, @DRUG$, indinavir, nefazodone, @DRUG$, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, @DRUG$, indinavir, nefazodone, nelfinavir, @DRUG$, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, @DRUG$, indinavir, nefazodone, nelfinavir, ritonavir, @DRUG$, telithromycin, voriconizole) may increases sunitinib concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, @DRUG$, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, @DRUG$, voriconizole) may increases sunitinib concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, @DRUG$, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, @DRUG$) may increases sunitinib concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, @DRUG$, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases @DRUG$ concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, @DRUG$, @DRUG$, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, @DRUG$, nefazodone, @DRUG$, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, @DRUG$, nefazodone, nelfinavir, @DRUG$, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, @DRUG$, nefazodone, nelfinavir, ritonavir, @DRUG$, telithromycin, voriconizole) may increases sunitinib concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, @DRUG$, nefazodone, nelfinavir, ritonavir, saquinavir, @DRUG$, voriconizole) may increases sunitinib concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, @DRUG$, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, @DRUG$) may increases sunitinib concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, @DRUG$, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases @DRUG$ concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, @DRUG$, @DRUG$, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, @DRUG$, nelfinavir, @DRUG$, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, @DRUG$, nelfinavir, ritonavir, @DRUG$, telithromycin, voriconizole) may increases sunitinib concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, @DRUG$, nelfinavir, ritonavir, saquinavir, @DRUG$, voriconizole) may increases sunitinib concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, @DRUG$, nelfinavir, ritonavir, saquinavir, telithromycin, @DRUG$) may increases sunitinib concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, @DRUG$, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases @DRUG$ concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, @DRUG$, @DRUG$, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, @DRUG$, ritonavir, @DRUG$, telithromycin, voriconizole) may increases sunitinib concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, @DRUG$, ritonavir, saquinavir, @DRUG$, voriconizole) may increases sunitinib concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, @DRUG$, ritonavir, saquinavir, telithromycin, @DRUG$) may increases sunitinib concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, @DRUG$, ritonavir, saquinavir, telithromycin, voriconizole) may increases @DRUG$ concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, @DRUG$, @DRUG$, telithromycin, voriconizole) may increases sunitinib concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, @DRUG$, saquinavir, @DRUG$, voriconizole) may increases sunitinib concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, @DRUG$, saquinavir, telithromycin, @DRUG$) may increases sunitinib concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, @DRUG$, saquinavir, telithromycin, voriconizole) may increases @DRUG$ concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, @DRUG$, @DRUG$, voriconizole) may increases sunitinib concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, @DRUG$, telithromycin, @DRUG$) may increases sunitinib concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, @DRUG$, telithromycin, voriconizole) may increases @DRUG$ concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, @DRUG$, @DRUG$) may increases sunitinib concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, @DRUG$, voriconizole) may increases @DRUG$ concentrations. DDI-false
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, @DRUG$) may increases @DRUG$ concentrations. DDI-false
Co-administration of @DRUG$ with inducers of the CYP3A4 family (e.g., @DRUG$, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. DDI-false
Co-administration of @DRUG$ with inducers of the CYP3A4 family (e.g., dexamethasone, @DRUG$, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. DDI-mechanism
Co-administration of @DRUG$ with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, @DRUG$, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. DDI-mechanism
Co-administration of @DRUG$ with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, @DRUG$, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. DDI-mechanism
Co-administration of @DRUG$ with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, @DRUG$, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. DDI-mechanism
Co-administration of @DRUG$ with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, @DRUG$, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. DDI-mechanism
Co-administration of @DRUG$ with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, @DRUG$, St. Johns Wort) may decrease sunitinib concentrations. DDI-mechanism
Co-administration of @DRUG$ with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease @DRUG$ concentrations. DDI-mechanism
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., @DRUG$, @DRUG$, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. DDI-false
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., @DRUG$, phenytoin, @DRUG$, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. DDI-false
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., @DRUG$, phenytoin, carbamazepine, @DRUG$, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. DDI-false
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., @DRUG$, phenytoin, carbamazepine, rifampin, @DRUG$, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. DDI-false
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., @DRUG$, phenytoin, carbamazepine, rifampin, rifabutin, @DRUG$, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. DDI-false
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., @DRUG$, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, @DRUG$, St. Johns Wort) may decrease sunitinib concentrations. DDI-false
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., @DRUG$, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease @DRUG$ concentrations. DDI-false
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, @DRUG$, @DRUG$, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. DDI-false
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, @DRUG$, carbamazepine, @DRUG$, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. DDI-false
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, @DRUG$, carbamazepine, rifampin, @DRUG$, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. DDI-false
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, @DRUG$, carbamazepine, rifampin, rifabutin, @DRUG$, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. DDI-false
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, @DRUG$, carbamazepine, rifampin, rifabutin, rifapentin, @DRUG$, St. Johns Wort) may decrease sunitinib concentrations. DDI-false
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, @DRUG$, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease @DRUG$ concentrations. DDI-false
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, @DRUG$, @DRUG$, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. DDI-false
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, @DRUG$, rifampin, @DRUG$, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. DDI-false
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, @DRUG$, rifampin, rifabutin, @DRUG$, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. DDI-false
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, @DRUG$, rifampin, rifabutin, rifapentin, @DRUG$, St. Johns Wort) may decrease sunitinib concentrations. DDI-false
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, @DRUG$, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease @DRUG$ concentrations. DDI-false
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, @DRUG$, @DRUG$, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. DDI-false
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, @DRUG$, rifabutin, @DRUG$, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. DDI-false
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, @DRUG$, rifabutin, rifapentin, @DRUG$, St. Johns Wort) may decrease sunitinib concentrations. DDI-false
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, @DRUG$, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease @DRUG$ concentrations. DDI-false
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, @DRUG$, @DRUG$, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. DDI-false
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, @DRUG$, rifapentin, @DRUG$, St. Johns Wort) may decrease sunitinib concentrations. DDI-false
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, @DRUG$, rifapentin, phenobarbital, St. Johns Wort) may decrease @DRUG$ concentrations. DDI-false
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, @DRUG$, @DRUG$, St. Johns Wort) may decrease sunitinib concentrations. DDI-false
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, @DRUG$, phenobarbital, St. Johns Wort) may decrease @DRUG$ concentrations. DDI-false
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, @DRUG$, St. Johns Wort) may decrease @DRUG$ concentrations. DDI-false
@DRUG$: Excessive reductions in blood pressure may occur in patients on diuretic therapy when @DRUG$ are started. DDI-false
The possibility of hypotensive effects with @DRUG$    can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with @DRUG$   . If this is not possible, the starting dose of moexpril should be reduced.. DDI-false
The possibility of hypotensive effects with @DRUG$    can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with UNIVASC   . If this is not possible, the starting dose of @DRUG$ should be reduced.. DDI-false
The possibility of hypotensive effects with UNIVASC    can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with @DRUG$   . If this is not possible, the starting dose of @DRUG$ should be reduced.. DDI-false
@DRUG$    has been used in clinical trials concomitantly with @DRUG$, diuretics, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. DDI-false
@DRUG$    has been used in clinical trials concomitantly with calcium-channel-blocking agents, @DRUG$, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. DDI-false
@DRUG$    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, @DRUG$, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. DDI-false
@DRUG$    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, @DRUG$, oral hypoglycemic agents, and cholesterol-lowering agents. DDI-false
@DRUG$    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, digoxin, oral @DRUG$, and cholesterol-lowering agents. DDI-false
UNIVASC    has been used in clinical trials concomitantly with @DRUG$, @DRUG$, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. DDI-false
UNIVASC    has been used in clinical trials concomitantly with @DRUG$, diuretics, @DRUG$, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. DDI-false
UNIVASC    has been used in clinical trials concomitantly with @DRUG$, diuretics, H2 blockers, @DRUG$, oral hypoglycemic agents, and cholesterol-lowering agents. DDI-false
UNIVASC    has been used in clinical trials concomitantly with @DRUG$, diuretics, H2 blockers, digoxin, oral @DRUG$, and cholesterol-lowering agents. DDI-false
UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, @DRUG$, @DRUG$, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. DDI-false
UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, @DRUG$, H2 blockers, @DRUG$, oral hypoglycemic agents, and cholesterol-lowering agents. DDI-false
UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, @DRUG$, H2 blockers, digoxin, oral @DRUG$, and cholesterol-lowering agents. DDI-false
UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, @DRUG$, @DRUG$, oral hypoglycemic agents, and cholesterol-lowering agents. DDI-false
UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, @DRUG$, digoxin, oral @DRUG$, and cholesterol-lowering agents. DDI-false
UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, @DRUG$, oral @DRUG$, and cholesterol-lowering agents. DDI-false
@DRUG$ Supplements and @DRUG$: UNIVASC    can increase serum potassium because it decreases aldosterone secretion. DDI-false
@DRUG$ Supplements and Potassium-Sparing Diuretics: @DRUG$    can increase serum potassium because it decreases aldosterone secretion. DDI-false
Potassium Supplements and @DRUG$: @DRUG$    can increase serum potassium because it decreases aldosterone secretion. DDI-false
Use of @DRUG$ (@DRUG$, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. DDI-false
Use of @DRUG$ (spironolactone, @DRUG$, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. DDI-false
Use of @DRUG$ (spironolactone, triamterene, @DRUG$) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. DDI-false
Use of @DRUG$ (spironolactone, triamterene, amiloride) or @DRUG$ supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. DDI-false
Use of @DRUG$ (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with @DRUG$ can increase the risk of hyperkalemia. DDI-false
Use of potassium-sparing diuretics (@DRUG$, @DRUG$, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. DDI-effect
Use of potassium-sparing diuretics (@DRUG$, triamterene, @DRUG$) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. DDI-false
Use of potassium-sparing diuretics (@DRUG$, triamterene, amiloride) or @DRUG$ supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. DDI-false
Use of potassium-sparing diuretics (@DRUG$, triamterene, amiloride) or potassium supplements concomitantly with @DRUG$ can increase the risk of hyperkalemia. DDI-false
Use of potassium-sparing diuretics (spironolactone, @DRUG$, @DRUG$) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. DDI-effect
Use of potassium-sparing diuretics (spironolactone, @DRUG$, amiloride) or @DRUG$ supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. DDI-false
Use of potassium-sparing diuretics (spironolactone, @DRUG$, amiloride) or potassium supplements concomitantly with @DRUG$ can increase the risk of hyperkalemia. DDI-false
Use of potassium-sparing diuretics (spironolactone, triamterene, @DRUG$) or @DRUG$ supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. DDI-effect
Use of potassium-sparing diuretics (spironolactone, triamterene, @DRUG$) or potassium supplements concomitantly with @DRUG$ can increase the risk of hyperkalemia. DDI-false
Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or @DRUG$ supplements concomitantly with @DRUG$ can increase the risk of hyperkalemia. DDI-effect
Oral @DRUG$: Interaction studies with @DRUG$ failed to identify any clinically important effect on the serum concentrations of the anticoagulant or on its anticoagulant effect. DDI-effect
Oral @DRUG$: Interaction studies with warfarin failed to identify any clinically important effect on the serum concentrations of the @DRUG$ or on its anticoagulant effect. DDI-false
Oral Anticoagulants: Interaction studies with @DRUG$ failed to identify any clinically important effect on the serum concentrations of the @DRUG$ or on its anticoagulant effect. DDI-false
@DRUG$: Increased serum @DRUG$ levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. DDI-false
@DRUG$: Increased serum lithium levels and symptoms of @DRUG$ toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. DDI-false
@DRUG$: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving @DRUG$ during therapy with lithium. DDI-false
@DRUG$: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with @DRUG$. DDI-false
Lithium: Increased serum @DRUG$ levels and symptoms of @DRUG$ toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. DDI-false
Lithium: Increased serum @DRUG$ levels and symptoms of lithium toxicity have been reported in patients receiving @DRUG$ during therapy with lithium. DDI-false
Lithium: Increased serum @DRUG$ levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with @DRUG$. DDI-false
Lithium: Increased serum lithium levels and symptoms of @DRUG$ toxicity have been reported in patients receiving @DRUG$ during therapy with lithium. DDI-false
Lithium: Increased serum lithium levels and symptoms of @DRUG$ toxicity have been reported in patients receiving ACE inhibitors during therapy with @DRUG$. DDI-false
Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving @DRUG$ during therapy with @DRUG$. DDI-false
If a @DRUG$ is also used, the risk of @DRUG$ toxicity may be increased. DDI-mechanism
Other Agents: No clinically important pharmacokinetic interactions occurred when @DRUG$    was administered concomitantly with @DRUG$, digoxin, or cimetidine. DDI-effect
Other Agents: No clinically important pharmacokinetic interactions occurred when @DRUG$    was administered concomitantly with hydrochlorothiazide, @DRUG$, or cimetidine. DDI-false
Other Agents: No clinically important pharmacokinetic interactions occurred when @DRUG$    was administered concomitantly with hydrochlorothiazide, digoxin, or @DRUG$. DDI-false
Other Agents: No clinically important pharmacokinetic interactions occurred when UNIVASC    was administered concomitantly with @DRUG$, @DRUG$, or cimetidine. DDI-false
Other Agents: No clinically important pharmacokinetic interactions occurred when UNIVASC    was administered concomitantly with @DRUG$, digoxin, or @DRUG$. DDI-false
Other Agents: No clinically important pharmacokinetic interactions occurred when UNIVASC    was administered concomitantly with hydrochlorothiazide, @DRUG$, or @DRUG$. DDI-false
Concomitant administration of substances that are also tubularly secreted (e.g., @DRUG$) could potentially result in delayed clearance of @DRUG$. DDI-false
Although @DRUG$ (400 mg qid) can be administered with @DRUG$ in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering ibuprofen concurrently with ALIMTA to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min). DDI-mechanism
Although @DRUG$ (400 mg qid) can be administered with ALIMTA in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering @DRUG$ concurrently with ALIMTA to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min). DDI-advise
Although @DRUG$ (400 mg qid) can be administered with ALIMTA in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering ibuprofen concurrently with @DRUG$ to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min). DDI-false
Although ibuprofen (400 mg qid) can be administered with @DRUG$ in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering @DRUG$ concurrently with ALIMTA to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min). DDI-false
Although ibuprofen (400 mg qid) can be administered with @DRUG$ in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering ibuprofen concurrently with @DRUG$ to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min). DDI-false
Although ibuprofen (400 mg qid) can be administered with ALIMTA in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering @DRUG$ concurrently with @DRUG$ to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min). DDI-false
Patients with mild to moderate renal insufficiency should avoid taking @DRUG$ with short elimination half-lives for a period of 2 days before, the day of, and 2 days following administration of @DRUG$. DDI-advise
In the absence of data regarding potential interaction between @DRUG$ and @DRUG$ with longer half-lives, all patients taking these NSAIDs should interrupt dosing for at least 5 days before, the day of, and 2 days following ALIMTA administration. DDI-false
In the absence of data regarding potential interaction between @DRUG$ and NSAIDs with longer half-lives, all patients taking these @DRUG$ should interrupt dosing for at least 5 days before, the day of, and 2 days following ALIMTA administration. DDI-false
In the absence of data regarding potential interaction between @DRUG$ and NSAIDs with longer half-lives, all patients taking these NSAIDs should interrupt dosing for at least 5 days before, the day of, and 2 days following @DRUG$ administration. DDI-false
In the absence of data regarding potential interaction between ALIMTA and @DRUG$ with longer half-lives, all patients taking these @DRUG$ should interrupt dosing for at least 5 days before, the day of, and 2 days following ALIMTA administration. DDI-false
In the absence of data regarding potential interaction between ALIMTA and @DRUG$ with longer half-lives, all patients taking these NSAIDs should interrupt dosing for at least 5 days before, the day of, and 2 days following @DRUG$ administration. DDI-false
In the absence of data regarding potential interaction between ALIMTA and NSAIDs with longer half-lives, all patients taking these @DRUG$ should interrupt dosing for at least 5 days before, the day of, and 2 days following @DRUG$ administration. DDI-false
Prothrombin time or other suitable anticoagulation test should be monitored if @DRUG$ is administered with @DRUG$. DDI-advise
Concurrent use of @DRUG$ with oral @DRUG$ may render oral contraceptives less effective. DDI-advise
Concurrent use of @DRUG$ with oral contraceptives may render oral @DRUG$ less effective. DDI-effect
Concurrent use of antibacterial drugs with oral @DRUG$ may render oral @DRUG$ less effective. DDI-false
@DRUG$ may interact with the following drugs: @DRUG$ and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
@DRUG$ may interact with the following drugs: aspirin and other @DRUG$ (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-int
@DRUG$ may interact with the following drugs: aspirin and other NSAIDs (may lower @DRUG$ levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-int
@DRUG$ may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), @DRUG$ (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
@DRUG$ may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral @DRUG$ is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-int
@DRUG$ may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), @DRUG$ (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
@DRUG$ may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease @DRUG$ levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-int
@DRUG$ may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), @DRUG$ (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
@DRUG$ may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), @DRUG$ (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-int
@DRUG$ may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of @DRUG$ with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-int
@DRUG$ may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with @DRUG$ can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-int
@DRUG$ may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), @DRUG$ and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
@DRUG$ may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and @DRUG$ (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-int
@DRUG$ may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of @DRUG$ and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-int
@DRUG$ may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and @DRUG$ may interfere with the efficacy of the corticosteroids). DDI-int
@DRUG$ may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the @DRUG$). DDI-int
Melatonin may interact with the following drugs: @DRUG$ and other @DRUG$ (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-int
Melatonin may interact with the following drugs: @DRUG$ and other NSAIDs (may lower @DRUG$ levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: @DRUG$ and other NSAIDs (may lower melatonin levels), @DRUG$ (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: @DRUG$ and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral @DRUG$ is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: @DRUG$ and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), @DRUG$ (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: @DRUG$ and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease @DRUG$ levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: @DRUG$ and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), @DRUG$ (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: @DRUG$ and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), @DRUG$ (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: @DRUG$ and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of @DRUG$ with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: @DRUG$ and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with @DRUG$ can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: @DRUG$ and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), @DRUG$ and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: @DRUG$ and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and @DRUG$ (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: @DRUG$ and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of @DRUG$ and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: @DRUG$ and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and @DRUG$ may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: @DRUG$ and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the @DRUG$). DDI-false
Melatonin may interact with the following drugs: aspirin and other @DRUG$ (may lower @DRUG$ levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other @DRUG$ (may lower melatonin levels), @DRUG$ (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other @DRUG$ (may lower melatonin levels), fluvoxamine (bioavailability of oral @DRUG$ is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other @DRUG$ (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), @DRUG$ (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other @DRUG$ (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease @DRUG$ levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other @DRUG$ (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), @DRUG$ (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other @DRUG$ (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), @DRUG$ (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other @DRUG$ (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of @DRUG$ with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other @DRUG$ (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with @DRUG$ can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other @DRUG$ (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), @DRUG$ and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other @DRUG$ (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and @DRUG$ (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other @DRUG$ (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of @DRUG$ and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other @DRUG$ (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and @DRUG$ may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other @DRUG$ (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the @DRUG$). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower @DRUG$ levels), @DRUG$ (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower @DRUG$ levels), fluvoxamine (bioavailability of oral @DRUG$ is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower @DRUG$ levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), @DRUG$ (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower @DRUG$ levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease @DRUG$ levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower @DRUG$ levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), @DRUG$ (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower @DRUG$ levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), @DRUG$ (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower @DRUG$ levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of @DRUG$ with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower @DRUG$ levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with @DRUG$ can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower @DRUG$ levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), @DRUG$ and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower @DRUG$ levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and @DRUG$ (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower @DRUG$ levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of @DRUG$ and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower @DRUG$ levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and @DRUG$ may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower @DRUG$ levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the @DRUG$). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), @DRUG$ (bioavailability of oral @DRUG$ is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), @DRUG$ (bioavailability of oral melatonin is increased with coadministration), @DRUG$ (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), @DRUG$ (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease @DRUG$ levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), @DRUG$ (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), @DRUG$ (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), @DRUG$ (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), @DRUG$ (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), @DRUG$ (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of @DRUG$ with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), @DRUG$ (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with @DRUG$ can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), @DRUG$ (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), @DRUG$ and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), @DRUG$ (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and @DRUG$ (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), @DRUG$ (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of @DRUG$ and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), @DRUG$ (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and @DRUG$ may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), @DRUG$ (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the @DRUG$). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral @DRUG$ is increased with coadministration), @DRUG$ (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral @DRUG$ is increased with coadministration), beta blockers (may decrease @DRUG$ levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral @DRUG$ is increased with coadministration), beta blockers (may decrease melatonin levels), @DRUG$ (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral @DRUG$ is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), @DRUG$ (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral @DRUG$ is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of @DRUG$ with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral @DRUG$ is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with @DRUG$ can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral @DRUG$ is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), @DRUG$ and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral @DRUG$ is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and @DRUG$ (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral @DRUG$ is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of @DRUG$ and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral @DRUG$ is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and @DRUG$ may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral @DRUG$ is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the @DRUG$). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), @DRUG$ (may decrease @DRUG$ levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), @DRUG$ (may decrease melatonin levels), @DRUG$ (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), @DRUG$ (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), @DRUG$ (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), @DRUG$ (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of @DRUG$ with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), @DRUG$ (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with @DRUG$ can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), @DRUG$ (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), @DRUG$ and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), @DRUG$ (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and @DRUG$ (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), @DRUG$ (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of @DRUG$ and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), @DRUG$ (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and @DRUG$ may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), @DRUG$ (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the @DRUG$). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease @DRUG$ levels), @DRUG$ (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease @DRUG$ levels), fluoxetine (reports of psychotic episodes when coadministered), @DRUG$ (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease @DRUG$ levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of @DRUG$ with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease @DRUG$ levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with @DRUG$ can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease @DRUG$ levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), @DRUG$ and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease @DRUG$ levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and @DRUG$ (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease @DRUG$ levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of @DRUG$ and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease @DRUG$ levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and @DRUG$ may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease @DRUG$ levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the @DRUG$). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), @DRUG$ (reports of psychotic episodes when coadministered), @DRUG$ (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), @DRUG$ (reports of psychotic episodes when coadministered), progestin (coadministration of @DRUG$ with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), @DRUG$ (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with @DRUG$ can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), @DRUG$ (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), @DRUG$ and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), @DRUG$ (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and @DRUG$ (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), @DRUG$ (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of @DRUG$ and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), @DRUG$ (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and @DRUG$ may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), @DRUG$ (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the @DRUG$). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), @DRUG$ (coadministration of @DRUG$ with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), @DRUG$ (coadministration of melatonin with @DRUG$ can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), @DRUG$ (coadministration of melatonin with progestin can inhibit ovarian function in women), @DRUG$ and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), @DRUG$ (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and @DRUG$ (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), @DRUG$ (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of @DRUG$ and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), @DRUG$ (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and @DRUG$ may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), @DRUG$ (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the @DRUG$). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of @DRUG$ with @DRUG$ can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of @DRUG$ with progestin can inhibit ovarian function in women), @DRUG$ and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-effect
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of @DRUG$ with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and @DRUG$ (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of @DRUG$ with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of @DRUG$ and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of @DRUG$ with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and @DRUG$ may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of @DRUG$ with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the @DRUG$). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with @DRUG$ can inhibit ovarian function in women), @DRUG$ and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with @DRUG$ can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and @DRUG$ (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with @DRUG$ can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of @DRUG$ and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with @DRUG$ can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and @DRUG$ may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with @DRUG$ can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the @DRUG$). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), @DRUG$ and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and @DRUG$ (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), @DRUG$ and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of @DRUG$ and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), @DRUG$ and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and @DRUG$ may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), @DRUG$ and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the @DRUG$). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and @DRUG$ (coadministration of @DRUG$ and corticosteroids may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and @DRUG$ (coadministration of melatonin and @DRUG$ may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and @DRUG$ (coadministration of melatonin and corticosteroids may interfere with the efficacy of the @DRUG$). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of @DRUG$ and @DRUG$ may interfere with the efficacy of the corticosteroids). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of @DRUG$ and corticosteroids may interfere with the efficacy of the @DRUG$). DDI-false
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and @DRUG$ may interfere with the efficacy of the @DRUG$). DDI-false
In vitro studies with human liver microsomes showed that @DRUG$ does not inhibit the metabolism of @DRUG$, ethinylestradiol, ethoxycoumarin, and cyclosporine. DDI-false
In vitro studies with human liver microsomes showed that @DRUG$ does not inhibit the metabolism of tolbutamide, @DRUG$, ethoxycoumarin, and cyclosporine. DDI-false
In vitro studies with human liver microsomes showed that @DRUG$ does not inhibit the metabolism of tolbutamide, ethinylestradiol, @DRUG$, and cyclosporine. DDI-false
In vitro studies with human liver microsomes showed that @DRUG$ does not inhibit the metabolism of tolbutamide, ethinylestradiol, ethoxycoumarin, and @DRUG$. DDI-false
In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of @DRUG$, @DRUG$, ethoxycoumarin, and cyclosporine. DDI-false
In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of @DRUG$, ethinylestradiol, @DRUG$, and cyclosporine. DDI-false
In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of @DRUG$, ethinylestradiol, ethoxycoumarin, and @DRUG$. DDI-false
In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, @DRUG$, @DRUG$, and cyclosporine. DDI-false
In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, @DRUG$, ethoxycoumarin, and @DRUG$. DDI-false
In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, ethinylestradiol, @DRUG$, and @DRUG$. DDI-false
This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as @DRUG$,    -blockers, @DRUG$ (SSRIs), and monoamine oxidase inhibitors (MAO-Is) Type B, if they have a narrow therapeutic window. DDI-false
This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as @DRUG$,    -blockers, selective serotonin reuptake inhibitors (@DRUG$), and monoamine oxidase inhibitors (MAO-Is) Type B, if they have a narrow therapeutic window. DDI-false
This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as @DRUG$,    -blockers, selective serotonin reuptake inhibitors (SSRIs), and @DRUG$, if they have a narrow therapeutic window. DDI-false
This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as tricyclic antidepressants,    -blockers, @DRUG$ (@DRUG$), and monoamine oxidase inhibitors (MAO-Is) Type B, if they have a narrow therapeutic window. DDI-false
This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as tricyclic antidepressants,    -blockers, @DRUG$ (SSRIs), and @DRUG$, if they have a narrow therapeutic window. DDI-false
This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as tricyclic antidepressants,    -blockers, selective serotonin reuptake inhibitors (@DRUG$), and @DRUG$, if they have a narrow therapeutic window. DDI-false
In vivo drug-drug interaction studies conducted in normal volunteer subjects showed that @DRUG$ does not affect the clearance of @DRUG$ or digoxin. DDI-false
In vivo drug-drug interaction studies conducted in normal volunteer subjects showed that @DRUG$ does not affect the clearance of antipyrine or @DRUG$. DDI-false
In vivo drug-drug interaction studies conducted in normal volunteer subjects showed that terbinafine does not affect the clearance of @DRUG$ or @DRUG$. DDI-false
@DRUG$ decreases the clearance of @DRUG$ by 19%. DDI-false
@DRUG$ increases the clearance of @DRUG$ by 15%. DDI-mechanism
There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral @DRUG$ and @DRUG$, however, a causal relationship between LAMISIL    Tablets and these changes has not been established. DDI-mechanism
There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral @DRUG$ and warfarin, however, a causal relationship between @DRUG$    Tablets and these changes has not been established. DDI-effect
There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral terbinafine and @DRUG$, however, a causal relationship between @DRUG$    Tablets and these changes has not been established. DDI-false
@DRUG$ clearance is increased 100% by @DRUG$, a CyP450 enzyme inducer, and decreased 33% by cimetidine, a CyP450 enzyme inhibitor. DDI-false
@DRUG$ clearance is increased 100% by rifampin, a CyP450 enzyme inducer, and decreased 33% by @DRUG$, a CyP450 enzyme inhibitor. DDI-mechanism
Terbinafine clearance is increased 100% by @DRUG$, a CyP450 enzyme inducer, and decreased 33% by @DRUG$, a CyP450 enzyme inhibitor. DDI-mechanism
@DRUG$ clearance is unaffected by @DRUG$. DDI-false
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral @DRUG$, hormone replacement therapies, @DRUG$, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers. DDI-false
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral @DRUG$, hormone replacement therapies, hypoglycemics, @DRUG$, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers. DDI-false
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral @DRUG$, hormone replacement therapies, hypoglycemics, theophyllines, @DRUG$, thiazide diuretics, beta blockers, and calcium channel blockers. DDI-false
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral @DRUG$, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, @DRUG$, beta blockers, and calcium channel blockers. DDI-false
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral @DRUG$, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, @DRUG$, and calcium channel blockers. DDI-false
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral @DRUG$, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and @DRUG$. DDI-false
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, @DRUG$, @DRUG$, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers. DDI-false
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, @DRUG$, theophyllines, @DRUG$, thiazide diuretics, beta blockers, and calcium channel blockers. DDI-false
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, @DRUG$, theophyllines, phenytoins, @DRUG$, beta blockers, and calcium channel blockers. DDI-false
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, @DRUG$, theophyllines, phenytoins, thiazide diuretics, @DRUG$, and calcium channel blockers. DDI-false
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, @DRUG$, theophyllines, phenytoins, thiazide diuretics, beta blockers, and @DRUG$. DDI-false
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, @DRUG$, @DRUG$, thiazide diuretics, beta blockers, and calcium channel blockers. DDI-false
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, @DRUG$, phenytoins, @DRUG$, beta blockers, and calcium channel blockers. DDI-false
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, @DRUG$, phenytoins, thiazide diuretics, @DRUG$, and calcium channel blockers. DDI-false
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, @DRUG$, phenytoins, thiazide diuretics, beta blockers, and @DRUG$. DDI-false
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, @DRUG$, @DRUG$, beta blockers, and calcium channel blockers. DDI-false
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, @DRUG$, thiazide diuretics, @DRUG$, and calcium channel blockers. DDI-false
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, @DRUG$, thiazide diuretics, beta blockers, and @DRUG$. DDI-false
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, @DRUG$, @DRUG$, and calcium channel blockers. DDI-false
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, @DRUG$, beta blockers, and @DRUG$. DDI-false
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, @DRUG$, and @DRUG$. DDI-false
@DRUG$ has been reported to prolong the elimination half-life of @DRUG$ and may lead to severe bone marrow suppression; DDI-false
a reduction of the @DRUG$ dosage should be considered in patients receiving @DRUG$ concurrently. DDI-mechanism
The concurrent use of @DRUG$ and @DRUG$ has been reported in one case to result in reduced streptozocin cytotoxicity. DDI-advise
The concurrent use of @DRUG$ and phenytoin has been reported in one case to result in reduced @DRUG$ cytotoxicity. DDI-effect
The concurrent use of streptozocin and @DRUG$ has been reported in one case to result in reduced @DRUG$ cytotoxicity. DDI-false
@DRUG$: @DRUG$ causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with EVISTA. DDI-false
@DRUG$: Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of @DRUG$ and should not be coadministered with EVISTA. DDI-false
@DRUG$: Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with @DRUG$. DDI-false
Cholestyramine: @DRUG$ causes a 60% reduction in the absorption and enterohepatic cycling of @DRUG$ and should not be coadministered with EVISTA. DDI-false
Cholestyramine: @DRUG$ causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with @DRUG$. DDI-mechanism
Cholestyramine: Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of @DRUG$ and should not be coadministered with @DRUG$. DDI-advise
@DRUG$: The coadministration of @DRUG$ and warfarin has not been assessed under chronic conditions. DDI-false
@DRUG$: The coadministration of EVISTA and @DRUG$ has not been assessed under chronic conditions. DDI-false
Warfarin: The coadministration of @DRUG$ and @DRUG$ has not been assessed under chronic conditions. DDI-false
If @DRUG$ is given concurrently with @DRUG$, prothrombin time should be monitored. DDI-false
In vitro, @DRUG$ did not affect the binding of @DRUG$, phenytoin, or tamoxifen. DDI-advise
In vitro, @DRUG$ did not affect the binding of warfarin, @DRUG$, or tamoxifen. DDI-false
In vitro, @DRUG$ did not affect the binding of warfarin, phenytoin, or @DRUG$. DDI-false
In vitro, raloxifene did not affect the binding of @DRUG$, @DRUG$, or tamoxifen. DDI-false
In vitro, raloxifene did not affect the binding of @DRUG$, phenytoin, or @DRUG$. DDI-false
In vitro, raloxifene did not affect the binding of warfarin, @DRUG$, or @DRUG$. DDI-false
Caution should be used when @DRUG$ is coadministered with other highly protein-bound drugs, such as @DRUG$, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. DDI-false
Caution should be used when @DRUG$ is coadministered with other highly protein-bound drugs, such as clofibrate, @DRUG$, naproxen, ibuprofen, diazepam, and diazoxide. DDI-advise
Caution should be used when @DRUG$ is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, @DRUG$, ibuprofen, diazepam, and diazoxide. DDI-advise
Caution should be used when @DRUG$ is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, @DRUG$, diazepam, and diazoxide. DDI-advise
Caution should be used when @DRUG$ is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, @DRUG$, and diazoxide. DDI-advise
Caution should be used when @DRUG$ is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and @DRUG$. DDI-advise
Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as @DRUG$, @DRUG$, naproxen, ibuprofen, diazepam, and diazoxide. DDI-advise
Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as @DRUG$, indomethacin, @DRUG$, ibuprofen, diazepam, and diazoxide. DDI-false
Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as @DRUG$, indomethacin, naproxen, @DRUG$, diazepam, and diazoxide. DDI-false
Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as @DRUG$, indomethacin, naproxen, ibuprofen, @DRUG$, and diazoxide. DDI-false
Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as @DRUG$, indomethacin, naproxen, ibuprofen, diazepam, and @DRUG$. DDI-false
Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, @DRUG$, @DRUG$, ibuprofen, diazepam, and diazoxide. DDI-false
Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, @DRUG$, naproxen, @DRUG$, diazepam, and diazoxide. DDI-false
Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, @DRUG$, naproxen, ibuprofen, @DRUG$, and diazoxide. DDI-false
Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, @DRUG$, naproxen, ibuprofen, diazepam, and @DRUG$. DDI-false
Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, @DRUG$, @DRUG$, diazepam, and diazoxide. DDI-false
Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, @DRUG$, ibuprofen, @DRUG$, and diazoxide. DDI-false
Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, @DRUG$, ibuprofen, diazepam, and @DRUG$. DDI-false
Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, @DRUG$, @DRUG$, and diazoxide. DDI-false
Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, @DRUG$, diazepam, and @DRUG$. DDI-false
Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, @DRUG$, and @DRUG$. DDI-false
@DRUG$ may increase the effects of @DRUG$, tolbutamide, and uricosurics. DDI-false
@DRUG$ may increase the effects of barbiturates, @DRUG$, and uricosurics. DDI-effect
@DRUG$ may increase the effects of barbiturates, tolbutamide, and @DRUG$. DDI-effect
Sulfamethizole may increase the effects of @DRUG$, @DRUG$, and uricosurics. DDI-effect
Sulfamethizole may increase the effects of @DRUG$, tolbutamide, and @DRUG$. DDI-false
Sulfamethizole may increase the effects of barbiturates, @DRUG$, and @DRUG$. DDI-false
It may also interact with @DRUG$ (increased thrombocytopenia), @DRUG$ (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin). DDI-false
It may also interact with @DRUG$ (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), @DRUG$ (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin). DDI-false
It may also interact with @DRUG$ (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), @DRUG$ (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin). DDI-false
It may also interact with @DRUG$ (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), @DRUG$ (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin). DDI-false
It may also interact with @DRUG$ (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of @DRUG$), phenytoin (decreased hepatic clearance of phenytoin). DDI-false
It may also interact with @DRUG$ (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), @DRUG$ (decreased hepatic clearance of phenytoin). DDI-false
It may also interact with @DRUG$ (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of @DRUG$). DDI-false
It may also interact with thiazides (increased thrombocytopenia), @DRUG$ (increased nephrotoxicity), @DRUG$ (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin). DDI-false
It may also interact with thiazides (increased thrombocytopenia), @DRUG$ (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), @DRUG$ (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin). DDI-false
It may also interact with thiazides (increased thrombocytopenia), @DRUG$ (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), @DRUG$ (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin). DDI-false
It may also interact with thiazides (increased thrombocytopenia), @DRUG$ (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of @DRUG$), phenytoin (decreased hepatic clearance of phenytoin). DDI-false
It may also interact with thiazides (increased thrombocytopenia), @DRUG$ (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), @DRUG$ (decreased hepatic clearance of phenytoin). DDI-false
It may also interact with thiazides (increased thrombocytopenia), @DRUG$ (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of @DRUG$). DDI-false
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), @DRUG$ (increased hypoglycemic response), @DRUG$ (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin). DDI-false
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), @DRUG$ (increased hypoglycemic response), warfarin (increased anticoagulant effect), @DRUG$ (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin). DDI-false
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), @DRUG$ (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of @DRUG$), phenytoin (decreased hepatic clearance of phenytoin). DDI-false
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), @DRUG$ (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), @DRUG$ (decreased hepatic clearance of phenytoin). DDI-false
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), @DRUG$ (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of @DRUG$). DDI-false
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), @DRUG$ (increased anticoagulant effect), @DRUG$ (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin). DDI-false
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), @DRUG$ (increased anticoagulant effect), methotrexate (decreased renal excretion of @DRUG$), phenytoin (decreased hepatic clearance of phenytoin). DDI-false
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), @DRUG$ (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), @DRUG$ (decreased hepatic clearance of phenytoin). DDI-false
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), @DRUG$ (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of @DRUG$). DDI-false
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), @DRUG$ (decreased renal excretion of @DRUG$), phenytoin (decreased hepatic clearance of phenytoin). DDI-false
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), @DRUG$ (decreased renal excretion of methotrexate), @DRUG$ (decreased hepatic clearance of phenytoin). DDI-false
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), @DRUG$ (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of @DRUG$). DDI-false
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of @DRUG$), @DRUG$ (decreased hepatic clearance of phenytoin). DDI-false
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of @DRUG$), phenytoin (decreased hepatic clearance of @DRUG$). DDI-false
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), @DRUG$ (decreased hepatic clearance of @DRUG$). DDI-false
@DRUG$, such as the @DRUG$ (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); DDI-false
@DRUG$, such as the neuroleptics (@DRUG$, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); DDI-false
@DRUG$, such as the neuroleptics (phenothiazines, @DRUG$, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); DDI-false
@DRUG$, such as the neuroleptics (phenothiazines, butyrophenones, @DRUG$ ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); DDI-false
@DRUG$, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or @DRUG$, ordinarily should not be administered concurrently with Permax (a dopamine agonist); DDI-false
@DRUG$, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with @DRUG$ (a dopamine agonist); DDI-false
@DRUG$, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a @DRUG$); DDI-advise
Dopamine antagonists, such as the @DRUG$ (@DRUG$, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); DDI-advise
Dopamine antagonists, such as the @DRUG$ (phenothiazines, @DRUG$, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); DDI-false
Dopamine antagonists, such as the @DRUG$ (phenothiazines, butyrophenones, @DRUG$ ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); DDI-false
Dopamine antagonists, such as the @DRUG$ (phenothiazines, butyrophenones, thioxanthines ) or @DRUG$, ordinarily should not be administered concurrently with Permax (a dopamine agonist); DDI-false
Dopamine antagonists, such as the @DRUG$ (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with @DRUG$ (a dopamine agonist); DDI-false
Dopamine antagonists, such as the @DRUG$ (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a @DRUG$); DDI-advise
Dopamine antagonists, such as the neuroleptics (@DRUG$, @DRUG$, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); DDI-advise
Dopamine antagonists, such as the neuroleptics (@DRUG$, butyrophenones, @DRUG$ ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); DDI-false
Dopamine antagonists, such as the neuroleptics (@DRUG$, butyrophenones, thioxanthines ) or @DRUG$, ordinarily should not be administered concurrently with Permax (a dopamine agonist); DDI-false
Dopamine antagonists, such as the neuroleptics (@DRUG$, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with @DRUG$ (a dopamine agonist); DDI-false
Dopamine antagonists, such as the neuroleptics (@DRUG$, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a @DRUG$); DDI-advise
Dopamine antagonists, such as the neuroleptics (phenothiazines, @DRUG$, @DRUG$ ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); DDI-false
Dopamine antagonists, such as the neuroleptics (phenothiazines, @DRUG$, thioxanthines ) or @DRUG$, ordinarily should not be administered concurrently with Permax (a dopamine agonist); DDI-false
Dopamine antagonists, such as the neuroleptics (phenothiazines, @DRUG$, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with @DRUG$ (a dopamine agonist); DDI-false
Dopamine antagonists, such as the neuroleptics (phenothiazines, @DRUG$, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a @DRUG$); DDI-advise
Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, @DRUG$ ) or @DRUG$, ordinarily should not be administered concurrently with Permax (a dopamine agonist); DDI-false
Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, @DRUG$ ) or metoclopramide, ordinarily should not be administered concurrently with @DRUG$ (a dopamine agonist); DDI-false
Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, @DRUG$ ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a @DRUG$); DDI-advise
Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or @DRUG$, ordinarily should not be administered concurrently with @DRUG$ (a dopamine agonist); DDI-false
Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or @DRUG$, ordinarily should not be administered concurrently with Permax (a @DRUG$); DDI-advise
Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with @DRUG$ (a @DRUG$); DDI-advise
Because @DRUG$ is approximately 90% bound to plasma proteins, caution should be exercised if @DRUG$ is coadministered with other drugs known to affect protein binding. DDI-false
Drug Interactions: Women on oral @DRUG$ have shown a significant increase in plasma @DRUG$ levels. DDI-false
The effects of @DRUG$ on gastrointestinal motility are antagonized by @DRUG$ and narcotic analgesics. DDI-mechanism
The effects of @DRUG$ on gastrointestinal motility are antagonized by anticholinergic drugs and @DRUG$. DDI-effect
The effects of metoclopramide on gastrointestinal motility are antagonized by @DRUG$ and @DRUG$. DDI-effect
Additive sedative effects can occur when @DRUG$ is given with @DRUG$, sedatives, hypnotics, narcotics, or tranquilizers. DDI-false
Additive sedative effects can occur when @DRUG$ is given with alcohol, @DRUG$, hypnotics, narcotics, or tranquilizers. DDI-effect
Additive sedative effects can occur when @DRUG$ is given with alcohol, sedatives, @DRUG$, narcotics, or tranquilizers. DDI-effect
Additive sedative effects can occur when @DRUG$ is given with alcohol, sedatives, hypnotics, @DRUG$, or tranquilizers. DDI-effect
Additive sedative effects can occur when @DRUG$ is given with alcohol, sedatives, hypnotics, narcotics, or @DRUG$. DDI-effect
Additive sedative effects can occur when metoclopramide is given with @DRUG$, @DRUG$, hypnotics, narcotics, or tranquilizers. DDI-effect
Additive sedative effects can occur when metoclopramide is given with @DRUG$, sedatives, @DRUG$, narcotics, or tranquilizers. DDI-false
Additive sedative effects can occur when metoclopramide is given with @DRUG$, sedatives, hypnotics, @DRUG$, or tranquilizers. DDI-false
Additive sedative effects can occur when metoclopramide is given with @DRUG$, sedatives, hypnotics, narcotics, or @DRUG$. DDI-false
Additive sedative effects can occur when metoclopramide is given with alcohol, @DRUG$, @DRUG$, narcotics, or tranquilizers. DDI-false
Additive sedative effects can occur when metoclopramide is given with alcohol, @DRUG$, hypnotics, @DRUG$, or tranquilizers. DDI-false
Additive sedative effects can occur when metoclopramide is given with alcohol, @DRUG$, hypnotics, narcotics, or @DRUG$. DDI-false
Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, @DRUG$, @DRUG$, or tranquilizers. DDI-false
Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, @DRUG$, narcotics, or @DRUG$. DDI-false
Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, @DRUG$, or @DRUG$. DDI-false
The finding that @DRUG$ releases catecholamines in patients with essential hypertension suggests that it should be used cautiously, if at all, in patients receiving @DRUG$. DDI-false
Absorption of drugs from the stomach may be diminished (e.g., @DRUG$) by @DRUG$, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). DDI-advise
Absorption of drugs from the stomach may be diminished (e.g., @DRUG$) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., @DRUG$, tetracycline, levodopa, ethanol, cyclosporine). DDI-false
Absorption of drugs from the stomach may be diminished (e.g., @DRUG$) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, @DRUG$, levodopa, ethanol, cyclosporine). DDI-false
Absorption of drugs from the stomach may be diminished (e.g., @DRUG$) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, @DRUG$, ethanol, cyclosporine). DDI-false
Absorption of drugs from the stomach may be diminished (e.g., @DRUG$) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, @DRUG$, cyclosporine). DDI-false
Absorption of drugs from the stomach may be diminished (e.g., @DRUG$) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, @DRUG$). DDI-false
Absorption of drugs from the stomach may be diminished (e.g., digoxin) by @DRUG$, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., @DRUG$, tetracycline, levodopa, ethanol, cyclosporine). DDI-false
Absorption of drugs from the stomach may be diminished (e.g., digoxin) by @DRUG$, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, @DRUG$, levodopa, ethanol, cyclosporine). DDI-false
Absorption of drugs from the stomach may be diminished (e.g., digoxin) by @DRUG$, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, @DRUG$, ethanol, cyclosporine). DDI-false
Absorption of drugs from the stomach may be diminished (e.g., digoxin) by @DRUG$, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, @DRUG$, cyclosporine). DDI-false
Absorption of drugs from the stomach may be diminished (e.g., digoxin) by @DRUG$, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, @DRUG$). DDI-false
Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., @DRUG$, @DRUG$, levodopa, ethanol, cyclosporine). DDI-false
Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., @DRUG$, tetracycline, @DRUG$, ethanol, cyclosporine). DDI-false
Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., @DRUG$, tetracycline, levodopa, @DRUG$, cyclosporine). DDI-false
Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., @DRUG$, tetracycline, levodopa, ethanol, @DRUG$). DDI-false
Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, @DRUG$, @DRUG$, ethanol, cyclosporine). DDI-false
Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, @DRUG$, levodopa, @DRUG$, cyclosporine). DDI-false
Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, @DRUG$, levodopa, ethanol, @DRUG$). DDI-false
Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, @DRUG$, @DRUG$, cyclosporine). DDI-false
Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, @DRUG$, ethanol, @DRUG$). DDI-false
Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, @DRUG$, @DRUG$). DDI-false
Because the action of @DRUG$ will influence the delivery of food to the intestines and thus the rate of absorption, @DRUG$ dosage or timing of dosage may require adjustment. DDI-false
Drugs that induce hepatic enzymes such as @DRUG$, @DRUG$ and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. DDI-false
Drugs that induce hepatic enzymes such as @DRUG$, phenytoin and @DRUG$ may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. DDI-false
Drugs that induce hepatic enzymes such as @DRUG$, phenytoin and rifampin may increase the clearance of @DRUG$ and may require increases in corticosteroid dose to achieve the desired response. DDI-false
Drugs that induce hepatic enzymes such as @DRUG$, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in @DRUG$ dose to achieve the desired response. DDI-mechanism
Drugs that induce hepatic enzymes such as phenobarbital, @DRUG$ and @DRUG$ may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. DDI-false
Drugs that induce hepatic enzymes such as phenobarbital, @DRUG$ and rifampin may increase the clearance of @DRUG$ and may require increases in corticosteroid dose to achieve the desired response. DDI-false
Drugs that induce hepatic enzymes such as phenobarbital, @DRUG$ and rifampin may increase the clearance of corticosteroids and may require increases in @DRUG$ dose to achieve the desired response. DDI-mechanism
Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and @DRUG$ may increase the clearance of @DRUG$ and may require increases in corticosteroid dose to achieve the desired response. DDI-false
Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and @DRUG$ may increase the clearance of corticosteroids and may require increases in @DRUG$ dose to achieve the desired response. DDI-mechanism
Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of @DRUG$ and may require increases in @DRUG$ dose to achieve the desired response. DDI-false
Drugs such as @DRUG$ and @DRUG$ may inhibit the metabolism of corticosteroids and thus decrease their clearance. DDI-false
Drugs such as @DRUG$ and ketoconazole may inhibit the metabolism of @DRUG$ and thus decrease their clearance. DDI-false
Drugs such as troleandomycin and @DRUG$ may inhibit the metabolism of @DRUG$ and thus decrease their clearance. DDI-mechanism
@DRUG$ may increase the clearance of chronic high dose @DRUG$. DDI-mechanism
This could lead to decreased @DRUG$ serum levels or increase the risk of @DRUG$ toxicity when corticosteroid is withdrawn. DDI-effect
This could lead to decreased @DRUG$ serum levels or increase the risk of salicylate toxicity when @DRUG$ is withdrawn. DDI-false
This could lead to decreased salicylate serum levels or increase the risk of @DRUG$ toxicity when @DRUG$ is withdrawn. DDI-false
@DRUG$ should be used cautiously in conjunction with @DRUG$ in patients suffering from hypoprothrombinemia. DDI-effect
The effect of @DRUG$ on oral @DRUG$ is variable. DDI-advise
There are reports of enhanced as well as diminished effects of @DRUG$ when given concurrently with @DRUG$. DDI-false
Co-administration of oral @DRUG$ 200 mg twice daily increased @DRUG$ geometric mean AUC(0-24) and Cmax by 81% after topical application of retapamulin ointment, 1% on the abraded skin of healthy adult males. DDI-effect
Co-administration of oral @DRUG$ 200 mg twice daily increased retapamulin geometric mean AUC(0-24) and Cmax by 81% after topical application of @DRUG$ ointment, 1% on the abraded skin of healthy adult males. DDI-mechanism
Co-administration of oral ketoconazole 200 mg twice daily increased @DRUG$ geometric mean AUC(0-24) and Cmax by 81% after topical application of @DRUG$ ointment, 1% on the abraded skin of healthy adult males. DDI-false
Due to low systemic exposure to @DRUG$ following topical application in patients, dosage adjustments for @DRUG$ are unnecessary when co-administered with CYP3A4 inhibitors, such as ketoconazole. DDI-false
Due to low systemic exposure to @DRUG$ following topical application in patients, dosage adjustments for retapamulin are unnecessary when co-administered with CYP3A4 inhibitors, such as @DRUG$. DDI-false
Due to low systemic exposure to retapamulin following topical application in patients, dosage adjustments for @DRUG$ are unnecessary when co-administered with CYP3A4 inhibitors, such as @DRUG$. DDI-false
Based on in vitro P450 inhibition studies and the low systemic exposure observed following topical application of @DRUG$, @DRUG$ is unlikely to affect the metabolism of other P450 substrates. DDI-advise
@DRUG$ may interact with @DRUG$ (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
@DRUG$ may interact with antidepressants (@DRUG$ type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-int
@DRUG$ may interact with antidepressants (tricyclic type), @DRUG$ (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-int
@DRUG$ may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., @DRUG$, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-int
@DRUG$ may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, @DRUG$, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-int
@DRUG$ may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, @DRUG$, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-int
@DRUG$ may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, @DRUG$, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-int
@DRUG$ may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, @DRUG$, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-int
@DRUG$ may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, @DRUG$), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-int
@DRUG$ may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), @DRUG$, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-int
@DRUG$ may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, @DRUG$, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-int
@DRUG$ may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, @DRUG$ (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-int
@DRUG$ may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., @DRUG$), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-int
@DRUG$ may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other @DRUG$, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-int
@DRUG$ may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, @DRUG$ supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-int
@DRUG$ may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-int
@DRUG$ may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, @DRUG$ (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-int
@DRUG$ may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-int
@DRUG$ may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-@DRUG$), phenothiazines (e.g., chlorpromazine, promethazine). DDI-int
@DRUG$ may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), @DRUG$ (e.g., chlorpromazine, promethazine). DDI-int
@DRUG$ may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., @DRUG$, promethazine). DDI-int
@DRUG$ may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, @DRUG$). DDI-int
Methscopolamine may interact with @DRUG$ (@DRUG$ type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-int
Methscopolamine may interact with @DRUG$ (tricyclic type), @DRUG$ (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with @DRUG$ (tricyclic type), MAO inhibitors (e.g., @DRUG$, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with @DRUG$ (tricyclic type), MAO inhibitors (e.g., phenelzine, @DRUG$, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with @DRUG$ (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, @DRUG$, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with @DRUG$ (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, @DRUG$, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with @DRUG$ (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, @DRUG$, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with @DRUG$ (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, @DRUG$), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with @DRUG$ (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), @DRUG$, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with @DRUG$ (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, @DRUG$, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with @DRUG$ (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, @DRUG$ (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with @DRUG$ (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., @DRUG$), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with @DRUG$ (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other @DRUG$, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with @DRUG$ (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, @DRUG$ supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with @DRUG$ (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with @DRUG$ (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, @DRUG$ (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with @DRUG$ (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with @DRUG$ (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-@DRUG$), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with @DRUG$ (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), @DRUG$ (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with @DRUG$ (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., @DRUG$, promethazine). DDI-false
Methscopolamine may interact with @DRUG$ (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, @DRUG$). DDI-false
Methscopolamine may interact with antidepressants (@DRUG$ type), @DRUG$ (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (@DRUG$ type), MAO inhibitors (e.g., @DRUG$, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (@DRUG$ type), MAO inhibitors (e.g., phenelzine, @DRUG$, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (@DRUG$ type), MAO inhibitors (e.g., phenelzine, linezolid, @DRUG$, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (@DRUG$ type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, @DRUG$, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (@DRUG$ type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, @DRUG$, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (@DRUG$ type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, @DRUG$), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (@DRUG$ type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), @DRUG$, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (@DRUG$ type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, @DRUG$, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (@DRUG$ type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, @DRUG$ (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (@DRUG$ type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., @DRUG$), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (@DRUG$ type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other @DRUG$, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (@DRUG$ type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, @DRUG$ supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (@DRUG$ type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (@DRUG$ type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, @DRUG$ (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (@DRUG$ type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (@DRUG$ type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-@DRUG$), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (@DRUG$ type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), @DRUG$ (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (@DRUG$ type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., @DRUG$, promethazine). DDI-false
Methscopolamine may interact with antidepressants (@DRUG$ type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, @DRUG$). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), @DRUG$ (e.g., @DRUG$, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), @DRUG$ (e.g., phenelzine, @DRUG$, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), @DRUG$ (e.g., phenelzine, linezolid, @DRUG$, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), @DRUG$ (e.g., phenelzine, linezolid, tranylcypromine, @DRUG$, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), @DRUG$ (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, @DRUG$, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), @DRUG$ (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, @DRUG$), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), @DRUG$ (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), @DRUG$, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), @DRUG$ (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, @DRUG$, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), @DRUG$ (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, @DRUG$ (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), @DRUG$ (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., @DRUG$), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), @DRUG$ (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other @DRUG$, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), @DRUG$ (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, @DRUG$ supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), @DRUG$ (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), @DRUG$ (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, @DRUG$ (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), @DRUG$ (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), @DRUG$ (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-@DRUG$), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), @DRUG$ (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), @DRUG$ (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), @DRUG$ (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., @DRUG$, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), @DRUG$ (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, @DRUG$). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., @DRUG$, @DRUG$, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., @DRUG$, linezolid, @DRUG$, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., @DRUG$, linezolid, tranylcypromine, @DRUG$, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., @DRUG$, linezolid, tranylcypromine, isocarboxazid, @DRUG$, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., @DRUG$, linezolid, tranylcypromine, isocarboxazid, selegiline, @DRUG$), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., @DRUG$, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), @DRUG$, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., @DRUG$, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, @DRUG$, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., @DRUG$, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, @DRUG$ (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., @DRUG$, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., @DRUG$), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., @DRUG$, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other @DRUG$, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., @DRUG$, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, @DRUG$ supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., @DRUG$, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., @DRUG$, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, @DRUG$ (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., @DRUG$, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., @DRUG$, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-@DRUG$), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., @DRUG$, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), @DRUG$ (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., @DRUG$, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., @DRUG$, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., @DRUG$, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, @DRUG$). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, @DRUG$, @DRUG$, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, @DRUG$, tranylcypromine, @DRUG$, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, @DRUG$, tranylcypromine, isocarboxazid, @DRUG$, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, @DRUG$, tranylcypromine, isocarboxazid, selegiline, @DRUG$), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, @DRUG$, tranylcypromine, isocarboxazid, selegiline, furazolidone), @DRUG$, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, @DRUG$, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, @DRUG$, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, @DRUG$, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, @DRUG$ (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, @DRUG$, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., @DRUG$), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, @DRUG$, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other @DRUG$, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, @DRUG$, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, @DRUG$ supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, @DRUG$, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, @DRUG$, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, @DRUG$ (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, @DRUG$, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, @DRUG$, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-@DRUG$), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, @DRUG$, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), @DRUG$ (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, @DRUG$, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., @DRUG$, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, @DRUG$, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, @DRUG$). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, @DRUG$, @DRUG$, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, @DRUG$, isocarboxazid, @DRUG$, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, @DRUG$, isocarboxazid, selegiline, @DRUG$), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, @DRUG$, isocarboxazid, selegiline, furazolidone), @DRUG$, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, @DRUG$, isocarboxazid, selegiline, furazolidone), quinidine, @DRUG$, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, @DRUG$, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, @DRUG$ (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, @DRUG$, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., @DRUG$), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, @DRUG$, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other @DRUG$, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, @DRUG$, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, @DRUG$ supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, @DRUG$, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, @DRUG$, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, @DRUG$ (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, @DRUG$, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, @DRUG$, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-@DRUG$), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, @DRUG$, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), @DRUG$ (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, @DRUG$, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., @DRUG$, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, @DRUG$, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, @DRUG$). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, @DRUG$, @DRUG$, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, @DRUG$, selegiline, @DRUG$), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, @DRUG$, selegiline, furazolidone), @DRUG$, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, @DRUG$, selegiline, furazolidone), quinidine, @DRUG$, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, @DRUG$, selegiline, furazolidone), quinidine, amantadine, @DRUG$ (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, @DRUG$, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., @DRUG$), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, @DRUG$, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other @DRUG$, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, @DRUG$, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, @DRUG$ supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, @DRUG$, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, @DRUG$, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, @DRUG$ (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, @DRUG$, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, @DRUG$, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-@DRUG$), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, @DRUG$, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), @DRUG$ (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, @DRUG$, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., @DRUG$, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, @DRUG$, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, @DRUG$). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, @DRUG$, @DRUG$), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, @DRUG$, furazolidone), @DRUG$, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, @DRUG$, furazolidone), quinidine, @DRUG$, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, @DRUG$, furazolidone), quinidine, amantadine, @DRUG$ (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, @DRUG$, furazolidone), quinidine, amantadine, antihistamines (e.g., @DRUG$), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, @DRUG$, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other @DRUG$, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, @DRUG$, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, @DRUG$ supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, @DRUG$, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, @DRUG$, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, @DRUG$ (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, @DRUG$, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, @DRUG$, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-@DRUG$), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, @DRUG$, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), @DRUG$ (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, @DRUG$, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., @DRUG$, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, @DRUG$, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, @DRUG$). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, @DRUG$), @DRUG$, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, @DRUG$), quinidine, @DRUG$, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, @DRUG$), quinidine, amantadine, @DRUG$ (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, @DRUG$), quinidine, amantadine, antihistamines (e.g., @DRUG$), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, @DRUG$), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other @DRUG$, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, @DRUG$), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, @DRUG$ supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, @DRUG$), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, @DRUG$), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, @DRUG$ (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, @DRUG$), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, @DRUG$), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-@DRUG$), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, @DRUG$), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), @DRUG$ (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, @DRUG$), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., @DRUG$, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, @DRUG$), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, @DRUG$). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), @DRUG$, @DRUG$, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), @DRUG$, amantadine, @DRUG$ (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), @DRUG$, amantadine, antihistamines (e.g., @DRUG$), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), @DRUG$, amantadine, antihistamines (e.g., diphenhydramine), other @DRUG$, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), @DRUG$, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, @DRUG$ supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), @DRUG$, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), @DRUG$, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, @DRUG$ (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), @DRUG$, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), @DRUG$, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-@DRUG$), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), @DRUG$, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), @DRUG$ (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), @DRUG$, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., @DRUG$, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), @DRUG$, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, @DRUG$). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, @DRUG$, @DRUG$ (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, @DRUG$, antihistamines (e.g., @DRUG$), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, @DRUG$, antihistamines (e.g., diphenhydramine), other @DRUG$, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, @DRUG$, antihistamines (e.g., diphenhydramine), other anticholinergics, @DRUG$ supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, @DRUG$, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, @DRUG$, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, @DRUG$ (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, @DRUG$, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, @DRUG$, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-@DRUG$), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, @DRUG$, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), @DRUG$ (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, @DRUG$, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., @DRUG$, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, @DRUG$, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, @DRUG$). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, @DRUG$ (e.g., @DRUG$), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, @DRUG$ (e.g., diphenhydramine), other @DRUG$, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, @DRUG$ (e.g., diphenhydramine), other anticholinergics, @DRUG$ supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, @DRUG$ (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, @DRUG$ (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, @DRUG$ (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, @DRUG$ (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, @DRUG$ (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-@DRUG$), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, @DRUG$ (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), @DRUG$ (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, @DRUG$ (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., @DRUG$, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, @DRUG$ (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, @DRUG$). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., @DRUG$), other @DRUG$, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., @DRUG$), other anticholinergics, @DRUG$ supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., @DRUG$), other anticholinergics, potassium chloride supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., @DRUG$), other anticholinergics, potassium chloride supplements, antacids, @DRUG$ (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., @DRUG$), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., @DRUG$), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-@DRUG$), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., @DRUG$), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), @DRUG$ (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., @DRUG$), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., @DRUG$, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., @DRUG$), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, @DRUG$). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other @DRUG$, @DRUG$ supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other @DRUG$, potassium chloride supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other @DRUG$, potassium chloride supplements, antacids, @DRUG$ (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other @DRUG$, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other @DRUG$, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-@DRUG$), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other @DRUG$, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), @DRUG$ (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other @DRUG$, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., @DRUG$, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other @DRUG$, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, @DRUG$). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, @DRUG$ supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, @DRUG$ supplements, antacids, @DRUG$ (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, @DRUG$ supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, @DRUG$ supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-@DRUG$), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, @DRUG$ supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), @DRUG$ (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, @DRUG$ supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., @DRUG$, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, @DRUG$ supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, @DRUG$). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, @DRUG$, @DRUG$ (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., kaolin-@DRUG$), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), @DRUG$ (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., @DRUG$, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, @DRUG$, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, @DRUG$). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, @DRUG$ (e.g., @DRUG$-pectin), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, @DRUG$ (e.g., kaolin-@DRUG$), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, @DRUG$ (e.g., kaolin-pectin), @DRUG$ (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, @DRUG$ (e.g., kaolin-pectin), phenothiazines (e.g., @DRUG$, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, @DRUG$ (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, @DRUG$). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-@DRUG$), phenothiazines (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-pectin), @DRUG$ (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-pectin), phenothiazines (e.g., @DRUG$, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., @DRUG$-pectin), phenothiazines (e.g., chlorpromazine, @DRUG$). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-@DRUG$), @DRUG$ (e.g., chlorpromazine, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-@DRUG$), phenothiazines (e.g., @DRUG$, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-@DRUG$), phenothiazines (e.g., chlorpromazine, @DRUG$). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), @DRUG$ (e.g., @DRUG$, promethazine). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), @DRUG$ (e.g., chlorpromazine, @DRUG$). DDI-false
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., @DRUG$, @DRUG$). DDI-false
Although this has not occurred in in vitro studies with @DRUG$, interactions with @DRUG$ have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs. DDI-false
Although this has not occurred in in vitro studies with @DRUG$, interactions with coumarin-type anticoagulants have been reported with @DRUG$ since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs. DDI-false
Although this has not occurred in in vitro studies with @DRUG$, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering @DRUG$ to patients on coumarin-type anticoagulants and other highly protein-bound drugs. DDI-false
Although this has not occurred in in vitro studies with @DRUG$, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on @DRUG$ and other highly protein-bound drugs. DDI-false
Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with @DRUG$ have been reported with @DRUG$ since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs. DDI-false
Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with @DRUG$ have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering @DRUG$ to patients on coumarin-type anticoagulants and other highly protein-bound drugs. DDI-false
Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with @DRUG$ have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on @DRUG$ and other highly protein-bound drugs. DDI-false
Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with @DRUG$ since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering @DRUG$ to patients on coumarin-type anticoagulants and other highly protein-bound drugs. DDI-false
Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with @DRUG$ since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on @DRUG$ and other highly protein-bound drugs. DDI-false
Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering @DRUG$ to patients on @DRUG$ and other highly protein-bound drugs. DDI-false
Plasma levels of @DRUG$ are depressed to approximately 80% of their normal values when @DRUG$ is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. DDI-advise
Plasma levels of @DRUG$ are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with @DRUG$ (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. DDI-false
Plasma levels of @DRUG$ are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of @DRUG$ has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. DDI-false
Plasma levels of @DRUG$ are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on @DRUG$ plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. DDI-false
Plasma levels of @DRUG$ are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . @DRUG$, including FELDENE, have been reported to increase steady state plasma lithium levels. DDI-false
Plasma levels of @DRUG$ are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including @DRUG$, have been reported to increase steady state plasma lithium levels. DDI-false
Plasma levels of @DRUG$ are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma @DRUG$ levels. DDI-false
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when @DRUG$ is administered in conjunction with @DRUG$ (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. DDI-false
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when @DRUG$ is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of @DRUG$ has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. DDI-mechanism
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when @DRUG$ is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on @DRUG$ plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. DDI-false
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when @DRUG$ is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . @DRUG$, including FELDENE, have been reported to increase steady state plasma lithium levels. DDI-false
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when @DRUG$ is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including @DRUG$, have been reported to increase steady state plasma lithium levels. DDI-false
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when @DRUG$ is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma @DRUG$ levels. DDI-false
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with @DRUG$ (3900 mg/day), but concomitant administration of @DRUG$ has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. DDI-false
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with @DRUG$ (3900 mg/day), but concomitant administration of antacids has no effect on @DRUG$ plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. DDI-false
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with @DRUG$ (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . @DRUG$, including FELDENE, have been reported to increase steady state plasma lithium levels. DDI-false
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with @DRUG$ (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including @DRUG$, have been reported to increase steady state plasma lithium levels. DDI-false
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with @DRUG$ (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma @DRUG$ levels. DDI-false
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of @DRUG$ has no effect on @DRUG$ plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. DDI-false
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of @DRUG$ has no effect on piroxicam plasma levels . @DRUG$, including FELDENE, have been reported to increase steady state plasma lithium levels. DDI-false
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of @DRUG$ has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including @DRUG$, have been reported to increase steady state plasma lithium levels. DDI-false
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of @DRUG$ has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma @DRUG$ levels. DDI-false
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on @DRUG$ plasma levels . @DRUG$, including FELDENE, have been reported to increase steady state plasma lithium levels. DDI-false
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on @DRUG$ plasma levels . Nonsteroidal anti-inflammatory agents, including @DRUG$, have been reported to increase steady state plasma lithium levels. DDI-false
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on @DRUG$ plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma @DRUG$ levels. DDI-false
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . @DRUG$, including @DRUG$, have been reported to increase steady state plasma lithium levels. DDI-false
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . @DRUG$, including FELDENE, have been reported to increase steady state plasma @DRUG$ levels. DDI-false
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including @DRUG$, have been reported to increase steady state plasma @DRUG$ levels. DDI-mechanism
It is recommended that plasma @DRUG$ levels be monitored when initiating, adjusting and discontinuing @DRUG$. DDI-mechanism
When administered concurrently, @DRUG$ may increase the effects of oral @DRUG$; DDI-false
Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with @DRUG$ with and without @DRUG$ or platelet aggregation inhibitors. DDI-effect
Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with @DRUG$ with and without anticoagulants or @DRUG$. DDI-effect
Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with TRENTAL with and without @DRUG$ or @DRUG$. DDI-effect
Concomitant administration of @DRUG$ and @DRUG$-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals. DDI-false
Concomitant administration of @DRUG$ and theophylline-containing drugs leads to increased @DRUG$ levels and theophylline toxicity in some individuals. DDI-effect
Concomitant administration of @DRUG$ and theophylline-containing drugs leads to increased theophylline levels and @DRUG$ toxicity in some individuals. DDI-false
Concomitant administration of TRENTAL and @DRUG$-containing drugs leads to increased @DRUG$ levels and theophylline toxicity in some individuals. DDI-false
Concomitant administration of TRENTAL and @DRUG$-containing drugs leads to increased theophylline levels and @DRUG$ toxicity in some individuals. DDI-false
Concomitant administration of TRENTAL and theophylline-containing drugs leads to increased @DRUG$ levels and @DRUG$ toxicity in some individuals. DDI-false
@DRUG$ has been used concurrently with @DRUG$, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. DDI-false
@DRUG$ has been used concurrently with antihypertensive drugs, @DRUG$, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. DDI-false
@DRUG$ has been used concurrently with antihypertensive drugs, beta blockers, @DRUG$, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. DDI-false
@DRUG$ has been used concurrently with antihypertensive drugs, beta blockers, digitalis, @DRUG$, antidiabetic agents, and antiarrhythmics, without observed problems. DDI-false
@DRUG$ has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, @DRUG$, and antiarrhythmics, without observed problems. DDI-false
@DRUG$ has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and @DRUG$, without observed problems. DDI-false
TRENTAL has been used concurrently with @DRUG$, @DRUG$, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. DDI-false
TRENTAL has been used concurrently with @DRUG$, beta blockers, @DRUG$, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. DDI-false
TRENTAL has been used concurrently with @DRUG$, beta blockers, digitalis, @DRUG$, antidiabetic agents, and antiarrhythmics, without observed problems. DDI-false
TRENTAL has been used concurrently with @DRUG$, beta blockers, digitalis, diuretics, @DRUG$, and antiarrhythmics, without observed problems. DDI-false
TRENTAL has been used concurrently with @DRUG$, beta blockers, digitalis, diuretics, antidiabetic agents, and @DRUG$, without observed problems. DDI-false
TRENTAL has been used concurrently with antihypertensive drugs, @DRUG$, @DRUG$, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. DDI-false
TRENTAL has been used concurrently with antihypertensive drugs, @DRUG$, digitalis, @DRUG$, antidiabetic agents, and antiarrhythmics, without observed problems. DDI-false
TRENTAL has been used concurrently with antihypertensive drugs, @DRUG$, digitalis, diuretics, @DRUG$, and antiarrhythmics, without observed problems. DDI-false
TRENTAL has been used concurrently with antihypertensive drugs, @DRUG$, digitalis, diuretics, antidiabetic agents, and @DRUG$, without observed problems. DDI-false
TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, @DRUG$, @DRUG$, antidiabetic agents, and antiarrhythmics, without observed problems. DDI-false
TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, @DRUG$, diuretics, @DRUG$, and antiarrhythmics, without observed problems. DDI-false
TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, @DRUG$, diuretics, antidiabetic agents, and @DRUG$, without observed problems. DDI-false
TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, @DRUG$, @DRUG$, and antiarrhythmics, without observed problems. DDI-false
TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, @DRUG$, antidiabetic agents, and @DRUG$, without observed problems. DDI-false
TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, @DRUG$, and @DRUG$, without observed problems. DDI-false
Drug Interactions: The use of @DRUG$    (@DRUG$) Injection before succinylcholine, for the purpose of attenuating some of the side effects of succinylcholine, has not been studied. DDI-false
Drug Interactions: The use of @DRUG$    (rocuronium bromide) Injection before @DRUG$, for the purpose of attenuating some of the side effects of succinylcholine, has not been studied. DDI-false
Drug Interactions: The use of @DRUG$    (rocuronium bromide) Injection before succinylcholine, for the purpose of attenuating some of the side effects of @DRUG$, has not been studied. DDI-false
Drug Interactions: The use of ZEMURON    (@DRUG$) Injection before @DRUG$, for the purpose of attenuating some of the side effects of succinylcholine, has not been studied. DDI-false
Drug Interactions: The use of ZEMURON    (@DRUG$) Injection before succinylcholine, for the purpose of attenuating some of the side effects of @DRUG$, has not been studied. DDI-false
Drug Interactions: The use of ZEMURON    (rocuronium bromide) Injection before @DRUG$, for the purpose of attenuating some of the side effects of @DRUG$, has not been studied. DDI-false
If @DRUG$    is administered following administration of @DRUG$, it should not be given until recovery from succinylcholine has been observed. DDI-false
If @DRUG$    is administered following administration of succinylcholine, it should not be given until recovery from @DRUG$ has been observed. DDI-advise
If ZEMURON    is administered following administration of @DRUG$, it should not be given until recovery from @DRUG$ has been observed. DDI-false
The median duration of action of @DRUG$    0.6 mg/kg administered after a 1 mg/kg dose of @DRUG$ when T 1 returned to 75% of control was 36 minutes (range 14-57, n=12) vs. DDI-false
There are no controlled studies documenting the use of @DRUG$    before or after other @DRUG$. DDI-false
Concurrent administration of @DRUG$ (e.g., @DRUG$, tetracycline) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth. DDI-false
Concurrent administration of @DRUG$ (e.g., erythromycin, @DRUG$) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth. DDI-false
Concurrent administration of @DRUG$ (e.g., erythromycin, tetracycline) may diminish the bactericidal effects of @DRUG$ by slowing the rate of bacterial growth. DDI-false
Concurrent administration of bacteriostatic antibiotics (e.g., @DRUG$, @DRUG$) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth. DDI-effect
Concurrent administration of bacteriostatic antibiotics (e.g., @DRUG$, tetracycline) may diminish the bactericidal effects of @DRUG$ by slowing the rate of bacterial growth. DDI-false
Concurrent administration of bacteriostatic antibiotics (e.g., erythromycin, @DRUG$) may diminish the bactericidal effects of @DRUG$ by slowing the rate of bacterial growth. DDI-effect
@DRUG$ blood levels may be prolonged by concurrent administration of @DRUG$ which blocks the renal tubular secretion of penicillins. DDI-effect
@DRUG$ blood levels may be prolonged by concurrent administration of probenecid which blocks the renal tubular secretion of @DRUG$. DDI-mechanism
Penicillin blood levels may be prolonged by concurrent administration of @DRUG$ which blocks the renal tubular secretion of @DRUG$. DDI-false
Displacement of @DRUG$ from plasma protein binding sites will elevate the level of free @DRUG$ in the serum. DDI-mechanism
Catecholamine-depleting drugs (e.g., @DRUG$) may have an additive effect when given with @DRUG$. DDI-false
@DRUG$ has been used with a variety of @DRUG$, including hydrochlorothiazide, hydralazine, and guanethidine without unexpected adverse interactions. DDI-effect
@DRUG$ has been used with a variety of antihypertensive agents, including @DRUG$, hydralazine, and guanethidine without unexpected adverse interactions. DDI-false
@DRUG$ has been used with a variety of antihypertensive agents, including hydrochlorothiazide, @DRUG$, and guanethidine without unexpected adverse interactions. DDI-false
@DRUG$ has been used with a variety of antihypertensive agents, including hydrochlorothiazide, hydralazine, and @DRUG$ without unexpected adverse interactions. DDI-false
Pindolol has been used with a variety of @DRUG$, including @DRUG$, hydralazine, and guanethidine without unexpected adverse interactions. DDI-false
Pindolol has been used with a variety of @DRUG$, including hydrochlorothiazide, @DRUG$, and guanethidine without unexpected adverse interactions. DDI-false
Pindolol has been used with a variety of @DRUG$, including hydrochlorothiazide, hydralazine, and @DRUG$ without unexpected adverse interactions. DDI-false
Pindolol has been used with a variety of antihypertensive agents, including @DRUG$, @DRUG$, and guanethidine without unexpected adverse interactions. DDI-false
Pindolol has been used with a variety of antihypertensive agents, including @DRUG$, hydralazine, and @DRUG$ without unexpected adverse interactions. DDI-false
Pindolol has been used with a variety of antihypertensive agents, including hydrochlorothiazide, @DRUG$, and @DRUG$ without unexpected adverse interactions. DDI-false
@DRUG$ has been shown to increase serum @DRUG$ levels when both drugs are co-administered. DDI-false
Although specific drug or food interactions with @DRUG$ have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that @DRUG$, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). DDI-mechanism
Although specific drug or food interactions with @DRUG$ have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, @DRUG$, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). DDI-false
Although specific drug or food interactions with @DRUG$ have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, @DRUG$, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). DDI-false
Although specific drug or food interactions with @DRUG$ have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of @DRUG$). DDI-false
Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that @DRUG$, @DRUG$, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). DDI-false
Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that @DRUG$, itraconazole, @DRUG$, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). DDI-false
Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that @DRUG$, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of @DRUG$). DDI-false
Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, @DRUG$, @DRUG$, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). DDI-mechanism
Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, @DRUG$, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of @DRUG$). DDI-false
Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, @DRUG$, and grapefruit juice may inhibit its metabolism (increasing serum levels of @DRUG$). DDI-mechanism
Furthermore, @DRUG$, @DRUG$, St. DDI-mechanism
John   s Wort, and certain @DRUG$ (@DRUG$, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). DDI-false
John   s Wort, and certain @DRUG$ (phenytoin, @DRUG$, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). DDI-false
John   s Wort, and certain @DRUG$ (phenytoin, phenobarbital, @DRUG$) may induce mifepristone metabolism (lowering serum levels of mifepristone). DDI-false
John   s Wort, and certain @DRUG$ (phenytoin, phenobarbital, carbamazepine) may induce @DRUG$ metabolism (lowering serum levels of mifepristone). DDI-false
John   s Wort, and certain @DRUG$ (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of @DRUG$). DDI-mechanism
John   s Wort, and certain anticonvulsants (@DRUG$, @DRUG$, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). DDI-false
John   s Wort, and certain anticonvulsants (@DRUG$, phenobarbital, @DRUG$) may induce mifepristone metabolism (lowering serum levels of mifepristone). DDI-false
John   s Wort, and certain anticonvulsants (@DRUG$, phenobarbital, carbamazepine) may induce @DRUG$ metabolism (lowering serum levels of mifepristone). DDI-false
John   s Wort, and certain anticonvulsants (@DRUG$, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of @DRUG$). DDI-mechanism
John   s Wort, and certain anticonvulsants (phenytoin, @DRUG$, @DRUG$) may induce mifepristone metabolism (lowering serum levels of mifepristone). DDI-false
John   s Wort, and certain anticonvulsants (phenytoin, @DRUG$, carbamazepine) may induce @DRUG$ metabolism (lowering serum levels of mifepristone). DDI-false
John   s Wort, and certain anticonvulsants (phenytoin, @DRUG$, carbamazepine) may induce mifepristone metabolism (lowering serum levels of @DRUG$). DDI-mechanism
John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, @DRUG$) may induce @DRUG$ metabolism (lowering serum levels of mifepristone). DDI-false
John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, @DRUG$) may induce mifepristone metabolism (lowering serum levels of @DRUG$). DDI-mechanism
John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce @DRUG$ metabolism (lowering serum levels of @DRUG$). DDI-false
Concomitant administration of @DRUG$ and @DRUG$ has been associated with erythema and histamine-like flushing and anaphylactoid reactions. DDI-false
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as @DRUG$, @DRUG$, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring. DDI-effect
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as @DRUG$, aminoglycosides, @DRUG$, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring. DDI-false
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as @DRUG$, aminoglycosides, bacitracin, @DRUG$, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring. DDI-false
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as @DRUG$, aminoglycosides, bacitracin, polymyxin B, @DRUG$, viomycin, or cisplatin, when indicated, requires careful monitoring. DDI-false
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as @DRUG$, aminoglycosides, bacitracin, polymyxin B, colistin, @DRUG$, or cisplatin, when indicated, requires careful monitoring. DDI-false
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as @DRUG$, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or @DRUG$, when indicated, requires careful monitoring. DDI-false
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, @DRUG$, @DRUG$, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring. DDI-false
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, @DRUG$, bacitracin, @DRUG$, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring. DDI-false
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, @DRUG$, bacitracin, polymyxin B, @DRUG$, viomycin, or cisplatin, when indicated, requires careful monitoring. DDI-false
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, @DRUG$, bacitracin, polymyxin B, colistin, @DRUG$, or cisplatin, when indicated, requires careful monitoring. DDI-false
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, @DRUG$, bacitracin, polymyxin B, colistin, viomycin, or @DRUG$, when indicated, requires careful monitoring. DDI-false
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, @DRUG$, @DRUG$, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring. DDI-false
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, @DRUG$, polymyxin B, @DRUG$, viomycin, or cisplatin, when indicated, requires careful monitoring. DDI-false
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, @DRUG$, polymyxin B, colistin, @DRUG$, or cisplatin, when indicated, requires careful monitoring. DDI-false
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, @DRUG$, polymyxin B, colistin, viomycin, or @DRUG$, when indicated, requires careful monitoring. DDI-false
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, @DRUG$, @DRUG$, viomycin, or cisplatin, when indicated, requires careful monitoring. DDI-false
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, @DRUG$, colistin, @DRUG$, or cisplatin, when indicated, requires careful monitoring. DDI-false
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, @DRUG$, colistin, viomycin, or @DRUG$, when indicated, requires careful monitoring. DDI-false
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, @DRUG$, @DRUG$, or cisplatin, when indicated, requires careful monitoring. DDI-false
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, @DRUG$, viomycin, or @DRUG$, when indicated, requires careful monitoring. DDI-false
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, @DRUG$, or @DRUG$, when indicated, requires careful monitoring. DDI-false
Potential for @DRUG$    to Affect Other Drugs @DRUG$ is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes. DDI-false
Given the primary CNS effects of @DRUG$, @DRUG$    should be used with caution in combination with other centrally acting drugs and alcohol. DDI-false
Given the primary CNS effects of @DRUG$, INVEGA    should be used with caution in combination with other @DRUG$ and alcohol. DDI-false
Given the primary CNS effects of @DRUG$, INVEGA    should be used with caution in combination with other centrally acting drugs and @DRUG$. DDI-false
Given the primary CNS effects of paliperidone, @DRUG$    should be used with caution in combination with other @DRUG$ and alcohol. DDI-false
Given the primary CNS effects of paliperidone, @DRUG$    should be used with caution in combination with other centrally acting drugs and @DRUG$. DDI-false
Given the primary CNS effects of paliperidone, INVEGA    should be used with caution in combination with other @DRUG$ and @DRUG$. DDI-advise
@DRUG$ may antagonize the effect of @DRUG$ and other dopamine agonists. DDI-false
@DRUG$ may antagonize the effect of levodopa and other @DRUG$. DDI-effect
Paliperidone may antagonize the effect of @DRUG$ and other @DRUG$. DDI-effect
Potential for Other Drugs to Affect @DRUG$    @DRUG$ is not a substrate of CYP1A2, CYP2A6, CYP2C9, and CYP2C19, so that an interaction with inhibitors or inducers of these isozymes is unlikely. DDI-false
The interaction of @DRUG$ (@DRUG$) with other drugs has not been studied in humans. DDI-false
Decreased seizure threshold has been reported in patients receiving @DRUG$ concomitantly with @DRUG$. DDI-false
CYP 3A4 Inhibitors (e.g. @DRUG$ and @DRUG$) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. DDI-effect
CYP 3A4 Inhibitors (e.g. @DRUG$ and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain @DRUG$ (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. DDI-false
CYP 3A4 Inhibitors (e.g. @DRUG$ and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. @DRUG$ and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. DDI-false
CYP 3A4 Inhibitors (e.g. @DRUG$ and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and @DRUG$) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. DDI-false
CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and @DRUG$) There have been rare reports of serious adverse events in connection with the coadministration of certain @DRUG$ (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. DDI-false
CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and @DRUG$) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. @DRUG$ and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. DDI-false
CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and @DRUG$) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and @DRUG$) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. DDI-false
CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain @DRUG$ (e.g. @DRUG$ and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. DDI-false
CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain @DRUG$ (e.g. dihydroergotamine and @DRUG$) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. DDI-false
CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. @DRUG$ and @DRUG$) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., @DRUG$, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, @DRUG$, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, troleandomycin, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, troleandomycin, clarithromycin), @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., @DRUG$, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, @DRUG$, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, @DRUG$, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, @DRUG$) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or @DRUG$ (e.g., ketoconazole, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., @DRUG$, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, @DRUG$, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, @DRUG$). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, @DRUG$, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, troleandomycin, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, troleandomycin, clarithromycin), @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, troleandomycin, clarithromycin), HIV protease or @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., @DRUG$, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, @DRUG$, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, @DRUG$, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, @DRUG$) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or @DRUG$ (e.g., ketoconazole, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., @DRUG$, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, @DRUG$, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, @DRUG$). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, @DRUG$, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, @DRUG$, clarithromycin), @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, @DRUG$, clarithromycin), HIV protease or @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, @DRUG$, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., @DRUG$, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, @DRUG$, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, @DRUG$, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, @DRUG$, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, @DRUG$, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, @DRUG$, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, @DRUG$) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, @DRUG$, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or @DRUG$ (e.g., ketoconazole, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, @DRUG$, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., @DRUG$, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, @DRUG$, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, @DRUG$, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, @DRUG$, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, @DRUG$). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, @DRUG$), @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, @DRUG$), HIV protease or @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., @DRUG$, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, @DRUG$, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, @DRUG$, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, @DRUG$) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or @DRUG$ (e.g., ketoconazole, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., @DRUG$, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, @DRUG$, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, @DRUG$). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), @DRUG-DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), @DRUG$ (e.g., @DRUG$, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), @DRUG$ (e.g., ritonavir, @DRUG$, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), @DRUG$ (e.g., ritonavir, indinavir, @DRUG$, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, @DRUG$) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or @DRUG$ (e.g., ketoconazole, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., @DRUG$, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, @DRUG$, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, @DRUG$). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or @DRUG$ (e.g., @DRUG$, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or @DRUG$ (e.g., ritonavir, @DRUG$, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or @DRUG$ (e.g., ritonavir, indinavir, @DRUG$, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, @DRUG$) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or @DRUG$ (e.g., ketoconazole, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., @DRUG$, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, @DRUG$, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, @DRUG$). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., @DRUG$, @DRUG$, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., @DRUG$, indinavir, @DRUG$, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., @DRUG$, indinavir, nelfinavir, @DRUG$) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., @DRUG$, indinavir, nelfinavir, delavirdine) or @DRUG$ (e.g., ketoconazole, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., @DRUG$, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., @DRUG$, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., @DRUG$, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, @DRUG$, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., @DRUG$, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, @DRUG$). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, @DRUG$, @DRUG$, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, @DRUG$, nelfinavir, @DRUG$) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, @DRUG$, nelfinavir, delavirdine) or @DRUG$ (e.g., ketoconazole, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, @DRUG$, nelfinavir, delavirdine) or azole antifungals (e.g., @DRUG$, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, @DRUG$, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, @DRUG$, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, @DRUG$, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, @DRUG$). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, @DRUG$, @DRUG$) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, @DRUG$, delavirdine) or @DRUG$ (e.g., ketoconazole, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, @DRUG$, delavirdine) or azole antifungals (e.g., @DRUG$, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, @DRUG$, delavirdine) or azole antifungals (e.g., ketoconazole, @DRUG$, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, @DRUG$, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, @DRUG$). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, @DRUG$) or @DRUG$ (e.g., ketoconazole, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, @DRUG$) or azole antifungals (e.g., @DRUG$, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, @DRUG$) or azole antifungals (e.g., ketoconazole, @DRUG$, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, @DRUG$) or azole antifungals (e.g., ketoconazole, itraconazole, @DRUG$). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or @DRUG$ (e.g., @DRUG$, itraconazole, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or @DRUG$ (e.g., ketoconazole, @DRUG$, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or @DRUG$ (e.g., ketoconazole, itraconazole, @DRUG$). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., @DRUG$, @DRUG$, voriconazole). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., @DRUG$, itraconazole, @DRUG$). DDI-false
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, @DRUG$, @DRUG$). DDI-false
Less potent inhibitors include @DRUG$, @DRUG$, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. DDI-false
Less potent inhibitors include @DRUG$, nefazodone, @DRUG$, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. DDI-false
Less potent inhibitors include @DRUG$, nefazodone, fluconazole, grapefruit juice, @DRUG$, fluvoxamine, zileuton, and clotrimazole. DDI-false
Less potent inhibitors include @DRUG$, nefazodone, fluconazole, grapefruit juice, fluoxetine, @DRUG$, zileuton, and clotrimazole. DDI-false
Less potent inhibitors include @DRUG$, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, @DRUG$, and clotrimazole. DDI-false
Less potent inhibitors include @DRUG$, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and @DRUG$. DDI-false
Less potent inhibitors include saquinavir, @DRUG$, @DRUG$, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. DDI-false
Less potent inhibitors include saquinavir, @DRUG$, fluconazole, grapefruit juice, @DRUG$, fluvoxamine, zileuton, and clotrimazole. DDI-false
Less potent inhibitors include saquinavir, @DRUG$, fluconazole, grapefruit juice, fluoxetine, @DRUG$, zileuton, and clotrimazole. DDI-false
Less potent inhibitors include saquinavir, @DRUG$, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, @DRUG$, and clotrimazole. DDI-false
Less potent inhibitors include saquinavir, @DRUG$, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and @DRUG$. DDI-false
Less potent inhibitors include saquinavir, nefazodone, @DRUG$, grapefruit juice, @DRUG$, fluvoxamine, zileuton, and clotrimazole. DDI-false
Less potent inhibitors include saquinavir, nefazodone, @DRUG$, grapefruit juice, fluoxetine, @DRUG$, zileuton, and clotrimazole. DDI-false
Less potent inhibitors include saquinavir, nefazodone, @DRUG$, grapefruit juice, fluoxetine, fluvoxamine, @DRUG$, and clotrimazole. DDI-false
Less potent inhibitors include saquinavir, nefazodone, @DRUG$, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and @DRUG$. DDI-false
Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, @DRUG$, @DRUG$, zileuton, and clotrimazole. DDI-false
Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, @DRUG$, fluvoxamine, @DRUG$, and clotrimazole. DDI-false
Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, @DRUG$, fluvoxamine, zileuton, and @DRUG$. DDI-false
Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, @DRUG$, @DRUG$, and clotrimazole. DDI-false
Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, @DRUG$, zileuton, and @DRUG$. DDI-false
Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, @DRUG$, and @DRUG$. DDI-false
Caution should be exercised when @DRUG$    (@DRUG$) is used concurrently with other vasoconstrictors or ergot alkaloids. DDI-false
Caution should be exercised when @DRUG$    (methylergonovine maleate) is used concurrently with other @DRUG$ or ergot alkaloids. DDI-false
Caution should be exercised when @DRUG$    (methylergonovine maleate) is used concurrently with other vasoconstrictors or @DRUG$. DDI-advise
Caution should be exercised when Methergine    (@DRUG$) is used concurrently with other @DRUG$ or ergot alkaloids. DDI-advise
Caution should be exercised when Methergine    (@DRUG$) is used concurrently with other vasoconstrictors or @DRUG$. DDI-advise
Caution should be exercised when Methergine    (methylergonovine maleate) is used concurrently with other @DRUG$ or @DRUG$. DDI-false
To minimize CNS depression and possible potentiation, @DRUG$, @DRUG$, narcotics, hypotensive agents or phenothiazines should be used with caution. DDI-false
To minimize CNS depression and possible potentiation, @DRUG$, antihistamines, @DRUG$, hypotensive agents or phenothiazines should be used with caution. DDI-false
To minimize CNS depression and possible potentiation, @DRUG$, antihistamines, narcotics, @DRUG$ or phenothiazines should be used with caution. DDI-false
To minimize CNS depression and possible potentiation, @DRUG$, antihistamines, narcotics, hypotensive agents or @DRUG$ should be used with caution. DDI-false
To minimize CNS depression and possible potentiation, barbiturates, @DRUG$, @DRUG$, hypotensive agents or phenothiazines should be used with caution. DDI-false
To minimize CNS depression and possible potentiation, barbiturates, @DRUG$, narcotics, @DRUG$ or phenothiazines should be used with caution. DDI-false
To minimize CNS depression and possible potentiation, barbiturates, @DRUG$, narcotics, hypotensive agents or @DRUG$ should be used with caution. DDI-false
To minimize CNS depression and possible potentiation, barbiturates, antihistamines, @DRUG$, @DRUG$ or phenothiazines should be used with caution. DDI-false
To minimize CNS depression and possible potentiation, barbiturates, antihistamines, @DRUG$, hypotensive agents or @DRUG$ should be used with caution. DDI-false
To minimize CNS depression and possible potentiation, barbiturates, antihistamines, narcotics, @DRUG$ or @DRUG$ should be used with caution. DDI-false
Because @DRUG$ exhibits some monoamine oxidase inhibitory activity, @DRUG$, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. DDI-false
Because @DRUG$ exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, @DRUG$ drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. DDI-false
Because @DRUG$ exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., @DRUG$, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. DDI-false
Because @DRUG$ exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, @DRUG$) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. DDI-advise
Because @DRUG$ exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high @DRUG$ content, such as wine, yogurt, ripe cheese and bananas, should be avoided. DDI-advise
Because Matulane exhibits some monoamine oxidase inhibitory activity, @DRUG$, @DRUG$ drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. DDI-false
Because Matulane exhibits some monoamine oxidase inhibitory activity, @DRUG$, tricyclic antidepressant drugs (e.g., @DRUG$, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. DDI-false
Because Matulane exhibits some monoamine oxidase inhibitory activity, @DRUG$, tricyclic antidepressant drugs (e.g., amitriptyline HCl, @DRUG$) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. DDI-false
Because Matulane exhibits some monoamine oxidase inhibitory activity, @DRUG$, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high @DRUG$ content, such as wine, yogurt, ripe cheese and bananas, should be avoided. DDI-false
Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, @DRUG$ drugs (e.g., @DRUG$, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. DDI-false
Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, @DRUG$ drugs (e.g., amitriptyline HCl, @DRUG$) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. DDI-false
Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, @DRUG$ drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high @DRUG$ content, such as wine, yogurt, ripe cheese and bananas, should be avoided. DDI-false
Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., @DRUG$, @DRUG$) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. DDI-false
Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., @DRUG$, imipramine HCl) and other drugs and foods with known high @DRUG$ content, such as wine, yogurt, ripe cheese and bananas, should be avoided. DDI-false
Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, @DRUG$) and other drugs and foods with known high @DRUG$ content, such as wine, yogurt, ripe cheese and bananas, should be avoided. DDI-false
No cross-resistance with other @DRUG$, radiotherapy or @DRUG$ has been demonstrated. DDI-false
@DRUG$ are capable of potentiating @DRUG$ (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) DDI-false
@DRUG$ are capable of potentiating CNS depressants (e.g., @DRUG$, anesthetics, opiates, alcohol, etc.) DDI-effect
@DRUG$ are capable of potentiating CNS depressants (e.g., barbiturates, @DRUG$, opiates, alcohol, etc.) DDI-effect
@DRUG$ are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, @DRUG$, alcohol, etc.) DDI-effect
@DRUG$ are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, @DRUG$, etc.) DDI-effect
Phenothiazines are capable of potentiating @DRUG$ (e.g., @DRUG$, anesthetics, opiates, alcohol, etc.) DDI-effect
Phenothiazines are capable of potentiating @DRUG$ (e.g., barbiturates, @DRUG$, opiates, alcohol, etc.) DDI-false
Phenothiazines are capable of potentiating @DRUG$ (e.g., barbiturates, anesthetics, @DRUG$, alcohol, etc.) DDI-false
Phenothiazines are capable of potentiating @DRUG$ (e.g., barbiturates, anesthetics, opiates, @DRUG$, etc.) DDI-false
Phenothiazines are capable of potentiating CNS depressants (e.g., @DRUG$, @DRUG$, opiates, alcohol, etc.) DDI-false
Phenothiazines are capable of potentiating CNS depressants (e.g., @DRUG$, anesthetics, @DRUG$, alcohol, etc.) DDI-false
Phenothiazines are capable of potentiating CNS depressants (e.g., @DRUG$, anesthetics, opiates, @DRUG$, etc.) DDI-false
Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, @DRUG$, @DRUG$, alcohol, etc.) DDI-false
Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, @DRUG$, opiates, @DRUG$, etc.) DDI-false
Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, @DRUG$, @DRUG$, etc.) DDI-false
as well as @DRUG$ and @DRUG$. DDI-false
The metabolism of @DRUG$ is accelerated by @DRUG$; DDI-false
@DRUG$ inhibits the glucuronidation of @DRUG$ and could possibly potentiate acetaminophen toxicity. DDI-mechanism
@DRUG$ inhibits the glucuronidation of acetaminophen and could possibly potentiate @DRUG$ toxicity. DDI-mechanism
Metopirone inhibits the glucuronidation of @DRUG$ and could possibly potentiate @DRUG$ toxicity. DDI-effect
Preliminary evidence suggests that @DRUG$ inhibits @DRUG$ metabolism and may result in an increase in plasma concentrations of mebendazole. DDI-false
Preliminary evidence suggests that @DRUG$ inhibits mebendazole metabolism and may result in an increase in plasma concentrations of @DRUG$. DDI-mechanism
Preliminary evidence suggests that cimetidine inhibits @DRUG$ metabolism and may result in an increase in plasma concentrations of @DRUG$. DDI-mechanism
Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, @DRUG$, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, @DRUG$, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, @DRUG$, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, @DRUG$, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, @DRUG$, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of @DRUG$ with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or @DRUG$. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, @DRUG$, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, @DRUG$, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, @DRUG$, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, @DRUG$, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, @DRUG$, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, @DRUG$, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: @DRUG$, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or @DRUG$. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, @DRUG$, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, @DRUG$, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, @DRUG$, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, @DRUG$, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, @DRUG$, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, @DRUG$, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or @DRUG$. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, @DRUG$, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, @DRUG$, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, @DRUG$, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, @DRUG$, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, @DRUG$, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, @DRUG$, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or @DRUG$. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, @DRUG$, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, @DRUG$, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, @DRUG$, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, @DRUG$, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, @DRUG$, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, @DRUG$, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or @DRUG$. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, @DRUG$, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, @DRUG$, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, @DRUG$, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, @DRUG$, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, @DRUG$, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, @DRUG$, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, @DRUG$, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or @DRUG$. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, @DRUG$, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, @DRUG$, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, @DRUG$, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, @DRUG$, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, @DRUG$, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, @DRUG$ (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or @DRUG$. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), @DRUG$, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, @DRUG$, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, @DRUG$, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, @DRUG$, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, digoxin, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, digoxin, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, @DRUG$, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, @DRUG$, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, @DRUG$, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, @DRUG$, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, @DRUG$), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or @DRUG$. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, @DRUG$, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, @DRUG$, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, @DRUG$, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, digoxin, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, digoxin, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, @DRUG$, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, @DRUG$, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, @DRUG$, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, @DRUG$, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), @DRUG$, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or @DRUG$. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, @DRUG$, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, @DRUG$, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, digoxin, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, digoxin, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, digoxin, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, @DRUG$, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, @DRUG$, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, @DRUG$, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, @DRUG$, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, @DRUG$, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or @DRUG$. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, @DRUG$, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, digoxin, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, digoxin, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, digoxin, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, digoxin, ethanol, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, @DRUG$, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, @DRUG$, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, @DRUG$, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, @DRUG$, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, @DRUG$, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or @DRUG$. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, @DRUG$, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, @DRUG$, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, @DRUG$, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, @DRUG$, ethanol, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, @DRUG$, ethanol, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, @DRUG$, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, @DRUG$, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, @DRUG$, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, @DRUG$, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, @DRUG$, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, @DRUG$, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, @DRUG$, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, @DRUG$, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, @DRUG$, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, @DRUG$, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, @DRUG$, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, @DRUG$, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or @DRUG$. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, @DRUG$, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, @DRUG$, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, @DRUG$, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, @DRUG$, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, @DRUG$, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, @DRUG$, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, @DRUG$, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, @DRUG$, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or @DRUG$. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, @DRUG$, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, @DRUG$, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, @DRUG$, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, @DRUG$, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, @DRUG$, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, @DRUG$, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, @DRUG$, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or @DRUG$. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral @DRUG$ (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/@DRUG$), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, @DRUG$, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, @DRUG$, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, @DRUG$, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, @DRUG$, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral @DRUG$ (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or @DRUG$. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (@DRUG$/@DRUG$), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, phenytoin, @DRUG$, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, @DRUG$, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, @DRUG$, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, @DRUG$, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (@DRUG$/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or @DRUG$. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), @DRUG$, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, @DRUG$, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, nifedipine, @DRUG$, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, nifedipine, phenytoin, @DRUG$, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, nifedipine, phenytoin, warfarin, @DRUG$, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, nifedipine, phenytoin, warfarin, midazolam, @DRUG$, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, @DRUG$, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/@DRUG$), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or @DRUG$. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, @DRUG$, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, @DRUG$, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, @DRUG$, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, warfarin, @DRUG$, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, warfarin, midazolam, @DRUG$, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, @DRUG$, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), @DRUG$, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or @DRUG$. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, @DRUG$, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, @DRUG$, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, warfarin, @DRUG$, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, warfarin, midazolam, @DRUG$, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, warfarin, midazolam, clarithromycin, @DRUG$, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, @DRUG$, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or @DRUG$. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, @DRUG$, midazolam, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, warfarin, @DRUG$, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, warfarin, midazolam, @DRUG$, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, warfarin, midazolam, clarithromycin, @DRUG$, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, @DRUG$, warfarin, midazolam, clarithromycin, metronidazole, or @DRUG$. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, @DRUG$, @DRUG$, clarithromycin, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, @DRUG$, midazolam, @DRUG$, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, @DRUG$, midazolam, clarithromycin, @DRUG$, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, @DRUG$, midazolam, clarithromycin, metronidazole, or @DRUG$. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, @DRUG$, @DRUG$, metronidazole, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, @DRUG$, clarithromycin, @DRUG$, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, @DRUG$, clarithromycin, metronidazole, or @DRUG$. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, @DRUG$, @DRUG$, or amoxicillin. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, @DRUG$, metronidazole, or @DRUG$. DDI-false
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, @DRUG$, or @DRUG$. DDI-false
Therefore, when coadministered with @DRUG$, adjustment of the dosage of @DRUG$ or of such drugs may not be necessary. DDI-false
There have been postmarketing reports of increased INR and prothrombin time in patients receiving @DRUG$, including @DRUG$, and warfarin concomitantly. DDI-advise
There have been postmarketing reports of increased INR and prothrombin time in patients receiving @DRUG$, including pantoprazole, and @DRUG$ concomitantly. DDI-false
There have been postmarketing reports of increased INR and prothrombin time in patients receiving proton pump inhibitors, including @DRUG$, and @DRUG$ concomitantly. DDI-effect
Patients treated with @DRUG$ and @DRUG$ concomitantly should be monitored for increases in INR and prothrombin time. DDI-effect
Because of profound and long lasting inhibition of gastric acid secretion, @DRUG$ may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, @DRUG$, ampicillin esters, and iron salts). DDI-advise
Because of profound and long lasting inhibition of gastric acid secretion, @DRUG$ may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, @DRUG$ esters, and iron salts). DDI-mechanism
Because of profound and long lasting inhibition of gastric acid secretion, @DRUG$ may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and @DRUG$ salts). DDI-mechanism
Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, @DRUG$, @DRUG$ esters, and iron salts). DDI-mechanism
Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, @DRUG$, ampicillin esters, and @DRUG$ salts). DDI-false
Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, @DRUG$ esters, and @DRUG$ salts). DDI-false
Laboratory Tests There have been reports of false-positive urine screening tests for @DRUG$ (@DRUG$) in patients receiving most proton pump inhibitors, including pantoprazole. DDI-false
Laboratory Tests There have been reports of false-positive urine screening tests for @DRUG$ (THC) in patients receiving most @DRUG$, including pantoprazole. DDI-false
Laboratory Tests There have been reports of false-positive urine screening tests for @DRUG$ (THC) in patients receiving most proton pump inhibitors, including @DRUG$. DDI-false
Laboratory Tests There have been reports of false-positive urine screening tests for tetrahydrocannabinol (@DRUG$) in patients receiving most @DRUG$, including pantoprazole. DDI-false
Laboratory Tests There have been reports of false-positive urine screening tests for tetrahydrocannabinol (@DRUG$) in patients receiving most proton pump inhibitors, including @DRUG$. DDI-false
Laboratory Tests There have been reports of false-positive urine screening tests for tetrahydrocannabinol (THC) in patients receiving most @DRUG$, including @DRUG$. DDI-false
@DRUG$ may increase the effects of @DRUG$, tolbutamide, and uricosurics. DDI-false
@DRUG$ may increase the effects of barbiturates, @DRUG$, and uricosurics. DDI-effect
@DRUG$ may increase the effects of barbiturates, tolbutamide, and @DRUG$. DDI-effect
Sulfoxone may increase the effects of @DRUG$, @DRUG$, and uricosurics. DDI-effect
Sulfoxone may increase the effects of @DRUG$, tolbutamide, and @DRUG$. DDI-false
Sulfoxone may increase the effects of barbiturates, @DRUG$, and @DRUG$. DDI-false
It may also interact with @DRUG$ (increased thrombocytopenia), @DRUG$ (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin). DDI-false
It may also interact with @DRUG$ (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), @DRUG$ (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin). DDI-false
It may also interact with @DRUG$ (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), @DRUG$ (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin). DDI-false
It may also interact with @DRUG$ (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), @DRUG$ (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin). DDI-false
It may also interact with @DRUG$ (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of @DRUG$), phenytoin (decreased hepatic clearance of phenytoin). DDI-false
It may also interact with @DRUG$ (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), @DRUG$ (decreased hepatic clearance of phenytoin). DDI-false
It may also interact with @DRUG$ (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of @DRUG$). DDI-false
It may also interact with thiazides (increased thrombocytopenia), @DRUG$ (increased nephrotoxicity), @DRUG$ (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin). DDI-false
It may also interact with thiazides (increased thrombocytopenia), @DRUG$ (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), @DRUG$ (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin). DDI-false
It may also interact with thiazides (increased thrombocytopenia), @DRUG$ (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), @DRUG$ (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin). DDI-false
It may also interact with thiazides (increased thrombocytopenia), @DRUG$ (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of @DRUG$), phenytoin (decreased hepatic clearance of phenytoin). DDI-false
It may also interact with thiazides (increased thrombocytopenia), @DRUG$ (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), @DRUG$ (decreased hepatic clearance of phenytoin). DDI-false
It may also interact with thiazides (increased thrombocytopenia), @DRUG$ (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of @DRUG$). DDI-false
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), @DRUG$ (increased hypoglycemic response), @DRUG$ (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin). DDI-false
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), @DRUG$ (increased hypoglycemic response), warfarin (increased anticoagulant effect), @DRUG$ (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin). DDI-false
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), @DRUG$ (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of @DRUG$), phenytoin (decreased hepatic clearance of phenytoin). DDI-false
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), @DRUG$ (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), @DRUG$ (decreased hepatic clearance of phenytoin). DDI-false
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), @DRUG$ (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of @DRUG$). DDI-false
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), @DRUG$ (increased anticoagulant effect), @DRUG$ (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin). DDI-false
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), @DRUG$ (increased anticoagulant effect), methotrexate (decreased renal excretion of @DRUG$), phenytoin (decreased hepatic clearance of phenytoin). DDI-false
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), @DRUG$ (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), @DRUG$ (decreased hepatic clearance of phenytoin). DDI-false
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), @DRUG$ (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of @DRUG$). DDI-false
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), @DRUG$ (decreased renal excretion of @DRUG$), phenytoin (decreased hepatic clearance of phenytoin). DDI-false
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), @DRUG$ (decreased renal excretion of methotrexate), @DRUG$ (decreased hepatic clearance of phenytoin). DDI-false
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), @DRUG$ (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of @DRUG$). DDI-false
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of @DRUG$), @DRUG$ (decreased hepatic clearance of phenytoin). DDI-false
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of @DRUG$), phenytoin (decreased hepatic clearance of @DRUG$). DDI-false
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), @DRUG$ (decreased hepatic clearance of @DRUG$). DDI-false
@DRUG$ may compete with other drugs, such as @DRUG$, for sites of metabolism in the liver, thus elevating the serum levels of such compounds to potentially toxic levels. DDI-false
Therefore, when concomitant use of @DRUG$ and @DRUG$ is anticipated, it may be necessary to monitor blood levels and/or reduce the dosage of such compounds. DDI-mechanism
Administration of @DRUG$ decreases oral clearance of @DRUG$ by about 5%. DDI-advise
Pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of @DRUG$ or @DRUG$ to warrant dosage adjustment when megestrol acetate is administered with these drugs. DDI-mechanism
Pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of @DRUG$ or rifabutin to warrant dosage adjustment when @DRUG$ is administered with these drugs. DDI-false
Pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of zidovudine or @DRUG$ to warrant dosage adjustment when @DRUG$ is administered with these drugs. DDI-false
A pharmacokinetic study demonstrated that coadministration of @DRUG$ and @DRUG$ results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of indinavir. DDI-false
A pharmacokinetic study demonstrated that coadministration of @DRUG$ and indinavir results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of @DRUG$. DDI-mechanism
A pharmacokinetic study demonstrated that coadministration of megestrol acetate and @DRUG$ results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of @DRUG$. DDI-false
Administration of a higher dose of @DRUG$ should be considered when coadministering with @DRUG$. DDI-false
The effects of @DRUG$, @DRUG$ or rifabutin on the pharmacokinetics of megestrol acetate were not studied. DDI-advise
The effects of @DRUG$, zidovudine or @DRUG$ on the pharmacokinetics of megestrol acetate were not studied. DDI-false
The effects of @DRUG$, zidovudine or rifabutin on the pharmacokinetics of @DRUG$ were not studied. DDI-false
The effects of indinavir, @DRUG$ or @DRUG$ on the pharmacokinetics of megestrol acetate were not studied. DDI-false
The effects of indinavir, @DRUG$ or rifabutin on the pharmacokinetics of @DRUG$ were not studied. DDI-false
The effects of indinavir, zidovudine or @DRUG$ on the pharmacokinetics of @DRUG$ were not studied. DDI-false
@DRUG$, particularly @DRUG$, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all. DDI-false
@DRUG$, particularly metaraminol, may cause serious cardiac arrhythmias during @DRUG$ anesthesia and therefore should be used only with great caution or not at all. DDI-false
Vasopressors, particularly @DRUG$, may cause serious cardiac arrhythmias during @DRUG$ anesthesia and therefore should be used only with great caution or not at all. DDI-effect
@DRUG$ - The pressor effect of @DRUG$ is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). DDI-effect
@DRUG$ - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving @DRUG$ (MAOI). DDI-false
@DRUG$ - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (@DRUG$). DDI-false
MAO Inhibitors - The pressor effect of @DRUG$ is markedly potentiated in patients receiving @DRUG$ (MAOI). DDI-false
MAO Inhibitors - The pressor effect of @DRUG$ is markedly potentiated in patients receiving monoamine oxidase inhibitors (@DRUG$). DDI-effect
MAO Inhibitors - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving @DRUG$ (@DRUG$). DDI-effect
The pressor response of @DRUG$ may also be potentiated by @DRUG$. DDI-false
The CNS-depressant effect of @DRUG$ is additive with that of other @DRUG$, including alcohol. DDI-effect
The CNS-depressant effect of @DRUG$ is additive with that of other CNS depressants, including @DRUG$. DDI-effect
The CNS-depressant effect of propoxyphene is additive with that of other @DRUG$, including @DRUG$. DDI-effect
Such occurrences have been reported when @DRUG$ was administered to patients on @DRUG$, anticonvulsants, or warfarin-like drugs. DDI-false
Such occurrences have been reported when @DRUG$ was administered to patients on antidepressants, @DRUG$, or warfarin-like drugs. DDI-effect
Such occurrences have been reported when @DRUG$ was administered to patients on antidepressants, anticonvulsants, or @DRUG$-like drugs. DDI-effect
Such occurrences have been reported when propoxyphene was administered to patients on @DRUG$, @DRUG$, or warfarin-like drugs. DDI-effect
Such occurrences have been reported when propoxyphene was administered to patients on @DRUG$, anticonvulsants, or @DRUG$-like drugs. DDI-false
Such occurrences have been reported when propoxyphene was administered to patients on antidepressants, @DRUG$, or @DRUG$-like drugs. DDI-false
Reduced absorption of @DRUG$ and @DRUG$ have been reported when those agents were administered concomitantly with sulfasalazine. DDI-false
Reduced absorption of @DRUG$ and digoxin have been reported when those agents were administered concomitantly with @DRUG$. DDI-false
Reduced absorption of folic acid and @DRUG$ have been reported when those agents were administered concomitantly with @DRUG$. DDI-mechanism
When daily doses of @DRUG$ 2 g and weekly doses of @DRUG$ 7.5 mg were coadministered to 15 rheumatoid arthritis patients in a drug-drug interaction study, the pharmacokinetic disposition of the drugs was not altered. DDI-mechanism
Daily doses of @DRUG$ 2 g (maximum 3 g) and weekly doses of @DRUG$ 7.5 mg (maximum 15 mg) were administered alone or in combination to 310 rheumatoid arthritis patients in two controlled 52-week clinical studies. DDI-false
@DRUG$: There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of @DRUG$ with the co-administration of 100 mg sitagliptin for 10 days. DDI-false
@DRUG$: There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of digoxin with the co-administration of 100 mg @DRUG$ for 10 days. DDI-false
Digoxin: There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of @DRUG$ with the co-administration of 100 mg @DRUG$ for 10 days. DDI-false
No dosage adjustment of @DRUG$ or @DRUG$ is recommended. DDI-mechanism
While co-administration of @DRUG$    appeared to increase the clearance of @DRUG$ by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of Cerezyme. DDI-false
While co-administration of @DRUG$    appeared to increase the clearance of Cerezyme by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of @DRUG$. DDI-mechanism
While co-administration of ZAVESCA    appeared to increase the clearance of @DRUG$ by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of @DRUG$. DDI-false
Combination therapy with @DRUG$    (@DRUG$) and ZAVESCA    is not indicated. DDI-false
Combination therapy with @DRUG$    (imiglucerase) and @DRUG$    is not indicated. DDI-false
Combination therapy with Cerezyme    (@DRUG$) and @DRUG$    is not indicated. DDI-advise
@DRUG$ may reverse the analgesic activity of @DRUG$. DDI-false
Concurrent use with @DRUG$ including @DRUG$, sumatriptan, and nicotine (e.g. smoking) may result in enhanced vasoconstriction. DDI-effect
Concurrent use with @DRUG$ including ergot alkaloids, @DRUG$, and nicotine (e.g. smoking) may result in enhanced vasoconstriction. DDI-false
Concurrent use with @DRUG$ including ergot alkaloids, sumatriptan, and @DRUG$ (e.g. smoking) may result in enhanced vasoconstriction. DDI-false
Concurrent use with vasoconstrictor agents including @DRUG$, @DRUG$, and nicotine (e.g. smoking) may result in enhanced vasoconstriction. DDI-false
Concurrent use with vasoconstrictor agents including @DRUG$, sumatriptan, and @DRUG$ (e.g. smoking) may result in enhanced vasoconstriction. DDI-false
Concurrent use with vasoconstrictor agents including ergot alkaloids, @DRUG$, and @DRUG$ (e.g. smoking) may result in enhanced vasoconstriction. DDI-false
Interactions for @DRUG$ (@DRUG$):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants DDI-false
Interactions for @DRUG$ (Thiamine):  @DRUG$, Oral Contraceptives, Stavudine, Tricyclic Antidepressants DDI-false
Interactions for @DRUG$ (Thiamine):  Loop Diuretics, Oral @DRUG$, Stavudine, Tricyclic Antidepressants DDI-false
Interactions for @DRUG$ (Thiamine):  Loop Diuretics, Oral Contraceptives, @DRUG$, Tricyclic Antidepressants DDI-false
Interactions for @DRUG$ (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, @DRUG$ DDI-false
Interactions for Vitamin B1 (@DRUG$):  @DRUG$, Oral Contraceptives, Stavudine, Tricyclic Antidepressants DDI-false
Interactions for Vitamin B1 (@DRUG$):  Loop Diuretics, Oral @DRUG$, Stavudine, Tricyclic Antidepressants DDI-false
Interactions for Vitamin B1 (@DRUG$):  Loop Diuretics, Oral Contraceptives, @DRUG$, Tricyclic Antidepressants DDI-false
Interactions for Vitamin B1 (@DRUG$):  Loop Diuretics, Oral Contraceptives, Stavudine, @DRUG$ DDI-false
Interactions for Vitamin B1 (Thiamine):  @DRUG$, Oral @DRUG$, Stavudine, Tricyclic Antidepressants DDI-false
Interactions for Vitamin B1 (Thiamine):  @DRUG$, Oral Contraceptives, @DRUG$, Tricyclic Antidepressants DDI-false
Interactions for Vitamin B1 (Thiamine):  @DRUG$, Oral Contraceptives, Stavudine, @DRUG$ DDI-false
Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral @DRUG$, @DRUG$, Tricyclic Antidepressants DDI-false
Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral @DRUG$, Stavudine, @DRUG$ DDI-false
Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, @DRUG$, @DRUG$ DDI-false
Interactions for @DRUG$ (@DRUG$):  Alcohol - impairs the intestinal absorption of riboflavin DDI-false
Interactions for @DRUG$ (Riboflavin):  @DRUG$ - impairs the intestinal absorption of riboflavin DDI-false
Interactions for @DRUG$ (Riboflavin):  Alcohol - impairs the intestinal absorption of @DRUG$ DDI-false
Interactions for Vitamin B2 (@DRUG$):  @DRUG$ - impairs the intestinal absorption of riboflavin DDI-false
Interactions for Vitamin B2 (@DRUG$):  Alcohol - impairs the intestinal absorption of @DRUG$ DDI-false
Interactions for Vitamin B2 (Riboflavin):  @DRUG$ - impairs the intestinal absorption of @DRUG$ DDI-false
@DRUG$ - concurrent use decreases gastrointestinal absorption of @DRUG$; DDI-mechanism
requirements for @DRUG$ may be increased in patients receiving @DRUG$. DDI-false
@DRUG$ can interact with @DRUG$, antichlolinergic, TCA, MAOIs, and alcohol. DDI-advise
@DRUG$ can interact with CNS depressant, @DRUG$, TCA, MAOIs, and alcohol. DDI-int
@DRUG$ can interact with CNS depressant, antichlolinergic, @DRUG$, MAOIs, and alcohol. DDI-int
@DRUG$ can interact with CNS depressant, antichlolinergic, TCA, @DRUG$, and alcohol. DDI-int
@DRUG$ can interact with CNS depressant, antichlolinergic, TCA, MAOIs, and @DRUG$. DDI-int
Mequitazine can interact with @DRUG$, @DRUG$, TCA, MAOIs, and alcohol. DDI-int
Mequitazine can interact with @DRUG$, antichlolinergic, @DRUG$, MAOIs, and alcohol. DDI-false
Mequitazine can interact with @DRUG$, antichlolinergic, TCA, @DRUG$, and alcohol. DDI-false
Mequitazine can interact with @DRUG$, antichlolinergic, TCA, MAOIs, and @DRUG$. DDI-false
Mequitazine can interact with CNS depressant, @DRUG$, @DRUG$, MAOIs, and alcohol. DDI-false
Mequitazine can interact with CNS depressant, @DRUG$, TCA, @DRUG$, and alcohol. DDI-false
Mequitazine can interact with CNS depressant, @DRUG$, TCA, MAOIs, and @DRUG$. DDI-false
Mequitazine can interact with CNS depressant, antichlolinergic, @DRUG$, @DRUG$, and alcohol. DDI-false
Mequitazine can interact with CNS depressant, antichlolinergic, @DRUG$, MAOIs, and @DRUG$. DDI-false
Mequitazine can interact with CNS depressant, antichlolinergic, TCA, @DRUG$, and @DRUG$. DDI-false
@DRUG$: Absorption of a single dose of @DRUG$ was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. DDI-false
@DRUG$: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking @DRUG$-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. DDI-false
@DRUG$: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-@DRUG$ containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. DDI-false
@DRUG$: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing @DRUG$ (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. DDI-false
@DRUG$: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when @DRUG$ was administered alone under fasting conditions. DDI-false
Antacids: Absorption of a single dose of @DRUG$ was decreased when administered to 12 stable renal transplant patients also taking @DRUG$-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. DDI-false
Antacids: Absorption of a single dose of @DRUG$ was decreased when administered to 12 stable renal transplant patients also taking magnesium-@DRUG$ containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. DDI-mechanism
Antacids: Absorption of a single dose of @DRUG$ was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing @DRUG$ (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. DDI-false
Antacids: Absorption of a single dose of @DRUG$ was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when @DRUG$ was administered alone under fasting conditions. DDI-false
Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking @DRUG$-@DRUG$ containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. DDI-false
Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking @DRUG$-aluminum containing @DRUG$ (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. DDI-false
Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking @DRUG$-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when @DRUG$ was administered alone under fasting conditions. DDI-false
Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-@DRUG$ containing @DRUG$ (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. DDI-false
Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-@DRUG$ containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when @DRUG$ was administered alone under fasting conditions. DDI-false
Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing @DRUG$ (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when @DRUG$ was administered alone under fasting conditions. DDI-false
It is recommended that @DRUG$ and @DRUG$ not be administered simultaneously. DDI-false
However, in a drug-drug interaction study, mean @DRUG$ AUC was decreased by 15% when coadministered with @DRUG$. DDI-advise
Therefore, it is recommended that oral @DRUG$ are co- administered with @DRUG$ with caution and additional birth control methods be considered. DDI-mechanism
@DRUG$: During treatment with @DRUG$, the use of live attenuated vaccines should be avoided and patients should be advised that vaccinations may be less effective. DDI-advise
@DRUG$: During treatment with Myfortic, the use of @DRUG$ should be avoided and patients should be advised that vaccinations may be less effective. DDI-false
Live Vaccines: During treatment with @DRUG$, the use of @DRUG$ should be avoided and patients should be advised that vaccinations may be less effective. DDI-false
Interference of @DRUG$ hydrolysis may lead to less @DRUG$ available for absorption. DDI-advise
@DRUG$: When studied in stable renal transplant patients, @DRUG$, USP (MODIFIED) pharmacokinetics were unaffected by steady state dosing of Myfortic. DDI-false
@DRUG$: When studied in stable renal transplant patients, cyclosporine, USP (MODIFIED) pharmacokinetics were unaffected by steady state dosing of @DRUG$. DDI-false
Cyclosporine: When studied in stable renal transplant patients, @DRUG$, USP (MODIFIED) pharmacokinetics were unaffected by steady state dosing of @DRUG$. DDI-false
@DRUG$/@DRUG$: may be taken with Myfortic; DDI-false
@DRUG$/Ganciclovir: may be taken with @DRUG$; DDI-false
Acyclovir/@DRUG$: may be taken with @DRUG$; DDI-false
Both @DRUG$/@DRUG$ and MPAG concentrations are increased in the presence of renal impairment, their coexistence may compete for tubular secretion and further increase in the concentrations of the two. DDI-false
Both @DRUG$/ganciclovir and @DRUG$ concentrations are increased in the presence of renal impairment, their coexistence may compete for tubular secretion and further increase in the concentrations of the two. DDI-false
Both acyclovir/@DRUG$ and @DRUG$ concentrations are increased in the presence of renal impairment, their coexistence may compete for tubular secretion and further increase in the concentrations of the two. DDI-false
@DRUG$/@DRUG$: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. DDI-false
@DRUG$/Mycophenolate Mofetil: Given that @DRUG$ and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. DDI-false
@DRUG$/Mycophenolate Mofetil: Given that azathioprine and @DRUG$ inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. DDI-false
@DRUG$/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that @DRUG$ not be administered concomitantly with azathioprine or mycophenolate mofetil. DDI-false
@DRUG$/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with @DRUG$ or mycophenolate mofetil. DDI-false
@DRUG$/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or @DRUG$. DDI-false
Azathioprine/@DRUG$: Given that @DRUG$ and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. DDI-false
Azathioprine/@DRUG$: Given that azathioprine and @DRUG$ inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. DDI-false
Azathioprine/@DRUG$: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that @DRUG$ not be administered concomitantly with azathioprine or mycophenolate mofetil. DDI-false
Azathioprine/@DRUG$: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with @DRUG$ or mycophenolate mofetil. DDI-false
Azathioprine/@DRUG$: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or @DRUG$. DDI-false
Azathioprine/Mycophenolate Mofetil: Given that @DRUG$ and @DRUG$ inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. DDI-false
Azathioprine/Mycophenolate Mofetil: Given that @DRUG$ and mycophenolate mofetil inhibit purine metabolism, it is recommended that @DRUG$ not be administered concomitantly with azathioprine or mycophenolate mofetil. DDI-false
Azathioprine/Mycophenolate Mofetil: Given that @DRUG$ and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with @DRUG$ or mycophenolate mofetil. DDI-false
Azathioprine/Mycophenolate Mofetil: Given that @DRUG$ and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or @DRUG$. DDI-false
Azathioprine/Mycophenolate Mofetil: Given that azathioprine and @DRUG$ inhibit purine metabolism, it is recommended that @DRUG$ not be administered concomitantly with azathioprine or mycophenolate mofetil. DDI-false
Azathioprine/Mycophenolate Mofetil: Given that azathioprine and @DRUG$ inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with @DRUG$ or mycophenolate mofetil. DDI-false
Azathioprine/Mycophenolate Mofetil: Given that azathioprine and @DRUG$ inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or @DRUG$. DDI-false
Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that @DRUG$ not be administered concomitantly with @DRUG$ or mycophenolate mofetil. DDI-false
Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that @DRUG$ not be administered concomitantly with azathioprine or @DRUG$. DDI-advise
Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with @DRUG$ or @DRUG$. DDI-advise
@DRUG$ and Drugs that Bind Bile Acids: These drugs interrupt enterohepatic recirculation and reduce @DRUG$ exposure when coadministered with mycophenolate mofetil. DDI-false
@DRUG$ and Drugs that Bind Bile Acids: These drugs interrupt enterohepatic recirculation and reduce MPA exposure when coadministered with @DRUG$. DDI-false
Cholestyramine and Drugs that Bind Bile Acids: These drugs interrupt enterohepatic recirculation and reduce @DRUG$ exposure when coadministered with @DRUG$. DDI-false
Therefore, do not administer @DRUG$ with @DRUG$ or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of Myfortic. DDI-false
Therefore, do not administer @DRUG$ with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral @DRUG$, because of the potential to reduce the efficacy of Myfortic. DDI-advise
Therefore, do not administer @DRUG$ with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of @DRUG$. DDI-false
Therefore, do not administer Myfortic with @DRUG$ or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral @DRUG$, because of the potential to reduce the efficacy of Myfortic. DDI-false
Therefore, do not administer Myfortic with @DRUG$ or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of @DRUG$. DDI-false
Therefore, do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral @DRUG$, because of the potential to reduce the efficacy of @DRUG$. DDI-false
Oral @DRUG$: Given the different metabolism of @DRUG$ and oral contraceptives, no drug interaction between these two classes of drug is expected. DDI-false
Oral @DRUG$: Given the different metabolism of Myfortic and oral @DRUG$, no drug interaction between these two classes of drug is expected. DDI-false
Oral Contraceptives: Given the different metabolism of @DRUG$ and oral @DRUG$, no drug interaction between these two classes of drug is expected. DDI-false
These include @DRUG$, @DRUG$, and oral and inhaled steroids. DDI-false
These include @DRUG$, methylxanthines, and oral and inhaled @DRUG$. DDI-false
These include sympathomimetic bronchodilators, @DRUG$, and oral and inhaled @DRUG$. DDI-false
However, the co   administration of @DRUG$ with other @DRUG$   containing drugs (e.g., ipratropium) has not been studied and is therefore not recommended. DDI-false
However, the co   administration of @DRUG$ with other anticholinergic   containing drugs (e.g., @DRUG$) has not been studied and is therefore not recommended. DDI-advise
However, the co   administration of SPIRIVA with other @DRUG$   containing drugs (e.g., @DRUG$) has not been studied and is therefore not recommended. DDI-advise
Interaction with Other @DRUG$: @DRUG$ SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). DDI-false
Interaction with Other @DRUG$: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER @DRUG$, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). DDI-false
Interaction with Other @DRUG$: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL @DRUG$, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). DDI-false
Interaction with Other @DRUG$: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, @DRUG$, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). DDI-false
Interaction with Other @DRUG$: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER @DRUG$, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). DDI-false
Interaction with Other @DRUG$: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, @DRUG$ (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). DDI-false
Interaction with Other @DRUG$: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING @DRUG$), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). DDI-false
Interaction with Other @DRUG$: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), @DRUG$ AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). DDI-false
Interaction with Other @DRUG$: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER @DRUG$ (INCLUDING ALCOHOL). DDI-false
Interaction with Other @DRUG$: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING @DRUG$). DDI-false
Interaction with Other Central Nervous System Depressants: @DRUG$ SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER @DRUG$, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). DDI-false
Interaction with Other Central Nervous System Depressants: @DRUG$ SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL @DRUG$, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). DDI-false
Interaction with Other Central Nervous System Depressants: @DRUG$ SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, @DRUG$, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). DDI-false
Interaction with Other Central Nervous System Depressants: @DRUG$ SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER @DRUG$, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). DDI-false
Interaction with Other Central Nervous System Depressants: @DRUG$ SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, @DRUG$ (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). DDI-false
Interaction with Other Central Nervous System Depressants: @DRUG$ SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING @DRUG$), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). DDI-false
Interaction with Other Central Nervous System Depressants: @DRUG$ SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), @DRUG$ AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). DDI-false
Interaction with Other Central Nervous System Depressants: @DRUG$ SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER @DRUG$ (INCLUDING ALCOHOL). DDI-false
Interaction with Other Central Nervous System Depressants: @DRUG$ SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING @DRUG$). DDI-false
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER @DRUG$, GENERAL @DRUG$, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). DDI-false
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER @DRUG$, GENERAL ANESTHETICS, @DRUG$, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). DDI-false
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER @DRUG$, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER @DRUG$, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). DDI-false
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER @DRUG$, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, @DRUG$ (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). DDI-false
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER @DRUG$, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING @DRUG$), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). DDI-false
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER @DRUG$, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), @DRUG$ AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). DDI-false
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER @DRUG$, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER @DRUG$ (INCLUDING ALCOHOL). DDI-false
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER @DRUG$, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING @DRUG$). DDI-false
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL @DRUG$, @DRUG$, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). DDI-false
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL @DRUG$, PHENOTHIAZINES, OTHER @DRUG$, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). DDI-false
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL @DRUG$, PHENOTHIAZINES, OTHER TRANQUILIZERS, @DRUG$ (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). DDI-false
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL @DRUG$, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING @DRUG$), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). DDI-false
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL @DRUG$, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), @DRUG$ AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). DDI-false
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL @DRUG$, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER @DRUG$ (INCLUDING ALCOHOL). DDI-false
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL @DRUG$, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING @DRUG$). DDI-false
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, @DRUG$, OTHER @DRUG$, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). DDI-false
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, @DRUG$, OTHER TRANQUILIZERS, @DRUG$ (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). DDI-false
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, @DRUG$, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING @DRUG$), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). DDI-false
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, @DRUG$, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), @DRUG$ AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). DDI-false
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, @DRUG$, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER @DRUG$ (INCLUDING ALCOHOL). DDI-false
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, @DRUG$, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING @DRUG$). DDI-false
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER @DRUG$, @DRUG$ (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). DDI-false
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER @DRUG$, SEDATIVE-HYPNOTICS (INCLUDING @DRUG$), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). DDI-false
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER @DRUG$, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), @DRUG$ AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). DDI-false
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER @DRUG$, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER @DRUG$ (INCLUDING ALCOHOL). DDI-false
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER @DRUG$, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING @DRUG$). DDI-false
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, @DRUG$ (INCLUDING @DRUG$), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). DDI-false
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, @DRUG$ (INCLUDING BARBITURATES), @DRUG$ AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). DDI-false
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, @DRUG$ (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER @DRUG$ (INCLUDING ALCOHOL). DDI-false
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, @DRUG$ (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING @DRUG$). DDI-false
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING @DRUG$), @DRUG$ AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). DDI-false
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING @DRUG$), TRICYCLIC ANTIDEPRESSANTS AND OTHER @DRUG$ (INCLUDING ALCOHOL). DDI-false
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING @DRUG$), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING @DRUG$). DDI-false
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), @DRUG$ AND OTHER @DRUG$ (INCLUDING ALCOHOL). DDI-false
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), @DRUG$ AND OTHER CNS DEPRESSANTS (INCLUDING @DRUG$). DDI-false
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER @DRUG$ (INCLUDING @DRUG$). DDI-false
Drug-Drug Interactions: The pharmacokinetic and pharmacodynamic interactions between @DRUG$ capsules and other @DRUG$ have not been determined. DDI-false
However, interactions may be expected and @DRUG$ capsules should NOT be used in combination with other @DRUG$. DDI-false
The pharmacokinetic interaction between @DRUG$ and @DRUG$ capsules was investigated. DDI-advise
Therefore, @DRUG$ capsules should be used with caution in combination with @DRUG$, particularly at doses higher than 0.4 mg. DDI-false
Results from limited in vitro and in vivo drug-drug interaction studies between @DRUG$ and @DRUG$ are inconclusive. DDI-advise
Therefore, caution should be exercised with concomitant administration of @DRUG$ and @DRUG$ capsules. DDI-false
Catecholamine-depleting drugs (e.g., @DRUG$) may have an additive effect when given with @DRUG$. DDI-advise
Concomitant administrations not recommended:  - @DRUG$ and @DRUG$: Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter. DDI-effect
Concomitant administrations not recommended:  - @DRUG$ and astemizole: Certain @DRUG$ interact with terfenadine and astemizole leading to increased serum concentrations of the latter. DDI-false
Concomitant administrations not recommended:  - @DRUG$ and astemizole: Certain macrolides interact with @DRUG$ and astemizole leading to increased serum concentrations of the latter. DDI-false
Concomitant administrations not recommended:  - @DRUG$ and astemizole: Certain macrolides interact with terfenadine and @DRUG$ leading to increased serum concentrations of the latter. DDI-false
Concomitant administrations not recommended:  - Terfenadine and @DRUG$: Certain @DRUG$ interact with terfenadine and astemizole leading to increased serum concentrations of the latter. DDI-false
Concomitant administrations not recommended:  - Terfenadine and @DRUG$: Certain macrolides interact with @DRUG$ and astemizole leading to increased serum concentrations of the latter. DDI-false
Concomitant administrations not recommended:  - Terfenadine and @DRUG$: Certain macrolides interact with terfenadine and @DRUG$ leading to increased serum concentrations of the latter. DDI-false
Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain @DRUG$ interact with @DRUG$ and astemizole leading to increased serum concentrations of the latter. DDI-false
Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain @DRUG$ interact with terfenadine and @DRUG$ leading to increased serum concentrations of the latter. DDI-mechanism
Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain macrolides interact with @DRUG$ and @DRUG$ leading to increased serum concentrations of the latter. DDI-mechanism
Although such a reaction has not been demonstrated with @DRUG$, concomitant administration of @DRUG$ with terfenadine or astemizole is not recommended. DDI-false
Although such a reaction has not been demonstrated with @DRUG$, concomitant administration of roxithromycin with @DRUG$ or astemizole is not recommended. DDI-false
Although such a reaction has not been demonstrated with @DRUG$, concomitant administration of roxithromycin with terfenadine or @DRUG$ is not recommended. DDI-false
Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of @DRUG$ with @DRUG$ or astemizole is not recommended. DDI-false
Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of @DRUG$ with terfenadine or @DRUG$ is not recommended. DDI-advise
Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of roxithromycin with @DRUG$ or @DRUG$ is not recommended. DDI-advise
- @DRUG$, @DRUG$: Other drugs such as cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials. DDI-false
- @DRUG$, pimozide: Other drugs such as @DRUG$ or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials. DDI-false
- @DRUG$, pimozide: Other drugs such as cisapride or @DRUG$, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials. DDI-false
- @DRUG$, pimozide: Other drugs such as cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some @DRUG$. DDI-false
- Cisapride, @DRUG$: Other drugs such as @DRUG$ or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials. DDI-false
- Cisapride, @DRUG$: Other drugs such as cisapride or @DRUG$, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials. DDI-false
- Cisapride, @DRUG$: Other drugs such as cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some @DRUG$. DDI-false
- Cisapride, pimozide: Other drugs such as @DRUG$ or @DRUG$, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials. DDI-false
- Cisapride, pimozide: Other drugs such as @DRUG$ or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some @DRUG$. DDI-false
- Cisapride, pimozide: Other drugs such as cisapride or @DRUG$, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some @DRUG$. DDI-false
Although such a risk is not verified for @DRUG$, combination of @DRUG$ with such drugs is not recommended. DDI-false
@DRUG$: The effects of chronic @DRUG$ use on the metabolism of rimantadine are not known. DDI-false
@DRUG$: The effects of chronic cimetidine use on the metabolism of @DRUG$ are not known. DDI-false
Cimetidine: The effects of chronic @DRUG$ use on the metabolism of @DRUG$ are not known. DDI-false
When a single 100 mg dose of @DRUG$ was administered one hour after the initiation of @DRUG$ (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine). DDI-false
When a single 100 mg dose of @DRUG$ was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total @DRUG$ clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine). DDI-mechanism
When a single 100 mg dose of @DRUG$ was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total @DRUG$ clearance in the same subjects in the absence of cimetidine). DDI-false
When a single 100 mg dose of @DRUG$ was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of @DRUG$). DDI-false
When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of @DRUG$ (300 mg four times a day), the apparent total @DRUG$ clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine). DDI-false
When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of @DRUG$ (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total @DRUG$ clearance in the same subjects in the absence of cimetidine). DDI-false
When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of @DRUG$ (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of @DRUG$). DDI-false
When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total @DRUG$ clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total @DRUG$ clearance in the same subjects in the absence of cimetidine). DDI-false
When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total @DRUG$ clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of @DRUG$). DDI-false
When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total @DRUG$ clearance in the same subjects in the absence of @DRUG$). DDI-false
@DRUG$: @DRUG$, 100 mg, was given twice daily for 13 days to 12 healthy volunteers. DDI-false
Coadministration with @DRUG$ reduced the peak concentration and AUC values for @DRUG$ by approximately 11%. DDI-false
@DRUG$: @DRUG$, 100 mg, was given twice daily fro 13 days to 12 healthy volunteers. DDI-mechanism
Peak plasma concentrations and AUC of @DRUG$ were reduced approximately 10% in the presence of @DRUG$. DDI-false
Because @DRUG$ have been shown to depress plasma prothrombin activity, patients who are on @DRUG$ therapy may require downward adjustment of their anticoagulant dosage. DDI-mechanism
Because @DRUG$ have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their @DRUG$ dosage. DDI-advise
Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on @DRUG$ therapy may require downward adjustment of their @DRUG$ dosage. DDI-false
Since bacteriostatic drugs may interfere with the bactericidal action of @DRUG$, it is advisable to avoid giving @DRUG$ in conjunction with penicillin. DDI-false
Since bacteriostatic drugs may interfere with the bactericidal action of @DRUG$, it is advisable to avoid giving tetracycline class drugs in conjunction with @DRUG$. DDI-false
Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving @DRUG$ in conjunction with @DRUG$. DDI-false
Absorption of @DRUG$ is impaired by @DRUG$ containing aluminum, calcium or magnesium, and iron-containing preparations. DDI-advise
Absorption of @DRUG$ is impaired by antacids containing @DRUG$, calcium or magnesium, and iron-containing preparations. DDI-false
Absorption of @DRUG$ is impaired by antacids containing aluminum, @DRUG$ or magnesium, and iron-containing preparations. DDI-mechanism
Absorption of @DRUG$ is impaired by antacids containing aluminum, calcium or @DRUG$, and iron-containing preparations. DDI-mechanism
Absorption of @DRUG$ is impaired by antacids containing aluminum, calcium or magnesium, and @DRUG$-containing preparations. DDI-mechanism
Absorption of tetracyclines is impaired by @DRUG$ containing @DRUG$, calcium or magnesium, and iron-containing preparations. DDI-mechanism
Absorption of tetracyclines is impaired by @DRUG$ containing aluminum, @DRUG$ or magnesium, and iron-containing preparations. DDI-false
Absorption of tetracyclines is impaired by @DRUG$ containing aluminum, calcium or @DRUG$, and iron-containing preparations. DDI-false
Absorption of tetracyclines is impaired by @DRUG$ containing aluminum, calcium or magnesium, and @DRUG$-containing preparations. DDI-false
Absorption of tetracyclines is impaired by antacids containing @DRUG$, @DRUG$ or magnesium, and iron-containing preparations. DDI-false
Absorption of tetracyclines is impaired by antacids containing @DRUG$, calcium or @DRUG$, and iron-containing preparations. DDI-false
Absorption of tetracyclines is impaired by antacids containing @DRUG$, calcium or magnesium, and @DRUG$-containing preparations. DDI-false
Absorption of tetracyclines is impaired by antacids containing aluminum, @DRUG$ or @DRUG$, and iron-containing preparations. DDI-false
Absorption of tetracyclines is impaired by antacids containing aluminum, @DRUG$ or magnesium, and @DRUG$-containing preparations. DDI-false
Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or @DRUG$, and @DRUG$-containing preparations. DDI-false
The concurrent use of @DRUG$ and @DRUG$ has been reported to result in fatal renal toxicity. DDI-false
Concurrent use of @DRUG$ with oral @DRUG$ may render oral contraceptives less effective. DDI-effect
Concurrent use of @DRUG$ with oral contraceptives may render oral @DRUG$ less effective. DDI-effect
Concurrent use of tetracyclines with oral @DRUG$ may render oral @DRUG$ less effective. DDI-false
Administration of @DRUG$ in combination with @DRUG$ resulted in a two-fold decrease in HERCEPTIN clearance in a non-human primate study and in a 1.5-fold increase in HERCEPTIN serum levels in clinical studies. DDI-false
Administration of @DRUG$ in combination with HERCEPTIN resulted in a two-fold decrease in @DRUG$ clearance in a non-human primate study and in a 1.5-fold increase in HERCEPTIN serum levels in clinical studies. DDI-mechanism
Administration of @DRUG$ in combination with HERCEPTIN resulted in a two-fold decrease in HERCEPTIN clearance in a non-human primate study and in a 1.5-fold increase in @DRUG$ serum levels in clinical studies. DDI-false
Administration of paclitaxel in combination with @DRUG$ resulted in a two-fold decrease in @DRUG$ clearance in a non-human primate study and in a 1.5-fold increase in HERCEPTIN serum levels in clinical studies. DDI-false
Administration of paclitaxel in combination with @DRUG$ resulted in a two-fold decrease in HERCEPTIN clearance in a non-human primate study and in a 1.5-fold increase in @DRUG$ serum levels in clinical studies. DDI-false
Administration of paclitaxel in combination with HERCEPTIN resulted in a two-fold decrease in @DRUG$ clearance in a non-human primate study and in a 1.5-fold increase in @DRUG$ serum levels in clinical studies. DDI-false
The concomitant use of @DRUG$ with other @DRUG$ that produce dry mouth, constipation, and other anticholinergic pharmacological effects may increase the frequency and/or severity of such effects. DDI-false
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with @DRUG$ have not been conducted, @DRUG$ has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). DDI-effect
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with @DRUG$ have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. @DRUG$, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). DDI-false
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with @DRUG$ have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, @DRUG$, pancuronium, morphine, vancomycin, metformin and tenofovir). DDI-false
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with @DRUG$ have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, @DRUG$, morphine, vancomycin, metformin and tenofovir). DDI-false
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with @DRUG$ have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, @DRUG$, vancomycin, metformin and tenofovir). DDI-false
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with @DRUG$ have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, @DRUG$, metformin and tenofovir). DDI-false
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with @DRUG$ have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, @DRUG$ and tenofovir). DDI-false
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with @DRUG$ have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and @DRUG$). DDI-false
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, @DRUG$ has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. @DRUG$, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). DDI-false
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, @DRUG$ has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, @DRUG$, pancuronium, morphine, vancomycin, metformin and tenofovir). DDI-false
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, @DRUG$ has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, @DRUG$, morphine, vancomycin, metformin and tenofovir). DDI-false
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, @DRUG$ has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, @DRUG$, vancomycin, metformin and tenofovir). DDI-false
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, @DRUG$ has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, @DRUG$, metformin and tenofovir). DDI-false
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, @DRUG$ has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, @DRUG$ and tenofovir). DDI-false
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, @DRUG$ has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and @DRUG$). DDI-false
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. @DRUG$, @DRUG$, pancuronium, morphine, vancomycin, metformin and tenofovir). DDI-false
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. @DRUG$, procainamide, @DRUG$, morphine, vancomycin, metformin and tenofovir). DDI-false
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. @DRUG$, procainamide, pancuronium, @DRUG$, vancomycin, metformin and tenofovir). DDI-false
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. @DRUG$, procainamide, pancuronium, morphine, @DRUG$, metformin and tenofovir). DDI-false
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. @DRUG$, procainamide, pancuronium, morphine, vancomycin, @DRUG$ and tenofovir). DDI-false
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. @DRUG$, procainamide, pancuronium, morphine, vancomycin, metformin and @DRUG$). DDI-false
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, @DRUG$, @DRUG$, morphine, vancomycin, metformin and tenofovir). DDI-false
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, @DRUG$, pancuronium, @DRUG$, vancomycin, metformin and tenofovir). DDI-false
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, @DRUG$, pancuronium, morphine, @DRUG$, metformin and tenofovir). DDI-false
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, @DRUG$, pancuronium, morphine, vancomycin, @DRUG$ and tenofovir). DDI-false
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, @DRUG$, pancuronium, morphine, vancomycin, metformin and @DRUG$). DDI-false
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, @DRUG$, @DRUG$, vancomycin, metformin and tenofovir). DDI-false
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, @DRUG$, morphine, @DRUG$, metformin and tenofovir). DDI-false
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, @DRUG$, morphine, vancomycin, @DRUG$ and tenofovir). DDI-false
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, @DRUG$, morphine, vancomycin, metformin and @DRUG$). DDI-false
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, @DRUG$, @DRUG$, metformin and tenofovir). DDI-false
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, @DRUG$, vancomycin, @DRUG$ and tenofovir). DDI-false
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, @DRUG$, vancomycin, metformin and @DRUG$). DDI-false
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, @DRUG$, @DRUG$ and tenofovir). DDI-false
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, @DRUG$, metformin and @DRUG$). DDI-false
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, @DRUG$ and @DRUG$). DDI-false
Coadministration of @DRUG$ with drugs that are eliminated by active renal tubular secretion may increase the serum concentration of @DRUG$ and/or the coadministered drug due to competition for this elimination pathway. DDI-false
Caution should be observed in administering @DRUG$ to patients receiving @DRUG$ or haloperidol because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis. DDI-false
Caution should be observed in administering @DRUG$ to patients receiving phenothiazines or @DRUG$ because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis. DDI-advise
Caution should be observed in administering DEMSER to patients receiving @DRUG$ or @DRUG$ because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis. DDI-advise
Concurrent use of @DRUG$ with @DRUG$ or other CNS depressants can increase their sedative effects. DDI-false
Concurrent use of @DRUG$ with alcohol or other @DRUG$ can increase their sedative effects. DDI-effect
Concurrent use of DEMSER with @DRUG$ or other @DRUG$ can increase their sedative effects. DDI-effect
You cannot take @DRUG$ if you have taken a @DRUG$ (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. DDI-false
You cannot take @DRUG$ if you have taken a monoamine oxidase inhibitor (@DRUG$) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. DDI-false
You cannot take @DRUG$ if you have taken a monoamine oxidase inhibitor (MAOI) such as @DRUG$ (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. DDI-false
You cannot take @DRUG$ if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (@DRUG$), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. DDI-false
You cannot take @DRUG$ if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), @DRUG$ (Parnate), or phenelzine (Nardil) in the last 14 days. DDI-false
You cannot take @DRUG$ if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (@DRUG$), or phenelzine (Nardil) in the last 14 days. DDI-false
You cannot take @DRUG$ if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or @DRUG$ (Nardil) in the last 14 days. DDI-false
You cannot take @DRUG$ if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (@DRUG$) in the last 14 days. DDI-false
You cannot take mazindol if you have taken a @DRUG$ (@DRUG$) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. DDI-false
You cannot take mazindol if you have taken a @DRUG$ (MAOI) such as @DRUG$ (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. DDI-false
You cannot take mazindol if you have taken a @DRUG$ (MAOI) such as isocarboxazid (@DRUG$), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. DDI-false
You cannot take mazindol if you have taken a @DRUG$ (MAOI) such as isocarboxazid (Marplan), @DRUG$ (Parnate), or phenelzine (Nardil) in the last 14 days. DDI-false
You cannot take mazindol if you have taken a @DRUG$ (MAOI) such as isocarboxazid (Marplan), tranylcypromine (@DRUG$), or phenelzine (Nardil) in the last 14 days. DDI-false
You cannot take mazindol if you have taken a @DRUG$ (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or @DRUG$ (Nardil) in the last 14 days. DDI-false
You cannot take mazindol if you have taken a @DRUG$ (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (@DRUG$) in the last 14 days. DDI-false
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (@DRUG$) such as @DRUG$ (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. DDI-false
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (@DRUG$) such as isocarboxazid (@DRUG$), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. DDI-false
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (@DRUG$) such as isocarboxazid (Marplan), @DRUG$ (Parnate), or phenelzine (Nardil) in the last 14 days. DDI-false
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (@DRUG$) such as isocarboxazid (Marplan), tranylcypromine (@DRUG$), or phenelzine (Nardil) in the last 14 days. DDI-false
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (@DRUG$) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or @DRUG$ (Nardil) in the last 14 days. DDI-false
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (@DRUG$) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (@DRUG$) in the last 14 days. DDI-false
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as @DRUG$ (@DRUG$), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. DDI-false
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as @DRUG$ (Marplan), @DRUG$ (Parnate), or phenelzine (Nardil) in the last 14 days. DDI-false
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as @DRUG$ (Marplan), tranylcypromine (@DRUG$), or phenelzine (Nardil) in the last 14 days. DDI-false
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as @DRUG$ (Marplan), tranylcypromine (Parnate), or @DRUG$ (Nardil) in the last 14 days. DDI-false
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as @DRUG$ (Marplan), tranylcypromine (Parnate), or phenelzine (@DRUG$) in the last 14 days. DDI-false
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (@DRUG$), @DRUG$ (Parnate), or phenelzine (Nardil) in the last 14 days. DDI-false
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (@DRUG$), tranylcypromine (@DRUG$), or phenelzine (Nardil) in the last 14 days. DDI-false
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (@DRUG$), tranylcypromine (Parnate), or @DRUG$ (Nardil) in the last 14 days. DDI-false
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (@DRUG$), tranylcypromine (Parnate), or phenelzine (@DRUG$) in the last 14 days. DDI-false
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), @DRUG$ (@DRUG$), or phenelzine (Nardil) in the last 14 days. DDI-false
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), @DRUG$ (Parnate), or @DRUG$ (Nardil) in the last 14 days. DDI-false
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), @DRUG$ (Parnate), or phenelzine (@DRUG$) in the last 14 days. DDI-false
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (@DRUG$), or @DRUG$ (Nardil) in the last 14 days. DDI-false
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (@DRUG$), or phenelzine (@DRUG$) in the last 14 days. DDI-false
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or @DRUG$ (@DRUG$) in the last 14 days. DDI-false
Changes in @DRUG$ and other diabetes drug therapies may be necessary during treatment with @DRUG$. DDI-false
@DRUG$ may reduce the effects of @DRUG$ (Ismelin). DDI-advise
@DRUG$ may reduce the effects of guanethidine (@DRUG$). DDI-effect
Mazindol may reduce the effects of @DRUG$ (@DRUG$). DDI-effect
Before taking this medication, tell your doctor if you are taking a @DRUG$ such as @DRUG$ (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a @DRUG$ such as amitriptyline (@DRUG$), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a @DRUG$ such as amitriptyline (Elavil), @DRUG$ (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a @DRUG$ such as amitriptyline (Elavil), amoxapine (@DRUG$), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a @DRUG$ such as amitriptyline (Elavil), amoxapine (Asendin), @DRUG$ (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a @DRUG$ such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (@DRUG$), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a @DRUG$ such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), @DRUG$ (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a @DRUG$ such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (@DRUG$), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a @DRUG$ such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), @DRUG$ (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a @DRUG$ such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (@DRUG$), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a @DRUG$ such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), @DRUG$ (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a @DRUG$ such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (@DRUG$), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a @DRUG$ such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), @DRUG$ (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a @DRUG$ such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (@DRUG$), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a @DRUG$ such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or @DRUG$ (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a @DRUG$ such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (@DRUG$). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as @DRUG$ (@DRUG$), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as @DRUG$ (Elavil), @DRUG$ (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as @DRUG$ (Elavil), amoxapine (@DRUG$), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as @DRUG$ (Elavil), amoxapine (Asendin), @DRUG$ (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as @DRUG$ (Elavil), amoxapine (Asendin), doxepin (@DRUG$), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as @DRUG$ (Elavil), amoxapine (Asendin), doxepin (Sinequan), @DRUG$ (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as @DRUG$ (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (@DRUG$), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as @DRUG$ (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), @DRUG$ (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as @DRUG$ (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (@DRUG$), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as @DRUG$ (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), @DRUG$ (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as @DRUG$ (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (@DRUG$), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as @DRUG$ (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), @DRUG$ (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as @DRUG$ (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (@DRUG$), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as @DRUG$ (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or @DRUG$ (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as @DRUG$ (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (@DRUG$). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (@DRUG$), @DRUG$ (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (@DRUG$), amoxapine (@DRUG$), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (@DRUG$), amoxapine (Asendin), @DRUG$ (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (@DRUG$), amoxapine (Asendin), doxepin (@DRUG$), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (@DRUG$), amoxapine (Asendin), doxepin (Sinequan), @DRUG$ (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (@DRUG$), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (@DRUG$), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (@DRUG$), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), @DRUG$ (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (@DRUG$), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (@DRUG$), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (@DRUG$), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), @DRUG$ (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (@DRUG$), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (@DRUG$), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (@DRUG$), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), @DRUG$ (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (@DRUG$), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (@DRUG$), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (@DRUG$), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or @DRUG$ (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (@DRUG$), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (@DRUG$). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), @DRUG$ (@DRUG$), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), @DRUG$ (Asendin), @DRUG$ (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), @DRUG$ (Asendin), doxepin (@DRUG$), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), @DRUG$ (Asendin), doxepin (Sinequan), @DRUG$ (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), @DRUG$ (Asendin), doxepin (Sinequan), nortriptyline (@DRUG$), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), @DRUG$ (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), @DRUG$ (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), @DRUG$ (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (@DRUG$), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), @DRUG$ (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), @DRUG$ (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), @DRUG$ (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (@DRUG$), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), @DRUG$ (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), @DRUG$ (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), @DRUG$ (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (@DRUG$), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), @DRUG$ (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or @DRUG$ (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), @DRUG$ (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (@DRUG$). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (@DRUG$), @DRUG$ (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (@DRUG$), doxepin (@DRUG$), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (@DRUG$), doxepin (Sinequan), @DRUG$ (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (@DRUG$), doxepin (Sinequan), nortriptyline (@DRUG$), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (@DRUG$), doxepin (Sinequan), nortriptyline (Pamelor), @DRUG$ (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (@DRUG$), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (@DRUG$), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (@DRUG$), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), @DRUG$ (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (@DRUG$), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (@DRUG$), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (@DRUG$), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), @DRUG$ (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (@DRUG$), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (@DRUG$), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (@DRUG$), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or @DRUG$ (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (@DRUG$), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (@DRUG$). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), @DRUG$ (@DRUG$), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), @DRUG$ (Sinequan), @DRUG$ (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), @DRUG$ (Sinequan), nortriptyline (@DRUG$), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), @DRUG$ (Sinequan), nortriptyline (Pamelor), @DRUG$ (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), @DRUG$ (Sinequan), nortriptyline (Pamelor), imipramine (@DRUG$), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), @DRUG$ (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), @DRUG$ (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), @DRUG$ (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (@DRUG$), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), @DRUG$ (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), @DRUG$ (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), @DRUG$ (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (@DRUG$), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), @DRUG$ (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or @DRUG$ (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), @DRUG$ (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (@DRUG$). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (@DRUG$), @DRUG$ (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (@DRUG$), nortriptyline (@DRUG$), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (@DRUG$), nortriptyline (Pamelor), @DRUG$ (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (@DRUG$), nortriptyline (Pamelor), imipramine (@DRUG$), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (@DRUG$), nortriptyline (Pamelor), imipramine (Tofranil), @DRUG$ (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (@DRUG$), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (@DRUG$), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (@DRUG$), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), @DRUG$ (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (@DRUG$), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (@DRUG$), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (@DRUG$), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or @DRUG$ (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (@DRUG$), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (@DRUG$). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), @DRUG$ (@DRUG$), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), @DRUG$ (Pamelor), @DRUG$ (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), @DRUG$ (Pamelor), imipramine (@DRUG$), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), @DRUG$ (Pamelor), imipramine (Tofranil), @DRUG$ (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), @DRUG$ (Pamelor), imipramine (Tofranil), clomipramine (@DRUG$), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), @DRUG$ (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), @DRUG$ (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), @DRUG$ (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (@DRUG$), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), @DRUG$ (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or @DRUG$ (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), @DRUG$ (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (@DRUG$). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (@DRUG$), @DRUG$ (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (@DRUG$), imipramine (@DRUG$), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (@DRUG$), imipramine (Tofranil), @DRUG$ (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (@DRUG$), imipramine (Tofranil), clomipramine (@DRUG$), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (@DRUG$), imipramine (Tofranil), clomipramine (Anafranil), @DRUG$ (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (@DRUG$), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (@DRUG$), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (@DRUG$), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or @DRUG$ (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (@DRUG$), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (@DRUG$). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), @DRUG$ (@DRUG$), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), @DRUG$ (Tofranil), @DRUG$ (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), @DRUG$ (Tofranil), clomipramine (@DRUG$), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), @DRUG$ (Tofranil), clomipramine (Anafranil), @DRUG$ (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), @DRUG$ (Tofranil), clomipramine (Anafranil), protriptyline (@DRUG$), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), @DRUG$ (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or @DRUG$ (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), @DRUG$ (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (@DRUG$). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (@DRUG$), @DRUG$ (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (@DRUG$), clomipramine (@DRUG$), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (@DRUG$), clomipramine (Anafranil), @DRUG$ (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (@DRUG$), clomipramine (Anafranil), protriptyline (@DRUG$), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (@DRUG$), clomipramine (Anafranil), protriptyline (Vivactil), or @DRUG$ (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (@DRUG$), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (@DRUG$). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), @DRUG$ (@DRUG$), protriptyline (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), @DRUG$ (Anafranil), @DRUG$ (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), @DRUG$ (Anafranil), protriptyline (@DRUG$), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), @DRUG$ (Anafranil), protriptyline (Vivactil), or @DRUG$ (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), @DRUG$ (Anafranil), protriptyline (Vivactil), or desipramine (@DRUG$). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (@DRUG$), @DRUG$ (Vivactil), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (@DRUG$), protriptyline (@DRUG$), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (@DRUG$), protriptyline (Vivactil), or @DRUG$ (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (@DRUG$), protriptyline (Vivactil), or desipramine (@DRUG$). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), @DRUG$ (@DRUG$), or desipramine (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), @DRUG$ (Vivactil), or @DRUG$ (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), @DRUG$ (Vivactil), or desipramine (@DRUG$). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (@DRUG$), or @DRUG$ (Norpramin). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (@DRUG$), or desipramine (@DRUG$). DDI-false
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or @DRUG$ (@DRUG$). DDI-false
@DRUG$ has been reported to accelerate the metabolism of @DRUG$ by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for warfarin. DDI-false
@DRUG$ has been reported to accelerate the metabolism of warfarin by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for @DRUG$. DDI-mechanism
Mitotane has been reported to accelerate the metabolism of @DRUG$ by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for @DRUG$. DDI-false
Therefore, physicians should closely monitor patients for a change in @DRUG$ dosage requirements when administering @DRUG$ to patients on coumarin-type anticoagulants. DDI-false
Therefore, physicians should closely monitor patients for a change in @DRUG$ dosage requirements when administering Mitotane to patients on @DRUG$. DDI-false
Therefore, physicians should closely monitor patients for a change in anticoagulant dosage requirements when administering @DRUG$ to patients on @DRUG$. DDI-false
Because there is a theoretical basis that these effects may be additive, use of @DRUG$-containing or @DRUG$ (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided. DDI-advise
Because there is a theoretical basis that these effects may be additive, use of @DRUG$-containing or ergot-type medications (like @DRUG$ or methysergide) and sumatriptan within 24 hours of each other should be avoided. DDI-false
Because there is a theoretical basis that these effects may be additive, use of @DRUG$-containing or ergot-type medications (like dihydroergotamine or @DRUG$) and sumatriptan within 24 hours of each other should be avoided. DDI-false
Because there is a theoretical basis that these effects may be additive, use of @DRUG$-containing or ergot-type medications (like dihydroergotamine or methysergide) and @DRUG$ within 24 hours of each other should be avoided. DDI-false
Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or @DRUG$ (like @DRUG$ or methysergide) and sumatriptan within 24 hours of each other should be avoided. DDI-advise
Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or @DRUG$ (like dihydroergotamine or @DRUG$) and sumatriptan within 24 hours of each other should be avoided. DDI-false
Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or @DRUG$ (like dihydroergotamine or methysergide) and @DRUG$ within 24 hours of each other should be avoided. DDI-false
Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like @DRUG$ or @DRUG$) and sumatriptan within 24 hours of each other should be avoided. DDI-advise
Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like @DRUG$ or methysergide) and @DRUG$ within 24 hours of each other should be avoided. DDI-false
Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or @DRUG$) and @DRUG$ within 24 hours of each other should be avoided. DDI-advise
@DRUG$ reduce @DRUG$ clearance, significantly increasing systemic exposure. DDI-advise
Therefore, the use of @DRUG$ tablets in patients receiving @DRUG$ is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. DDI-mechanism
Therefore, the use of @DRUG$ tablets in patients receiving MAO-A inhibitors is contraindicated . @DRUG$ (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. DDI-advise
Therefore, the use of @DRUG$ tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (@DRUG$) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. DDI-false
Therefore, the use of @DRUG$ tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., @DRUG$, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. DDI-false
Therefore, the use of @DRUG$ tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, @DRUG$, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. DDI-false
Therefore, the use of @DRUG$ tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, @DRUG$, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. DDI-false
Therefore, the use of @DRUG$ tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, @DRUG$) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. DDI-false
Therefore, the use of @DRUG$ tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with @DRUG$. DDI-false
Therefore, the use of sumatriptan succinate tablets in patients receiving @DRUG$ is contraindicated . @DRUG$ (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. DDI-false
Therefore, the use of sumatriptan succinate tablets in patients receiving @DRUG$ is contraindicated . Selective serotonin reuptake inhibitors (@DRUG$) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. DDI-false
Therefore, the use of sumatriptan succinate tablets in patients receiving @DRUG$ is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., @DRUG$, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. DDI-false
Therefore, the use of sumatriptan succinate tablets in patients receiving @DRUG$ is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, @DRUG$, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. DDI-false
Therefore, the use of sumatriptan succinate tablets in patients receiving @DRUG$ is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, @DRUG$, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. DDI-false
Therefore, the use of sumatriptan succinate tablets in patients receiving @DRUG$ is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, @DRUG$) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. DDI-false
Therefore, the use of sumatriptan succinate tablets in patients receiving @DRUG$ is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with @DRUG$. DDI-false
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . @DRUG$ (@DRUG$) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. DDI-false
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . @DRUG$ (SSRIs) (e.g., @DRUG$, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. DDI-false
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . @DRUG$ (SSRIs) (e.g., fluoxetine, @DRUG$, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. DDI-false
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . @DRUG$ (SSRIs) (e.g., fluoxetine, fluvoxamine, @DRUG$, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. DDI-false
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . @DRUG$ (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, @DRUG$) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. DDI-false
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . @DRUG$ (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with @DRUG$. DDI-false
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (@DRUG$) (e.g., @DRUG$, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. DDI-effect
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (@DRUG$) (e.g., fluoxetine, @DRUG$, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. DDI-false
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (@DRUG$) (e.g., fluoxetine, fluvoxamine, @DRUG$, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. DDI-false
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (@DRUG$) (e.g., fluoxetine, fluvoxamine, paroxetine, @DRUG$) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. DDI-false
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (@DRUG$) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with @DRUG$. DDI-false
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., @DRUG$, @DRUG$, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. DDI-effect
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., @DRUG$, fluvoxamine, @DRUG$, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. DDI-false
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., @DRUG$, fluvoxamine, paroxetine, @DRUG$) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. DDI-false
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., @DRUG$, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with @DRUG$. DDI-false
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, @DRUG$, @DRUG$, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. DDI-effect
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, @DRUG$, paroxetine, @DRUG$) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. DDI-false
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, @DRUG$, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with @DRUG$. DDI-false
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, @DRUG$, @DRUG$) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. DDI-effect
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, @DRUG$, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with @DRUG$. DDI-false
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, @DRUG$) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with @DRUG$. DDI-effect
If concomitant treatment with @DRUG$ and an @DRUG$ is clinically warranted, appropriate observation of the patient is advised. DDI-effect
The bioavailability of @DRUG$ is decreased 80% by @DRUG$, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. DDI-advise
The bioavailability of @DRUG$ is decreased 80% by calcium, when @DRUG$ and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. DDI-mechanism
The bioavailability of @DRUG$ is decreased 80% by calcium, when calcium and @DRUG$ are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. DDI-false
The bioavailability of @DRUG$ is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some @DRUG$- or magnesium-containing antacids, when administered 1 hour before SKELID. DDI-false
The bioavailability of @DRUG$ is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or @DRUG$-containing antacids, when administered 1 hour before SKELID. DDI-false
The bioavailability of @DRUG$ is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing @DRUG$, when administered 1 hour before SKELID. DDI-false
The bioavailability of @DRUG$ is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before @DRUG$. DDI-false
The bioavailability of SKELID is decreased 80% by @DRUG$, when @DRUG$ and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. DDI-false
The bioavailability of SKELID is decreased 80% by @DRUG$, when calcium and @DRUG$ are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. DDI-false
The bioavailability of SKELID is decreased 80% by @DRUG$, when calcium and SKELID are administered at the same time, and 60% by some @DRUG$- or magnesium-containing antacids, when administered 1 hour before SKELID. DDI-false
The bioavailability of SKELID is decreased 80% by @DRUG$, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or @DRUG$-containing antacids, when administered 1 hour before SKELID. DDI-false
The bioavailability of SKELID is decreased 80% by @DRUG$, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing @DRUG$, when administered 1 hour before SKELID. DDI-false
The bioavailability of SKELID is decreased 80% by @DRUG$, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before @DRUG$. DDI-false
The bioavailability of SKELID is decreased 80% by calcium, when @DRUG$ and @DRUG$ are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. DDI-false
The bioavailability of SKELID is decreased 80% by calcium, when @DRUG$ and SKELID are administered at the same time, and 60% by some @DRUG$- or magnesium-containing antacids, when administered 1 hour before SKELID. DDI-false
The bioavailability of SKELID is decreased 80% by calcium, when @DRUG$ and SKELID are administered at the same time, and 60% by some aluminum- or @DRUG$-containing antacids, when administered 1 hour before SKELID. DDI-false
The bioavailability of SKELID is decreased 80% by calcium, when @DRUG$ and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing @DRUG$, when administered 1 hour before SKELID. DDI-false
The bioavailability of SKELID is decreased 80% by calcium, when @DRUG$ and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before @DRUG$. DDI-false
The bioavailability of SKELID is decreased 80% by calcium, when calcium and @DRUG$ are administered at the same time, and 60% by some @DRUG$- or magnesium-containing antacids, when administered 1 hour before SKELID. DDI-false
The bioavailability of SKELID is decreased 80% by calcium, when calcium and @DRUG$ are administered at the same time, and 60% by some aluminum- or @DRUG$-containing antacids, when administered 1 hour before SKELID. DDI-false
The bioavailability of SKELID is decreased 80% by calcium, when calcium and @DRUG$ are administered at the same time, and 60% by some aluminum- or magnesium-containing @DRUG$, when administered 1 hour before SKELID. DDI-false
The bioavailability of SKELID is decreased 80% by calcium, when calcium and @DRUG$ are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before @DRUG$. DDI-false
The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some @DRUG$- or @DRUG$-containing antacids, when administered 1 hour before SKELID. DDI-false
The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some @DRUG$- or magnesium-containing @DRUG$, when administered 1 hour before SKELID. DDI-false
The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some @DRUG$- or magnesium-containing antacids, when administered 1 hour before @DRUG$. DDI-false
The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or @DRUG$-containing @DRUG$, when administered 1 hour before SKELID. DDI-false
The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or @DRUG$-containing antacids, when administered 1 hour before @DRUG$. DDI-false
The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing @DRUG$, when administered 1 hour before @DRUG$. DDI-false
@DRUG$ may decrease bioavailability of @DRUG$ by up to 50% when taken 2 hours after SKELID. DDI-false
@DRUG$ may decrease bioavailability of SKELID by up to 50% when taken 2 hours after @DRUG$. DDI-mechanism
Aspirin may decrease bioavailability of @DRUG$ by up to 50% when taken 2 hours after @DRUG$. DDI-mechanism
The bioavailability of @DRUG$ is increased 2-4 fold by @DRUG$ but is not significantly altered by coadministration of diclofenac. DDI-false
The bioavailability of @DRUG$ is increased 2-4 fold by indomethacin but is not significantly altered by coadministration of @DRUG$. DDI-mechanism
The bioavailability of SKELID is increased 2-4 fold by @DRUG$ but is not significantly altered by coadministration of @DRUG$. DDI-false
The pharmacokinetic parameters of @DRUG$ are not significantly modified by @DRUG$ coadministration. DDI-false
In vitro studies show that @DRUG$ does not displace @DRUG$ from its binding site on protein. DDI-false
There is usually complete cross-resistance between @DRUG$ (@DRUG$) and TABLOID brand Thioguanine. DDI-false
There is usually complete cross-resistance between @DRUG$ (mercaptopurine) and @DRUG$ brand Thioguanine. DDI-false
There is usually complete cross-resistance between @DRUG$ (mercaptopurine) and TABLOID brand @DRUG$. DDI-false
There is usually complete cross-resistance between PURINETHOL (@DRUG$) and @DRUG$ brand Thioguanine. DDI-false
There is usually complete cross-resistance between PURINETHOL (@DRUG$) and TABLOID brand @DRUG$. DDI-false
There is usually complete cross-resistance between PURINETHOL (mercaptopurine) and @DRUG$ brand @DRUG$. DDI-false
As there is in vitro evidence that @DRUG$ (e.g., @DRUG$, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy. DDI-false
As there is in vitro evidence that @DRUG$ (e.g., olsalazine, @DRUG$, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy. DDI-false
As there is in vitro evidence that @DRUG$ (e.g., olsalazine, mesalazine, or @DRUG$) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy. DDI-false
As there is in vitro evidence that @DRUG$ (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent @DRUG$ therapy. DDI-false
As there is in vitro evidence that aminosalicylate derivatives (e.g., @DRUG$, @DRUG$, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy. DDI-advise
As there is in vitro evidence that aminosalicylate derivatives (e.g., @DRUG$, mesalazine, or @DRUG$) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy. DDI-false
As there is in vitro evidence that aminosalicylate derivatives (e.g., @DRUG$, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent @DRUG$ therapy. DDI-false
As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, @DRUG$, or @DRUG$) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy. DDI-advise
As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, @DRUG$, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent @DRUG$ therapy. DDI-false
As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or @DRUG$) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent @DRUG$ therapy. DDI-advise
Other eye drops or medications such as @DRUG$ (@DRUG$) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic. DDI-advise
Other eye drops or medications such as @DRUG$ (Miochol) and @DRUG$ (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic. DDI-false
Other eye drops or medications such as @DRUG$ (Miochol) and carbachol (@DRUG$, Isopto Carbachol) may decrease the effects of suprofen ophthalmic. DDI-false
Other eye drops or medications such as @DRUG$ (Miochol) and carbachol (Carboptic, @DRUG$) may decrease the effects of suprofen ophthalmic. DDI-false
Other eye drops or medications such as @DRUG$ (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of @DRUG$ ophthalmic. DDI-false
Other eye drops or medications such as acetylcholine chloride (@DRUG$) and @DRUG$ (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic. DDI-effect
Other eye drops or medications such as acetylcholine chloride (@DRUG$) and carbachol (@DRUG$, Isopto Carbachol) may decrease the effects of suprofen ophthalmic. DDI-false
Other eye drops or medications such as acetylcholine chloride (@DRUG$) and carbachol (Carboptic, @DRUG$) may decrease the effects of suprofen ophthalmic. DDI-false
Other eye drops or medications such as acetylcholine chloride (@DRUG$) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of @DRUG$ ophthalmic. DDI-false
Other eye drops or medications such as acetylcholine chloride (Miochol) and @DRUG$ (@DRUG$, Isopto Carbachol) may decrease the effects of suprofen ophthalmic. DDI-effect
Other eye drops or medications such as acetylcholine chloride (Miochol) and @DRUG$ (Carboptic, @DRUG$) may decrease the effects of suprofen ophthalmic. DDI-false
Other eye drops or medications such as acetylcholine chloride (Miochol) and @DRUG$ (Carboptic, Isopto Carbachol) may decrease the effects of @DRUG$ ophthalmic. DDI-false
Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (@DRUG$, @DRUG$) may decrease the effects of suprofen ophthalmic. DDI-effect
Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (@DRUG$, Isopto Carbachol) may decrease the effects of @DRUG$ ophthalmic. DDI-false
Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, @DRUG$) may decrease the effects of @DRUG$ ophthalmic. DDI-effect
@DRUG$, particularly @DRUG$, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all. DDI-effect
@DRUG$, particularly metaraminol, may cause serious cardiac arrhythmias during @DRUG$ anesthesia and therefore should be used only with great caution or not at all. DDI-false
Vasopressors, particularly @DRUG$, may cause serious cardiac arrhythmias during @DRUG$ anesthesia and therefore should be used only with great caution or not at all. DDI-effect
@DRUG$: The pressor effect of @DRUG$ is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). DDI-effect
@DRUG$: The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving @DRUG$ (MAOI). DDI-false
@DRUG$: The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (@DRUG$). DDI-false
MAO Inhibitors: The pressor effect of @DRUG$ is markedly potentiated in patients receiving @DRUG$ (MAOI). DDI-false
MAO Inhibitors: The pressor effect of @DRUG$ is markedly potentiated in patients receiving monoamine oxidase inhibitors (@DRUG$). DDI-effect
MAO Inhibitors: The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving @DRUG$ (@DRUG$). DDI-effect
The pressor response of @DRUG$ may also be potentiated by @DRUG$. DDI-false
A multiple dose drug-drug interaction study demonstrated that @DRUG$ approximately doubled @DRUG$ AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. DDI-effect
A multiple dose drug-drug interaction study demonstrated that @DRUG$ approximately doubled paricalcitol AUC0-   . Since @DRUG$ is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that @DRUG$ approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and @DRUG$ le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that @DRUG$ approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing @DRUG$ with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that @DRUG$ approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with @DRUG$ and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that @DRUG$ approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including @DRUG$, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that @DRUG$ approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, @DRUG$, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that @DRUG$ approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, @DRUG$, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that @DRUG$ approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, @DRUG$, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that @DRUG$ approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, @DRUG$, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that @DRUG$ approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, @DRUG$, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that @DRUG$ approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, @DRUG$, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that @DRUG$ approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, @DRUG$, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that @DRUG$ approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, @DRUG$ or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that @DRUG$ approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or @DRUG$. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled @DRUG$ AUC0-   . Since @DRUG$ is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled @DRUG$ AUC0-   . Since paricalcitol is partially metabolized by CYP3A and @DRUG$ le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled @DRUG$ AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing @DRUG$ with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled @DRUG$ AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with @DRUG$ and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled @DRUG$ AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including @DRUG$, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled @DRUG$ AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, @DRUG$, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled @DRUG$ AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, @DRUG$, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled @DRUG$ AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, @DRUG$, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled @DRUG$ AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, @DRUG$, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled @DRUG$ AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, @DRUG$, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled @DRUG$ AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, @DRUG$, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled @DRUG$ AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, @DRUG$, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled @DRUG$ AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, @DRUG$ or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled @DRUG$ AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or @DRUG$. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since @DRUG$ is partially metabolized by CYP3A and @DRUG$ le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since @DRUG$ is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing @DRUG$ with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since @DRUG$ is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with @DRUG$ and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since @DRUG$ is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including @DRUG$, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since @DRUG$ is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, @DRUG$, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since @DRUG$ is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, @DRUG$, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since @DRUG$ is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, @DRUG$, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since @DRUG$ is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, @DRUG$, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since @DRUG$ is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, @DRUG$, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since @DRUG$ is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, @DRUG$, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since @DRUG$ is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, @DRUG$, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since @DRUG$ is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, @DRUG$ or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since @DRUG$ is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or @DRUG$. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and @DRUG$ le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing @DRUG$ with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and @DRUG$ le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with @DRUG$ and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and @DRUG$ le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including @DRUG$, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and @DRUG$ le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, @DRUG$, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and @DRUG$ le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, @DRUG$, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and @DRUG$ le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, @DRUG$, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and @DRUG$ le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, @DRUG$, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and @DRUG$ le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, @DRUG$, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and @DRUG$ le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, @DRUG$, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and @DRUG$ le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, @DRUG$, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and @DRUG$ le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, @DRUG$ or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and @DRUG$ le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or @DRUG$. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing @DRUG$ with @DRUG$ and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing @DRUG$ with ketoconazole and other strong P450 3A inhibitors including @DRUG$, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. DDI-advise
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing @DRUG$ with ketoconazole and other strong P450 3A inhibitors including atazanavir, @DRUG$, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing @DRUG$ with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, @DRUG$, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing @DRUG$ with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, @DRUG$, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing @DRUG$ with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, @DRUG$, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing @DRUG$ with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, @DRUG$, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing @DRUG$ with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, @DRUG$, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing @DRUG$ with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, @DRUG$, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing @DRUG$ with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, @DRUG$ or voriconazole. DDI-advise
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing @DRUG$ with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or @DRUG$. DDI-advise
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with @DRUG$ and other strong P450 3A inhibitors including @DRUG$, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. DDI-advise
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with @DRUG$ and other strong P450 3A inhibitors including atazanavir, @DRUG$, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with @DRUG$ and other strong P450 3A inhibitors including atazanavir, clarithromycin, @DRUG$, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with @DRUG$ and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, @DRUG$, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with @DRUG$ and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, @DRUG$, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with @DRUG$ and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, @DRUG$, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with @DRUG$ and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, @DRUG$, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with @DRUG$ and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, @DRUG$, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with @DRUG$ and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, @DRUG$ or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with @DRUG$ and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or @DRUG$. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including @DRUG$, @DRUG$, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including @DRUG$, clarithromycin, @DRUG$, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including @DRUG$, clarithromycin, indinavir, @DRUG$, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including @DRUG$, clarithromycin, indinavir, itraconazole, @DRUG$, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including @DRUG$, clarithromycin, indinavir, itraconazole, nefazodone, @DRUG$, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including @DRUG$, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, @DRUG$, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including @DRUG$, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, @DRUG$, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including @DRUG$, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, @DRUG$ or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including @DRUG$, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or @DRUG$. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, @DRUG$, @DRUG$, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, @DRUG$, indinavir, @DRUG$, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, @DRUG$, indinavir, itraconazole, @DRUG$, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, @DRUG$, indinavir, itraconazole, nefazodone, @DRUG$, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, @DRUG$, indinavir, itraconazole, nefazodone, nelfinavir, @DRUG$, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, @DRUG$, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, @DRUG$, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, @DRUG$, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, @DRUG$ or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, @DRUG$, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or @DRUG$. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, @DRUG$, @DRUG$, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, @DRUG$, itraconazole, @DRUG$, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, @DRUG$, itraconazole, nefazodone, @DRUG$, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, @DRUG$, itraconazole, nefazodone, nelfinavir, @DRUG$, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, @DRUG$, itraconazole, nefazodone, nelfinavir, ritonavir, @DRUG$, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, @DRUG$, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, @DRUG$ or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, @DRUG$, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or @DRUG$. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, @DRUG$, @DRUG$, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, @DRUG$, nefazodone, @DRUG$, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, @DRUG$, nefazodone, nelfinavir, @DRUG$, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, @DRUG$, nefazodone, nelfinavir, ritonavir, @DRUG$, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, @DRUG$, nefazodone, nelfinavir, ritonavir, saquinavir, @DRUG$ or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, @DRUG$, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or @DRUG$. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, @DRUG$, @DRUG$, ritonavir, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, @DRUG$, nelfinavir, @DRUG$, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, @DRUG$, nelfinavir, ritonavir, @DRUG$, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, @DRUG$, nelfinavir, ritonavir, saquinavir, @DRUG$ or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, @DRUG$, nelfinavir, ritonavir, saquinavir, telithromycin or @DRUG$. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, @DRUG$, @DRUG$, saquinavir, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, @DRUG$, ritonavir, @DRUG$, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, @DRUG$, ritonavir, saquinavir, @DRUG$ or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, @DRUG$, ritonavir, saquinavir, telithromycin or @DRUG$. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, @DRUG$, @DRUG$, telithromycin or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, @DRUG$, saquinavir, @DRUG$ or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, @DRUG$, saquinavir, telithromycin or @DRUG$. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, @DRUG$, @DRUG$ or voriconazole. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, @DRUG$, telithromycin or @DRUG$. DDI-false
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, @DRUG$ or @DRUG$. DDI-false
Dose adjustment of @DRUG$ Capsules may be required, and iPTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor such as @DRUG$. DDI-false
Drugs that impair intestinal absorption of @DRUG$, such as @DRUG$, may interfere with the absorption of Zemplar Capsules. DDI-advise
Drugs that impair intestinal absorption of @DRUG$, such as cholestyramine, may interfere with the absorption of @DRUG$ Capsules. DDI-false
Drugs that impair intestinal absorption of fat-soluble vitamins, such as @DRUG$, may interfere with the absorption of @DRUG$ Capsules. DDI-false
@DRUG$ competitively inhibits the intracellular phosphorylation of @DRUG$. DDI-mechanism
Therefore, use of @DRUG$ in combination with @DRUG$ should be avoided. DDI-mechanism
In vitro data indicate that the phosphorylation of @DRUG$ is also inhibited at relevant concentrations by @DRUG$ and ribavirin. DDI-advise
In vitro data indicate that the phosphorylation of @DRUG$ is also inhibited at relevant concentrations by doxorubicin and @DRUG$. DDI-mechanism
In vitro data indicate that the phosphorylation of stavudine is also inhibited at relevant concentrations by @DRUG$ and @DRUG$. DDI-mechanism
No pharmacokinetic interaction between 85 mg/m2 @DRUG$ and infusional @DRUG$ has been observed in patients treated every 2 weeks. DDI-false
Increases of @DRUG$ plasma concentrations by approximately 20% have been observed with doses of 130 mg/m2 @DRUG$ dosed every 3 weeks. DDI-false
@DRUG$ is not known to interact with other drugs including @DRUG$ supplements; DDI-mechanism
Concomitant administration of @DRUG$ with other chelation therapy, such as @DRUG$ is not recommended. DDI-false
@DRUG$ may accentuate the orthostatic hypotension that may occur with @DRUG$. DDI-advise
Antihypertensive effects of @DRUG$ and related compounds may be counteracted when @DRUG$ are used concomitantly. DDI-effect
Concomitant administration of @DRUG$ with @DRUG$ results in increased plasma levels of both drugs. DDI-effect
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between @DRUG$ and @DRUG$, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. DDI-mechanism
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between @DRUG$ and mycophenolate mofetil, @DRUG$, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. DDI-false
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between @DRUG$ and mycophenolate mofetil, cyclosporine, @DRUG$, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. DDI-false
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between @DRUG$ and mycophenolate mofetil, cyclosporine, tacrolimus, @DRUG$, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. DDI-false
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between @DRUG$ and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, @DRUG$, nifedipine, fluconazole, ritonavir, and rifampin. DDI-false
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between @DRUG$ and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, @DRUG$, fluconazole, ritonavir, and rifampin. DDI-false
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between @DRUG$ and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, @DRUG$, ritonavir, and rifampin. DDI-false
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between @DRUG$ and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, @DRUG$, and rifampin. DDI-false
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between @DRUG$ and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and @DRUG$. DDI-false
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and @DRUG$, @DRUG$, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. DDI-false
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and @DRUG$, cyclosporine, @DRUG$, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. DDI-false
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and @DRUG$, cyclosporine, tacrolimus, @DRUG$, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. DDI-false
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and @DRUG$, cyclosporine, tacrolimus, prednisolone, @DRUG$, nifedipine, fluconazole, ritonavir, and rifampin. DDI-false
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and @DRUG$, cyclosporine, tacrolimus, prednisolone, sirolimus, @DRUG$, fluconazole, ritonavir, and rifampin. DDI-false
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and @DRUG$, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, @DRUG$, ritonavir, and rifampin. DDI-false
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and @DRUG$, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, @DRUG$, and rifampin. DDI-false
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and @DRUG$, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and @DRUG$. DDI-false
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, @DRUG$, @DRUG$, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. DDI-false
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, @DRUG$, tacrolimus, @DRUG$, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. DDI-false
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, @DRUG$, tacrolimus, prednisolone, @DRUG$, nifedipine, fluconazole, ritonavir, and rifampin. DDI-false
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, @DRUG$, tacrolimus, prednisolone, sirolimus, @DRUG$, fluconazole, ritonavir, and rifampin. DDI-false
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, @DRUG$, tacrolimus, prednisolone, sirolimus, nifedipine, @DRUG$, ritonavir, and rifampin. DDI-false
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, @DRUG$, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, @DRUG$, and rifampin. DDI-false
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, @DRUG$, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and @DRUG$. DDI-false
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, @DRUG$, @DRUG$, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. DDI-false
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, @DRUG$, prednisolone, @DRUG$, nifedipine, fluconazole, ritonavir, and rifampin. DDI-false
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, @DRUG$, prednisolone, sirolimus, @DRUG$, fluconazole, ritonavir, and rifampin. DDI-false
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, @DRUG$, prednisolone, sirolimus, nifedipine, @DRUG$, ritonavir, and rifampin. DDI-false
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, @DRUG$, prednisolone, sirolimus, nifedipine, fluconazole, @DRUG$, and rifampin. DDI-false
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, @DRUG$, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and @DRUG$. DDI-false
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, @DRUG$, @DRUG$, nifedipine, fluconazole, ritonavir, and rifampin. DDI-false
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, @DRUG$, sirolimus, @DRUG$, fluconazole, ritonavir, and rifampin. DDI-false
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, @DRUG$, sirolimus, nifedipine, @DRUG$, ritonavir, and rifampin. DDI-false
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, @DRUG$, sirolimus, nifedipine, fluconazole, @DRUG$, and rifampin. DDI-false
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, @DRUG$, sirolimus, nifedipine, fluconazole, ritonavir, and @DRUG$. DDI-false
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, @DRUG$, @DRUG$, fluconazole, ritonavir, and rifampin. DDI-false
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, @DRUG$, nifedipine, @DRUG$, ritonavir, and rifampin. DDI-false
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, @DRUG$, nifedipine, fluconazole, @DRUG$, and rifampin. DDI-false
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, @DRUG$, nifedipine, fluconazole, ritonavir, and @DRUG$. DDI-false
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, @DRUG$, @DRUG$, ritonavir, and rifampin. DDI-false
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, @DRUG$, fluconazole, @DRUG$, and rifampin. DDI-false
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, @DRUG$, fluconazole, ritonavir, and @DRUG$. DDI-false
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, @DRUG$, @DRUG$, and rifampin. DDI-false
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, @DRUG$, ritonavir, and @DRUG$. DDI-false
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, @DRUG$, and @DRUG$. DDI-false
There was no effect of a single dose or multiple doses of @DRUG$ on @DRUG$, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics. DDI-false
There was no effect of a single dose or multiple doses of @DRUG$ on mycophenolate mofetil, @DRUG$, tacrolimus, prednisolone, and fluconazole pharmacokinetics. DDI-false
There was no effect of a single dose or multiple doses of @DRUG$ on mycophenolate mofetil, cyclosporine, @DRUG$, prednisolone, and fluconazole pharmacokinetics. DDI-false
There was no effect of a single dose or multiple doses of @DRUG$ on mycophenolate mofetil, cyclosporine, tacrolimus, @DRUG$, and fluconazole pharmacokinetics. DDI-false
There was no effect of a single dose or multiple doses of @DRUG$ on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and @DRUG$ pharmacokinetics. DDI-false
There was no effect of a single dose or multiple doses of MYCAMINE on @DRUG$, @DRUG$, tacrolimus, prednisolone, and fluconazole pharmacokinetics. DDI-false
There was no effect of a single dose or multiple doses of MYCAMINE on @DRUG$, cyclosporine, @DRUG$, prednisolone, and fluconazole pharmacokinetics. DDI-false
There was no effect of a single dose or multiple doses of MYCAMINE on @DRUG$, cyclosporine, tacrolimus, @DRUG$, and fluconazole pharmacokinetics. DDI-false
There was no effect of a single dose or multiple doses of MYCAMINE on @DRUG$, cyclosporine, tacrolimus, prednisolone, and @DRUG$ pharmacokinetics. DDI-false
There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, @DRUG$, @DRUG$, prednisolone, and fluconazole pharmacokinetics. DDI-false
There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, @DRUG$, tacrolimus, @DRUG$, and fluconazole pharmacokinetics. DDI-false
There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, @DRUG$, tacrolimus, prednisolone, and @DRUG$ pharmacokinetics. DDI-false
There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, @DRUG$, @DRUG$, and fluconazole pharmacokinetics. DDI-false
There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, @DRUG$, prednisolone, and @DRUG$ pharmacokinetics. DDI-false
There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, tacrolimus, @DRUG$, and @DRUG$ pharmacokinetics. DDI-false
@DRUG$ AUC was increased by 21% with no effect on Cmax in the presence of steady-state @DRUG$ compared with sirolimus alone. DDI-false
@DRUG$ AUC was increased by 21% with no effect on Cmax in the presence of steady-state MYCAMINE compared with @DRUG$ alone. DDI-mechanism
Sirolimus AUC was increased by 21% with no effect on Cmax in the presence of steady-state @DRUG$ compared with @DRUG$ alone. DDI-false
@DRUG$ AUC and Cmax were increased by 18% and 42%, respectively, in the presence of steady-state @DRUG$ compared with nifedipine alone. DDI-false
@DRUG$ AUC and Cmax were increased by 18% and 42%, respectively, in the presence of steady-state MYCAMINE compared with @DRUG$ alone. DDI-mechanism
Nifedipine AUC and Cmax were increased by 18% and 42%, respectively, in the presence of steady-state @DRUG$ compared with @DRUG$ alone. DDI-false
Patients receiving @DRUG$ or @DRUG$ in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. DDI-false
Patients receiving @DRUG$ or nifedipine in combination with @DRUG$ should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. DDI-false
Patients receiving @DRUG$ or nifedipine in combination with MYCAMINE should be monitored for @DRUG$ or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. DDI-advise
Patients receiving @DRUG$ or nifedipine in combination with MYCAMINE should be monitored for sirolimus or @DRUG$ toxicity and sirolimus or nifedipine dosage should be reduced if necessary. DDI-false
Patients receiving @DRUG$ or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and @DRUG$ or nifedipine dosage should be reduced if necessary. DDI-false
Patients receiving @DRUG$ or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or @DRUG$ dosage should be reduced if necessary. DDI-false
Patients receiving sirolimus or @DRUG$ in combination with @DRUG$ should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. DDI-false
Patients receiving sirolimus or @DRUG$ in combination with MYCAMINE should be monitored for @DRUG$ or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. DDI-false
Patients receiving sirolimus or @DRUG$ in combination with MYCAMINE should be monitored for sirolimus or @DRUG$ toxicity and sirolimus or nifedipine dosage should be reduced if necessary. DDI-false
Patients receiving sirolimus or @DRUG$ in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and @DRUG$ or nifedipine dosage should be reduced if necessary. DDI-false
Patients receiving sirolimus or @DRUG$ in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or @DRUG$ dosage should be reduced if necessary. DDI-false
Patients receiving sirolimus or nifedipine in combination with @DRUG$ should be monitored for @DRUG$ or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. DDI-false
Patients receiving sirolimus or nifedipine in combination with @DRUG$ should be monitored for sirolimus or @DRUG$ toxicity and sirolimus or nifedipine dosage should be reduced if necessary. DDI-false
Patients receiving sirolimus or nifedipine in combination with @DRUG$ should be monitored for sirolimus or nifedipine toxicity and @DRUG$ or nifedipine dosage should be reduced if necessary. DDI-false
Patients receiving sirolimus or nifedipine in combination with @DRUG$ should be monitored for sirolimus or nifedipine toxicity and sirolimus or @DRUG$ dosage should be reduced if necessary. DDI-false
Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for @DRUG$ or @DRUG$ toxicity and sirolimus or nifedipine dosage should be reduced if necessary. DDI-false
Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for @DRUG$ or nifedipine toxicity and @DRUG$ or nifedipine dosage should be reduced if necessary. DDI-false
Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for @DRUG$ or nifedipine toxicity and sirolimus or @DRUG$ dosage should be reduced if necessary. DDI-false
Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or @DRUG$ toxicity and @DRUG$ or nifedipine dosage should be reduced if necessary. DDI-false
Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or @DRUG$ toxicity and sirolimus or @DRUG$ dosage should be reduced if necessary. DDI-false
Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and @DRUG$ or @DRUG$ dosage should be reduced if necessary. DDI-false
Hypokalemia may develop during concomitant use of @DRUG$ or @DRUG$. DDI-false
@DRUG$ may decrease arterial responsiveness to @DRUG$. DDI-false
@DRUG$ may increase the responsiveness of @DRUG$. DDI-effect
@DRUG$ renal clearance is reduced by @DRUG$, increasing the risk of lithium toxicity. DDI-effect
@DRUG$ renal clearance is reduced by thiazides, increasing the risk of @DRUG$ toxicity. DDI-mechanism
Lithium renal clearance is reduced by @DRUG$, increasing the risk of @DRUG$ toxicity. DDI-false
@DRUG$ may add to or potentiate the action of other @DRUG$. DDI-false
Potentiation occurs with @DRUG-DRUG$. DDI-effect
@DRUG$/@DRUG$: Carbidopa/Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10). DDI-false
@DRUG$/Levodopa: @DRUG$/Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10). DDI-false
@DRUG$/Levodopa: Carbidopa/@DRUG$ does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10). DDI-false
@DRUG$/Levodopa: Carbidopa/Levodopa does not influence the pharmacokinetics of @DRUG$ in healthy volunteers (N= 10). DDI-false
Carbidopa/@DRUG$: @DRUG$/Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10). DDI-false
Carbidopa/@DRUG$: Carbidopa/@DRUG$ does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10). DDI-false
Carbidopa/@DRUG$: Carbidopa/Levodopa does not influence the pharmacokinetics of @DRUG$ in healthy volunteers (N= 10). DDI-false
Carbidopa/Levodopa: @DRUG$/@DRUG$ does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10). DDI-false
Carbidopa/Levodopa: @DRUG$/Levodopa does not influence the pharmacokinetics of @DRUG$ in healthy volunteers (N= 10). DDI-false
Carbidopa/Levodopa: Carbidopa/@DRUG$ does not influence the pharmacokinetics of @DRUG$ in healthy volunteers (N= 10). DDI-false
@DRUG$: Since @DRUG$ is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. DDI-false
@DRUG$: Since pramipexole is a @DRUG$, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. DDI-false
@DRUG$: Since pramipexole is a dopamine agonist, it is possible that @DRUG$, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. DDI-false
@DRUG$: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the @DRUG$ (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. DDI-false
@DRUG$: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (@DRUG$, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. DDI-false
@DRUG$: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, @DRUG$, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. DDI-false
@DRUG$: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, @DRUG$) or metoclopramide, may diminish the effectiveness of MIRAPEX. DDI-false
@DRUG$: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or @DRUG$, may diminish the effectiveness of MIRAPEX. DDI-false
@DRUG$: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of @DRUG$. DDI-false
Dopamine antagonists: Since @DRUG$ is a @DRUG$, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. DDI-false
Dopamine antagonists: Since @DRUG$ is a dopamine agonist, it is possible that @DRUG$, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. DDI-false
Dopamine antagonists: Since @DRUG$ is a dopamine agonist, it is possible that dopamine antagonists, such as the @DRUG$ (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. DDI-false
Dopamine antagonists: Since @DRUG$ is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (@DRUG$, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. DDI-false
Dopamine antagonists: Since @DRUG$ is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, @DRUG$, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. DDI-false
Dopamine antagonists: Since @DRUG$ is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, @DRUG$) or metoclopramide, may diminish the effectiveness of MIRAPEX. DDI-false
Dopamine antagonists: Since @DRUG$ is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or @DRUG$, may diminish the effectiveness of MIRAPEX. DDI-false
Dopamine antagonists: Since @DRUG$ is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of @DRUG$. DDI-false
Dopamine antagonists: Since pramipexole is a @DRUG$, it is possible that @DRUG$, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. DDI-false
Dopamine antagonists: Since pramipexole is a @DRUG$, it is possible that dopamine antagonists, such as the @DRUG$ (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. DDI-false
Dopamine antagonists: Since pramipexole is a @DRUG$, it is possible that dopamine antagonists, such as the neuroleptics (@DRUG$, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. DDI-false
Dopamine antagonists: Since pramipexole is a @DRUG$, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, @DRUG$, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. DDI-false
Dopamine antagonists: Since pramipexole is a @DRUG$, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, @DRUG$) or metoclopramide, may diminish the effectiveness of MIRAPEX. DDI-false
Dopamine antagonists: Since pramipexole is a @DRUG$, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or @DRUG$, may diminish the effectiveness of MIRAPEX. DDI-false
Dopamine antagonists: Since pramipexole is a @DRUG$, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of @DRUG$. DDI-false
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that @DRUG$, such as the @DRUG$ (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. DDI-false
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that @DRUG$, such as the neuroleptics (@DRUG$, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. DDI-false
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that @DRUG$, such as the neuroleptics (phenothiazines, @DRUG$, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. DDI-false
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that @DRUG$, such as the neuroleptics (phenothiazines, butyrophenones, @DRUG$) or metoclopramide, may diminish the effectiveness of MIRAPEX. DDI-false
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that @DRUG$, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or @DRUG$, may diminish the effectiveness of MIRAPEX. DDI-false
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that @DRUG$, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of @DRUG$. DDI-false
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the @DRUG$ (@DRUG$, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. DDI-false
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the @DRUG$ (phenothiazines, @DRUG$, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. DDI-false
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the @DRUG$ (phenothiazines, butyrophenones, @DRUG$) or metoclopramide, may diminish the effectiveness of MIRAPEX. DDI-false
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the @DRUG$ (phenothiazines, butyrophenones, thioxanthenes) or @DRUG$, may diminish the effectiveness of MIRAPEX. DDI-false
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the @DRUG$ (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of @DRUG$. DDI-false
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (@DRUG$, @DRUG$, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. DDI-false
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (@DRUG$, butyrophenones, @DRUG$) or metoclopramide, may diminish the effectiveness of MIRAPEX. DDI-false
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (@DRUG$, butyrophenones, thioxanthenes) or @DRUG$, may diminish the effectiveness of MIRAPEX. DDI-false
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (@DRUG$, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of @DRUG$. DDI-false
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, @DRUG$, @DRUG$) or metoclopramide, may diminish the effectiveness of MIRAPEX. DDI-false
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, @DRUG$, thioxanthenes) or @DRUG$, may diminish the effectiveness of MIRAPEX. DDI-false
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, @DRUG$, thioxanthenes) or metoclopramide, may diminish the effectiveness of @DRUG$. DDI-false
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, @DRUG$) or @DRUG$, may diminish the effectiveness of MIRAPEX. DDI-false
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, @DRUG$) or metoclopramide, may diminish the effectiveness of @DRUG$. DDI-false
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or @DRUG$, may diminish the effectiveness of @DRUG$. DDI-effect
@DRUG$: In healthy volunteers (N= 11), @DRUG$ did not influence the pharmacokinetics of pramipexole. DDI-effect
@DRUG$: In healthy volunteers (N= 11), selegiline did not influence the pharmacokinetics of @DRUG$. DDI-false
Selegiline: In healthy volunteers (N= 11), @DRUG$ did not influence the pharmacokinetics of @DRUG$. DDI-false
@DRUG$: Population pharmacokinetic analysis suggests that @DRUG$ is unlikely to alter the oral clearance of pramipexole (N= 54). DDI-false
@DRUG$: Population pharmacokinetic analysis suggests that amantadine is unlikely to alter the oral clearance of @DRUG$ (N= 54). DDI-false
Amantadine: Population pharmacokinetic analysis suggests that @DRUG$ is unlikely to alter the oral clearance of @DRUG$ (N= 54). DDI-false
@DRUG$: @DRUG$, a known inhibitor of renal tubular secretion of organic bases via the cationic transport system, caused a 50% increase in pramipexole AUC and a 40% increase in half-life (N= 12). DDI-false
@DRUG$: Cimetidine, a known inhibitor of renal tubular secretion of organic bases via the cationic transport system, caused a 50% increase in @DRUG$ AUC and a 40% increase in half-life (N= 12). DDI-false
Cimetidine: @DRUG$, a known inhibitor of renal tubular secretion of organic bases via the cationic transport system, caused a 50% increase in @DRUG$ AUC and a 40% increase in half-life (N= 12). DDI-false
@DRUG$: @DRUG$, a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter, did not noticeably influence pramipexole pharmacokinetics (N= 12). DDI-mechanism
@DRUG$: Probenecid, a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter, did not noticeably influence @DRUG$ pharmacokinetics (N= 12). DDI-false
Probenecid: @DRUG$, a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter, did not noticeably influence @DRUG$ pharmacokinetics (N= 12). DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., @DRUG$, @DRUG$, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., @DRUG$, ranitidine, @DRUG$, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., @DRUG$, ranitidine, diltiazem, @DRUG$, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., @DRUG$, ranitidine, diltiazem, triamterene, @DRUG$, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., @DRUG$, ranitidine, diltiazem, triamterene, verapamil, @DRUG$, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., @DRUG$, ranitidine, diltiazem, triamterene, verapamil, quinidine, and @DRUG$) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., @DRUG$, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of @DRUG$ by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., @DRUG$, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., @DRUG$, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-mechanism
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., @DRUG$, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, @DRUG$, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., @DRUG$, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, @DRUG$, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., @DRUG$, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, @DRUG$, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., @DRUG$, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and @DRUG$) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., @DRUG$, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of @DRUG$. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, @DRUG$, @DRUG$, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, @DRUG$, diltiazem, @DRUG$, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, @DRUG$, diltiazem, triamterene, @DRUG$, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, @DRUG$, diltiazem, triamterene, verapamil, @DRUG$, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, @DRUG$, diltiazem, triamterene, verapamil, quinidine, and @DRUG$) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, @DRUG$, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of @DRUG$ by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, @DRUG$, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., @DRUG$, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-mechanism
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, @DRUG$, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, @DRUG$, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, @DRUG$, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, @DRUG$, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, @DRUG$, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, @DRUG$, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, @DRUG$, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and @DRUG$) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, @DRUG$, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of @DRUG$. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, @DRUG$, @DRUG$, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, @DRUG$, triamterene, @DRUG$, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, @DRUG$, triamterene, verapamil, @DRUG$, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, @DRUG$, triamterene, verapamil, quinidine, and @DRUG$) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, @DRUG$, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of @DRUG$ by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, @DRUG$, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., @DRUG$, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-mechanism
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, @DRUG$, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, @DRUG$, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, @DRUG$, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, @DRUG$, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, @DRUG$, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, @DRUG$, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, @DRUG$, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and @DRUG$) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, @DRUG$, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of @DRUG$. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, @DRUG$, @DRUG$, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, @DRUG$, verapamil, @DRUG$, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, @DRUG$, verapamil, quinidine, and @DRUG$) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, @DRUG$, verapamil, quinidine, and quinine) decreases the oral clearance of @DRUG$ by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, @DRUG$, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., @DRUG$, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-mechanism
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, @DRUG$, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, @DRUG$, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, @DRUG$, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, @DRUG$, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, @DRUG$, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, @DRUG$, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, @DRUG$, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and @DRUG$) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, @DRUG$, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of @DRUG$. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, @DRUG$, @DRUG$, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, @DRUG$, quinidine, and @DRUG$) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, @DRUG$, quinidine, and quinine) decreases the oral clearance of @DRUG$ by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, @DRUG$, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., @DRUG$, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-mechanism
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, @DRUG$, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, @DRUG$, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, @DRUG$, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, @DRUG$, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, @DRUG$, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, @DRUG$, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, @DRUG$, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and @DRUG$) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, @DRUG$, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of @DRUG$. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, @DRUG$, and @DRUG$) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, @DRUG$, and quinine) decreases the oral clearance of @DRUG$ by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, @DRUG$, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., @DRUG$, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-mechanism
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, @DRUG$, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, @DRUG$, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, @DRUG$, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, @DRUG$, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, @DRUG$, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, @DRUG$, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, @DRUG$, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and @DRUG$) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, @DRUG$, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of @DRUG$. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and @DRUG$) decreases the oral clearance of @DRUG$ by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and @DRUG$) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., @DRUG$, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-mechanism
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and @DRUG$) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, @DRUG$, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and @DRUG$) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, @DRUG$, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and @DRUG$) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, @DRUG$, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and @DRUG$) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and @DRUG$) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and @DRUG$) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of @DRUG$. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of @DRUG$ by about 20%, while those secreted by the anionic transport system (e.g., @DRUG$, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of @DRUG$ by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, @DRUG$, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of @DRUG$ by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, @DRUG$, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of @DRUG$ by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, @DRUG$, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of @DRUG$ by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and @DRUG$) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of @DRUG$ by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of @DRUG$. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., @DRUG$, @DRUG$, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., @DRUG$, penicillins, @DRUG$, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., @DRUG$, penicillins, indomethacin, @DRUG$, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., @DRUG$, penicillins, indomethacin, hydrochlorothiazide, and @DRUG$) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., @DRUG$, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of @DRUG$. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, @DRUG$, @DRUG$, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, @DRUG$, indomethacin, @DRUG$, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, @DRUG$, indomethacin, hydrochlorothiazide, and @DRUG$) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, @DRUG$, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of @DRUG$. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, @DRUG$, @DRUG$, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, @DRUG$, hydrochlorothiazide, and @DRUG$) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, @DRUG$, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of @DRUG$. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, @DRUG$, and @DRUG$) are likely to have little effect on the oral clearance of pramipexole. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, @DRUG$, and chlorpropamide) are likely to have little effect on the oral clearance of @DRUG$. DDI-false
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and @DRUG$) are likely to have little effect on the oral clearance of @DRUG$. DDI-false
CYP interactions: Inhibitors of cytochrome P450 enzymes would not be expected to affect @DRUG$ elimination because @DRUG$ is not appreciably metabolized by these enzymes in vivo or in vitro. DDI-false
Do not exceed a 5 mg daily dose of @DRUG$ when administered with therapeutic doses of @DRUG$ or other potent CYP3A4 inhibitors. DDI-false
Patients with Congenital or Acquired QT Prolongation In a study of the effect of @DRUG$ on the QT interval in 76 healthy women, the QT prolonging effect appeared less with @DRUG$ 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of solifenacin 30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose. DDI-advise
Patients with Congenital or Acquired QT Prolongation In a study of the effect of @DRUG$ on the QT interval in 76 healthy women, the QT prolonging effect appeared less with solifenacin 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of @DRUG$ 30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose. DDI-false
Patients with Congenital or Acquired QT Prolongation In a study of the effect of @DRUG$ on the QT interval in 76 healthy women, the QT prolonging effect appeared less with solifenacin 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of solifenacin 30 mg did not appear as large as that of the positive control @DRUG$ at its therapeutic dose. DDI-false
Patients with Congenital or Acquired QT Prolongation In a study of the effect of solifenacin on the QT interval in 76 healthy women, the QT prolonging effect appeared less with @DRUG$ 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of @DRUG$ 30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose. DDI-false
Patients with Congenital or Acquired QT Prolongation In a study of the effect of solifenacin on the QT interval in 76 healthy women, the QT prolonging effect appeared less with @DRUG$ 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of solifenacin 30 mg did not appear as large as that of the positive control @DRUG$ at its therapeutic dose. DDI-false
Patients with Congenital or Acquired QT Prolongation In a study of the effect of solifenacin on the QT interval in 76 healthy women, the QT prolonging effect appeared less with solifenacin 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of @DRUG$ 30 mg did not appear as large as that of the positive control @DRUG$ at its therapeutic dose. DDI-false
@DRUG$ at a Dose of 10 mg Once Daily Dosed to Pharmacokinetic Steady State  - did not cause clinically significant changes in the kinetics of a single intravenous dose of @DRUG$ (predominantly a cytochrome P450 1A2 substrate). DDI-false
- did not change the pharmacokinetic profile of @DRUG$ (a substrate of cytochromes P450 2A6 and 2C9) or influence the effect of a single 30-mg oral dose of @DRUG$ on prothrombin time or the INR (International Normalized Ratio). DDI-false
In drug-interaction studies, the recommended clinical dose of @DRUG$ did not have clinically important effects on the pharmacokinetics of the following drugs: @DRUG$, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. DDI-false
In drug-interaction studies, the recommended clinical dose of @DRUG$ did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, @DRUG$, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. DDI-false
In drug-interaction studies, the recommended clinical dose of @DRUG$ did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, @DRUG$, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. DDI-false
In drug-interaction studies, the recommended clinical dose of @DRUG$ did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral @DRUG$ (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. DDI-false
In drug-interaction studies, the recommended clinical dose of @DRUG$ did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (@DRUG$ 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. DDI-false
In drug-interaction studies, the recommended clinical dose of @DRUG$ did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/@DRUG$ 35 mcg), terfenadine, digoxin, and warfarin. DDI-false
In drug-interaction studies, the recommended clinical dose of @DRUG$ did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), @DRUG$, digoxin, and warfarin. DDI-false
In drug-interaction studies, the recommended clinical dose of @DRUG$ did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, @DRUG$, and warfarin. DDI-false
In drug-interaction studies, the recommended clinical dose of @DRUG$ did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and @DRUG$. DDI-false
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: @DRUG$, @DRUG$, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. DDI-false
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: @DRUG$, prednisone, @DRUG$, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. DDI-false
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: @DRUG$, prednisone, prednisolone, oral @DRUG$ (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. DDI-false
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: @DRUG$, prednisone, prednisolone, oral contraceptives (@DRUG$ 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. DDI-false
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: @DRUG$, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/@DRUG$ 35 mcg), terfenadine, digoxin, and warfarin. DDI-false
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: @DRUG$, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), @DRUG$, digoxin, and warfarin. DDI-false
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: @DRUG$, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, @DRUG$, and warfarin. DDI-false
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: @DRUG$, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and @DRUG$. DDI-false
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, @DRUG$, @DRUG$, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. DDI-false
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, @DRUG$, prednisolone, oral @DRUG$ (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. DDI-false
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, @DRUG$, prednisolone, oral contraceptives (@DRUG$ 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. DDI-false
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, @DRUG$, prednisolone, oral contraceptives (norethindrone 1 mg/@DRUG$ 35 mcg), terfenadine, digoxin, and warfarin. DDI-false
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, @DRUG$, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), @DRUG$, digoxin, and warfarin. DDI-false
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, @DRUG$, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, @DRUG$, and warfarin. DDI-false
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, @DRUG$, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and @DRUG$. DDI-false
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, @DRUG$, oral @DRUG$ (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. DDI-false
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, @DRUG$, oral contraceptives (@DRUG$ 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. DDI-false
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, @DRUG$, oral contraceptives (norethindrone 1 mg/@DRUG$ 35 mcg), terfenadine, digoxin, and warfarin. DDI-false
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, @DRUG$, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), @DRUG$, digoxin, and warfarin. DDI-false
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, @DRUG$, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, @DRUG$, and warfarin. DDI-false
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, @DRUG$, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and @DRUG$. DDI-false
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral @DRUG$ (@DRUG$ 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. DDI-false
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral @DRUG$ (norethindrone 1 mg/@DRUG$ 35 mcg), terfenadine, digoxin, and warfarin. DDI-false
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral @DRUG$ (norethindrone 1 mg/ethinyl estradiol 35 mcg), @DRUG$, digoxin, and warfarin. DDI-false
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral @DRUG$ (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, @DRUG$, and warfarin. DDI-false
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral @DRUG$ (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and @DRUG$. DDI-false
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (@DRUG$ 1 mg/@DRUG$ 35 mcg), terfenadine, digoxin, and warfarin. DDI-false
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (@DRUG$ 1 mg/ethinyl estradiol 35 mcg), @DRUG$, digoxin, and warfarin. DDI-false
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (@DRUG$ 1 mg/ethinyl estradiol 35 mcg), terfenadine, @DRUG$, and warfarin. DDI-false
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (@DRUG$ 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and @DRUG$. DDI-false
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/@DRUG$ 35 mcg), @DRUG$, digoxin, and warfarin. DDI-false
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/@DRUG$ 35 mcg), terfenadine, @DRUG$, and warfarin. DDI-false
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/@DRUG$ 35 mcg), terfenadine, digoxin, and @DRUG$. DDI-false
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), @DRUG$, @DRUG$, and warfarin. DDI-false
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), @DRUG$, digoxin, and @DRUG$. DDI-false
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, @DRUG$, and @DRUG$. DDI-false
These medications included @DRUG$, @DRUG$, non-steroidal anti-inflammatory agents, benzodiazepines, and decongestants. DDI-false
These medications included @DRUG$, sedative hypnotics, @DRUG$, benzodiazepines, and decongestants. DDI-false
These medications included @DRUG$, sedative hypnotics, non-steroidal anti-inflammatory agents, @DRUG$, and decongestants. DDI-false
These medications included @DRUG$, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, and @DRUG$. DDI-false
These medications included thyroid hormones, @DRUG$, @DRUG$, benzodiazepines, and decongestants. DDI-false
These medications included thyroid hormones, @DRUG$, non-steroidal anti-inflammatory agents, @DRUG$, and decongestants. DDI-false
These medications included thyroid hormones, @DRUG$, non-steroidal anti-inflammatory agents, benzodiazepines, and @DRUG$. DDI-false
These medications included thyroid hormones, sedative hypnotics, @DRUG$, @DRUG$, and decongestants. DDI-false
These medications included thyroid hormones, sedative hypnotics, @DRUG$, benzodiazepines, and @DRUG$. DDI-false
These medications included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, @DRUG$, and @DRUG$. DDI-false
@DRUG$, which induces hepatic metabolism, decreased the AUC of @DRUG$ approximately 40% following a single 10-mg dose of montelukast. DDI-false
@DRUG$, which induces hepatic metabolism, decreased the AUC of montelukast approximately 40% following a single 10-mg dose of @DRUG$. DDI-mechanism
Phenobarbital, which induces hepatic metabolism, decreased the AUC of @DRUG$ approximately 40% following a single 10-mg dose of @DRUG$. DDI-false
It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as @DRUG$ or @DRUG$, are co-administered with montelukast. DDI-false
It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as @DRUG$ or rifampin, are co-administered with @DRUG$. DDI-false
It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or @DRUG$, are co-administered with @DRUG$. DDI-advise
- did not change the plasma concentration profile of @DRUG$ (a substrate of cytochrome P450 3A4) or @DRUG$, its carboxylated metabolite, and did not prolong the QTc interval following co-administration with terfenadine 60 mg twice daily. DDI-advise
- did not change the plasma concentration profile of @DRUG$ (a substrate of cytochrome P450 3A4) or fexofenadine, its carboxylated metabolite, and did not prolong the QTc interval following co-administration with @DRUG$ 60 mg twice daily. DDI-false
- did not change the plasma concentration profile of terfenadine (a substrate of cytochrome P450 3A4) or @DRUG$, its carboxylated metabolite, and did not prolong the QTc interval following co-administration with @DRUG$ 60 mg twice daily. DDI-false
@DRUG$ at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral @DRUG$ containing norethindrone 1 mg/ethinyl estradiol 35 mcg. DDI-false
@DRUG$ at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing @DRUG$ 1 mg/ethinyl estradiol 35 mcg. DDI-false
@DRUG$ at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing norethindrone 1 mg/ethinyl @DRUG$ 35 mcg. DDI-false
Montelukast at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral @DRUG$ containing @DRUG$ 1 mg/ethinyl estradiol 35 mcg. DDI-false
Montelukast at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral @DRUG$ containing norethindrone 1 mg/ethinyl @DRUG$ 35 mcg. DDI-false
Montelukast at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing @DRUG$ 1 mg/ethinyl @DRUG$ 35 mcg. DDI-false
- did not cause any clinically significant change in plasma profiles of @DRUG$ or @DRUG$ following administration of either oral prednisone or intravenous prednisolone. DDI-false
- did not cause any clinically significant change in plasma profiles of @DRUG$ or prednisolone following administration of either oral @DRUG$ or intravenous prednisolone. DDI-false
- did not cause any clinically significant change in plasma profiles of @DRUG$ or prednisolone following administration of either oral prednisone or intravenous @DRUG$. DDI-false
- did not cause any clinically significant change in plasma profiles of prednisone or @DRUG$ following administration of either oral @DRUG$ or intravenous prednisolone. DDI-false
- did not cause any clinically significant change in plasma profiles of prednisone or @DRUG$ following administration of either oral prednisone or intravenous @DRUG$. DDI-false
- did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral @DRUG$ or intravenous @DRUG$. DDI-false
@DRUG$, which induces hepatic metabolism, decreased the AUC of @DRUG$ approximately 40% following a single 10-mg dose of montelukast. DDI-false
@DRUG$, which induces hepatic metabolism, decreased the AUC of montelukast approximately 40% following a single 10-mg dose of @DRUG$. DDI-mechanism
Phenobarbital, which induces hepatic metabolism, decreased the AUC of @DRUG$ approximately 40% following a single 10-mg dose of @DRUG$. DDI-false
It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as @DRUG$ or @DRUG$, are co-administered with montelukast. DDI-false
It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as @DRUG$ or rifampin, are co-administered with @DRUG$. DDI-false
It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or @DRUG$, are co-administered with @DRUG$. DDI-advise
In a pharmacokinetic study of 18 chronic hepatitis C patients concomitantly receiving @DRUG$, treatment with @DRUG$ once weekly for 4 weeks was associated with a mean increase of 16% in methadone AUC; DDI-advise
In a pharmacokinetic study of 18 chronic hepatitis C patients concomitantly receiving @DRUG$, treatment with PEG-Intron once weekly for 4 weeks was associated with a mean increase of 16% in @DRUG$ AUC; DDI-false
In a pharmacokinetic study of 18 chronic hepatitis C patients concomitantly receiving methadone, treatment with @DRUG$ once weekly for 4 weeks was associated with a mean increase of 16% in @DRUG$ AUC; DDI-false
However, the impairment of motor skills produced by @DRUG$ has been shown to be additive with those caused by @DRUG$. DDI-mechanism
Accordingly, patients should be advised to avoid @DRUG$ and other similar drugs while taking @DRUG$. DDI-effect
Drugs Affecting Hepatic Metabolism The metabolism and pharmacokinetics of @DRUG$    (@DRUG$) Orally Disintegrating Tablets may be affected by the induction or inhibition of drug-metab-olizing enzymes. DDI-advise
While in vitro studies have shown that @DRUG$ is not a potent inhibitor of any of these enzymes, an indication that @DRUG$ is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome P450 enzymes, the concomitant use of REMERON SolTab with most other drugs metabolized by these enzymes has not been formally studied. DDI-false
While in vitro studies have shown that @DRUG$ is not a potent inhibitor of any of these enzymes, an indication that mirtazapine is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome P450 enzymes, the concomitant use of @DRUG$ with most other drugs metabolized by these enzymes has not been formally studied. DDI-false
While in vitro studies have shown that mirtazapine is not a potent inhibitor of any of these enzymes, an indication that @DRUG$ is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome P450 enzymes, the concomitant use of @DRUG$ with most other drugs metabolized by these enzymes has not been formally studied. DDI-false
@DRUG$: Concomitant administration of @DRUG$ (equivalent to 60 g) had a minimal effect on plasma levels of mirtazapine (15 mg) in 6 healthy male subjects. DDI-false
@DRUG$: Concomitant administration of alcohol (equivalent to 60 g) had a minimal effect on plasma levels of @DRUG$ (15 mg) in 6 healthy male subjects. DDI-false
Alcohol: Concomitant administration of @DRUG$ (equivalent to 60 g) had a minimal effect on plasma levels of @DRUG$ (15 mg) in 6 healthy male subjects. DDI-false
However, the impairment of cognitive and motor skills produced by @DRUG$    were shown to be additive with those produced by @DRUG$. DDI-false
Accordingly, patients should be advised to avoid @DRUG$ while taking @DRUG$. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. DDI-effect
Accordingly, patients should be advised to avoid @DRUG$ while taking REMERON SolTab. @DRUG$: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. DDI-advise
Accordingly, patients should be advised to avoid @DRUG$ while taking REMERON SolTab. Diazepam: Concomitant administration of @DRUG$ (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. DDI-false
Accordingly, patients should be advised to avoid @DRUG$ while taking REMERON SolTab. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of @DRUG$ (15 mg) in 12 healthy subjects. DDI-false
Accordingly, patients should be advised to avoid alcohol while taking @DRUG$. @DRUG$: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. DDI-false
Accordingly, patients should be advised to avoid alcohol while taking @DRUG$. Diazepam: Concomitant administration of @DRUG$ (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. DDI-false
Accordingly, patients should be advised to avoid alcohol while taking @DRUG$. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of @DRUG$ (15 mg) in 12 healthy subjects. DDI-false
Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. @DRUG$: Concomitant administration of @DRUG$ (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. DDI-false
Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. @DRUG$: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of @DRUG$ (15 mg) in 12 healthy subjects. DDI-false
Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam: Concomitant administration of @DRUG$ (15 mg) had a minimal effect on plasma levels of @DRUG$ (15 mg) in 12 healthy subjects. DDI-false
@DRUG$: Spontaneous adverse reaction reports of patients taking concomitant @DRUG$ with recommended doses of terfenadine demonstrate QT interval prolongation and rare serious cardiac events, e.g. DDI-false
@DRUG$: Spontaneous adverse reaction reports of patients taking concomitant ketoconazole with recommended doses of @DRUG$ demonstrate QT interval prolongation and rare serious cardiac events, e.g. DDI-false
Ketoconazole: Spontaneous adverse reaction reports of patients taking concomitant @DRUG$ with recommended doses of @DRUG$ demonstrate QT interval prolongation and rare serious cardiac events, e.g. DDI-false
A few spontaneous accounts of QT interval prolongation with ventricular arrhythmia including torsades de pointes, have been reported in patients receiving @DRUG$ or @DRUG$. DDI-effect
Concomitant administration of @DRUG$ with @DRUG$, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. DDI-false
Concomitant administration of @DRUG$ with clarithromycin, @DRUG$, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. DDI-advise
Concomitant administration of @DRUG$ with clarithromycin, erythromycin, or @DRUG$ is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. DDI-advise
Concomitant administration of @DRUG$ with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of @DRUG$ with other macrolide antibiotics, including azithromycin, is not recommended. DDI-advise
Concomitant administration of @DRUG$ with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other @DRUG$, including azithromycin, is not recommended. DDI-false
Concomitant administration of @DRUG$ with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including @DRUG$, is not recommended. DDI-false
Concomitant administration of terfenadine with @DRUG$, @DRUG$, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. DDI-false
Concomitant administration of terfenadine with @DRUG$, erythromycin, or @DRUG$ is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. DDI-false
Concomitant administration of terfenadine with @DRUG$, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of @DRUG$ with other macrolide antibiotics, including azithromycin, is not recommended. DDI-false
Concomitant administration of terfenadine with @DRUG$, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other @DRUG$, including azithromycin, is not recommended. DDI-false
Concomitant administration of terfenadine with @DRUG$, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including @DRUG$, is not recommended. DDI-false
Concomitant administration of terfenadine with clarithromycin, @DRUG$, or @DRUG$ is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. DDI-false
Concomitant administration of terfenadine with clarithromycin, @DRUG$, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of @DRUG$ with other macrolide antibiotics, including azithromycin, is not recommended. DDI-false
Concomitant administration of terfenadine with clarithromycin, @DRUG$, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other @DRUG$, including azithromycin, is not recommended. DDI-false
Concomitant administration of terfenadine with clarithromycin, @DRUG$, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including @DRUG$, is not recommended. DDI-false
Concomitant administration of terfenadine with clarithromycin, erythromycin, or @DRUG$ is contraindicated: Pending full characterization of potential interactions, concomitant administration of @DRUG$ with other macrolide antibiotics, including azithromycin, is not recommended. DDI-false
Concomitant administration of terfenadine with clarithromycin, erythromycin, or @DRUG$ is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other @DRUG$, including azithromycin, is not recommended. DDI-false
Concomitant administration of terfenadine with clarithromycin, erythromycin, or @DRUG$ is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including @DRUG$, is not recommended. DDI-false
Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of @DRUG$ with other @DRUG$, including azithromycin, is not recommended. DDI-false
Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of @DRUG$ with other macrolide antibiotics, including @DRUG$, is not recommended. DDI-advise
Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other @DRUG$, including @DRUG$, is not recommended. DDI-advise
Studies to evaluate potential interactions of @DRUG$ with @DRUG$ are in progress. DDI-false
Pharmacokinetic data indicate that @DRUG$ markedly inhibits the metabolism of @DRUG$, resulting in elevated plasma terfenadine levels. DDI-false
Pharmacokinetic data indicate that @DRUG$ markedly inhibits the metabolism of terfenadine, resulting in elevated plasma @DRUG$ levels. DDI-mechanism
Pharmacokinetic data indicate that ketoconazole markedly inhibits the metabolism of @DRUG$, resulting in elevated plasma @DRUG$ levels. DDI-false
Concomitant administration of @DRUG$ and @DRUG$ is contraindicated. DDI-false
@DRUG$: Torsades de pointes and elevated parent @DRUG$ levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources. DDI-advise
@DRUG$: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of @DRUG$ and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources. DDI-false
@DRUG$: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and @DRUG$ in clinical trials of itraconazole and from foreign post-marketing sources. DDI-false
@DRUG$: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of @DRUG$ and from foreign post-marketing sources. DDI-false
Itraconazole: Torsades de pointes and elevated parent @DRUG$ levels have been reported during concomitant use of @DRUG$ and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources. DDI-false
Itraconazole: Torsades de pointes and elevated parent @DRUG$ levels have been reported during concomitant use of terfenadine and @DRUG$ in clinical trials of itraconazole and from foreign post-marketing sources. DDI-false
Itraconazole: Torsades de pointes and elevated parent @DRUG$ levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of @DRUG$ and from foreign post-marketing sources. DDI-false
Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of @DRUG$ and @DRUG$ in clinical trials of itraconazole and from foreign post-marketing sources. DDI-false
Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of @DRUG$ and itraconazole in clinical trials of @DRUG$ and from foreign post-marketing sources. DDI-mechanism
Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and @DRUG$ in clinical trials of @DRUG$ and from foreign post-marketing sources. DDI-false
Concomitant administration of @DRUG$ and @DRUG$ is contraindicated. DDI-false
Due to the chemical similarity of other @DRUG$ (including @DRUG$, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. DDI-advise
Due to the chemical similarity of other @DRUG$ (including fluconazole, @DRUG$, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. DDI-false
Due to the chemical similarity of other @DRUG$ (including fluconazole, metronidazole, and @DRUG$) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. DDI-false
Due to the chemical similarity of other @DRUG$ (including fluconazole, metronidazole, and miconazole) to @DRUG$, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. DDI-false
Due to the chemical similarity of other @DRUG$ (including fluconazole, metronidazole, and miconazole) to ketoconazole, and @DRUG$, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. DDI-false
Due to the chemical similarity of other @DRUG$ (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with @DRUG$ is not recommended pending full examination of potential interactions. DDI-false
Due to the chemical similarity of other azole-type antifungal agents (including @DRUG$, @DRUG$, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. DDI-false
Due to the chemical similarity of other azole-type antifungal agents (including @DRUG$, metronidazole, and @DRUG$) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. DDI-false
Due to the chemical similarity of other azole-type antifungal agents (including @DRUG$, metronidazole, and miconazole) to @DRUG$, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. DDI-false
Due to the chemical similarity of other azole-type antifungal agents (including @DRUG$, metronidazole, and miconazole) to ketoconazole, and @DRUG$, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. DDI-false
Due to the chemical similarity of other azole-type antifungal agents (including @DRUG$, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with @DRUG$ is not recommended pending full examination of potential interactions. DDI-false
Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, @DRUG$, and @DRUG$) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. DDI-false
Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, @DRUG$, and miconazole) to @DRUG$, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. DDI-false
Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, @DRUG$, and miconazole) to ketoconazole, and @DRUG$, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. DDI-false
Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, @DRUG$, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with @DRUG$ is not recommended pending full examination of potential interactions. DDI-false
Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and @DRUG$) to @DRUG$, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. DDI-false
Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and @DRUG$) to ketoconazole, and @DRUG$, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. DDI-false
Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and @DRUG$) to ketoconazole, and itraconazole, concomitant use of these products with @DRUG$ is not recommended pending full examination of potential interactions. DDI-false
Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to @DRUG$, and @DRUG$, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. DDI-false
Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to @DRUG$, and itraconazole, concomitant use of these products with @DRUG$ is not recommended pending full examination of potential interactions. DDI-false
Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and @DRUG$, concomitant use of these products with @DRUG$ is not recommended pending full examination of potential interactions. DDI-false
@DRUG$: Clinical drug interaction studies indicate that @DRUG$ and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. DDI-false
@DRUG$: Clinical drug interaction studies indicate that erythromycin and @DRUG$ can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. DDI-false
@DRUG$: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on @DRUG$ metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. DDI-false
@DRUG$: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of @DRUG$, but to a lesser extent. DDI-false
Macrolides: Clinical drug interaction studies indicate that @DRUG$ and @DRUG$ can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. DDI-false
Macrolides: Clinical drug interaction studies indicate that @DRUG$ and clarithromycin can exert an effect on @DRUG$ metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. DDI-false
Macrolides: Clinical drug interaction studies indicate that @DRUG$ and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of @DRUG$, but to a lesser extent. DDI-mechanism
Macrolides: Clinical drug interaction studies indicate that erythromycin and @DRUG$ can exert an effect on @DRUG$ metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. DDI-false
Macrolides: Clinical drug interaction studies indicate that erythromycin and @DRUG$ can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of @DRUG$, but to a lesser extent. DDI-mechanism
Macrolides: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on @DRUG$ metabolism by a mechanism which may be similar to that of @DRUG$, but to a lesser extent. DDI-false
Acromegalic patients with diabetes mellitus being treated with @DRUG$ and/or oral @DRUG$ agents may require dose reductions of these therapeutic agents after the initiation of therapy with SOMAVERT. DDI-false
Acromegalic patients with diabetes mellitus being treated with @DRUG$ and/or oral hypoglycemic agents may require dose reductions of these therapeutic agents after the initiation of therapy with @DRUG$. DDI-false
Acromegalic patients with diabetes mellitus being treated with insulin and/or oral @DRUG$ agents may require dose reductions of these therapeutic agents after the initiation of therapy with @DRUG$. DDI-advise
In clinical studies, patients on @DRUG$ often needed higher serum @DRUG$ concentrations to achieve appropriate IGF-I suppression compared with patients not receiving opioids. DDI-advise
In clinical studies, patients on @DRUG$ often needed higher serum pegvisomant concentrations to achieve appropriate IGF-I suppression compared with patients not receiving @DRUG$. DDI-advise
In clinical studies, patients on opioids often needed higher serum @DRUG$ concentrations to achieve appropriate IGF-I suppression compared with patients not receiving @DRUG$. DDI-false
@DRUG$ should be used with caution in digitalized patients, since the combination of @DRUG$ and sympathomimetic amines may cause ectopic arrhythmias. DDI-false
@DRUG$ should be used with caution in digitalized patients, since the combination of digitalis and @DRUG$ may cause ectopic arrhythmias. DDI-false
ARAMINE should be used with caution in digitalized patients, since the combination of @DRUG$ and @DRUG$ may cause ectopic arrhythmias. DDI-false
@DRUG$ or @DRUG$ may potentiate the action of sympathomimetic amines. DDI-effect
@DRUG$ or tricyclic antidepressants may potentiate the action of @DRUG$. DDI-false
Monoamine oxidase inhibitors or @DRUG$ may potentiate the action of @DRUG$. DDI-effect
@DRUG$, a bacteriostatic @DRUG$, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided. DDI-effect
@DRUG$, a bacteriostatic antibiotic, may antagonize the bactericidal effect of @DRUG$ and concurrent use of these drugs should be avoided. DDI-false
Tetracycline, a bacteriostatic @DRUG$, may antagonize the bactericidal effect of @DRUG$ and concurrent use of these drugs should be avoided. DDI-effect
Concomitant use of @DRUG$ with @DRUG$ may result in an adverse drug interaction. DDI-false
@DRUG$ has been studied on a background of @DRUG$ and heparin. DDI-effect
@DRUG$ has been studied on a background of aspirin and @DRUG$. DDI-false
AGGRASTAT has been studied on a background of @DRUG$ and @DRUG$. DDI-false
The use of @DRUG$, in combination with @DRUG$ and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see DDI-false
The use of @DRUG$, in combination with heparin and @DRUG$, has been associated with an increase in bleeding compared to heparin and aspirin alone (see DDI-false
The use of @DRUG$, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to @DRUG$ and aspirin alone (see DDI-false
The use of @DRUG$, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and @DRUG$ alone (see DDI-false
The use of AGGRASTAT, in combination with @DRUG$ and @DRUG$, has been associated with an increase in bleeding compared to heparin and aspirin alone (see DDI-false
The use of AGGRASTAT, in combination with @DRUG$ and aspirin, has been associated with an increase in bleeding compared to @DRUG$ and aspirin alone (see DDI-false
The use of AGGRASTAT, in combination with @DRUG$ and aspirin, has been associated with an increase in bleeding compared to heparin and @DRUG$ alone (see DDI-false
The use of AGGRASTAT, in combination with heparin and @DRUG$, has been associated with an increase in bleeding compared to @DRUG$ and aspirin alone (see DDI-false
The use of AGGRASTAT, in combination with heparin and @DRUG$, has been associated with an increase in bleeding compared to heparin and @DRUG$ alone (see DDI-false
The use of AGGRASTAT, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to @DRUG$ and @DRUG$ alone (see DDI-false
Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when @DRUG$ is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of @DRUG$, protease inhibitors, calcium channel antagonists, and macrolide antibiotics). DDI-false
Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when @DRUG$ is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, @DRUG$, calcium channel antagonists, and macrolide antibiotics). DDI-advise
Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when @DRUG$ is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, @DRUG$, and macrolide antibiotics). DDI-advise
Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when @DRUG$ is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and @DRUG$). DDI-advise
Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of @DRUG$, @DRUG$, calcium channel antagonists, and macrolide antibiotics). DDI-advise
Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of @DRUG$, protease inhibitors, @DRUG$, and macrolide antibiotics). DDI-false
Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of @DRUG$, protease inhibitors, calcium channel antagonists, and @DRUG$). DDI-false
Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, @DRUG$, @DRUG$, and macrolide antibiotics). DDI-false
Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, @DRUG$, calcium channel antagonists, and @DRUG$). DDI-false
Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, @DRUG$, and @DRUG$). DDI-false
Drugs such as @DRUG$, @DRUG$, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. DDI-false
Drugs such as @DRUG$, diltiazem, @DRUG$, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. DDI-false
Drugs such as @DRUG$, diltiazem, verapamil, @DRUG$, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. DDI-false
Drugs such as @DRUG$, diltiazem, verapamil, ketoconazole, @DRUG$ and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. DDI-false
Drugs such as @DRUG$, diltiazem, verapamil, ketoconazole, fluconazole and @DRUG$ were shown to significantly increase the C max and AUC of orally administered midazolam. DDI-false
Drugs such as @DRUG$, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered @DRUG$. DDI-false
Drugs such as erythromycin, @DRUG$, @DRUG$, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. DDI-mechanism
Drugs such as erythromycin, @DRUG$, verapamil, @DRUG$, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. DDI-false
Drugs such as erythromycin, @DRUG$, verapamil, ketoconazole, @DRUG$ and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. DDI-false
Drugs such as erythromycin, @DRUG$, verapamil, ketoconazole, fluconazole and @DRUG$ were shown to significantly increase the C max and AUC of orally administered midazolam. DDI-false
Drugs such as erythromycin, @DRUG$, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered @DRUG$. DDI-false
Drugs such as erythromycin, diltiazem, @DRUG$, @DRUG$, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. DDI-mechanism
Drugs such as erythromycin, diltiazem, @DRUG$, ketoconazole, @DRUG$ and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. DDI-false
Drugs such as erythromycin, diltiazem, @DRUG$, ketoconazole, fluconazole and @DRUG$ were shown to significantly increase the C max and AUC of orally administered midazolam. DDI-false
Drugs such as erythromycin, diltiazem, @DRUG$, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered @DRUG$. DDI-false
Drugs such as erythromycin, diltiazem, verapamil, @DRUG$, @DRUG$ and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. DDI-mechanism
Drugs such as erythromycin, diltiazem, verapamil, @DRUG$, fluconazole and @DRUG$ were shown to significantly increase the C max and AUC of orally administered midazolam. DDI-false
Drugs such as erythromycin, diltiazem, verapamil, @DRUG$, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered @DRUG$. DDI-false
Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, @DRUG$ and @DRUG$ were shown to significantly increase the C max and AUC of orally administered midazolam. DDI-mechanism
Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, @DRUG$ and itraconazole were shown to significantly increase the C max and AUC of orally administered @DRUG$. DDI-false
Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and @DRUG$ were shown to significantly increase the C max and AUC of orally administered @DRUG$. DDI-mechanism
The sedative effect of @DRUG$ is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly @DRUG$ (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. DDI-mechanism
The sedative effect of @DRUG$ is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, @DRUG$, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. DDI-effect
The sedative effect of @DRUG$ is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, @DRUG$ and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. DDI-effect
The sedative effect of @DRUG$ is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and @DRUG$), propofol, ketamine, nitrous oxide, secobarbital and droperidol. DDI-effect
The sedative effect of @DRUG$ is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), @DRUG$, ketamine, nitrous oxide, secobarbital and droperidol. DDI-effect
The sedative effect of @DRUG$ is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, @DRUG$, nitrous oxide, secobarbital and droperidol. DDI-effect
The sedative effect of @DRUG$ is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, @DRUG$, secobarbital and droperidol. DDI-effect
The sedative effect of @DRUG$ is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, @DRUG$ and droperidol. DDI-effect
The sedative effect of @DRUG$ is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and @DRUG$. DDI-effect
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly @DRUG$ (eg, @DRUG$, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. DDI-effect
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly @DRUG$ (eg, morphine, @DRUG$ and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. DDI-false
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly @DRUG$ (eg, morphine, meperidine and @DRUG$), propofol, ketamine, nitrous oxide, secobarbital and droperidol. DDI-false
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly @DRUG$ (eg, morphine, meperidine and fentanyl), @DRUG$, ketamine, nitrous oxide, secobarbital and droperidol. DDI-false
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly @DRUG$ (eg, morphine, meperidine and fentanyl), propofol, @DRUG$, nitrous oxide, secobarbital and droperidol. DDI-false
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly @DRUG$ (eg, morphine, meperidine and fentanyl), propofol, ketamine, @DRUG$, secobarbital and droperidol. DDI-false
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly @DRUG$ (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, @DRUG$ and droperidol. DDI-false
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly @DRUG$ (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and @DRUG$. DDI-false
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, @DRUG$, @DRUG$ and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. DDI-false
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, @DRUG$, meperidine and @DRUG$), propofol, ketamine, nitrous oxide, secobarbital and droperidol. DDI-false
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, @DRUG$, meperidine and fentanyl), @DRUG$, ketamine, nitrous oxide, secobarbital and droperidol. DDI-false
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, @DRUG$, meperidine and fentanyl), propofol, @DRUG$, nitrous oxide, secobarbital and droperidol. DDI-false
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, @DRUG$, meperidine and fentanyl), propofol, ketamine, @DRUG$, secobarbital and droperidol. DDI-false
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, @DRUG$, meperidine and fentanyl), propofol, ketamine, nitrous oxide, @DRUG$ and droperidol. DDI-false
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, @DRUG$, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and @DRUG$. DDI-false
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, @DRUG$ and @DRUG$), propofol, ketamine, nitrous oxide, secobarbital and droperidol. DDI-false
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, @DRUG$ and fentanyl), @DRUG$, ketamine, nitrous oxide, secobarbital and droperidol. DDI-false
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, @DRUG$ and fentanyl), propofol, @DRUG$, nitrous oxide, secobarbital and droperidol. DDI-false
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, @DRUG$ and fentanyl), propofol, ketamine, @DRUG$, secobarbital and droperidol. DDI-false
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, @DRUG$ and fentanyl), propofol, ketamine, nitrous oxide, @DRUG$ and droperidol. DDI-false
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, @DRUG$ and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and @DRUG$. DDI-false
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and @DRUG$), @DRUG$, ketamine, nitrous oxide, secobarbital and droperidol. DDI-false
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and @DRUG$), propofol, @DRUG$, nitrous oxide, secobarbital and droperidol. DDI-false
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and @DRUG$), propofol, ketamine, @DRUG$, secobarbital and droperidol. DDI-false
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and @DRUG$), propofol, ketamine, nitrous oxide, @DRUG$ and droperidol. DDI-false
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and @DRUG$), propofol, ketamine, nitrous oxide, secobarbital and @DRUG$. DDI-false
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), @DRUG$, @DRUG$, nitrous oxide, secobarbital and droperidol. DDI-false
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), @DRUG$, ketamine, @DRUG$, secobarbital and droperidol. DDI-false
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), @DRUG$, ketamine, nitrous oxide, @DRUG$ and droperidol. DDI-false
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), @DRUG$, ketamine, nitrous oxide, secobarbital and @DRUG$. DDI-false
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, @DRUG$, @DRUG$, secobarbital and droperidol. DDI-false
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, @DRUG$, nitrous oxide, @DRUG$ and droperidol. DDI-false
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, @DRUG$, nitrous oxide, secobarbital and @DRUG$. DDI-false
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, @DRUG$, @DRUG$ and droperidol. DDI-false
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, @DRUG$, secobarbital and @DRUG$. DDI-false
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, @DRUG$ and @DRUG$. DDI-false
No significant adverse interactions with common premedications (such as @DRUG$, @DRUG$, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed. DDI-false
No significant adverse interactions with common premedications (such as @DRUG$, scopolamine, @DRUG$, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed. DDI-false
No significant adverse interactions with common premedications (such as @DRUG$, scopolamine, glycopyrrolate, @DRUG$, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed. DDI-false
No significant adverse interactions with common premedications (such as @DRUG$, scopolamine, glycopyrrolate, diazepam, @DRUG$, and other muscle relaxants) or local anesthetics have been observed. DDI-false
No significant adverse interactions with common premedications (such as @DRUG$, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other @DRUG$) or local anesthetics have been observed. DDI-false
No significant adverse interactions with common premedications (such as @DRUG$, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local @DRUG$ have been observed. DDI-false
No significant adverse interactions with common premedications (such as atropine, @DRUG$, @DRUG$, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed. DDI-false
No significant adverse interactions with common premedications (such as atropine, @DRUG$, glycopyrrolate, @DRUG$, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed. DDI-false
No significant adverse interactions with common premedications (such as atropine, @DRUG$, glycopyrrolate, diazepam, @DRUG$, and other muscle relaxants) or local anesthetics have been observed. DDI-false
No significant adverse interactions with common premedications (such as atropine, @DRUG$, glycopyrrolate, diazepam, hydroxyzine, and other @DRUG$) or local anesthetics have been observed. DDI-false
No significant adverse interactions with common premedications (such as atropine, @DRUG$, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local @DRUG$ have been observed. DDI-false
No significant adverse interactions with common premedications (such as atropine, scopolamine, @DRUG$, @DRUG$, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed. DDI-false
No significant adverse interactions with common premedications (such as atropine, scopolamine, @DRUG$, diazepam, @DRUG$, and other muscle relaxants) or local anesthetics have been observed. DDI-false
No significant adverse interactions with common premedications (such as atropine, scopolamine, @DRUG$, diazepam, hydroxyzine, and other @DRUG$) or local anesthetics have been observed. DDI-false
No significant adverse interactions with common premedications (such as atropine, scopolamine, @DRUG$, diazepam, hydroxyzine, and other muscle relaxants) or local @DRUG$ have been observed. DDI-false
No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, @DRUG$, @DRUG$, and other muscle relaxants) or local anesthetics have been observed. DDI-false
No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, @DRUG$, hydroxyzine, and other @DRUG$) or local anesthetics have been observed. DDI-false
No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, @DRUG$, hydroxyzine, and other muscle relaxants) or local @DRUG$ have been observed. DDI-false
No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, @DRUG$, and other @DRUG$) or local anesthetics have been observed. DDI-false
No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, @DRUG$, and other muscle relaxants) or local @DRUG$ have been observed. DDI-false
No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other @DRUG$) or local @DRUG$ have been observed. DDI-false
Although not studied, the potent cytochrome P450 3A4 inhibitors @DRUG$ and @DRUG$ may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of midazolam. DDI-false
Although not studied, the potent cytochrome P450 3A4 inhibitors @DRUG$ and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of @DRUG$. DDI-false
Although not studied, the potent cytochrome P450 3A4 inhibitors ritonavir and @DRUG$ may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of @DRUG$. DDI-false
Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as @DRUG$, @DRUG$, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies. DDI-mechanism
Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as @DRUG$, carbamazepine, and @DRUG$, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies. DDI-false
Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as @DRUG$, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral @DRUG$ in adult studies. DDI-false
Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, @DRUG$, and @DRUG$, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies. DDI-false
Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, @DRUG$, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral @DRUG$ in adult studies. DDI-false
Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, carbamazepine, and @DRUG$, induce metabolism and caused a markedly decreased C max and AUC of oral @DRUG$ in adult studies. DDI-mechanism
The difficulty in achieving adequate sedation may have been the result of decreased absorption of the @DRUG$ due to both the gastrointestinal effects and stimulant effects of @DRUG$. DDI-mechanism
The concomitant use of other @DRUG$ including @DRUG$, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. DDI-mechanism
The concomitant use of other @DRUG$ including sedatives, @DRUG$, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. DDI-false
The concomitant use of other @DRUG$ including sedatives, hypnotics, @DRUG$, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. DDI-false
The concomitant use of other @DRUG$ including sedatives, hypnotics, tranquilizers, general @DRUG$, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. DDI-effect
The concomitant use of other @DRUG$ including sedatives, hypnotics, tranquilizers, general anesthetics, @DRUG$, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. DDI-effect
The concomitant use of other @DRUG$ including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other @DRUG$, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. DDI-effect
The concomitant use of other @DRUG$ including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, @DRUG$, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. DDI-effect
The concomitant use of other @DRUG$ including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, @DRUG$, and alcohol may produce additive CNS depressant effects. DDI-effect
The concomitant use of other @DRUG$ including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and @DRUG$ may produce additive CNS depressant effects. DDI-effect
The concomitant use of other CNS depressants including @DRUG$, @DRUG$, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. DDI-effect
The concomitant use of other CNS depressants including @DRUG$, hypnotics, @DRUG$, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. DDI-false
The concomitant use of other CNS depressants including @DRUG$, hypnotics, tranquilizers, general @DRUG$, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. DDI-false
The concomitant use of other CNS depressants including @DRUG$, hypnotics, tranquilizers, general anesthetics, @DRUG$, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. DDI-false
The concomitant use of other CNS depressants including @DRUG$, hypnotics, tranquilizers, general anesthetics, phenothiazines, other @DRUG$, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. DDI-false
The concomitant use of other CNS depressants including @DRUG$, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, @DRUG$, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. DDI-false
The concomitant use of other CNS depressants including @DRUG$, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, @DRUG$, and alcohol may produce additive CNS depressant effects. DDI-false
The concomitant use of other CNS depressants including @DRUG$, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and @DRUG$ may produce additive CNS depressant effects. DDI-false
The concomitant use of other CNS depressants including sedatives, @DRUG$, @DRUG$, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. DDI-effect
The concomitant use of other CNS depressants including sedatives, @DRUG$, tranquilizers, general @DRUG$, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. DDI-false
The concomitant use of other CNS depressants including sedatives, @DRUG$, tranquilizers, general anesthetics, @DRUG$, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. DDI-false
The concomitant use of other CNS depressants including sedatives, @DRUG$, tranquilizers, general anesthetics, phenothiazines, other @DRUG$, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. DDI-false
The concomitant use of other CNS depressants including sedatives, @DRUG$, tranquilizers, general anesthetics, phenothiazines, other opioids, @DRUG$, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. DDI-false
The concomitant use of other CNS depressants including sedatives, @DRUG$, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, @DRUG$, and alcohol may produce additive CNS depressant effects. DDI-false
The concomitant use of other CNS depressants including sedatives, @DRUG$, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and @DRUG$ may produce additive CNS depressant effects. DDI-false
The concomitant use of other CNS depressants including sedatives, hypnotics, @DRUG$, general @DRUG$, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. DDI-effect
The concomitant use of other CNS depressants including sedatives, hypnotics, @DRUG$, general anesthetics, @DRUG$, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. DDI-false
The concomitant use of other CNS depressants including sedatives, hypnotics, @DRUG$, general anesthetics, phenothiazines, other @DRUG$, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. DDI-false
The concomitant use of other CNS depressants including sedatives, hypnotics, @DRUG$, general anesthetics, phenothiazines, other opioids, @DRUG$, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. DDI-false
The concomitant use of other CNS depressants including sedatives, hypnotics, @DRUG$, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, @DRUG$, and alcohol may produce additive CNS depressant effects. DDI-false
The concomitant use of other CNS depressants including sedatives, hypnotics, @DRUG$, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and @DRUG$ may produce additive CNS depressant effects. DDI-false
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general @DRUG$, @DRUG$, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. DDI-effect
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general @DRUG$, phenothiazines, other @DRUG$, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. DDI-false
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general @DRUG$, phenothiazines, other opioids, @DRUG$, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. DDI-false
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general @DRUG$, phenothiazines, other opioids, tricyclic antidepressants, @DRUG$, and alcohol may produce additive CNS depressant effects. DDI-false
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general @DRUG$, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and @DRUG$ may produce additive CNS depressant effects. DDI-false
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, @DRUG$, other @DRUG$, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. DDI-false
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, @DRUG$, other opioids, @DRUG$, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. DDI-false
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, @DRUG$, other opioids, tricyclic antidepressants, @DRUG$, and alcohol may produce additive CNS depressant effects. DDI-false
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, @DRUG$, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and @DRUG$ may produce additive CNS depressant effects. DDI-false
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other @DRUG$, @DRUG$, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. DDI-effect
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other @DRUG$, tricyclic antidepressants, @DRUG$, and alcohol may produce additive CNS depressant effects. DDI-false
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other @DRUG$, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and @DRUG$ may produce additive CNS depressant effects. DDI-false
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, @DRUG$, @DRUG$, and alcohol may produce additive CNS depressant effects. DDI-false
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, @DRUG$, monoamine oxidase (MAO) inhibitors, and @DRUG$ may produce additive CNS depressant effects. DDI-false
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, @DRUG$, and @DRUG$ may produce additive CNS depressant effects. DDI-false
@DRUG$ or other medications with anticholinergic activity when used concurrently with @DRUG$ may result in increased risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. DDI-false
It has been reported that the incidence of bradycardia was increased when @DRUG$ was combined with @DRUG$ for induction of anesthesia. DDI-effect
In addition, CNS toxicity has been reported (confusion, disorientation, respiratory depression, apnea, seizures) following coadministration of @DRUG$ with @DRUG$; DDI-effect
Dosages of concomitantly administered @DRUG$ should be reduced by approximately half, because @DRUG$ amplifies the therapeutic actions and side-effects of opioids. DDI-effect
Dosages of concomitantly administered @DRUG$ should be reduced by approximately half, because levomepromazine amplifies the therapeutic actions and side-effects of @DRUG$. DDI-false
Dosages of concomitantly administered opioids should be reduced by approximately half, because @DRUG$ amplifies the therapeutic actions and side-effects of @DRUG$. DDI-false
Combination with @DRUG$ (@DRUG$) is associated with increased risk of seizures. DDI-effect
Additive sedative effects and confusional states may emerge if @DRUG$ is given with @DRUG$ or barbiturates. DDI-false
Additive sedative effects and confusional states may emerge if @DRUG$ is given with benzodiazepines or @DRUG$. DDI-effect
Additive sedative effects and confusional states may emerge if levomepromazine is given with @DRUG$ or @DRUG$. DDI-effect
Exert particular caution in combining @DRUG$ with other @DRUG$ (tricyclic antidepressants and antiparkinsonian-agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma. DDI-false
Exert particular caution in combining @DRUG$ with other anticholinergic drugs (@DRUG$ and antiparkinsonian-agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma. DDI-advise
Exert particular caution in combining @DRUG$ with other anticholinergic drugs (tricyclic antidepressants and @DRUG$): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma. DDI-advise
Exert particular caution in combining levomepromazine with other @DRUG$ (@DRUG$ and antiparkinsonian-agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma. DDI-advise
Exert particular caution in combining levomepromazine with other @DRUG$ (tricyclic antidepressants and @DRUG$): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma. DDI-false
Exert particular caution in combining levomepromazine with other anticholinergic drugs (@DRUG$ and @DRUG$): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma. DDI-false
@DRUG$ and/or stimulantes of the @DRUG$/amphetamine type may counteract the specific actions of levomepromazine. DDI-false
@DRUG$ and/or stimulantes of the ephedrine/@DRUG$ type may counteract the specific actions of levomepromazine. DDI-false
@DRUG$ and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of @DRUG$. DDI-false
Caffeine and/or stimulantes of the @DRUG$/@DRUG$ type may counteract the specific actions of levomepromazine. DDI-effect
Caffeine and/or stimulantes of the @DRUG$/amphetamine type may counteract the specific actions of @DRUG$. DDI-false
Caffeine and/or stimulantes of the ephedrine/@DRUG$ type may counteract the specific actions of @DRUG$. DDI-false
Usage with @DRUG$: Due to the potential for increased CNS depressants effects, @DRUG$ should be used with caution in patients who are currently receiving pentazocine. DDI-false
Usage with @DRUG$: Due to the potential for increased CNS depressants effects, alcohol should be used with caution in patients who are currently receiving @DRUG$. DDI-false
Usage with Alcohol: Due to the potential for increased CNS depressants effects, @DRUG$ should be used with caution in patients who are currently receiving @DRUG$. DDI-false
The CNS depressant effects of @DRUG$ may be additive with that of other @DRUG$.. DDI-advise
Limited evidence suggests that @DRUG$ may influence the intensity and duration of action of @DRUG$. DDI-effect
@DRUG$: In a multiple-dose study in 30 normal weight subjects, coadministration of @DRUG$ and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. DDI-effect
@DRUG$: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of @DRUG$ (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. DDI-false
@DRUG$: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of @DRUG$ pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. DDI-false
@DRUG$: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, @DRUG$ pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. DDI-false
@DRUG$: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to @DRUG$. DDI-false
Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of @DRUG$ and 40 grams of @DRUG$ (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. DDI-false
Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of @DRUG$ and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of @DRUG$ pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. DDI-false
Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of @DRUG$ and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, @DRUG$ pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. DDI-false
Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of @DRUG$ and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to @DRUG$. DDI-false
Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of @DRUG$ (e.g., approximately 3 glasses of wine) did not result in alteration of @DRUG$ pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. DDI-false
Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of @DRUG$ (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, @DRUG$ pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. DDI-false
Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of @DRUG$ (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to @DRUG$. DDI-false
Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of @DRUG$ pharmacokinetics, @DRUG$ pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. DDI-false
Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of @DRUG$ pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to @DRUG$. DDI-false
Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, @DRUG$ pharmacodynamics (fecal fat excretion), or systemic exposure to @DRUG$. DDI-false
@DRUG$: Preliminary data from a @DRUG$ and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. DDI-false
@DRUG$: Preliminary data from a XENICAL and @DRUG$ drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. DDI-false
@DRUG$: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in @DRUG$ plasma levels when XENICAL was coadministered with cyclosporine. DDI-false
@DRUG$: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when @DRUG$ was coadministered with cyclosporine. DDI-false
@DRUG$: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with @DRUG$. DDI-false
Cyclosporine: Preliminary data from a @DRUG$ and @DRUG$ drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. DDI-false
Cyclosporine: Preliminary data from a @DRUG$ and cyclosporine drug interaction study indicate a reduction in @DRUG$ plasma levels when XENICAL was coadministered with cyclosporine. DDI-false
Cyclosporine: Preliminary data from a @DRUG$ and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when @DRUG$ was coadministered with cyclosporine. DDI-false
Cyclosporine: Preliminary data from a @DRUG$ and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with @DRUG$. DDI-false
Cyclosporine: Preliminary data from a XENICAL and @DRUG$ drug interaction study indicate a reduction in @DRUG$ plasma levels when XENICAL was coadministered with cyclosporine. DDI-false
Cyclosporine: Preliminary data from a XENICAL and @DRUG$ drug interaction study indicate a reduction in cyclosporine plasma levels when @DRUG$ was coadministered with cyclosporine. DDI-false
Cyclosporine: Preliminary data from a XENICAL and @DRUG$ drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with @DRUG$. DDI-false
Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in @DRUG$ plasma levels when @DRUG$ was coadministered with cyclosporine. DDI-false
Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in @DRUG$ plasma levels when XENICAL was coadministered with @DRUG$. DDI-false
Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when @DRUG$ was coadministered with @DRUG$. DDI-false
@DRUG$: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving @DRUG$ 120 mg three times a day for 6 days, XENICAL did not affect the pharmacokinetics of pravastatin. DDI-mechanism
@DRUG$: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving XENICAL 120 mg three times a day for 6 days, @DRUG$ did not affect the pharmacokinetics of pravastatin. DDI-false
@DRUG$: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not affect the pharmacokinetics of @DRUG$. DDI-false
Pravastatin: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving @DRUG$ 120 mg three times a day for 6 days, @DRUG$ did not affect the pharmacokinetics of pravastatin. DDI-false
Pravastatin: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving @DRUG$ 120 mg three times a day for 6 days, XENICAL did not affect the pharmacokinetics of @DRUG$. DDI-false
Pravastatin: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving XENICAL 120 mg three times a day for 6 days, @DRUG$ did not affect the pharmacokinetics of @DRUG$. DDI-false
@DRUG$: In 12 normal-weight subjects, administration of @DRUG$ 120 mg three times a day for 16 days did not result in any change in either warfarin pharmacokinetics (both R- and S-enantiomers) or pharmacodynamics (prothrombin time and serum Factor VII). DDI-false
@DRUG$: In 12 normal-weight subjects, administration of XENICAL 120 mg three times a day for 16 days did not result in any change in either @DRUG$ pharmacokinetics (both R- and S-enantiomers) or pharmacodynamics (prothrombin time and serum Factor VII). DDI-false
Warfarin: In 12 normal-weight subjects, administration of @DRUG$ 120 mg three times a day for 16 days did not result in any change in either @DRUG$ pharmacokinetics (both R- and S-enantiomers) or pharmacodynamics (prothrombin time and serum Factor VII). DDI-false
Although undercarboxylated osteocalcin, a marker of vitamin K nutritional status, was unaltered with @DRUG$ administration, vitamin K levels tended to decline in subjects taking @DRUG$. DDI-false
Therefore, as @DRUG$ absorption may be decreased with @DRUG$, patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters. DDI-false
Therefore, as @DRUG$ absorption may be decreased with XENICAL, patients on chronic stable doses of @DRUG$ who are prescribed XENICAL should be monitored closely for changes in coagulation parameters. DDI-mechanism
Therefore, as @DRUG$ absorption may be decreased with XENICAL, patients on chronic stable doses of warfarin who are prescribed @DRUG$ should be monitored closely for changes in coagulation parameters. DDI-false
Therefore, as vitamin K absorption may be decreased with @DRUG$, patients on chronic stable doses of @DRUG$ who are prescribed XENICAL should be monitored closely for changes in coagulation parameters. DDI-false
Therefore, as vitamin K absorption may be decreased with @DRUG$, patients on chronic stable doses of warfarin who are prescribed @DRUG$ should be monitored closely for changes in coagulation parameters. DDI-false
Therefore, as vitamin K absorption may be decreased with XENICAL, patients on chronic stable doses of @DRUG$ who are prescribed @DRUG$ should be monitored closely for changes in coagulation parameters. DDI-false
@DRUG$: In 12 normal-weight subjects receiving @DRUG$ 120 mg three times a day for 6 days, XENICAL did not alter the pharmacokinetics of a single dose of digoxin. DDI-advise
@DRUG$: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, @DRUG$ did not alter the pharmacokinetics of a single dose of digoxin. DDI-false
@DRUG$: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not alter the pharmacokinetics of a single dose of @DRUG$. DDI-false
Digoxin: In 12 normal-weight subjects receiving @DRUG$ 120 mg three times a day for 6 days, @DRUG$ did not alter the pharmacokinetics of a single dose of digoxin. DDI-false
Digoxin: In 12 normal-weight subjects receiving @DRUG$ 120 mg three times a day for 6 days, XENICAL did not alter the pharmacokinetics of a single dose of @DRUG$. DDI-false
Digoxin: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, @DRUG$ did not alter the pharmacokinetics of a single dose of @DRUG$. DDI-false
@DRUG$ and Analogues: A pharmacokinetic interaction study showed a 30% reduction in @DRUG$ supplement absorption when concomitantly administered with XENICAL. DDI-false
@DRUG$ and Analogues: A pharmacokinetic interaction study showed a 30% reduction in beta-carotene supplement absorption when concomitantly administered with @DRUG$. DDI-false
Fat-soluble Vitamin Supplements and Analogues: A pharmacokinetic interaction study showed a 30% reduction in @DRUG$ supplement absorption when concomitantly administered with @DRUG$. DDI-false
@DRUG$ inhibited absorption of a @DRUG$ supplement by approximately 60%. DDI-mechanism
The effect of @DRUG$ on the absorption of supplemental @DRUG$, vitamin A, and nutritionally-derived vitamin K is not known at this time. DDI-mechanism
The effect of @DRUG$ on the absorption of supplemental vitamin D, @DRUG$, and nutritionally-derived vitamin K is not known at this time. DDI-false
The effect of @DRUG$ on the absorption of supplemental vitamin D, vitamin A, and nutritionally-derived @DRUG$ is not known at this time. DDI-false
The effect of orlistat on the absorption of supplemental @DRUG$, @DRUG$, and nutritionally-derived vitamin K is not known at this time. DDI-false
The effect of orlistat on the absorption of supplemental @DRUG$, vitamin A, and nutritionally-derived @DRUG$ is not known at this time. DDI-false
The effect of orlistat on the absorption of supplemental vitamin D, @DRUG$, and nutritionally-derived @DRUG$ is not known at this time. DDI-false
@DRUG$: In 12 normal-weight subjects receiving @DRUG$ 80 mg three times a day for 5 days, orlistat did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of glyburide. DDI-false
@DRUG$: In 12 normal-weight subjects receiving orlistat 80 mg three times a day for 5 days, @DRUG$ did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of glyburide. DDI-false
@DRUG$: In 12 normal-weight subjects receiving orlistat 80 mg three times a day for 5 days, orlistat did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of @DRUG$. DDI-false
Glyburide: In 12 normal-weight subjects receiving @DRUG$ 80 mg three times a day for 5 days, @DRUG$ did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of glyburide. DDI-false
Glyburide: In 12 normal-weight subjects receiving @DRUG$ 80 mg three times a day for 5 days, orlistat did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of @DRUG$. DDI-false
Glyburide: In 12 normal-weight subjects receiving orlistat 80 mg three times a day for 5 days, @DRUG$ did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of @DRUG$. DDI-false
@DRUG$ (extended-release tablets): In 17 normal-weight subjects receiving @DRUG$ 120 mg three times a day for 6 days, XENICAL did not alter the bioavailability of nifedipine (extended-release tablets). DDI-false
@DRUG$ (extended-release tablets): In 17 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, @DRUG$ did not alter the bioavailability of nifedipine (extended-release tablets). DDI-false
@DRUG$ (extended-release tablets): In 17 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not alter the bioavailability of @DRUG$ (extended-release tablets). DDI-false
Nifedipine (extended-release tablets): In 17 normal-weight subjects receiving @DRUG$ 120 mg three times a day for 6 days, @DRUG$ did not alter the bioavailability of nifedipine (extended-release tablets). DDI-false
Nifedipine (extended-release tablets): In 17 normal-weight subjects receiving @DRUG$ 120 mg three times a day for 6 days, XENICAL did not alter the bioavailability of @DRUG$ (extended-release tablets). DDI-false
Nifedipine (extended-release tablets): In 17 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, @DRUG$ did not alter the bioavailability of @DRUG$ (extended-release tablets). DDI-false
Oral @DRUG$: In 20 normal-weight female subjects, the treatment of @DRUG$ 120 mg three times a day for 23 days resulted in no changes in the ovulation-suppressing action of oral contraceptives. DDI-false
Oral @DRUG$: In 20 normal-weight female subjects, the treatment of XENICAL 120 mg three times a day for 23 days resulted in no changes in the ovulation-suppressing action of oral @DRUG$. DDI-false
Oral Contraceptives: In 20 normal-weight female subjects, the treatment of @DRUG$ 120 mg three times a day for 23 days resulted in no changes in the ovulation-suppressing action of oral @DRUG$. DDI-false
@DRUG$: In 12 normal-weight subjects receiving @DRUG$ 120 mg three times a day for 7 days, XENICAL did not alter the pharmacokinetics of a single 300-mg dose of phenytoin. DDI-false
@DRUG$: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 7 days, @DRUG$ did not alter the pharmacokinetics of a single 300-mg dose of phenytoin. DDI-false
@DRUG$: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 7 days, XENICAL did not alter the pharmacokinetics of a single 300-mg dose of @DRUG$. DDI-false
Phenytoin: In 12 normal-weight subjects receiving @DRUG$ 120 mg three times a day for 7 days, @DRUG$ did not alter the pharmacokinetics of a single 300-mg dose of phenytoin. DDI-false
Phenytoin: In 12 normal-weight subjects receiving @DRUG$ 120 mg three times a day for 7 days, XENICAL did not alter the pharmacokinetics of a single 300-mg dose of @DRUG$. DDI-false
Phenytoin: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 7 days, @DRUG$ did not alter the pharmacokinetics of a single 300-mg dose of @DRUG$. DDI-false
@DRUG$ competes with @DRUG$ for active tubular secretion and thus inhibits the renal excretion of meropenem. DDI-false
@DRUG$ competes with meropenem for active tubular secretion and thus inhibits the renal excretion of @DRUG$. DDI-false
Probenecid competes with @DRUG$ for active tubular secretion and thus inhibits the renal excretion of @DRUG$. DDI-mechanism
Therefore, the coadministration of @DRUG$ with @DRUG$ is not recommended. DDI-false
There is evidence that @DRUG$ may reduce serum levels of @DRUG$ to subtherapeutic levels (therapeutic range considered to be 50 to 100    g/mL total valproate). DDI-advise
There is evidence that @DRUG$ may reduce serum levels of valproic acid to subtherapeutic levels (therapeutic range considered to be 50 to 100    g/mL total @DRUG$). DDI-mechanism
There is evidence that meropenem may reduce serum levels of @DRUG$ to subtherapeutic levels (therapeutic range considered to be 50 to 100    g/mL total @DRUG$). DDI-false
Because @DRUG$ is metabolized by hepatic cytochrome P-450 drug-metabolizing enzymes (CYP3A4, CYP2D6, CYP1A2), inducers or inhibitors of these enzymes may change the clearance and, hence, the half-life of @DRUG$. DDI-false
@DRUG$, @DRUG$, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. DDI-false
@DRUG$, Carbamazepine, and @DRUG$: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. DDI-false
@DRUG$, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., @DRUG$, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. DDI-false
@DRUG$, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, @DRUG$, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. DDI-false
@DRUG$, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and @DRUG$), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. DDI-false
@DRUG$, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of @DRUG$ was significantly increased and ondansetron blood concentrations were decreased. DDI-false
@DRUG$, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and @DRUG$ blood concentrations were decreased. DDI-false
Phenytoin, @DRUG$, and @DRUG$: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. DDI-false
Phenytoin, @DRUG$, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., @DRUG$, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. DDI-false
Phenytoin, @DRUG$, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, @DRUG$, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. DDI-false
Phenytoin, @DRUG$, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and @DRUG$), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. DDI-false
Phenytoin, @DRUG$, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of @DRUG$ was significantly increased and ondansetron blood concentrations were decreased. DDI-false
Phenytoin, @DRUG$, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and @DRUG$ blood concentrations were decreased. DDI-false
Phenytoin, Carbamazepine, and @DRUG$: In patients treated with potent inducers of CYP3A4 (i.e., @DRUG$, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. DDI-false
Phenytoin, Carbamazepine, and @DRUG$: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, @DRUG$, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. DDI-false
Phenytoin, Carbamazepine, and @DRUG$: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and @DRUG$), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. DDI-false
Phenytoin, Carbamazepine, and @DRUG$: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of @DRUG$ was significantly increased and ondansetron blood concentrations were decreased. DDI-false
Phenytoin, Carbamazepine, and @DRUG$: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and @DRUG$ blood concentrations were decreased. DDI-false
Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., @DRUG$, @DRUG$, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. DDI-false
Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., @DRUG$, carbamazepine, and @DRUG$), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. DDI-false
Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., @DRUG$, carbamazepine, and rifampicin), the clearance of @DRUG$ was significantly increased and ondansetron blood concentrations were decreased. DDI-false
Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., @DRUG$, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and @DRUG$ blood concentrations were decreased. DDI-mechanism
Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, @DRUG$, and @DRUG$), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. DDI-false
Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, @DRUG$, and rifampicin), the clearance of @DRUG$ was significantly increased and ondansetron blood concentrations were decreased. DDI-false
Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, @DRUG$, and rifampicin), the clearance of ondansetron was significantly increased and @DRUG$ blood concentrations were decreased. DDI-mechanism
Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and @DRUG$), the clearance of @DRUG$ was significantly increased and ondansetron blood concentrations were decreased. DDI-mechanism
Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and @DRUG$), the clearance of ondansetron was significantly increased and @DRUG$ blood concentrations were decreased. DDI-mechanism
Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of @DRUG$ was significantly increased and @DRUG$ blood concentrations were decreased. DDI-mechanism
However, on the basis of available data, no dosage adjustment for @DRUG$ is recommended for patients on these drugs.1,3  @DRUG$: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. DDI-false
However, on the basis of available data, no dosage adjustment for @DRUG$ is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between @DRUG$ and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. DDI-false
However, on the basis of available data, no dosage adjustment for @DRUG$ is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and @DRUG$ has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. DDI-false
However, on the basis of available data, no dosage adjustment for @DRUG$ is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that @DRUG$ may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. DDI-false
However, on the basis of available data, no dosage adjustment for @DRUG$ is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of @DRUG$.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. DDI-false
However, on the basis of available data, no dosage adjustment for @DRUG$ is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by @DRUG$. DDI-false
However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  @DRUG$: Although no pharmacokinetic drug interaction between @DRUG$ and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. DDI-false
However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  @DRUG$: Although no pharmacokinetic drug interaction between ondansetron and @DRUG$ has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. DDI-false
However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  @DRUG$: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that @DRUG$ may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. DDI-false
However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  @DRUG$: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of @DRUG$.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. DDI-false
However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  @DRUG$: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by @DRUG$. DDI-false
However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between @DRUG$ and @DRUG$ has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. DDI-false
However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between @DRUG$ and tramadol has been observed, data from 2 small studies indicate that @DRUG$ may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. DDI-false
However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between @DRUG$ and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of @DRUG$.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. DDI-false
However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between @DRUG$ and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by @DRUG$. DDI-false
However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and @DRUG$ has been observed, data from 2 small studies indicate that @DRUG$ may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. DDI-false
However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and @DRUG$ has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of @DRUG$.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. DDI-false
However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and @DRUG$ has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by @DRUG$. DDI-false
However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that @DRUG$ may be associated with an increase in patient controlled administration of @DRUG$.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. DDI-false
However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that @DRUG$ may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by @DRUG$. DDI-advise
However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of @DRUG$.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by @DRUG$. DDI-false
In humans, @DRUG$, @DRUG$, and cisplatin do not affect the pharmacokinetics of ondansetron. DDI-false
In humans, @DRUG$, etoposide, and @DRUG$ do not affect the pharmacokinetics of ondansetron. DDI-false
In humans, @DRUG$, etoposide, and cisplatin do not affect the pharmacokinetics of @DRUG$. DDI-false
In humans, carmustine, @DRUG$, and @DRUG$ do not affect the pharmacokinetics of ondansetron. DDI-false
In humans, carmustine, @DRUG$, and cisplatin do not affect the pharmacokinetics of @DRUG$. DDI-false
In humans, carmustine, etoposide, and @DRUG$ do not affect the pharmacokinetics of @DRUG$. DDI-false
@DRUG$ did not increase blood levels of high-dose @DRUG$. DDI-false
CYP3A4 Inhibitors: @DRUG$, an inhibitor of the drug metabolizing enzyme CYP3A4, significantly increased plasma concentrations of @DRUG$ when coadministered to subjects who were poor metabolizers (see CLINICAL PHARMACOLOGY, Variability in Metabolism and Drug-Drug Interactions). DDI-false
For patients receiving @DRUG$ or other potent CYP3A4 inhibitors such as other @DRUG$ (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. DDI-mechanism
For patients receiving @DRUG$ or other potent CYP3A4 inhibitors such as other azole antifungals (eg, @DRUG$, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. DDI-false
For patients receiving @DRUG$ or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, @DRUG$) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. DDI-false
For patients receiving @DRUG$ or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or @DRUG$ (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. DDI-false
For patients receiving @DRUG$ or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, @DRUG$, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. DDI-false
For patients receiving @DRUG$ or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, @DRUG$) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. DDI-false
For patients receiving @DRUG$ or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or @DRUG$ or vinblastine, the recommended dose of DETROL LA is 2 mg daily. DDI-false
For patients receiving @DRUG$ or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or @DRUG$, the recommended dose of DETROL LA is 2 mg daily. DDI-false
For patients receiving @DRUG$ or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of @DRUG$ is 2 mg daily. DDI-false
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other @DRUG$ (eg, @DRUG$, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. DDI-advise
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other @DRUG$ (eg, itraconazole, @DRUG$) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. DDI-false
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other @DRUG$ (eg, itraconazole, miconazole) or @DRUG$ (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. DDI-false
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other @DRUG$ (eg, itraconazole, miconazole) or macrolide antibiotics (eg, @DRUG$, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. DDI-false
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other @DRUG$ (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, @DRUG$) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. DDI-false
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other @DRUG$ (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or @DRUG$ or vinblastine, the recommended dose of DETROL LA is 2 mg daily. DDI-false
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other @DRUG$ (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or @DRUG$, the recommended dose of DETROL LA is 2 mg daily. DDI-false
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other @DRUG$ (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of @DRUG$ is 2 mg daily. DDI-false
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, @DRUG$, @DRUG$) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. DDI-advise
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, @DRUG$, miconazole) or @DRUG$ (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. DDI-false
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, @DRUG$, miconazole) or macrolide antibiotics (eg, @DRUG$, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. DDI-false
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, @DRUG$, miconazole) or macrolide antibiotics (eg, erythromycin, @DRUG$) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. DDI-false
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, @DRUG$, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or @DRUG$ or vinblastine, the recommended dose of DETROL LA is 2 mg daily. DDI-false
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, @DRUG$, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or @DRUG$, the recommended dose of DETROL LA is 2 mg daily. DDI-false
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, @DRUG$, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of @DRUG$ is 2 mg daily. DDI-false
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, @DRUG$) or @DRUG$ (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. DDI-false
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, @DRUG$) or macrolide antibiotics (eg, @DRUG$, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. DDI-false
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, @DRUG$) or macrolide antibiotics (eg, erythromycin, @DRUG$) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. DDI-false
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, @DRUG$) or macrolide antibiotics (eg, erythromycin, clarithromycin) or @DRUG$ or vinblastine, the recommended dose of DETROL LA is 2 mg daily. DDI-false
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, @DRUG$) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or @DRUG$, the recommended dose of DETROL LA is 2 mg daily. DDI-false
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, @DRUG$) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of @DRUG$ is 2 mg daily. DDI-false
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or @DRUG$ (eg, @DRUG$, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. DDI-advise
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or @DRUG$ (eg, erythromycin, @DRUG$) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. DDI-false
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or @DRUG$ (eg, erythromycin, clarithromycin) or @DRUG$ or vinblastine, the recommended dose of DETROL LA is 2 mg daily. DDI-false
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or @DRUG$ (eg, erythromycin, clarithromycin) or cyclosporine or @DRUG$, the recommended dose of DETROL LA is 2 mg daily. DDI-false
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or @DRUG$ (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of @DRUG$ is 2 mg daily. DDI-false
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, @DRUG$, @DRUG$) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. DDI-advise
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, @DRUG$, clarithromycin) or @DRUG$ or vinblastine, the recommended dose of DETROL LA is 2 mg daily. DDI-false
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, @DRUG$, clarithromycin) or cyclosporine or @DRUG$, the recommended dose of DETROL LA is 2 mg daily. DDI-false
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, @DRUG$, clarithromycin) or cyclosporine or vinblastine, the recommended dose of @DRUG$ is 2 mg daily. DDI-false
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, @DRUG$) or @DRUG$ or vinblastine, the recommended dose of DETROL LA is 2 mg daily. DDI-false
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, @DRUG$) or cyclosporine or @DRUG$, the recommended dose of DETROL LA is 2 mg daily. DDI-false
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, @DRUG$) or cyclosporine or vinblastine, the recommended dose of @DRUG$ is 2 mg daily. DDI-false
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or @DRUG$ or @DRUG$, the recommended dose of DETROL LA is 2 mg daily. DDI-advise
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or @DRUG$ or vinblastine, the recommended dose of @DRUG$ is 2 mg daily. DDI-false
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or @DRUG$, the recommended dose of @DRUG$ is 2 mg daily. DDI-false
Since @DRUG$ is metabolized by a P450 enzyme system, drugs that induce or inhibit this drug metabolizing enzyme system may elicit important drug-drug interactions that may alter @DRUG$ plasma concentrations. DDI-false
Agents that might be coadministered with @DRUG$ in AIDS patients for other indications that could elicit this activity include @DRUG$, rifampin, rifabutin, ketoconazole, and fluconazole. DDI-false
Agents that might be coadministered with @DRUG$ in AIDS patients for other indications that could elicit this activity include erythromycin, @DRUG$, rifabutin, ketoconazole, and fluconazole. DDI-false
Agents that might be coadministered with @DRUG$ in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, @DRUG$, ketoconazole, and fluconazole. DDI-effect
Agents that might be coadministered with @DRUG$ in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, @DRUG$, and fluconazole. DDI-effect
Agents that might be coadministered with @DRUG$ in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and @DRUG$. DDI-false
Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include @DRUG$, @DRUG$, rifabutin, ketoconazole, and fluconazole. DDI-false
Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include @DRUG$, rifampin, @DRUG$, ketoconazole, and fluconazole. DDI-false
Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include @DRUG$, rifampin, rifabutin, @DRUG$, and fluconazole. DDI-false
Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include @DRUG$, rifampin, rifabutin, ketoconazole, and @DRUG$. DDI-false
Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, @DRUG$, @DRUG$, ketoconazole, and fluconazole. DDI-false
Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, @DRUG$, rifabutin, @DRUG$, and fluconazole. DDI-false
Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, @DRUG$, rifabutin, ketoconazole, and @DRUG$. DDI-false
Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, @DRUG$, @DRUG$, and fluconazole. DDI-false
Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, @DRUG$, ketoconazole, and @DRUG$. DDI-false
Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, @DRUG$, and @DRUG$. DDI-false
In vitro perfusion of isolated rat liver has shown that @DRUG$ caused a significant reduction in @DRUG$ metabolism and that acetaminophen altered the relative concentration of trimetrexate metabolites possibly by competing for sulfate metabolites. DDI-false
In vitro perfusion of isolated rat liver has shown that @DRUG$ caused a significant reduction in trimetrexate metabolism and that @DRUG$ altered the relative concentration of trimetrexate metabolites possibly by competing for sulfate metabolites. DDI-mechanism
In vitro perfusion of isolated rat liver has shown that cimetidine caused a significant reduction in @DRUG$ metabolism and that @DRUG$ altered the relative concentration of trimetrexate metabolites possibly by competing for sulfate metabolites. DDI-false
Based on an in vitro rat liver model, nitrogen substituted @DRUG$ (@DRUG$, ketoconazole, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism. DDI-false
Based on an in vitro rat liver model, nitrogen substituted @DRUG$ (clotrimazole, @DRUG$, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism. DDI-false
Based on an in vitro rat liver model, nitrogen substituted @DRUG$ (clotrimazole, ketoconazole, @DRUG$) were potent, non-competitive inhibitors of trimetrexate metabolism. DDI-false
Based on an in vitro rat liver model, nitrogen substituted @DRUG$ (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of @DRUG$ metabolism. DDI-false
Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (@DRUG$, @DRUG$, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism. DDI-mechanism
Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (@DRUG$, ketoconazole, @DRUG$) were potent, non-competitive inhibitors of trimetrexate metabolism. DDI-false
Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (@DRUG$, ketoconazole, miconazole) were potent, non-competitive inhibitors of @DRUG$ metabolism. DDI-false
Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, @DRUG$, @DRUG$) were potent, non-competitive inhibitors of trimetrexate metabolism. DDI-mechanism
Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, @DRUG$, miconazole) were potent, non-competitive inhibitors of @DRUG$ metabolism. DDI-false
Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, @DRUG$) were potent, non-competitive inhibitors of @DRUG$ metabolism. DDI-mechanism
@DRUG$: Prolongation of prothrombin time (PT) and International Normalized Ratio (INR) were observed in patients receiving @DRUG$ concomitantly with coumarin-derivative anticoagulants. DDI-mechanism
@DRUG$: Prolongation of prothrombin time (PT) and International Normalized Ratio (INR) were observed in patients receiving ZOLINZA concomitantly with @DRUG$. DDI-false
Coumarin-Derivative Anticoagulants: Prolongation of prothrombin time (PT) and International Normalized Ratio (INR) were observed in patients receiving @DRUG$ concomitantly with @DRUG$. DDI-false
Physicians should carefully monitor PT and INR in patients concurrently administered @DRUG$ and @DRUG$. DDI-effect
Other @DRUG$ Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of @DRUG$ and other HDAC inhibitors (e.g., valproic acid). DDI-advise
Other @DRUG$ Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other @DRUG$ (e.g., valproic acid). DDI-false
Other @DRUG$ Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other HDAC inhibitors (e.g., @DRUG$). DDI-false
Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of @DRUG$ and other @DRUG$ (e.g., valproic acid). DDI-false
Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of @DRUG$ and other HDAC inhibitors (e.g., @DRUG$). DDI-effect
Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other @DRUG$ (e.g., @DRUG$). DDI-effect
however, in patients with Paget's Disease prior @DRUG$ use appears to reduce the anti-resorptive response to @DRUG$ nasal spray. DDI-false
@DRUG$ should be used with care in patients taking other drugs that are capable of causing CNS effects such as @DRUG$, tranquilizers, or alcohol. DDI-false
@DRUG$ should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives, @DRUG$, or alcohol. DDI-advise
@DRUG$ should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives, tranquilizers, or @DRUG$. DDI-advise
Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as @DRUG$, @DRUG$, or alcohol. DDI-advise
Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as @DRUG$, tranquilizers, or @DRUG$. DDI-false
Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives, @DRUG$, or @DRUG$. DDI-false
e.g., other @DRUG$, @DRUG$ (including meclizine), tricyclic antidepressants, and muscle relaxants. DDI-false
e.g., other @DRUG$, antihistamines (including @DRUG$), tricyclic antidepressants, and muscle relaxants. DDI-false
e.g., other @DRUG$, antihistamines (including meclizine), @DRUG$, and muscle relaxants. DDI-false
e.g., other @DRUG$, antihistamines (including meclizine), tricyclic antidepressants, and @DRUG$. DDI-false
e.g., other belladonna alkaloids, @DRUG$ (including @DRUG$), tricyclic antidepressants, and muscle relaxants. DDI-false
e.g., other belladonna alkaloids, @DRUG$ (including meclizine), @DRUG$, and muscle relaxants. DDI-false
e.g., other belladonna alkaloids, @DRUG$ (including meclizine), tricyclic antidepressants, and @DRUG$. DDI-false
e.g., other belladonna alkaloids, antihistamines (including @DRUG$), @DRUG$, and muscle relaxants. DDI-false
e.g., other belladonna alkaloids, antihistamines (including @DRUG$), tricyclic antidepressants, and @DRUG$. DDI-false
e.g., other belladonna alkaloids, antihistamines (including meclizine), @DRUG$, and @DRUG$. DDI-false
Patients studied in clinical trials of @DRUG$ were routinely treated with @DRUG$ and aspirin. DDI-false
Patients studied in clinical trials of @DRUG$ were routinely treated with heparin and @DRUG$. DDI-false
Patients studied in clinical trials of TNKase were routinely treated with @DRUG$ and @DRUG$. DDI-false
@DRUG$ (such as @DRUG$ and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. DDI-false
@DRUG$ (such as heparin and @DRUG$) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. DDI-false
@DRUG$ (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as @DRUG$, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. DDI-false
@DRUG$ (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, @DRUG$, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. DDI-false
@DRUG$ (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after @DRUG$ therapy. DDI-false
Anticoagulants (such as @DRUG$ and @DRUG$) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. DDI-effect
Anticoagulants (such as @DRUG$ and vitamin K antagonists) and drugs that alter platelet function (such as @DRUG$, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. DDI-false
Anticoagulants (such as @DRUG$ and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, @DRUG$, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. DDI-false
Anticoagulants (such as @DRUG$ and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after @DRUG$ therapy. DDI-false
Anticoagulants (such as heparin and @DRUG$) and drugs that alter platelet function (such as @DRUG$, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. DDI-effect
Anticoagulants (such as heparin and @DRUG$) and drugs that alter platelet function (such as acetylsalicylic acid, @DRUG$, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. DDI-false
Anticoagulants (such as heparin and @DRUG$) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after @DRUG$ therapy. DDI-false
Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as @DRUG$, @DRUG$, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. DDI-effect
Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as @DRUG$, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after @DRUG$ therapy. DDI-false
Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, @DRUG$, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after @DRUG$ therapy. DDI-effect
@DRUG$ may interact with @DRUG$ or mitotane (causing too great a decrease in adrenal function). DDI-effect
@DRUG$ may interact with aminoglutethimide or @DRUG$ (causing too great a decrease in adrenal function). DDI-int
Trilostane may interact with @DRUG$ or @DRUG$ (causing too great a decrease in adrenal function). DDI-int
Although @DRUG$ (a mixture of three stereoisomers) has been administered safely following succinylcholine-facilitated tracheal intubation, the interaction between @DRUG$ and succinylcholine has not been systematically studied. DDI-false
Although @DRUG$ (a mixture of three stereoisomers) has been administered safely following succinylcholine-facilitated tracheal intubation, the interaction between MIVACRON and @DRUG$ has not been systematically studied. DDI-false
Although MIVACRON (a mixture of three stereoisomers) has been administered safely following succinylcholine-facilitated tracheal intubation, the interaction between @DRUG$ and @DRUG$ has not been systematically studied. DDI-false
Prior administration of @DRUG$ can potentiate the neuromuscular blocking effects of @DRUG$. DDI-false
Other drugs which may enhance the neuromuscular blocking action of @DRUG$ such as @DRUG$ include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. DDI-effect
Other drugs which may enhance the neuromuscular blocking action of @DRUG$ such as MIVACRON include certain @DRUG$ (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. DDI-effect
Other drugs which may enhance the neuromuscular blocking action of @DRUG$ such as MIVACRON include certain antibiotics (e.g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. DDI-effect
Other drugs which may enhance the neuromuscular blocking action of @DRUG$ such as MIVACRON include certain antibiotics (e.g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. DDI-effect
Other drugs which may enhance the neuromuscular blocking action of @DRUG$ such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. DDI-effect
Other drugs which may enhance the neuromuscular blocking action of @DRUG$ such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. DDI-effect
Other drugs which may enhance the neuromuscular blocking action of @DRUG$ such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. DDI-effect
Other drugs which may enhance the neuromuscular blocking action of @DRUG$ such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. DDI-effect
Other drugs which may enhance the neuromuscular blocking action of @DRUG$ such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. DDI-effect
Other drugs which may enhance the neuromuscular blocking action of @DRUG$ such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. DDI-effect
Other drugs which may enhance the neuromuscular blocking action of @DRUG$ such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine. DDI-effect
Other drugs which may enhance the neuromuscular blocking action of @DRUG$ such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine. DDI-effect
Other drugs which may enhance the neuromuscular blocking action of @DRUG$ such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine. DDI-effect
Other drugs which may enhance the neuromuscular blocking action of @DRUG$ such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine. DDI-effect
Other drugs which may enhance the neuromuscular blocking action of @DRUG$ such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$. DDI-effect
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain @DRUG$ (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. DDI-effect
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e.g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. DDI-effect
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e.g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. DDI-effect
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e.g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. DDI-effect
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. DDI-effect
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. DDI-effect
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. DDI-effect
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. DDI-effect
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. DDI-effect
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine. DDI-effect
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine. DDI-effect
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine. DDI-effect
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine. DDI-effect
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$. DDI-effect
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain @DRUG$ (e.g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. DDI-effect
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain @DRUG$ (e.g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain @DRUG$ (e.g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain @DRUG$ (e.g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain @DRUG$ (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain @DRUG$ (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain @DRUG$ (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain @DRUG$ (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain @DRUG$ (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain @DRUG$ (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain @DRUG$ (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain @DRUG$ (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain @DRUG$ (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., @DRUG$, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., @DRUG$, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., @DRUG$, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., @DRUG$, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, @DRUG$, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, @DRUG$, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, @DRUG$, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, @DRUG$, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, @DRUG$, local anesthetics, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local @DRUG$, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, @DRUG$, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and @DRUG$. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local @DRUG$, procainamide, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, @DRUG$, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and @DRUG$. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, @DRUG$, and quinidine. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and @DRUG$. DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and @DRUG$. DDI-false
The neuromuscular blocking effect of @DRUG$ may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral @DRUG$, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. DDI-false
The neuromuscular blocking effect of @DRUG$ may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, @DRUG$, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. DDI-effect
The neuromuscular blocking effect of @DRUG$ may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain @DRUG$) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. DDI-effect
The neuromuscular blocking effect of @DRUG$ may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing @DRUG$ has been demonstrated in patients chronically administered phenytoin or carbamazepine. DDI-effect
The neuromuscular blocking effect of @DRUG$ may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered @DRUG$ or carbamazepine. DDI-false
The neuromuscular blocking effect of @DRUG$ may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or @DRUG$. DDI-false
The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral @DRUG$, @DRUG$, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. DDI-effect
The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral @DRUG$, glucocorticoids, or certain @DRUG$) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. DDI-false
The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral @DRUG$, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing @DRUG$ has been demonstrated in patients chronically administered phenytoin or carbamazepine. DDI-false
The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral @DRUG$, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered @DRUG$ or carbamazepine. DDI-false
The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral @DRUG$, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or @DRUG$. DDI-false
The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, @DRUG$, or certain @DRUG$) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. DDI-false
The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, @DRUG$, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing @DRUG$ has been demonstrated in patients chronically administered phenytoin or carbamazepine. DDI-false
The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, @DRUG$, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered @DRUG$ or carbamazepine. DDI-false
The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, @DRUG$, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or @DRUG$. DDI-false
The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain @DRUG$) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing @DRUG$ has been demonstrated in patients chronically administered phenytoin or carbamazepine. DDI-false
The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain @DRUG$) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered @DRUG$ or carbamazepine. DDI-false
The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain @DRUG$) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or @DRUG$. DDI-false
The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing @DRUG$ has been demonstrated in patients chronically administered @DRUG$ or carbamazepine. DDI-false
The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing @DRUG$ has been demonstrated in patients chronically administered phenytoin or @DRUG$. DDI-effect
The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered @DRUG$ or @DRUG$. DDI-effect
While the effects of chronic @DRUG$ or @DRUG$ therapy on the action of MIVACRON are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher. DDI-false
While the effects of chronic @DRUG$ or carbamazepine therapy on the action of @DRUG$ are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher. DDI-false
While the effects of chronic phenytoin or @DRUG$ therapy on the action of @DRUG$ are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher. DDI-effect
Some drug interactions are:  - birth control pills - @DRUG$ - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as @DRUG$ or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants DDI-effect
Some drug interactions are:  - birth control pills - @DRUG$ - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or @DRUG$ - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - @DRUG$ - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain @DRUG$ given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - @DRUG$ - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - @DRUG$ - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - @DRUG$ - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - @DRUG$ - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - @DRUG$ - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - @DRUG$ - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - @DRUG$ - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - @DRUG$ or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - @DRUG$ - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or @DRUG$ - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - @DRUG$ - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local @DRUG$ such as procaine - general anesthetics - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - @DRUG$ - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as @DRUG$ - general anesthetics - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - @DRUG$ - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general @DRUG$ - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - @DRUG$ - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - @DRUG$ or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - @DRUG$ - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other @DRUG$ DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as @DRUG$ or @DRUG$ - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as @DRUG$ or carbamazepine - certain @DRUG$ given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as @DRUG$ or carbamazepine - certain antibiotics given by injection - @DRUG$ - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as @DRUG$ or carbamazepine - certain antibiotics given by injection - cisplatin - @DRUG$ - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as @DRUG$ or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - @DRUG$ - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as @DRUG$ or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - @DRUG$ or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as @DRUG$ or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or @DRUG$ - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as @DRUG$ or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local @DRUG$ such as procaine - general anesthetics - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as @DRUG$ or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as @DRUG$ - general anesthetics - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as @DRUG$ or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general @DRUG$ - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as @DRUG$ or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - @DRUG$ or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as @DRUG$ or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other @DRUG$ DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or @DRUG$ - certain @DRUG$ given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or @DRUG$ - certain antibiotics given by injection - @DRUG$ - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or @DRUG$ - certain antibiotics given by injection - cisplatin - @DRUG$ - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or @DRUG$ - certain antibiotics given by injection - cisplatin - edrophonium - @DRUG$ - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or @DRUG$ - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - @DRUG$ or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or @DRUG$ - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or @DRUG$ - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or @DRUG$ - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local @DRUG$ such as procaine - general anesthetics - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or @DRUG$ - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as @DRUG$ - general anesthetics - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or @DRUG$ - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general @DRUG$ - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or @DRUG$ - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - @DRUG$ or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or @DRUG$ - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other @DRUG$ DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain @DRUG$ given by injection - @DRUG$ - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain @DRUG$ given by injection - cisplatin - @DRUG$ - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain @DRUG$ given by injection - cisplatin - edrophonium - @DRUG$ - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain @DRUG$ given by injection - cisplatin - edrophonium - neostigmine - @DRUG$ or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain @DRUG$ given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or @DRUG$ - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain @DRUG$ given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local @DRUG$ such as procaine - general anesthetics - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain @DRUG$ given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as @DRUG$ - general anesthetics - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain @DRUG$ given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general @DRUG$ - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain @DRUG$ given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - @DRUG$ or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain @DRUG$ given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other @DRUG$ DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - @DRUG$ - @DRUG$ - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - @DRUG$ - edrophonium - @DRUG$ - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - @DRUG$ - edrophonium - neostigmine - @DRUG$ or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - @DRUG$ - edrophonium - neostigmine - polymyxin B or @DRUG$ - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - @DRUG$ - edrophonium - neostigmine - polymyxin B or bacitracin - local @DRUG$ such as procaine - general anesthetics - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - @DRUG$ - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as @DRUG$ - general anesthetics - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - @DRUG$ - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general @DRUG$ - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - @DRUG$ - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - @DRUG$ or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - @DRUG$ - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other @DRUG$ DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - @DRUG$ - @DRUG$ - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - @DRUG$ - neostigmine - @DRUG$ or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - @DRUG$ - neostigmine - polymyxin B or @DRUG$ - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - @DRUG$ - neostigmine - polymyxin B or bacitracin - local @DRUG$ such as procaine - general anesthetics - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - @DRUG$ - neostigmine - polymyxin B or bacitracin - local anesthetics such as @DRUG$ - general anesthetics - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - @DRUG$ - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general @DRUG$ - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - @DRUG$ - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - @DRUG$ or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - @DRUG$ - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other @DRUG$ DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - @DRUG$ - @DRUG$ or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - @DRUG$ - polymyxin B or @DRUG$ - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - @DRUG$ - polymyxin B or bacitracin - local @DRUG$ such as procaine - general anesthetics - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - @DRUG$ - polymyxin B or bacitracin - local anesthetics such as @DRUG$ - general anesthetics - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - @DRUG$ - polymyxin B or bacitracin - local anesthetics such as procaine - general @DRUG$ - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - @DRUG$ - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - @DRUG$ or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - @DRUG$ - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other @DRUG$ DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - @DRUG$ or @DRUG$ - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - @DRUG$ or bacitracin - local @DRUG$ such as procaine - general anesthetics - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - @DRUG$ or bacitracin - local anesthetics such as @DRUG$ - general anesthetics - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - @DRUG$ or bacitracin - local anesthetics such as procaine - general @DRUG$ - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - @DRUG$ or bacitracin - local anesthetics such as procaine - general anesthetics - @DRUG$ or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - @DRUG$ or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other @DRUG$ DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or @DRUG$ - local @DRUG$ such as procaine - general anesthetics - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or @DRUG$ - local anesthetics such as @DRUG$ - general anesthetics - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or @DRUG$ - local anesthetics such as procaine - general @DRUG$ - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or @DRUG$ - local anesthetics such as procaine - general anesthetics - @DRUG$ or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or @DRUG$ - local anesthetics such as procaine - general anesthetics - succinylcholine or other @DRUG$ DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local @DRUG$ such as @DRUG$ - general anesthetics - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local @DRUG$ such as procaine - general @DRUG$ - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local @DRUG$ such as procaine - general anesthetics - @DRUG$ or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local @DRUG$ such as procaine - general anesthetics - succinylcholine or other @DRUG$ DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as @DRUG$ - general @DRUG$ - succinylcholine or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as @DRUG$ - general anesthetics - @DRUG$ or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as @DRUG$ - general anesthetics - succinylcholine or other @DRUG$ DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general @DRUG$ - @DRUG$ or other muscle relaxants DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general @DRUG$ - succinylcholine or other @DRUG$ DDI-false
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - @DRUG$ or other @DRUG$ DDI-false
Evidence of spontaneous recovery from @DRUG$ should be observed before the administration of @DRUG$. DDI-false
The use of @DRUG$ before @DRUG$ to attenuate some of the side effects of succinylcholine has not been studied. DDI-advise
The use of @DRUG$ before succinylcholine to attenuate some of the side effects of @DRUG$ has not been studied. DDI-false
The use of MIVACRON before @DRUG$ to attenuate some of the side effects of @DRUG$ has not been studied. DDI-false
There are no clinical data on the use of @DRUG$ with other @DRUG$. DDI-false
@DRUG$ and @DRUG$ (administered with nitrous oxide/oxygen to achieve 1.25 M.C. DDI-false
@DRUG$ and enflurane (administered with @DRUG$/oxygen to achieve 1.25 M.C. DDI-false
@DRUG$ and enflurane (administered with nitrous oxide/@DRUG$ to achieve 1.25 M.C. DDI-false
Isoflurane and @DRUG$ (administered with @DRUG$/oxygen to achieve 1.25 M.C. DDI-false
Isoflurane and @DRUG$ (administered with nitrous oxide/@DRUG$ to achieve 1.25 M.C. DDI-false
Isoflurane and enflurane (administered with @DRUG$/@DRUG$ to achieve 1.25 M.C. DDI-false
A greater potentiation of the neuromuscular blocking effects of @DRUG$ may be expected with higher concentrations of @DRUG$ or isoflurane. DDI-false
A greater potentiation of the neuromuscular blocking effects of @DRUG$ may be expected with higher concentrations of enflurane or @DRUG$. DDI-effect
A greater potentiation of the neuromuscular blocking effects of MIVACRON may be expected with higher concentrations of @DRUG$ or @DRUG$. DDI-effect
@DRUG$: @DRUG$ increases the plasma concentrations of phenytoin. DDI-false
@DRUG$: DIFLUCAN increases the plasma concentrations of @DRUG$. DDI-false
Phenytoin: @DRUG$ increases the plasma concentrations of @DRUG$. DDI-false
Careful monitoring of @DRUG$ concentrations in patients receiving @DRUG$ and phenytoin is recommended. DDI-mechanism
Careful monitoring of @DRUG$ concentrations in patients receiving DIFLUCAN and @DRUG$ is recommended. DDI-false
Careful monitoring of phenytoin concentrations in patients receiving @DRUG$ and @DRUG$ is recommended. DDI-false
@DRUG$: @DRUG$ may significantly increase cyclosporine levels in renal transplant patients with or without renal impairment. DDI-advise
@DRUG$: DIFLUCAN may significantly increase @DRUG$ levels in renal transplant patients with or without renal impairment. DDI-false
Cyclosporine: @DRUG$ may significantly increase @DRUG$ levels in renal transplant patients with or without renal impairment. DDI-false
Careful monitoring of @DRUG$ concentrations and serum creatinine is recommended in patients receiving @DRUG$ and cyclosporine. DDI-mechanism
Careful monitoring of @DRUG$ concentrations and serum creatinine is recommended in patients receiving DIFLUCAN and @DRUG$. DDI-false
Careful monitoring of cyclosporine concentrations and serum creatinine is recommended in patients receiving @DRUG$ and @DRUG$. DDI-false
@DRUG$: @DRUG$ enhances the metabolism of concurrently administered DIFLUCAN. DDI-advise
@DRUG$: Rifampin enhances the metabolism of concurrently administered @DRUG$. DDI-false
Rifampin: @DRUG$ enhances the metabolism of concurrently administered @DRUG$. DDI-false
Depending on clinical circumstances, consideration should be given to increasing the dose of @DRUG$ when it is administered with @DRUG$. DDI-mechanism
@DRUG$: @DRUG$ increases the serum concentrations of theophylline. DDI-advise
@DRUG$: DIFLUCAN increases the serum concentrations of @DRUG$. DDI-false
Theophylline: @DRUG$ increases the serum concentrations of @DRUG$. DDI-false
Careful monitoring of serum @DRUG$ concentrations in patients receiving @DRUG$ and theophylline is recommended. DDI-mechanism
Careful monitoring of serum @DRUG$ concentrations in patients receiving DIFLUCAN and @DRUG$ is recommended. DDI-false
Careful monitoring of serum theophylline concentrations in patients receiving @DRUG$ and @DRUG$ is recommended. DDI-false
These are described in greater detail below:  Oral @DRUG$, @DRUG$, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-advise
These are described in greater detail below:  Oral @DRUG$, Coumarin-type anticoagulants, @DRUG$, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral @DRUG$, Coumarin-type anticoagulants, Phenytoin, @DRUG$, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral @DRUG$, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, @DRUG$, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral @DRUG$, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, @DRUG$, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral @DRUG$, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, @DRUG$, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral @DRUG$, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, @DRUG$, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral @DRUG$, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, @DRUG$, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral @DRUG$, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, @DRUG$, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral @DRUG$, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, @DRUG$, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral @DRUG$, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, @DRUG$,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral @DRUG$, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral @DRUG$: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral @DRUG$, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of @DRUG$ with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral @DRUG$, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral @DRUG$; DDI-false
These are described in greater detail below:  Oral hypoglycemics, @DRUG$, @DRUG$, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, @DRUG$, Phenytoin, @DRUG$, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, @DRUG$, Phenytoin, Cyclosporine, @DRUG$, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, @DRUG$, Phenytoin, Cyclosporine, Rifampin, @DRUG$, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, @DRUG$, Phenytoin, Cyclosporine, Rifampin, Theophylline, @DRUG$, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, @DRUG$, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, @DRUG$, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, @DRUG$, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, @DRUG$, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, @DRUG$, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, @DRUG$, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, @DRUG$, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, @DRUG$, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, @DRUG$, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, @DRUG$,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, @DRUG$, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral @DRUG$: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, @DRUG$, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of @DRUG$ with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, @DRUG$, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral @DRUG$; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, @DRUG$, @DRUG$, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, @DRUG$, Cyclosporine, @DRUG$, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, @DRUG$, Cyclosporine, Rifampin, @DRUG$, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, @DRUG$, Cyclosporine, Rifampin, Theophylline, @DRUG$, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, @DRUG$, Cyclosporine, Rifampin, Theophylline, Terfenadine, @DRUG$, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, @DRUG$, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, @DRUG$, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, @DRUG$, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, @DRUG$, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, @DRUG$, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, @DRUG$, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, @DRUG$, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, @DRUG$,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, @DRUG$, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral @DRUG$: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, @DRUG$, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of @DRUG$ with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, @DRUG$, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral @DRUG$; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, @DRUG$, @DRUG$, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, @DRUG$, Rifampin, @DRUG$, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, @DRUG$, Rifampin, Theophylline, @DRUG$, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, @DRUG$, Rifampin, Theophylline, Terfenadine, @DRUG$, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, @DRUG$, Rifampin, Theophylline, Terfenadine, Cisapride, @DRUG$, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, @DRUG$, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, @DRUG$, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, @DRUG$, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, @DRUG$, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, @DRUG$, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, @DRUG$,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, @DRUG$, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral @DRUG$: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, @DRUG$, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of @DRUG$ with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, @DRUG$, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral @DRUG$; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, @DRUG$, @DRUG$, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, @DRUG$, Theophylline, @DRUG$, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, @DRUG$, Theophylline, Terfenadine, @DRUG$, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, @DRUG$, Theophylline, Terfenadine, Cisapride, @DRUG$, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, @DRUG$, Theophylline, Terfenadine, Cisapride, Astemizole, @DRUG$, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, @DRUG$, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, @DRUG$, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, @DRUG$, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, @DRUG$,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, @DRUG$, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral @DRUG$: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, @DRUG$, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of @DRUG$ with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, @DRUG$, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral @DRUG$; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, @DRUG$, @DRUG$, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, @DRUG$, Terfenadine, @DRUG$, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, @DRUG$, Terfenadine, Cisapride, @DRUG$, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, @DRUG$, Terfenadine, Cisapride, Astemizole, @DRUG$, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, @DRUG$, Terfenadine, Cisapride, Astemizole, Rifabutin, @DRUG$, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, @DRUG$, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, @DRUG$,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, @DRUG$, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral @DRUG$: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, @DRUG$, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of @DRUG$ with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, @DRUG$, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral @DRUG$; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, @DRUG$, @DRUG$, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, @DRUG$, Cisapride, @DRUG$, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, @DRUG$, Cisapride, Astemizole, @DRUG$, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, @DRUG$, Cisapride, Astemizole, Rifabutin, @DRUG$, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, @DRUG$, Cisapride, Astemizole, Rifabutin, Tacrolimus, @DRUG$,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, @DRUG$, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral @DRUG$: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, @DRUG$, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of @DRUG$ with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, @DRUG$, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral @DRUG$; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, @DRUG$, @DRUG$, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, @DRUG$, Astemizole, @DRUG$, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, @DRUG$, Astemizole, Rifabutin, @DRUG$, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, @DRUG$, Astemizole, Rifabutin, Tacrolimus, @DRUG$,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, @DRUG$, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral @DRUG$: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, @DRUG$, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of @DRUG$ with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, @DRUG$, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral @DRUG$; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, @DRUG$, @DRUG$, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, @DRUG$, Rifabutin, @DRUG$, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, @DRUG$, Rifabutin, Tacrolimus, @DRUG$,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, @DRUG$, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral @DRUG$: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, @DRUG$, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of @DRUG$ with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, @DRUG$, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral @DRUG$; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, @DRUG$, @DRUG$, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, @DRUG$, Tacrolimus, @DRUG$,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, @DRUG$, Tacrolimus, Short-acting benzodiazepines,  Oral @DRUG$: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, @DRUG$, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of @DRUG$ with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, @DRUG$, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral @DRUG$; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, @DRUG$, @DRUG$,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, @DRUG$, Short-acting benzodiazepines,  Oral @DRUG$: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, @DRUG$, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of @DRUG$ with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, @DRUG$, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral @DRUG$; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, @DRUG$,  Oral @DRUG$: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, @DRUG$,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of @DRUG$ with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, @DRUG$,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral @DRUG$; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral @DRUG$: Clinically significant hypoglycemia may be precipitated by the use of @DRUG$ with oral hypoglycemic agents; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral @DRUG$: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral @DRUG$; DDI-false
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of @DRUG$ with oral @DRUG$; DDI-false
@DRUG$: Because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving @DRUG$ in conjunction with terfenadine, interaction studies have been performed. DDI-effect
@DRUG$: Because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving azole antifungals in conjunction with @DRUG$, interaction studies have been performed. DDI-false
Terfenadine: Because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving @DRUG$ in conjunction with @DRUG$, interaction studies have been performed. DDI-false
Another study at a 400-mg and 800-mg daily dose of @DRUG$ demonstrated that @DRUG$ taken in doses of 400 mg per day or greater significantly increases plasma levels of terfenadine when taken concomitantly. DDI-effect
Another study at a 400-mg and 800-mg daily dose of @DRUG$ demonstrated that DIFLUCAN taken in doses of 400 mg per day or greater significantly increases plasma levels of @DRUG$ when taken concomitantly. DDI-false
Another study at a 400-mg and 800-mg daily dose of fluconazole demonstrated that @DRUG$ taken in doses of 400 mg per day or greater significantly increases plasma levels of @DRUG$ when taken concomitantly. DDI-false
The combined use of @DRUG$ at doses of 400 mg or greater with @DRUG$ is contraindicated. DDI-mechanism
The coadministration of @DRUG$ at doses lower than 400 mg/day with @DRUG$ should be carefully monitored. DDI-advise
@DRUG$: There have been reports of cardiac events, including torsade de pointes in patients to whom @DRUG$ and cisapride were coadministered. DDI-advise
@DRUG$: There have been reports of cardiac events, including torsade de pointes in patients to whom fluconazole and @DRUG$ were coadministered. DDI-false
Cisapride: There have been reports of cardiac events, including torsade de pointes in patients to whom @DRUG$ and @DRUG$ were coadministered. DDI-false
A controlled study found that concomitant @DRUG$ 200 mg once daily and @DRUG$ 20 mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of QTc interval. DDI-effect
A controlled study found that concomitant @DRUG$ 200 mg once daily and cisapride 20 mg four times a day yielded a significant increase in @DRUG$ plasma levels and prolongation of QTc interval. DDI-mechanism
A controlled study found that concomitant fluconazole 200 mg once daily and @DRUG$ 20 mg four times a day yielded a significant increase in @DRUG$ plasma levels and prolongation of QTc interval. DDI-false
The combined use of @DRUG$ with @DRUG$ is contraindicated. DDI-false
@DRUG$: The use of @DRUG$ in patients concurrently taking astemizole or other drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these drugs. DDI-advise
@DRUG$: The use of fluconazole in patients concurrently taking @DRUG$ or other drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these drugs. DDI-false
Astemizole: The use of @DRUG$ in patients concurrently taking @DRUG$ or other drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these drugs. DDI-false
one fatality has been reported from hypoglycemia in association with combined @DRUG$ and @DRUG$ use. DDI-mechanism
@DRUG$: There have been reports of uveitis in patients to whom @DRUG$ and rifabutin were coadministered. DDI-effect
@DRUG$: There have been reports of uveitis in patients to whom fluconazole and @DRUG$ were coadministered. DDI-false
Rifabutin: There have been reports of uveitis in patients to whom @DRUG$ and @DRUG$ were coadministered. DDI-false
Patients receiving @DRUG$ and @DRUG$ concomitantly should be carefully monitored. DDI-effect
@DRUG$: There have been reports of nephrotoxicity in patients to whom @DRUG$ and tacrolimus were coadministered. DDI-advise
@DRUG$: There have been reports of nephrotoxicity in patients to whom fluconazole and @DRUG$ were coadministered. DDI-false
Tacrolimus: There have been reports of nephrotoxicity in patients to whom @DRUG$ and @DRUG$ were coadministered. DDI-false
Patients receiving @DRUG$ and @DRUG$ concomitantly should be carefully monitored. DDI-effect
@DRUG$: Following oral administration of @DRUG$, fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects. DDI-advise
@DRUG$: Following oral administration of midazolam, @DRUG$ resulted in substantial increases in midazolam concentrations and psychomotor effects. DDI-false
@DRUG$: Following oral administration of midazolam, fluconazole resulted in substantial increases in @DRUG$ concentrations and psychomotor effects. DDI-false
Short-acting Benzodiazepines: Following oral administration of @DRUG$, @DRUG$ resulted in substantial increases in midazolam concentrations and psychomotor effects. DDI-false
Short-acting Benzodiazepines: Following oral administration of @DRUG$, fluconazole resulted in substantial increases in @DRUG$ concentrations and psychomotor effects. DDI-mechanism
Short-acting Benzodiazepines: Following oral administration of midazolam, @DRUG$ resulted in substantial increases in @DRUG$ concentrations and psychomotor effects. DDI-false
This effect on @DRUG$ appears to be more pronounced following oral administration of @DRUG$ than with fluconazole administered intravenously. DDI-false
This effect on @DRUG$ appears to be more pronounced following oral administration of fluconazole than with @DRUG$ administered intravenously. DDI-false
This effect on midazolam appears to be more pronounced following oral administration of @DRUG$ than with @DRUG$ administered intravenously. DDI-false
If @DRUG$, which are metabolized by the cytochrome P450 system, are concomitantly administered with @DRUG$, consideration should be given to decreasing the benzodiazepine dosage, and the patients should be appropriately monitored. DDI-false
If @DRUG$, which are metabolized by the cytochrome P450 system, are concomitantly administered with fluconazole, consideration should be given to decreasing the @DRUG$ dosage, and the patients should be appropriately monitored. DDI-advise
If short-acting benzodiazepines, which are metabolized by the cytochrome P450 system, are concomitantly administered with @DRUG$, consideration should be given to decreasing the @DRUG$ dosage, and the patients should be appropriately monitored. DDI-false
@DRUG$ tablets coadministered with @DRUG$- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; DDI-false
@DRUG$ tablets coadministered with ethinyl estradiol- and @DRUG$-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; DDI-mechanism
@DRUG$ tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral @DRUG$ produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; DDI-mechanism
@DRUG$ tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in @DRUG$ and levonorgestrel levels; DDI-mechanism
@DRUG$ tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and @DRUG$ levels; DDI-false
Fluconazole tablets coadministered with @DRUG$- and @DRUG$-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; DDI-false
Fluconazole tablets coadministered with @DRUG$- and levonorgestrel-containing oral @DRUG$ produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; DDI-false
Fluconazole tablets coadministered with @DRUG$- and levonorgestrel-containing oral contraceptives produced an overall mean increase in @DRUG$ and levonorgestrel levels; DDI-false
Fluconazole tablets coadministered with @DRUG$- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and @DRUG$ levels; DDI-false
Fluconazole tablets coadministered with ethinyl estradiol- and @DRUG$-containing oral @DRUG$ produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; DDI-false
Fluconazole tablets coadministered with ethinyl estradiol- and @DRUG$-containing oral contraceptives produced an overall mean increase in @DRUG$ and levonorgestrel levels; DDI-false
Fluconazole tablets coadministered with ethinyl estradiol- and @DRUG$-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and @DRUG$ levels; DDI-false
Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral @DRUG$ produced an overall mean increase in @DRUG$ and levonorgestrel levels; DDI-false
Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral @DRUG$ produced an overall mean increase in ethinyl estradiol and @DRUG$ levels; DDI-false
Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in @DRUG$ and @DRUG$ levels; DDI-false
however, in some patients there were decreases up to 47% and 33% of @DRUG$ and @DRUG$ levels. DDI-false
@DRUG$ reduces the metabolism of @DRUG$, glyburide, and glipizide and increases the plasma concentration of these agents. DDI-false
@DRUG$ reduces the metabolism of tolbutamide, @DRUG$, and glipizide and increases the plasma concentration of these agents. DDI-mechanism
@DRUG$ reduces the metabolism of tolbutamide, glyburide, and @DRUG$ and increases the plasma concentration of these agents. DDI-mechanism
DIFLUCAN reduces the metabolism of @DRUG$, @DRUG$, and glipizide and increases the plasma concentration of these agents. DDI-mechanism
DIFLUCAN reduces the metabolism of @DRUG$, glyburide, and @DRUG$ and increases the plasma concentration of these agents. DDI-false
DIFLUCAN reduces the metabolism of tolbutamide, @DRUG$, and @DRUG$ and increases the plasma concentration of these agents. DDI-false
The data presently available indicate that the decreases in some individual @DRUG$ and @DRUG$ AUC values with fluconazole treatment are likely the result of random variation. DDI-false
The data presently available indicate that the decreases in some individual @DRUG$ and levonorgestrel AUC values with @DRUG$ treatment are likely the result of random variation. DDI-false
The data presently available indicate that the decreases in some individual ethinyl estradiol and @DRUG$ AUC values with @DRUG$ treatment are likely the result of random variation. DDI-false
While there is evidence that @DRUG$ can inhibit the metabolism of @DRUG$ and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. DDI-false
While there is evidence that @DRUG$ can inhibit the metabolism of ethinyl estradiol and @DRUG$, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. DDI-mechanism
While there is evidence that @DRUG$ can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that @DRUG$ is a net inducer of ethinyl estradiol or levonorgestrel metabolism. DDI-mechanism
While there is evidence that @DRUG$ can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of @DRUG$ or levonorgestrel metabolism. DDI-false
While there is evidence that @DRUG$ can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or @DRUG$ metabolism. DDI-false
While there is evidence that fluconazole can inhibit the metabolism of @DRUG$ and @DRUG$, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. DDI-false
While there is evidence that fluconazole can inhibit the metabolism of @DRUG$ and levonorgestrel, there is no evidence that @DRUG$ is a net inducer of ethinyl estradiol or levonorgestrel metabolism. DDI-false
While there is evidence that fluconazole can inhibit the metabolism of @DRUG$ and levonorgestrel, there is no evidence that fluconazole is a net inducer of @DRUG$ or levonorgestrel metabolism. DDI-false
While there is evidence that fluconazole can inhibit the metabolism of @DRUG$ and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or @DRUG$ metabolism. DDI-false
While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and @DRUG$, there is no evidence that @DRUG$ is a net inducer of ethinyl estradiol or levonorgestrel metabolism. DDI-false
While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and @DRUG$, there is no evidence that fluconazole is a net inducer of @DRUG$ or levonorgestrel metabolism. DDI-false
While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and @DRUG$, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or @DRUG$ metabolism. DDI-false
While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that @DRUG$ is a net inducer of @DRUG$ or levonorgestrel metabolism. DDI-false
While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that @DRUG$ is a net inducer of ethinyl estradiol or @DRUG$ metabolism. DDI-false
While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of @DRUG$ or @DRUG$ metabolism. DDI-false
When @DRUG$ is used concomitantly with these or other @DRUG$, blood glucose concentrations should be carefully monitored and the dose of the sulfonylurea should be adjusted as necessary. DDI-false
When @DRUG$ is used concomitantly with these or other sulfonylurea oral hypoglycemic agents, blood glucose concentrations should be carefully monitored and the dose of the @DRUG$ should be adjusted as necessary. DDI-advise
When DIFLUCAN is used concomitantly with these or other @DRUG$, blood glucose concentrations should be carefully monitored and the dose of the @DRUG$ should be adjusted as necessary. DDI-false
@DRUG$: Prothrombin time may be increased in patients receiving concomitant @DRUG$ and coumarin-type anticoagulants. DDI-false
@DRUG$: Prothrombin time may be increased in patients receiving concomitant DIFLUCAN and @DRUG$. DDI-false
Coumarin-type anticoagulants: Prothrombin time may be increased in patients receiving concomitant @DRUG$ and @DRUG$. DDI-false
In post-marketing experience, as with other @DRUG$, bleeding events (bruising, epistaxis, gastrointestinal bleeding, hematuria, and melena) have been reported in association with increases in prothrombin time in patients receiving @DRUG$ concurrently with warfarin. DDI-effect
In post-marketing experience, as with other @DRUG$, bleeding events (bruising, epistaxis, gastrointestinal bleeding, hematuria, and melena) have been reported in association with increases in prothrombin time in patients receiving fluconazole concurrently with @DRUG$. DDI-false
In post-marketing experience, as with other azole antifungals, bleeding events (bruising, epistaxis, gastrointestinal bleeding, hematuria, and melena) have been reported in association with increases in prothrombin time in patients receiving @DRUG$ concurrently with @DRUG$. DDI-false
Careful monitoring of prothrombin time in patients receiving @DRUG$ and @DRUG$ is recommended. DDI-effect
The interaction of @DRUG$, @DRUG$, with other drugs has not been well studied. DDI-advise
Use of @DRUG$ and @DRUG$ -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. DDI-false
Use of @DRUG$ and Antiplatelet Agents -- @DRUG$, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. DDI-false
Use of @DRUG$ and Antiplatelet Agents -- Streptase, @DRUG$, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. DDI-false
Use of @DRUG$ and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with @DRUG$ and anticoagulants, may cause bleeding complications. DDI-false
Use of @DRUG$ and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and @DRUG$, may cause bleeding complications. DDI-false
Use of Anticoagulants and @DRUG$ -- @DRUG$, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. DDI-false
Use of Anticoagulants and @DRUG$ -- Streptase, @DRUG$, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. DDI-false
Use of Anticoagulants and @DRUG$ -- Streptase, Streptokinase, alone or in combination with @DRUG$ and anticoagulants, may cause bleeding complications. DDI-false
Use of Anticoagulants and @DRUG$ -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and @DRUG$, may cause bleeding complications. DDI-false
Use of Anticoagulants and Antiplatelet Agents -- @DRUG$, @DRUG$, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. DDI-false
Use of Anticoagulants and Antiplatelet Agents -- @DRUG$, Streptokinase, alone or in combination with @DRUG$ and anticoagulants, may cause bleeding complications. DDI-false
Use of Anticoagulants and Antiplatelet Agents -- @DRUG$, Streptokinase, alone or in combination with antiplatelet agents and @DRUG$, may cause bleeding complications. DDI-false
Use of Anticoagulants and Antiplatelet Agents -- Streptase, @DRUG$, alone or in combination with @DRUG$ and anticoagulants, may cause bleeding complications. DDI-false
Use of Anticoagulants and Antiplatelet Agents -- Streptase, @DRUG$, alone or in combination with antiplatelet agents and @DRUG$, may cause bleeding complications. DDI-false
Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with @DRUG$ and @DRUG$, may cause bleeding complications. DDI-false
In the treatment of acute MI, @DRUG$, when not otherwise contraindicated, should be administered with @DRUG$ ( see below ). DDI-false
Anticoagulation and @DRUG$ After Treatment for Myocardial Infarction -- In the treatment of acute myocardial infarction, the use of @DRUG$ has been shown to reduce the incidence of reinfarction and stroke. DDI-advise
The addition of @DRUG$ to @DRUG$ causes a minimal increase in the risk of minor bleeding (3.9% vs. 3.1%), but does not appear to increase the incidence of major bleeding (see DDI-false
When @DRUG$ is used with other @DRUG$, potentiation of antihypertensive effect may occur. DDI-false
@DRUG$ does not interfere with measurement of @DRUG$ (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert VMA to vanillin. DDI-effect
@DRUG$ does not interfere with measurement of VMA (@DRUG$), a test for pheochromocytoma, by those methods which convert VMA to vanillin. DDI-false
@DRUG$ does not interfere with measurement of VMA (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert @DRUG$ to vanillin. DDI-false
@DRUG$ does not interfere with measurement of VMA (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert VMA to @DRUG$. DDI-false
Methyldopa does not interfere with measurement of @DRUG$ (@DRUG$), a test for pheochromocytoma, by those methods which convert VMA to vanillin. DDI-false
Methyldopa does not interfere with measurement of @DRUG$ (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert @DRUG$ to vanillin. DDI-false
Methyldopa does not interfere with measurement of @DRUG$ (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert VMA to @DRUG$. DDI-false
Methyldopa does not interfere with measurement of VMA (@DRUG$), a test for pheochromocytoma, by those methods which convert @DRUG$ to vanillin. DDI-false
Methyldopa does not interfere with measurement of VMA (@DRUG$), a test for pheochromocytoma, by those methods which convert VMA to @DRUG$. DDI-false
Methyldopa does not interfere with measurement of VMA (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert @DRUG$ to @DRUG$. DDI-false
Patients may require reduced doses of @DRUG$ when on @DRUG$. DDI-false
When @DRUG$ and @DRUG$ are given concomitantly the patient should be carefully monitored for symptoms of lithium toxicity. DDI-advise
When @DRUG$ and lithium are given concomitantly the patient should be carefully monitored for symptoms of @DRUG$ toxicity. DDI-advise
When methyldopa and @DRUG$ are given concomitantly the patient should be carefully monitored for symptoms of @DRUG$ toxicity. DDI-false
Several studies demonstrate a decrease in the bioavailability of @DRUG$ when it is ingested with @DRUG$ or ferrous gluconate. DDI-false
Several studies demonstrate a decrease in the bioavailability of @DRUG$ when it is ingested with ferrous sulfate or @DRUG$. DDI-mechanism
Several studies demonstrate a decrease in the bioavailability of methyldopa when it is ingested with @DRUG$ or @DRUG$. DDI-mechanism
Coadministration of @DRUG$ with @DRUG$ or ferrous gluconate is not recommended. DDI-false
Coadministration of @DRUG$ with ferrous sulfate or @DRUG$ is not recommended. DDI-advise
Coadministration of methyldopa with @DRUG$ or @DRUG$ is not recommended. DDI-advise
@DRUG$: Concurrent use of @DRUG$ and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride. DDI-false
@DRUG$: Concurrent use of procaine hydrochloride and @DRUG$ may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride. DDI-false
@DRUG$: Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since @DRUG$ inhibit the breakdown of procaine hydrochloride. DDI-false
@DRUG$: Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of @DRUG$. DDI-false
Anticholinesterases: Concurrent use of @DRUG$ and @DRUG$ may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride. DDI-false
Anticholinesterases: Concurrent use of @DRUG$ and anticholinesterase agents may result in increased systemic toxicity since @DRUG$ inhibit the breakdown of procaine hydrochloride. DDI-effect
Anticholinesterases: Concurrent use of @DRUG$ and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of @DRUG$. DDI-false
Anticholinesterases: Concurrent use of procaine hydrochloride and @DRUG$ may result in increased systemic toxicity since @DRUG$ inhibit the breakdown of procaine hydrochloride. DDI-false
Anticholinesterases: Concurrent use of procaine hydrochloride and @DRUG$ may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of @DRUG$. DDI-false
Anticholinesterases: Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since @DRUG$ inhibit the breakdown of @DRUG$. DDI-false
@DRUG$ medications: Concurrent use of @DRUG$ and CNS depressant medications may result in additive depressant effects. DDI-false
@DRUG$ medications: Concurrent use of procaine hydrochloride and @DRUG$ may result in additive depressant effects. DDI-false
CNS depressant medications: Concurrent use of @DRUG$ and @DRUG$ may result in additive depressant effects. DDI-false
@DRUG$: @DRUG$ may increase the diffusion rate of procaine hydrochloride, resulting in a decreased time of onset, but an increase in systemic toxicity. DDI-effect
@DRUG$: Hyaluronidase may increase the diffusion rate of @DRUG$, resulting in a decreased time of onset, but an increase in systemic toxicity. DDI-false
Hyaluronidase: @DRUG$ may increase the diffusion rate of @DRUG$, resulting in a decreased time of onset, but an increase in systemic toxicity. DDI-false
@DRUG$ (such as @DRUG$): Concurrent use of procaine hydrochloride and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade. DDI-mechanism
@DRUG$ (such as suxamethonium chloride): Concurrent use of @DRUG$ and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade. DDI-false
@DRUG$ (such as suxamethonium chloride): Concurrent use of procaine hydrochloride and @DRUG$ may result in prolongation or enhancement of the neuromuscular blockade. DDI-false
Neuromuscular blocking agents (such as @DRUG$): Concurrent use of @DRUG$ and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade. DDI-false
Neuromuscular blocking agents (such as @DRUG$): Concurrent use of procaine hydrochloride and @DRUG$ may result in prolongation or enhancement of the neuromuscular blockade. DDI-false
Neuromuscular blocking agents (such as suxamethonium chloride): Concurrent use of @DRUG$ and @DRUG$ may result in prolongation or enhancement of the neuromuscular blockade. DDI-false
@DRUG$: Concurrent use of @DRUG$ and sulfonamides may result in a reduction of the antibacterial action of the sulfonamide. DDI-effect
@DRUG$: Concurrent use of procaine hydrochloride and @DRUG$ may result in a reduction of the antibacterial action of the sulfonamide. DDI-false
@DRUG$: Concurrent use of procaine hydrochloride and sulfonamides may result in a reduction of the antibacterial action of the @DRUG$. DDI-false
Sulfonamides: Concurrent use of @DRUG$ and @DRUG$ may result in a reduction of the antibacterial action of the sulfonamide. DDI-false
Sulfonamides: Concurrent use of @DRUG$ and sulfonamides may result in a reduction of the antibacterial action of the @DRUG$. DDI-effect
Sulfonamides: Concurrent use of procaine hydrochloride and @DRUG$ may result in a reduction of the antibacterial action of the @DRUG$. DDI-false
@DRUG$: Concurrent use of @DRUG$ and procaine hydrochloride may extend the plasma half-life of procaine. DDI-false
@DRUG$: Concurrent use of acetazolamide and @DRUG$ may extend the plasma half-life of procaine. DDI-false
@DRUG$: Concurrent use of acetazolamide and procaine hydrochloride may extend the plasma half-life of @DRUG$. DDI-false
Acetazolamide: Concurrent use of @DRUG$ and @DRUG$ may extend the plasma half-life of procaine. DDI-false
Acetazolamide: Concurrent use of @DRUG$ and procaine hydrochloride may extend the plasma half-life of @DRUG$. DDI-mechanism
Acetazolamide: Concurrent use of acetazolamide and @DRUG$ may extend the plasma half-life of @DRUG$. DDI-false
@DRUG$: Patients on @DRUG$, and especially those started recently, may occasionally experience an excessive reduction of blood pressure after initiation of ACEON    Tablets therapy. DDI-false
@DRUG$: Patients on diuretics, and especially those started recently, may occasionally experience an excessive reduction of blood pressure after initiation of @DRUG$    Tablets therapy. DDI-false
Diuretics: Patients on @DRUG$, and especially those started recently, may occasionally experience an excessive reduction of blood pressure after initiation of @DRUG$    Tablets therapy. DDI-false
The possibility of hypotensive effects can be minimized by either discontinuing the @DRUG$ or increasing the salt intake prior to initiation of treatment with @DRUG$. DDI-effect
Use of a @DRUG$ may further increase the risk of @DRUG$ toxicity. DDI-effect
@DRUG$: A controlled pharmacokinetic study has shown no effect on plasma @DRUG$ concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. DDI-effect
@DRUG$: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with @DRUG$    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. DDI-false
@DRUG$: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of @DRUG$ on the plasma concentration of perindopril/perindoprilat has not been excluded. DDI-false
@DRUG$: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of @DRUG$/perindoprilat has not been excluded. DDI-false
@DRUG$: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/@DRUG$ has not been excluded. DDI-false
Digoxin: A controlled pharmacokinetic study has shown no effect on plasma @DRUG$ concentrations when coadministered with @DRUG$    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. DDI-false
Digoxin: A controlled pharmacokinetic study has shown no effect on plasma @DRUG$ concentrations when coadministered with ACEON    Tablets, but an effect of @DRUG$ on the plasma concentration of perindopril/perindoprilat has not been excluded. DDI-false
Digoxin: A controlled pharmacokinetic study has shown no effect on plasma @DRUG$ concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of @DRUG$/perindoprilat has not been excluded. DDI-false
Digoxin: A controlled pharmacokinetic study has shown no effect on plasma @DRUG$ concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/@DRUG$ has not been excluded. DDI-false
Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with @DRUG$    Tablets, but an effect of @DRUG$ on the plasma concentration of perindopril/perindoprilat has not been excluded. DDI-false
Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with @DRUG$    Tablets, but an effect of digoxin on the plasma concentration of @DRUG$/perindoprilat has not been excluded. DDI-false
Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with @DRUG$    Tablets, but an effect of digoxin on the plasma concentration of perindopril/@DRUG$ has not been excluded. DDI-false
Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of @DRUG$ on the plasma concentration of @DRUG$/perindoprilat has not been excluded. DDI-false
Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of @DRUG$ on the plasma concentration of perindopril/@DRUG$ has not been excluded. DDI-false
Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of @DRUG$/@DRUG$ has not been excluded. DDI-false
@DRUG$: Animal data have suggested the possibility of interaction between @DRUG$ and gentamicin. DDI-false
@DRUG$: Animal data have suggested the possibility of interaction between perindopril and @DRUG$. DDI-false
Gentamicin: Animal data have suggested the possibility of interaction between @DRUG$ and @DRUG$. DDI-false
Food Interaction: Oral administration of @DRUG$    Tablets with food does not significantly lower the rate or extent of @DRUG$ absorption relative to the fasted state. DDI-int
However, the extent of biotransformation of @DRUG$ to the active metabolite, @DRUG$, is reduced approximately 43%, resulting in a reduction in the plasma ACE inhibition curve of approximately 20%, probably clinically insignificant. DDI-false
If @DRUG$ cannot be interrupted, close medical supervision should be provided with the first dose of @DRUG$    Tablets, for at least two hours and until blood pressure has stabilized for another hour. DDI-mechanism
The rate and extent of @DRUG$ absorption and elimination are not affected by concomitant @DRUG$. DDI-false
The bioavailability of @DRUG$ was reduced by @DRUG$, however, and this was associated with a decrease in plasma ACE inhibition. DDI-false
@DRUG$ Supplements and @DRUG$: ACEON    Tablets may increase serum potassium because of its potential to decrease aldosterone production. DDI-mechanism
@DRUG$ Supplements and Potassium-Sparing Diuretics: @DRUG$    Tablets may increase serum potassium because of its potential to decrease aldosterone production. DDI-false
Potassium Supplements and @DRUG$: @DRUG$    Tablets may increase serum potassium because of its potential to decrease aldosterone production. DDI-false
Use of @DRUG$ (@DRUG$, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. DDI-false
Use of @DRUG$ (spironolactone, @DRUG$, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. DDI-false
Use of @DRUG$ (spironolactone, amiloride, @DRUG$ and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. DDI-false
Use of @DRUG$ (spironolactone, amiloride, triamterene and others), @DRUG$ supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. DDI-false
Use of @DRUG$ (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (@DRUG$, heparin, cyclosporine and others) can increase the risk of hyperkalemia. DDI-false
Use of @DRUG$ (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, @DRUG$, cyclosporine and others) can increase the risk of hyperkalemia. DDI-false
Use of @DRUG$ (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, @DRUG$ and others) can increase the risk of hyperkalemia. DDI-false
Use of potassium-sparing diuretics (@DRUG$, @DRUG$, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. DDI-false
Use of potassium-sparing diuretics (@DRUG$, amiloride, @DRUG$ and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. DDI-false
Use of potassium-sparing diuretics (@DRUG$, amiloride, triamterene and others), @DRUG$ supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. DDI-false
Use of potassium-sparing diuretics (@DRUG$, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (@DRUG$, heparin, cyclosporine and others) can increase the risk of hyperkalemia. DDI-false
Use of potassium-sparing diuretics (@DRUG$, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, @DRUG$, cyclosporine and others) can increase the risk of hyperkalemia. DDI-false
Use of potassium-sparing diuretics (@DRUG$, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, @DRUG$ and others) can increase the risk of hyperkalemia. DDI-false
Use of potassium-sparing diuretics (spironolactone, @DRUG$, @DRUG$ and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. DDI-false
Use of potassium-sparing diuretics (spironolactone, @DRUG$, triamterene and others), @DRUG$ supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. DDI-false
Use of potassium-sparing diuretics (spironolactone, @DRUG$, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (@DRUG$, heparin, cyclosporine and others) can increase the risk of hyperkalemia. DDI-false
Use of potassium-sparing diuretics (spironolactone, @DRUG$, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, @DRUG$, cyclosporine and others) can increase the risk of hyperkalemia. DDI-false
Use of potassium-sparing diuretics (spironolactone, @DRUG$, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, @DRUG$ and others) can increase the risk of hyperkalemia. DDI-false
Use of potassium-sparing diuretics (spironolactone, amiloride, @DRUG$ and others), @DRUG$ supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. DDI-false
Use of potassium-sparing diuretics (spironolactone, amiloride, @DRUG$ and others), potassium supplements or other drugs capable of increasing serum potassium (@DRUG$, heparin, cyclosporine and others) can increase the risk of hyperkalemia. DDI-false
Use of potassium-sparing diuretics (spironolactone, amiloride, @DRUG$ and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, @DRUG$, cyclosporine and others) can increase the risk of hyperkalemia. DDI-false
Use of potassium-sparing diuretics (spironolactone, amiloride, @DRUG$ and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, @DRUG$ and others) can increase the risk of hyperkalemia. DDI-false
Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), @DRUG$ supplements or other drugs capable of increasing serum potassium (@DRUG$, heparin, cyclosporine and others) can increase the risk of hyperkalemia. DDI-false
Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), @DRUG$ supplements or other drugs capable of increasing serum potassium (indomethacin, @DRUG$, cyclosporine and others) can increase the risk of hyperkalemia. DDI-false
Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), @DRUG$ supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, @DRUG$ and others) can increase the risk of hyperkalemia. DDI-false
Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (@DRUG$, @DRUG$, cyclosporine and others) can increase the risk of hyperkalemia. DDI-false
Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (@DRUG$, heparin, @DRUG$ and others) can increase the risk of hyperkalemia. DDI-false
Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, @DRUG$, @DRUG$ and others) can increase the risk of hyperkalemia. DDI-false
@DRUG$: Increased serum @DRUG$ and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy. DDI-false
@DRUG$: Increased serum lithium and symptoms of @DRUG$ toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy. DDI-false
@DRUG$: Increased serum lithium and symptoms of lithium toxicity have been reported in patients receiving concomitant @DRUG$ and ACE inhibitor therapy. DDI-false
Lithium: Increased serum @DRUG$ and symptoms of @DRUG$ toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy. DDI-false
Lithium: Increased serum @DRUG$ and symptoms of lithium toxicity have been reported in patients receiving concomitant @DRUG$ and ACE inhibitor therapy. DDI-false
Lithium: Increased serum lithium and symptoms of @DRUG$ toxicity have been reported in patients receiving concomitant @DRUG$ and ACE inhibitor therapy. DDI-false
@DRUG$ can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - @DRUG$: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine DDI-false
@DRUG$ can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - @DRUG$: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine DDI-false
@DRUG$ can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the @DRUG$ virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine DDI-false
@DRUG$ can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - @DRUG$: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine DDI-false
@DRUG$ can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - @DRUG$: may decrease patient's response to the vaccine DDI-int
@DRUG$ can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the @DRUG$ DDI-int
Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - @DRUG$: can increase seizure activity - @DRUG$: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine DDI-int
Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - @DRUG$: can increase seizure activity - Live virus vaccines: may potentiate the replication of the @DRUG$ virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine DDI-false
Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - @DRUG$: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - @DRUG$: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine DDI-false
Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - @DRUG$: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - @DRUG$: may decrease patient's response to the vaccine DDI-false
Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - @DRUG$: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the @DRUG$ DDI-false
Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - @DRUG$: may potentiate the replication of the @DRUG$ virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine DDI-false
Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - @DRUG$: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - @DRUG$: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine DDI-false
Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - @DRUG$: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - @DRUG$: may decrease patient's response to the vaccine DDI-false
Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - @DRUG$: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the @DRUG$ DDI-false
Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the @DRUG$ virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - @DRUG$: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine DDI-false
Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the @DRUG$ virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - @DRUG$: may decrease patient's response to the vaccine DDI-false
Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the @DRUG$ virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the @DRUG$ DDI-false
Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - @DRUG$: may cause shortness of breath and bronchospasm - @DRUG$: may decrease patient's response to the vaccine DDI-false
Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - @DRUG$: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the @DRUG$ DDI-false
Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - @DRUG$: may decrease patient's response to the @DRUG$ DDI-false
@DRUG$ inhibits some of the liver's ability to metabolize some other drugs - @DRUG$, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. DDI-false
@DRUG$ inhibits some of the liver's ability to metabolize some other drugs - terfenadine, @DRUG$, cisapride, cyclosporine, and tricyclic antidepressants. DDI-mechanism
@DRUG$ inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, @DRUG$, cyclosporine, and tricyclic antidepressants. DDI-mechanism
@DRUG$ inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, @DRUG$, and tricyclic antidepressants. DDI-mechanism
@DRUG$ inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and @DRUG$. DDI-mechanism
Posicor inhibits some of the liver's ability to metabolize some other drugs - @DRUG$, @DRUG$, cisapride, cyclosporine, and tricyclic antidepressants. DDI-mechanism
Posicor inhibits some of the liver's ability to metabolize some other drugs - @DRUG$, astemizole, @DRUG$, cyclosporine, and tricyclic antidepressants. DDI-false
Posicor inhibits some of the liver's ability to metabolize some other drugs - @DRUG$, astemizole, cisapride, @DRUG$, and tricyclic antidepressants. DDI-false
Posicor inhibits some of the liver's ability to metabolize some other drugs - @DRUG$, astemizole, cisapride, cyclosporine, and @DRUG$. DDI-false
Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, @DRUG$, @DRUG$, cyclosporine, and tricyclic antidepressants. DDI-false
Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, @DRUG$, cisapride, @DRUG$, and tricyclic antidepressants. DDI-false
Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, @DRUG$, cisapride, cyclosporine, and @DRUG$. DDI-false
Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, @DRUG$, @DRUG$, and tricyclic antidepressants. DDI-false
Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, @DRUG$, cyclosporine, and @DRUG$. DDI-false
Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, @DRUG$, and @DRUG$. DDI-false
The concomitant use of @DRUG$ with other @DRUG$ or with other agents which produce dry mouth, constipation, somnolence (drowsiness), and/or other anticholinergic-like effects may increase the frequency and/or severity of such effects. DDI-false
Mean @DRUG$ plasma concentrations were approximately 2 fold higher when @DRUG$ was administered with ketoconazole, a potent CYP3A4 inhibitor. DDI-effect
Mean @DRUG$ plasma concentrations were approximately 2 fold higher when DITROPAN XL was administered with @DRUG$, a potent CYP3A4 inhibitor. DDI-false
Mean oxybutynin chloride plasma concentrations were approximately 2 fold higher when @DRUG$ was administered with @DRUG$, a potent CYP3A4 inhibitor. DDI-false
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as @DRUG$ (e.g., @DRUG$ and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). DDI-mechanism
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as @DRUG$ (e.g., itraconazole and @DRUG$) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). DDI-false
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as @DRUG$ (e.g., itraconazole and miconazole) or @DRUG$ (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). DDI-false
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as @DRUG$ (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., @DRUG$ and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). DDI-false
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as @DRUG$ (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and @DRUG$), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). DDI-false
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as @DRUG$ (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter @DRUG$ mean pharmacokinetic parameters (i.e., Cmax and AUC). DDI-false
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., @DRUG$ and @DRUG$) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). DDI-false
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., @DRUG$ and miconazole) or @DRUG$ (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). DDI-false
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., @DRUG$ and miconazole) or macrolide antibiotics (e.g., @DRUG$ and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). DDI-false
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., @DRUG$ and miconazole) or macrolide antibiotics (e.g., erythromycin and @DRUG$), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). DDI-false
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., @DRUG$ and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter @DRUG$ mean pharmacokinetic parameters (i.e., Cmax and AUC). DDI-false
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and @DRUG$) or @DRUG$ (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). DDI-false
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and @DRUG$) or macrolide antibiotics (e.g., @DRUG$ and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). DDI-false
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and @DRUG$) or macrolide antibiotics (e.g., erythromycin and @DRUG$), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). DDI-false
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and @DRUG$) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter @DRUG$ mean pharmacokinetic parameters (i.e., Cmax and AUC). DDI-false
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or @DRUG$ (e.g., @DRUG$ and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). DDI-false
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or @DRUG$ (e.g., erythromycin and @DRUG$), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). DDI-false
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or @DRUG$ (e.g., erythromycin and clarithromycin), may alter @DRUG$ mean pharmacokinetic parameters (i.e., Cmax and AUC). DDI-false
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., @DRUG$ and @DRUG$), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). DDI-false
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., @DRUG$ and clarithromycin), may alter @DRUG$ mean pharmacokinetic parameters (i.e., Cmax and AUC). DDI-false
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and @DRUG$), may alter @DRUG$ mean pharmacokinetic parameters (i.e., Cmax and AUC). DDI-false
Concurrent ingestion of @DRUG$ (20 mL of @DRUG$ containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin. DDI-false
Concurrent ingestion of @DRUG$ (20 mL of antacid containing @DRUG$, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin. DDI-false
Concurrent ingestion of @DRUG$ (20 mL of antacid containing aluminum hydroxide, @DRUG$, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin. DDI-false
Concurrent ingestion of @DRUG$ (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and @DRUG$) did not significantly affect the exposure of oxybutynin or desethyloxybutynin. DDI-false
Concurrent ingestion of @DRUG$ (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of @DRUG$ or desethyloxybutynin. DDI-false
Concurrent ingestion of @DRUG$ (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or @DRUG$. DDI-false
Concurrent ingestion of antacid (20 mL of @DRUG$ containing @DRUG$, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin. DDI-false
Concurrent ingestion of antacid (20 mL of @DRUG$ containing aluminum hydroxide, @DRUG$, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin. DDI-false
Concurrent ingestion of antacid (20 mL of @DRUG$ containing aluminum hydroxide, magnesium hydroxide, and @DRUG$) did not significantly affect the exposure of oxybutynin or desethyloxybutynin. DDI-false
Concurrent ingestion of antacid (20 mL of @DRUG$ containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of @DRUG$ or desethyloxybutynin. DDI-false
Concurrent ingestion of antacid (20 mL of @DRUG$ containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or @DRUG$. DDI-false
Concurrent ingestion of antacid (20 mL of antacid containing @DRUG$, @DRUG$, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin. DDI-false
Concurrent ingestion of antacid (20 mL of antacid containing @DRUG$, magnesium hydroxide, and @DRUG$) did not significantly affect the exposure of oxybutynin or desethyloxybutynin. DDI-false
Concurrent ingestion of antacid (20 mL of antacid containing @DRUG$, magnesium hydroxide, and simethicone) did not significantly affect the exposure of @DRUG$ or desethyloxybutynin. DDI-false
Concurrent ingestion of antacid (20 mL of antacid containing @DRUG$, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or @DRUG$. DDI-false
Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, @DRUG$, and @DRUG$) did not significantly affect the exposure of oxybutynin or desethyloxybutynin. DDI-false
Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, @DRUG$, and simethicone) did not significantly affect the exposure of @DRUG$ or desethyloxybutynin. DDI-false
Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, @DRUG$, and simethicone) did not significantly affect the exposure of oxybutynin or @DRUG$. DDI-false
Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and @DRUG$) did not significantly affect the exposure of @DRUG$ or desethyloxybutynin. DDI-false
Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and @DRUG$) did not significantly affect the exposure of oxybutynin or @DRUG$. DDI-false
Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of @DRUG$ or @DRUG$. DDI-false
[Interaction between @DRUG$ and @DRUG$]. DDI-false
The drug interaction between @DRUG$ and @DRUG$ has been the subject of much study in recent years. DDI-false
Contradictory results regarding the effect of @DRUG$ on platelet reactivity and on clinical outcome in @DRUG$-treated patients have been reported in literature. DDI-false
Concomitant use of @DRUG$ and @DRUG$ was found to decrease the exposure (AUC) to clopidogrel's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by omeprazole of CYP2C19, a cytochrome P450 (CYP) enzyme. DDI-false
Concomitant use of @DRUG$ and clopidogrel was found to decrease the exposure (AUC) to clopidogrel's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by @DRUG$ of CYP2C19, a cytochrome P450 (CYP) enzyme. DDI-mechanism
Concomitant use of omeprazole and @DRUG$ was found to decrease the exposure (AUC) to clopidogrel's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by @DRUG$ of CYP2C19, a cytochrome P450 (CYP) enzyme. DDI-false
@DRUG$ has a much weaker effect on @DRUG$'s pharmacokinetics and on platelet reactivity during concomitant use. DDI-false
The influence of the other @DRUG$ when used simultaneously with @DRUG$ has not yet been investigated in adequately randomized studies. DDI-false
Regulatory agencies state that the combination of @DRUG$ and the CYP2C19 inhibitors @DRUG$ and esomeprazole should be avoided. DDI-false
Regulatory agencies state that the combination of @DRUG$ and the CYP2C19 inhibitors omeprazole and @DRUG$ should be avoided. DDI-false
Regulatory agencies state that the combination of clopidogrel and the CYP2C19 inhibitors @DRUG$ and @DRUG$ should be avoided. DDI-false
To date, there is no conclusive evidence of a clinically-relevant interaction between any of the @DRUG$ and @DRUG$. DDI-false
Interaction of @DRUG$ and @DRUG$, in vitro and in vivo, in human A375 melanoma cells. DDI-false
We evaluated mechanisms of interaction between the alkyating agent @DRUG$ (@DRUG$) and the pro-oxidant, imexon, in the human A375 melanoma cell line. DDI-false
We evaluated mechanisms of interaction between the alkyating agent @DRUG$ (DTIC) and the pro-oxidant, @DRUG$, in the human A375 melanoma cell line. DDI-false
We evaluated mechanisms of interaction between the alkyating agent dacarbazine (@DRUG$) and the pro-oxidant, @DRUG$, in the human A375 melanoma cell line. DDI-false
The effect of @DRUG$ and @DRUG$, alone and in combination, was evaluated for growth inhibition (MTT), radiolabeled drug uptake, cellular thiol content (HPLC), and DNA strand breaks (Comet assay). DDI-false
There was a >75% reduction in cellular glutathione and cysteine with @DRUG$ but not @DRUG$. DDI-false
@DRUG$ and @DRUG$ show additive effects in vitro but not in vivo in human A375 melanoma cells. DDI-false
Enhancement of humoral immune responses to inactivated Newcastle disease and @DRUG$ by oral administration of @DRUG$ in chickens. DDI-false
The objective of this study was to evaluate the effect of oral administration of @DRUG$ (@DRUG$) on the humoral immune responses of chickens to inactivated ND and AI vaccines. DDI-mechanism
The objective of this study was to evaluate the effect of oral administration of @DRUG$ (GSLS) on the humoral immune responses of chickens to @DRUG$. DDI-false
The objective of this study was to evaluate the effect of oral administration of @DRUG$ (GSLS) on the humoral immune responses of chickens to @DRUG$. DDI-false
The objective of this study was to evaluate the effect of oral administration of ginseng stem-and-leaf saponins (@DRUG$) on the humoral immune responses of chickens to @DRUG$. DDI-false
The objective of this study was to evaluate the effect of oral administration of ginseng stem-and-leaf saponins (@DRUG$) on the humoral immune responses of chickens to @DRUG$. DDI-false
The objective of this study was to evaluate the effect of oral administration of ginseng stem-and-leaf saponins (GSLS) on the humoral immune responses of chickens to @DRUG-DRUG$. DDI-false
In experiment 1, oral administration of @DRUG$ at a dose of 5 mg/kg of BW for 7 d on the immune response in chickens intramuscularly injected with @DRUG$ was evaluated. DDI-false
In experiment 2, the same regimen of @DRUG$ was administered to chickens inoculated with @DRUG$, and an enhanced serum antibody response to AI vaccination was also observed. DDI-false
Considering the safety of @DRUG$, because no adverse effect was found throughout the experiments, @DRUG$ may be a promising oral adjuvant to improve immunization in poultry. DDI-false
Protective effect of @DRUG$ and  @DRUG$ against the acute toxicity of diepoxybutane to human lymphocytes. DDI-false
(ii) @DRUG$ elicits a significant protective effect on DEB induced toxicity, which was potentiated by  @DRUG$. DDI-false
In the present study, we tested whether the highly specific metabotropic glutamate receptor 5 antagonist, @DRUG$, reduces dopaminergic and noradrenergic neuronal loss in monkeys rendered parkinsonian by chronic treatment with low doses of @DRUG$. DDI-effect
Weekly intramuscular @DRUG$ injections (0.2-0.5 mg/kg body weight), in combination with daily administration of @DRUG$ or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). DDI-false
Weekly intramuscular @DRUG$ injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (@DRUG$/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). DDI-false
Weekly intramuscular @DRUG$ injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/@DRUG$ versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). DDI-false
Weekly intramuscular @DRUG$ injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus @DRUG$/vehicle). DDI-false
Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of @DRUG$ or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (@DRUG$/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). DDI-false
Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of @DRUG$ or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/@DRUG$ versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). DDI-false
Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of @DRUG$ or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus @DRUG$/vehicle). DDI-false
Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (@DRUG$/@DRUG$ versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). DDI-false
Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (@DRUG$/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus @DRUG$/vehicle). DDI-false
Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/@DRUG$ versus @DRUG$/vehicle). DDI-false
After 21 weeks of @DRUG$ treatment, all @DRUG$/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected. DDI-false
After 21 weeks of @DRUG$ treatment, all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the @DRUG$/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected. DDI-false
After 21 weeks of @DRUG$ treatment, all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/@DRUG$-treated monkeys were significantly affected. DDI-false
After 21 weeks of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment, all @DRUG$/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the @DRUG$/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected. DDI-false
After 21 weeks of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment, all @DRUG$/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/@DRUG$-treated monkeys were significantly affected. DDI-false
After 21 weeks of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment, all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the @DRUG$/@DRUG$-treated monkeys were significantly affected. DDI-false
These behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data, and with post-mortem stereological counts of midbrain dopaminergic neurons, as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity, which were all significantly higher in @DRUG$/@DRUG$-treated animals than in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated monkeys. DDI-false
These behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data, and with post-mortem stereological counts of midbrain dopaminergic neurons, as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity, which were all significantly higher in @DRUG$/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated animals than in @DRUG$/vehicle-treated monkeys. DDI-false
These behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data, and with post-mortem stereological counts of midbrain dopaminergic neurons, as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity, which were all significantly higher in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/@DRUG$-treated animals than in @DRUG$/vehicle-treated monkeys. DDI-false
The @DRUG$ treatment also had a significant effect on the @DRUG$-induced loss of norepinephrine neurons in the locus coeruleus and adjoining A5 and A7 noradrenaline cell groups. DDI-false
In @DRUG$/vehicle-treated animals, almost 40% loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/A5/A7 noradrenaline cell groups, whereas the extent of neuronal loss was lower than 15% of control values in @DRUG$/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys. DDI-effect
In @DRUG$/vehicle-treated animals, almost 40% loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/A5/A7 noradrenaline cell groups, whereas the extent of neuronal loss was lower than 15% of control values in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/@DRUG$-treated monkeys. DDI-false
In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals, almost 40% loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/A5/A7 noradrenaline cell groups, whereas the extent of neuronal loss was lower than 15% of control values in @DRUG$/@DRUG$-treated monkeys. DDI-false
Our data demonstrate that chronic treatment with the metabotropic glutamate receptor 5 antagonist, @DRUG$, significantly reduces @DRUG$ toxicity towards dopaminergic and noradrenergic cell groups in non-human primates. DDI-false
In vitro activity of @DRUG$ combined with @DRUG$ against clinical isolates of methicillin-resistant Staphylococcus aureus. DDI-false
In vitro activity of @DRUG$ combined with fosfomycin against clinical isolates of @DRUG$-resistant Staphylococcus aureus. DDI-false
In vitro activity of minocycline combined with @DRUG$ against clinical isolates of @DRUG$-resistant Staphylococcus aureus. DDI-false
This study aimed to evaluate the in vitro activity of @DRUG$ combined with @DRUG$ against isolates of methicillin-resistant Staphylococcus aureus (MRSA). DDI-false
This study aimed to evaluate the in vitro activity of @DRUG$ combined with fosfomycin against isolates of @DRUG$-resistant Staphylococcus aureus (MRSA). DDI-false
This study aimed to evaluate the in vitro activity of minocycline combined with @DRUG$ against isolates of @DRUG$-resistant Staphylococcus aureus (MRSA). DDI-false
The susceptibility results for @DRUG$ and @DRUG$ were interpreted according to the most relevant criteria. DDI-false
The combination of @DRUG$ and @DRUG$ can be synergistic against MRSA. DDI-false
@DRUG$ enhances @DRUG$-mediated antibody-dependent cellular cytotoxicity by up-regulation of cell surface HER2 expression. DDI-effect
Although it was previously reported that @DRUG$ combined with @DRUG$ improved the progression-free survival rate compared with lapatinib alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents. DDI-effect
Although it was previously reported that @DRUG$ combined with Herceptin improved the progression-free survival rate compared with @DRUG$ alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents. DDI-effect
Although it was previously reported that @DRUG$ combined with Herceptin improved the progression-free survival rate compared with lapatinib alone for patients with @DRUG$-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents. DDI-false
Although it was previously reported that lapatinib combined with @DRUG$ improved the progression-free survival rate compared with @DRUG$ alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents. DDI-false
Although it was previously reported that lapatinib combined with @DRUG$ improved the progression-free survival rate compared with lapatinib alone for patients with @DRUG$-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents. DDI-false
Although it was previously reported that lapatinib combined with Herceptin improved the progression-free survival rate compared with @DRUG$ alone for patients with @DRUG$-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents. DDI-false
We evaluated how @DRUG$ interacts with @DRUG$ in HER2-positive breast cancer, with a particular focus on Herceptin-mediated antibody-dependent cellular cytotoxicity (ADCC). DDI-false
We evaluated how @DRUG$ interacts with Herceptin in HER2-positive breast cancer, with a particular focus on @DRUG$-mediated antibody-dependent cellular cytotoxicity (ADCC). DDI-false
We evaluated how lapatinib interacts with @DRUG$ in HER2-positive breast cancer, with a particular focus on @DRUG$-mediated antibody-dependent cellular cytotoxicity (ADCC). DDI-false
In an in vitro assay, @DRUG$ induced HER2 expression at the cell surface of HER2-positive breast cancer cell lines, leading to the enhancement of @DRUG$-mediated ADCC. DDI-false
Furthermore, we present a case report in which a second @DRUG$ treatment following @DRUG$ resulted in the marked shrinkage of multiple metastatic tumors in HER2-positive breast cancer. DDI-false
@DRUG$ may have the potential to convert @DRUG$-refractory to Herceptin-sensitive tumors in HER2-positive breast cancer by up-regulation of the cell surface expression of HER2. DDI-effect
@DRUG$ may have the potential to convert Herceptin-refractory to @DRUG$-sensitive tumors in HER2-positive breast cancer by up-regulation of the cell surface expression of HER2. DDI-false
Lapatinib may have the potential to convert @DRUG$-refractory to @DRUG$-sensitive tumors in HER2-positive breast cancer by up-regulation of the cell surface expression of HER2. DDI-false
Improved parathyroid hormone control by @DRUG$ is associated with reduction in @DRUG$ requirement in patients with end-stage renal disease. DDI-false
Uncontrolled hy-per-parathyroidism causes bone marrow fibrosis, leading to @DRUG$ (@DRUG$) resistance. DDI-false
Reduction of PTH by @DRUG$ is associated with a decrease in @DRUG$ requirement. DDI-false
Medical treatment with @DRUG$ is effective in reducing plasma parathyroid hormone (PTH) levels, but its effect on @DRUG$ dosing is unknown. DDI-false
The primary objective of the study was to ascertain the difference in @DRUG$ responsiveness before and after 12 months of @DRUG$ therapy. DDI-false
@DRUG$ does not inhibit the absorption of 5 milligrams of @DRUG$ at doses less than 800 milligrams in nonpregnant women. DDI-false
@DRUG$ does not inhibit the absorption of 5 milligrams of nonheme or @DRUG$ at doses less than 800 milligrams in nonpregnant women. DDI-false
Calcium does not inhibit the absorption of 5 milligrams of @DRUG-DRUG$ at doses less than 800 milligrams in nonpregnant women. DDI-false
@DRUG$ is the only known component in the diet that may affect absorption of both @DRUG$. DDI-false
@DRUG$ is the only known component in the diet that may affect absorption of both nonheme and @DRUG$. DDI-mechanism
Calcium is the only known component in the diet that may affect absorption of both @DRUG-DRUG$. DDI-mechanism
In conclusion, we demonstrated an isolated effect of @DRUG$ (as chloride) on absorption of 5 mg of iron provided as @DRUG$. DDI-false
In conclusion, we demonstrated an isolated effect of @DRUG$ (as chloride) on absorption of 5 mg of iron provided as nonheme (as sulfate) and @DRUG$. DDI-false
In conclusion, we demonstrated an isolated effect of calcium (as chloride) on absorption of 5 mg of iron provided as @DRUG-DRUG$. DDI-false
However, the evidence for a @DRUG$ effect on @DRUG$ absorption mainly comes from studies that did not isolate the effect of calcium from that of other dietary components, because it was detected in single-meal studies. DDI-false
However, the evidence for a @DRUG$ effect on iron absorption mainly comes from studies that did not isolate the effect of @DRUG$ from that of other dietary components, because it was detected in single-meal studies. DDI-false
However, the evidence for a calcium effect on @DRUG$ absorption mainly comes from studies that did not isolate the effect of @DRUG$ from that of other dietary components, because it was detected in single-meal studies. DDI-false
Our objective was to establish potential effects of @DRUG$ on absorption of @DRUG$ and the dose response for this effect in the absence of a meal. DDI-false
Our objective was to establish potential effects of @DRUG$ on absorption of nonheme and @DRUG$ and the dose response for this effect in the absence of a meal. DDI-false
Our objective was to establish potential effects of calcium on absorption of @DRUG-DRUG$ and the dose response for this effect in the absence of a meal. DDI-false
We evaluated the effects of @DRUG$ doses between 200 and 1500 mg on absorption of 5 mg @DRUG$ (as ferrous sulfate). DDI-false
We evaluated the effects of @DRUG$ doses between 200 and 1500 mg on absorption of 5 mg nonheme iron (as @DRUG$). DDI-false
We evaluated the effects of calcium doses between 200 and 1500 mg on absorption of 5 mg @DRUG$ (as @DRUG$). DDI-false
We also evaluated the effects of @DRUG$ doses between 200 and 800 mg on absorption of 5 mg @DRUG$ [as concentrated RBC (CRBC)]. DDI-false
@DRUG$ was administered as @DRUG$ in all studies and minerals were ingested on an empty stomach. DDI-false
@DRUG$ was administered as calcium chloride in all studies and @DRUG$ were ingested on an empty stomach. DDI-false
Calcium was administered as @DRUG$ in all studies and @DRUG$ were ingested on an empty stomach. DDI-false
@DRUG$ doses   1000 mg diminished @DRUG$ absorption by an average of 49.6%. DDI-false
A @DRUG$ dose of 800 mg diminished absorption of 5 mg @DRUG$ by 37.7%. DDI-mechanism
Synergistic interaction between @DRUG$ and @DRUG$ is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation. DDI-mechanism
@DRUG$ as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of @DRUG$ followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration. DDI-effect
@DRUG$ as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by @DRUG$ is superior to sunitinib followed by docetaxel and concurrent administration. DDI-false
@DRUG$ as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to @DRUG$ followed by docetaxel and concurrent administration. DDI-false
@DRUG$ as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by @DRUG$ and concurrent administration. DDI-false
Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of @DRUG$ followed by @DRUG$ is superior to sunitinib followed by docetaxel and concurrent administration. DDI-false
Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of @DRUG$ followed by sunitinib is superior to @DRUG$ followed by docetaxel and concurrent administration. DDI-effect
Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of @DRUG$ followed by sunitinib is superior to sunitinib followed by @DRUG$ and concurrent administration. DDI-false
Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by @DRUG$ is superior to @DRUG$ followed by docetaxel and concurrent administration. DDI-false
Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by @DRUG$ is superior to sunitinib followed by @DRUG$ and concurrent administration. DDI-false
Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to @DRUG$ followed by @DRUG$ and concurrent administration. DDI-false
This study was aimed to investigate the efficacy of single use of @DRUG$ and that of concurrent or sequential administration of @DRUG$ and docetaxel in NSCLC cell lines that are resistant to EGFR TKIs. DDI-false
This study was aimed to investigate the efficacy of single use of @DRUG$ and that of concurrent or sequential administration of sunitinib and @DRUG$ in NSCLC cell lines that are resistant to EGFR TKIs. DDI-false
This study was aimed to investigate the efficacy of single use of sunitinib and that of concurrent or sequential administration of @DRUG$ and @DRUG$ in NSCLC cell lines that are resistant to EGFR TKIs. DDI-false
NSCLC cell lines with EGFR T790M mutation and K-ras mutation were exposed to either @DRUG$ or @DRUG$ or both based on various sequential administrations. DDI-false
@DRUG$ exhibited dose-dependent growth inhibition in NSCLC cell lines and arrested cell cycle at G1 phase, whereas @DRUG$ arrested at S phase. DDI-false
Although single or concurrent use of @DRUG$ and @DRUG$ has some anti-proliferative effects, the sequential administrations of both drugs remarkably enhanced anti-tumor activity. DDI-false
When cells were exposed to @DRUG$ followed by @DRUG$, synergism was observed. DDI-effect
The molecular basis of this synergism is that the signaling pathways that were initially activated by @DRUG$ exposure were efficiently suppressed by the subsequent exposure to @DRUG$. DDI-effect
The @DRUG$ (@DRUG$), one of S-adenosylhomocysteine (AdoHcy) hydrolase inhibitors, has shown antitumor activities in a broad range of solid tumors and acute myeloid leukemia. DDI-effect
We also found that Bcl-2 was overexpressed in @DRUG$ insensitive cells, and cotreatment with @DRUG$ and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. DDI-false
We also found that Bcl-2 was overexpressed in @DRUG$ insensitive cells, and cotreatment with DZNep and @DRUG$, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. DDI-false
We also found that Bcl-2 was overexpressed in @DRUG$ insensitive cells, and cotreatment with DZNep and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of @DRUG$ insensitive MM cells. DDI-false
We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with @DRUG$ and @DRUG$, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. DDI-false
We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with @DRUG$ and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of @DRUG$ insensitive MM cells. DDI-effect
We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with DZNep and @DRUG$, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of @DRUG$ insensitive MM cells. DDI-false
In addition, @DRUG$ insensitivity might be associated with overexpression of Bcl-2, and the combination of @DRUG$ and DZNep could synergistically induced apoptosis. DDI-false
In addition, @DRUG$ insensitivity might be associated with overexpression of Bcl-2, and the combination of ABT-737 and @DRUG$ could synergistically induced apoptosis. DDI-false
In addition, DZNep insensitivity might be associated with overexpression of Bcl-2, and the combination of @DRUG$ and @DRUG$ could synergistically induced apoptosis. DDI-false
The authors report the case of an infant with confirmed congenital hypothyroidism on @DRUG$ who experienced a possible drug interaction with @DRUG$. DDI-effect
Questioning revealed the child was taking @DRUG$ drops before feeds while on @DRUG$. DDI-false
Drug interaction of @DRUG$ with @DRUG$ has not been reported previously and is not listed in the British National Formulary for Children. DDI-false
@DRUG$ locomotor sensitization and conditioned place preference in adolescent male and female rats neonatally treated with @DRUG$. DDI-false
The objective was to analyze the effects of neonatal @DRUG$ treatment on effects of @DRUG$ in adolescent rats using locomotor sensitization and conditioned place preference procedures. DDI-false
In female rats, neonatal @DRUG$ treatment enhanced @DRUG$ locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine. DDI-false
In female rats, neonatal @DRUG$ treatment enhanced amphetamine locomotor sensitization compared with @DRUG$-free controls sensitized to amphetamine. DDI-false
In female rats, neonatal @DRUG$ treatment enhanced amphetamine locomotor sensitization compared with quinpirole-free controls sensitized to @DRUG$. DDI-false
In female rats, neonatal quinpirole treatment enhanced @DRUG$ locomotor sensitization compared with @DRUG$-free controls sensitized to amphetamine. DDI-false
In female rats, neonatal quinpirole treatment enhanced @DRUG$ locomotor sensitization compared with quinpirole-free controls sensitized to @DRUG$. DDI-false
In female rats, neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with @DRUG$-free controls sensitized to @DRUG$. DDI-false
Male rats demonstrated sensitization to @DRUG$, although this was muted compared with female rats, and were unaffected by neonatal @DRUG$. DDI-false
Rats treated with neonatal @DRUG$ enhanced time spent in the @DRUG$-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. DDI-false
Rats treated with neonatal @DRUG$ enhanced time spent in the amphetamine-paired context compared with @DRUG$-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. DDI-false
Rats treated with neonatal @DRUG$ enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with @DRUG$, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. DDI-false
Rats treated with neonatal @DRUG$ enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with @DRUG$ spent more time in the drug-paired context compared with saline-treated controls. DDI-false
Rats treated with neonatal quinpirole enhanced time spent in the @DRUG$-paired context compared with @DRUG$-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. DDI-false
Rats treated with neonatal quinpirole enhanced time spent in the @DRUG$-paired context compared with quinpirole-free controls conditioned with @DRUG$, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. DDI-false
Rats treated with neonatal quinpirole enhanced time spent in the @DRUG$-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with @DRUG$ spent more time in the drug-paired context compared with saline-treated controls. DDI-false
Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with @DRUG$-free controls conditioned with @DRUG$, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. DDI-false
Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with @DRUG$-free controls conditioned with amphetamine, but only female controls conditioned with @DRUG$ spent more time in the drug-paired context compared with saline-treated controls. DDI-false
Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with @DRUG$, but only female controls conditioned with @DRUG$ spent more time in the drug-paired context compared with saline-treated controls. DDI-false
Effect of @DRUG$-mediated CYP3A4 inhibition on clinical pharmacokinetics of @DRUG$ (LBH589), an orally active histone deacetylase inhibitor. DDI-false
Effect of @DRUG$-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (@DRUG$), an orally active histone deacetylase inhibitor. DDI-false
Effect of @DRUG$-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active @DRUG$. DDI-false
Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of @DRUG$ (@DRUG$), an orally active histone deacetylase inhibitor. DDI-false
Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of @DRUG$ (LBH589), an orally active @DRUG$. DDI-false
Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (@DRUG$), an orally active @DRUG$. DDI-false
Co-administration of @DRUG$ with CYP3A inhibitors is feasible as the observed increase in @DRUG$ PK parameters was not considered clinically relevant. DDI-false
Considering the variability in exposure following enzyme inhibition and the fact that chronic dosing of @DRUG$ was not studied with CYP3A inhibitors, close monitoring of @DRUG$-related adverse events is necessary. DDI-false
This study evaluated the effect of a potent CYP3A inhibitor, @DRUG$, on the pharmacokinetics and safety of @DRUG$. DDI-false
On day 8, a single @DRUG$ dose was co-administered with @DRUG$. DDI-false
In the presence of @DRUG$, there was 1.6- and 1.8-fold increase in C (max) and AUC of @DRUG$, respectively. DDI-false
@DRUG$ and @DRUG$ had no effect, while quinidine appeared to augment precocene I toxicity. DDI-mechanism
@DRUG$ and sulfaphenazole had no effect, while @DRUG$ appeared to augment precocene I toxicity. DDI-false
@DRUG$ and sulfaphenazole had no effect, while quinidine appeared to augment @DRUG$ toxicity. DDI-false
Furafylline and @DRUG$ had no effect, while @DRUG$ appeared to augment precocene I toxicity. DDI-false
Furafylline and @DRUG$ had no effect, while quinidine appeared to augment @DRUG$ toxicity. DDI-false
Furafylline and sulfaphenazole had no effect, while @DRUG$ appeared to augment @DRUG$ toxicity. DDI-false
These results suggest that rat liver slices do not reproduce the reported in vivo biotransformation of @DRUG$ and therefore may not be an appropriate model for @DRUG$ metabolism. DDI-effect
The incubations were performed in the absence and presence of the non-specific CYP inhibitor, @DRUG$ (@DRUG$) and isoform-specific inhibitors. DDI-false
@DRUG$ decreased the toxicity of @DRUG$, increased exposure to parent compound, and decreased metabolite levels in a dose-dependent manner. DDI-false
Of the isoform-specific CYP inhibitors tested for an effect on the @DRUG$ metabolite profile, only @DRUG$ was noticeably effective, indicating a role of CYPs 2A6, 2C9, 2Cl9, and 2E1. DDI-mechanism
With respect to toxicity, the order of CYP inhibitor effectiveness was @DRUG$>@DRUG$~tranylcypromine>ketoconazole. DDI-false
With respect to toxicity, the order of CYP inhibitor effectiveness was @DRUG$>diethyldithiocarbamate~@DRUG$>ketoconazole. DDI-false
With respect to toxicity, the order of CYP inhibitor effectiveness was @DRUG$>diethyldithiocarbamate~tranylcypromine>@DRUG$. DDI-false
With respect to toxicity, the order of CYP inhibitor effectiveness was ABT>@DRUG$~@DRUG$>ketoconazole. DDI-false
With respect to toxicity, the order of CYP inhibitor effectiveness was ABT>@DRUG$~tranylcypromine>@DRUG$. DDI-false
With respect to toxicity, the order of CYP inhibitor effectiveness was ABT>diethyldithiocarbamate~@DRUG$>@DRUG$. DDI-false
To determine whether the co-injection of extracellular matrix degrading enzymes improves retinal transduction following intravitreal delivery of @DRUG$ (@DRUG$). DDI-false
@DRUG$ containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including @DRUG$, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. DDI-false
@DRUG$ containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, @DRUG$, heparinase III, or chondroitin ABC lyase. DDI-false
@DRUG$ containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, @DRUG$, or chondroitin ABC lyase. DDI-false
@DRUG$ containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or @DRUG$. DDI-false
AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including @DRUG$, @DRUG$, heparinase III, or chondroitin ABC lyase. DDI-false
AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including @DRUG$, hyaluronan lyase, @DRUG$, or chondroitin ABC lyase. DDI-false
AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including @DRUG$, hyaluronan lyase, heparinase III, or @DRUG$. DDI-false
AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, @DRUG$, @DRUG$, or chondroitin ABC lyase. DDI-false
AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, @DRUG$, heparinase III, or @DRUG$. DDI-false
AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, @DRUG$, or @DRUG$. DDI-false
The addition of @DRUG$ or @DRUG$ greatly enhanced transduction of the retinal ganglion cell layer and increased the depth of transduction into the outer retina. DDI-false
@DRUG$ had a limited effect and @DRUG$ was ineffective. DDI-false
Electroretinograms survived with higher concentrations of @DRUG$ and @DRUG$ than were required for optimal retinal transduction. DDI-false
@DRUG$-mediated retinal transduction is improved by co-injection of @DRUG$ or chondroitin ABC lyase. DDI-false
@DRUG$-mediated retinal transduction is improved by co-injection of heparinase III or @DRUG$. DDI-effect
AAV2-mediated retinal transduction is improved by co-injection of @DRUG$ or @DRUG$. DDI-effect
@DRUG$ (@DRUG$)--better than clopidogrel (Plavix) DDI-false
@DRUG$ (Brilinta)--better than @DRUG$ (Plavix) DDI-false
@DRUG$ (Brilinta)--better than clopidogrel (@DRUG$) DDI-false
Ticagrelor (@DRUG$)--better than @DRUG$ (Plavix) DDI-false
Ticagrelor (@DRUG$)--better than clopidogrel (@DRUG$) DDI-false
Ticagrelor (Brilinta)--better than @DRUG$ (@DRUG$) DDI-false
The FDA has approved @DRUG$ (@DRUG$-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). DDI-false
The FDA has approved @DRUG$ (Brilinta-AstraZeneca), an oral @DRUG$, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). DDI-false
The FDA has approved @DRUG$ (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose @DRUG$ to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). DDI-false
The FDA has approved ticagrelor (@DRUG$-AstraZeneca), an oral @DRUG$, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). DDI-false
The FDA has approved ticagrelor (@DRUG$-AstraZeneca), an oral antiplatelet drug, for use with low-dose @DRUG$ to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). DDI-false
The FDA has approved ticagrelor (Brilinta-AstraZeneca), an oral @DRUG$, for use with low-dose @DRUG$ to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). DDI-false
It will compete with @DRUG$ (@DRUG$) and prasugrel (Effient) for such use. DDI-false
It will compete with @DRUG$ (Plavix) and @DRUG$ (Effient) for such use. DDI-false
It will compete with @DRUG$ (Plavix) and prasugrel (@DRUG$) for such use. DDI-false
It will compete with clopidogrel (@DRUG$) and @DRUG$ (Effient) for such use. DDI-false
It will compete with clopidogrel (@DRUG$) and prasugrel (@DRUG$) for such use. DDI-false
It will compete with clopidogrel (Plavix) and @DRUG$ (@DRUG$) for such use. DDI-false
The role of p27(Kip1) in @DRUG$-enhanced @DRUG$ cytotoxicity in human ovarian cancer cells. DDI-false
Treatment of HEY xenograft-bearing mice with @DRUG$ plus @DRUG$ inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); DDI-false
Treatment of HEY xenograft-bearing mice with @DRUG$ plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, @DRUG$ + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); DDI-effect
Treatment of HEY xenograft-bearing mice with @DRUG$ plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + @DRUG$ vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); DDI-false
Treatment of HEY xenograft-bearing mice with @DRUG$ plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs @DRUG$: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); DDI-false
Treatment of HEY xenograft-bearing mice with dasatinib plus @DRUG$ inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, @DRUG$ + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); DDI-false
Treatment of HEY xenograft-bearing mice with dasatinib plus @DRUG$ inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + @DRUG$ vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); DDI-false
Treatment of HEY xenograft-bearing mice with dasatinib plus @DRUG$ inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs @DRUG$: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); DDI-false
Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, @DRUG$ + @DRUG$ vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); DDI-false
Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, @DRUG$ + paclitaxel vs @DRUG$: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); DDI-false
Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + @DRUG$ vs @DRUG$: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); DDI-false
@DRUG$ + @DRUG$ vs. DDI-false
The siRNA knockdown of p27(Kip1) decreased @DRUG$- and @DRUG$-induced apoptosis compared with a negative control siRNA (sub-G1 fraction, control siRNA vs. p27(Kip1) siRNA: 42.5% vs. 20.1%, difference = 22.4%, 95% CI = 20.1% to 24.7%, P = .017). DDI-false
Studies with forced expression and siRNA knockdown of Bcl-2 and Cdk1 suggest that @DRUG$-mediated induction of p27(Kip1) enhanced @DRUG$-induced apoptosis by negatively regulating Bcl-2 and Cdk1 expression. DDI-effect
Inhibition of Src family and Abl kinases with either siRNAs or @DRUG$ enhances @DRUG$ sensitivity of ovarian cancer cells through p27(Kip1)-mediated suppression of Bcl-2 and Cdk1 expression. DDI-effect
The effect of @DRUG$, an inhibitor of Src and Abl kinases, on @DRUG$ sensitivity was measured in ovarian cancer cells and HEY xenografts. DDI-effect
The roles of p27(Kip1), Bcl-2, and Cdk1 in apoptosis induced by @DRUG$ and @DRUG$ were assessed using a terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay, siRNA knockdown of gene expression, transfection with Bcl-2 and Cdk1 expression vectors, and flow cytometry. DDI-false
HEY cells treated with @DRUG$ plus @DRUG$ formed fewer colonies than did cells treated with either agent alone. DDI-false
Influence of @DRUG$ on @DRUG$ induced antinociception and its pharmacokinetics. DDI-effect
In the present study @DRUG$ (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of @DRUG$ evaluated by both acetic acid writhing and formalin test, when it was administered with ibuprofen. DDI-false
In the present study @DRUG$ (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of ibuprofen evaluated by both @DRUG$ writhing and formalin test, when it was administered with ibuprofen. DDI-effect
In the present study @DRUG$ (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of ibuprofen evaluated by both acetic acid writhing and formalin test, when it was administered with @DRUG$. DDI-false
In the present study piperine (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of @DRUG$ evaluated by both @DRUG$ writhing and formalin test, when it was administered with ibuprofen. DDI-false
In the present study piperine (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of @DRUG$ evaluated by both acetic acid writhing and formalin test, when it was administered with @DRUG$. DDI-false
In the present study piperine (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of ibuprofen evaluated by both @DRUG$ writhing and formalin test, when it was administered with @DRUG$. DDI-false
@DRUG$ plasma concentration was also increased when it was administered with @DRUG$. DDI-false
The synergistic antinociception activity of @DRUG$ when administered with @DRUG$ can be attributed to increased plasma concentration of ibuprofen. DDI-mechanism
The synergistic antinociception activity of @DRUG$ when administered with piperine can be attributed to increased plasma concentration of @DRUG$. DDI-effect
The synergistic antinociception activity of ibuprofen when administered with @DRUG$ can be attributed to increased plasma concentration of @DRUG$. DDI-false
From this study it can be concluded that @DRUG$ can be used as a bioenhancer along with @DRUG$. DDI-false
Prevention of emergence agitation in seven children receiving low-dose @DRUG$ and @DRUG$ total intravenous anesthesia. DDI-false
We retrospectively reviewed the records of 7 pediatric oncology patients who received low-dose @DRUG$ in conjunction with @DRUG$ for total intravenous anesthesia (TIVA) repeatedly for radiation therapy. DDI-false
EA signs were observed in all 7 patients in association with @DRUG$ TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low-dose @DRUG$ was added to propofol. DDI-false
EA signs were observed in all 7 patients in association with @DRUG$ TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low-dose ketamine was added to @DRUG$. DDI-false
EA signs were observed in all 7 patients in association with propofol TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low-dose @DRUG$ was added to @DRUG$. DDI-false
Based on this experience, we suggest that low-dose @DRUG$ added to @DRUG$ may be associated with prevention of EA in children with a history of EA with propofol TIVA. DDI-false
Based on this experience, we suggest that low-dose @DRUG$ added to propofol may be associated with prevention of EA in children with a history of EA with @DRUG$ TIVA. DDI-effect
Based on this experience, we suggest that low-dose ketamine added to @DRUG$ may be associated with prevention of EA in children with a history of EA with @DRUG$ TIVA. DDI-false
[Efficacy of fixed combination @DRUG$/@DRUG$ in hospitalized patients with hypertensive disease] DDI-false
Efficacy and tolerability of fixed @DRUG$/@DRUG$ combination was studied in 86 patients with hypertensive disease hospitalized in departments of general internal medicine or cardiology. DDI-false
We have demonstrated appropriateness of inhospital administration of fixed @DRUG$/@DRUG$ combination as an approach allowing to achieve target BP in shorter time, with the use of fewer antihypertensive drugs, and diminishing concealed inefficacy of treatment. DDI-false
We have demonstrated appropriateness of inhospital administration of fixed @DRUG$/valsartan combination as an approach allowing to achieve target BP in shorter time, with the use of fewer @DRUG$, and diminishing concealed inefficacy of treatment. DDI-false
We have demonstrated appropriateness of inhospital administration of fixed amlodipine/@DRUG$ combination as an approach allowing to achieve target BP in shorter time, with the use of fewer @DRUG$, and diminishing concealed inefficacy of treatment. DDI-false
All patients had indications for antihypertensive therapy and were randomized either to fixed combination @DRUG$/@DRUG$ (n=43) or to therapy which corresponded to the hospital formulary (n=43). DDI-false
Rate of achievement of target BP with fixed combination @DRUG$/@DRUG$ (93%) was comparable with that on traditional therapy (90%). DDI-false
But the use of fixed combination @DRUG$/@DRUG$ compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of antihypertensive drugs (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05). DDI-false
But the use of fixed combination @DRUG$/valsartan compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of @DRUG$ (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05). DDI-false
But the use of fixed combination amlodipine/@DRUG$ compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of @DRUG$ (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05). DDI-false
The aim of the present study was to investigate whether HB-EGF is a therapeutic target for T-ALL, and to further elucidate the antitumor effects of a specific inhibitor of HB-EGF, @DRUG$ (@DRUG$). DDI-false
We elucidated the expression of HB-EGF in T-ALL cell lines, and evaluated the effect of @DRUG$ on these cells alone or in combination with @DRUG$. DDI-false
@DRUG$ induced apoptosis, and furthermore, the combination of @DRUG$ plus doxorubicin enhanced cytotoxicity in a T-ALL cell line. DDI-false
@DRUG$ induced apoptosis, and furthermore, the combination of CRM197 plus @DRUG$ enhanced cytotoxicity in a T-ALL cell line. DDI-false
CRM197 induced apoptosis, and furthermore, the combination of @DRUG$ plus @DRUG$ enhanced cytotoxicity in a T-ALL cell line. DDI-false
Distinct synergistic action of @DRUG$ and @DRUG$ against Pseudomonas aeruginosa. DDI-effect
Synergism was also noted when @DRUG$ was combined with @DRUG$ and amikacin. DDI-effect
Synergism was also noted when @DRUG$ was combined with carbenicillin and @DRUG$. DDI-false
Synergism was also noted when methylglyoxal was combined with @DRUG$ and @DRUG$. DDI-effect
Results revealed that the strains were resistant to many drugs at high levels, only @DRUG$, @DRUG$, amikacin and ciprofloxacin showed resistances at comparatively lower levels. DDI-false
Results revealed that the strains were resistant to many drugs at high levels, only @DRUG$, carbenicillin, @DRUG$ and ciprofloxacin showed resistances at comparatively lower levels. DDI-false
Results revealed that the strains were resistant to many drugs at high levels, only @DRUG$, carbenicillin, amikacin and @DRUG$ showed resistances at comparatively lower levels. DDI-false
Results revealed that the strains were resistant to many drugs at high levels, only piperacillin, @DRUG$, @DRUG$ and ciprofloxacin showed resistances at comparatively lower levels. DDI-false
Results revealed that the strains were resistant to many drugs at high levels, only piperacillin, @DRUG$, amikacin and @DRUG$ showed resistances at comparatively lower levels. DDI-false
Results revealed that the strains were resistant to many drugs at high levels, only piperacillin, carbenicillin, @DRUG$ and @DRUG$ showed resistances at comparatively lower levels. DDI-false
Distinct and statistically significant synergism was observed between @DRUG$ and @DRUG$ by disc diffusion tests when compared with their individual effects. DDI-false
@DRUG$   failure in an HIV-positive woman on @DRUG$ therapy resulting in two ectopic pregnancies. DDI-effect
We present an interesting case of an HIV-positive woman on @DRUG$ therapy having tubal pregnancies on two separate occasions with @DRUG$ in place. DDI-false
@DRUG$, an @DRUG$, is the standard hormone treatment for breast cancer. DDI-false
Depression does not always require @DRUG$ therapy, and @DRUG$ have no proven preventive impact on hot flushes linked to the menopause. DDI-false
If in certain cases, an @DRUG$ is considered necessary, it may be advisable to replace @DRUG$ with anastrozole. DDI-false
If in certain cases, an @DRUG$ is considered necessary, it may be advisable to replace tamoxifen with @DRUG$. DDI-false
If in certain cases, an antidepressant is considered necessary, it may be advisable to replace @DRUG$ with @DRUG$. DDI-false
@DRUG$ and @DRUG$ reduce the plasma concentration of endoxifen by about 50%. DDI-false
@DRUG$ and fluoxetine reduce the plasma concentration of @DRUG$ by about 50%. DDI-false
Paroxetine and @DRUG$ reduce the plasma concentration of @DRUG$ by about 50%. DDI-mechanism
It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with @DRUG$ for breast cancer, especially @DRUG$ such as paroxetine and fluoxetine. DDI-mechanism
It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with @DRUG$ for breast cancer, especially SSRI antidepressants such as @DRUG$ and fluoxetine. DDI-false
It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with @DRUG$ for breast cancer, especially SSRI antidepressants such as paroxetine and @DRUG$. DDI-false
It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially @DRUG$ such as @DRUG$ and fluoxetine. DDI-false
It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially @DRUG$ such as paroxetine and @DRUG$. DDI-false
It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as @DRUG$ and @DRUG$. DDI-false
Phase I trial of @DRUG$ and @DRUG$ in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein. DDI-false
Phase I trial of @DRUG$ and CCI-779 in patients with relapsed multiple myeloma: evidence for @DRUG$-CCI-779 interaction via P-glycoprotein. DDI-false
Phase I trial of @DRUG$ and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-@DRUG$ interaction via P-glycoprotein. DDI-false
Phase I trial of lenalidomide and @DRUG$ in patients with relapsed multiple myeloma: evidence for @DRUG$-CCI-779 interaction via P-glycoprotein. DDI-false
Phase I trial of lenalidomide and @DRUG$ in patients with relapsed multiple myeloma: evidence for lenalidomide-@DRUG$ interaction via P-glycoprotein. DDI-false
Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for @DRUG$-@DRUG$ interaction via P-glycoprotein. DDI-false
The preclinical combination of @DRUG$ with the mTOR inhibitor @DRUG$ has displayed synergy in vitro and represents a novel combination in MM. DDI-int
In vivo CYP3A activity is significantly lower in @DRUG$-treated as compared with @DRUG$-treated renal allograft recipients. DDI-false
In vitro studies have identified @DRUG$ and @DRUG$ as CYP3A inhibitors. DDI-false
Systemic and apparent oral @DRUG$ clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in @DRUG$-treated patients (n = 20) than in matched tacrolimus-treated patients (n = 20). DDI-false
Systemic and apparent oral @DRUG$ clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in cyclosporine-treated patients (n = 20) than in matched @DRUG$-treated patients (n = 20). DDI-false
Systemic and apparent oral midazolam clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in @DRUG$-treated patients (n = 20) than in matched @DRUG$-treated patients (n = 20). DDI-false
The latter displayed @DRUG$ clearances similar to those in two larger cohorts of nonmatched @DRUG$-treated patients (n = 58 and n = 80) and to those receiving a calcineurin inhibitor-free regimen (n = 6). DDI-false
The latter displayed @DRUG$ clearances similar to those in two larger cohorts of nonmatched tacrolimus-treated patients (n = 58 and n = 80) and to those receiving a @DRUG$-free regimen (n = 6). DDI-false
The latter displayed midazolam clearances similar to those in two larger cohorts of nonmatched @DRUG$-treated patients (n = 58 and n = 80) and to those receiving a @DRUG$-free regimen (n = 6). DDI-false
This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving @DRUG$ than in those receiving @DRUG$, indicating that, at the doses generally used in clinical practice, cyclosporine is the stronger of the two with respect to CYP3A inhibition. DDI-false
This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving @DRUG$ than in those receiving tacrolimus, indicating that, at the doses generally used in clinical practice, @DRUG$ is the stronger of the two with respect to CYP3A inhibition. DDI-false
This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving cyclosporine than in those receiving @DRUG$, indicating that, at the doses generally used in clinical practice, @DRUG$ is the stronger of the two with respect to CYP3A inhibition. DDI-false
[Influence of @DRUG$ and @DRUG$ on MPTP-evoked behavior violations in C57BL/6 mice]. DDI-false
The effects of @DRUG$ @DRUG$ [(2-adamantyl)hexamethylenimine] (10 mg/kg, p. o.) DDI-false
The effects of @DRUG$ hemantane [@DRUG$] (10 mg/kg, p. o.) DDI-false
The effects of anti-parkinsonian drug @DRUG$ [@DRUG$] (10 mg/kg, p. o.) DDI-false
and/or @DRUG$ @DRUG$ (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP) (4 x 20 mg/kg, i. p.) DDI-false
and/or @DRUG$ doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin @DRUG$ (MPTP) (4 x 20 mg/kg, i. p.) DDI-false
and/or @DRUG$ doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (@DRUG$) (4 x 20 mg/kg, i. p.) DDI-false
and/or antibiotic drug @DRUG$ (100 mg/kg, p. o.), as well as that of neurotoxin @DRUG$ (MPTP) (4 x 20 mg/kg, i. p.) DDI-false
and/or antibiotic drug @DRUG$ (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (@DRUG$) (4 x 20 mg/kg, i. p.) DDI-false
and/or antibiotic drug doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin @DRUG$ (@DRUG$) (4 x 20 mg/kg, i. p.) DDI-false
Acute administration of @DRUG$ or @DRUG$ failed to influence locomotion in mice, while their combination normalized motor activity. DDI-false
Exposure to oral @DRUG$ is unaffected by @DRUG$ but greatly increased by ticlopidine. DDI-false
Exposure to oral @DRUG$ is unaffected by itraconazole but greatly increased by @DRUG$. DDI-false
Exposure to oral S-ketamine is unaffected by @DRUG$ but greatly increased by @DRUG$. DDI-effect
This study examined drug-drug interactions of oral @DRUG$ with the cytochrome P450 (CYP) 2B6 inhibitor @DRUG$ and the CYP3A inhibitor itraconazole. DDI-false
This study examined drug-drug interactions of oral @DRUG$ with the cytochrome P450 (CYP) 2B6 inhibitor ticlopidine and the CYP3A inhibitor @DRUG$. DDI-false
This study examined drug-drug interactions of oral S-ketamine with the cytochrome P450 (CYP) 2B6 inhibitor @DRUG$ and the CYP3A inhibitor @DRUG$. DDI-false
In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg @DRUG$ after pretreatments with oral @DRUG$ (250 mg twice daily), itraconazole (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks. DDI-false
In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg @DRUG$ after pretreatments with oral ticlopidine (250 mg twice daily), @DRUG$ (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks. DDI-false
In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg S-ketamine after pretreatments with oral @DRUG$ (250 mg twice daily), @DRUG$ (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks. DDI-false
@DRUG$ treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral @DRUG$ by 2.4-fold, whereas itraconazole treatment did not increase the exposure to S-ketamine. DDI-false
@DRUG$ treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold, whereas @DRUG$ treatment did not increase the exposure to S-ketamine. DDI-mechanism
@DRUG$ treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold, whereas itraconazole treatment did not increase the exposure to @DRUG$. DDI-false
Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral @DRUG$ by 2.4-fold, whereas @DRUG$ treatment did not increase the exposure to S-ketamine. DDI-false
Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral @DRUG$ by 2.4-fold, whereas itraconazole treatment did not increase the exposure to @DRUG$. DDI-false
Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold, whereas @DRUG$ treatment did not increase the exposure to @DRUG$. DDI-false
The ratio of @DRUG$ AUC(0-   ) to @DRUG$ AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo. DDI-false
The ratio of @DRUG$ AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the @DRUG$ (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo. DDI-false
The ratio of @DRUG$ AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and @DRUG$ phases (P = 0.006) as compared to placebo. DDI-false
The ratio of norketamine AUC(0-   ) to @DRUG$ AUC(0-   ) was significantly decreased in the @DRUG$ (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo. DDI-false
The ratio of norketamine AUC(0-   ) to @DRUG$ AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and @DRUG$ phases (P = 0.006) as compared to placebo. DDI-false
The ratio of norketamine AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the @DRUG$ (P &lt; 0.001) and @DRUG$ phases (P = 0.006) as compared to placebo. DDI-false
In the @DRUG$ and @DRUG$ phases, the areas under the effect-time curves (self-reported drowsiness and performance) were significantly higher than those in the placebo phase (P < 0.05). DDI-false
The findings suggest that the dosage of @DRUG$ should be reduced in patients receiving @DRUG$. DDI-false
Interaction of @DRUG$ with different @DRUG$ is antagonistic in breast but not in other cancer cells. DDI-advise
These results, if confirmed in-vivo, indicate that @DRUG$ is not a suitable chemosensitizer for breast cancer or with @DRUG$ for other cancers. DDI-false
This study investigates the ability of @DRUG$ to sensitize cells from different origins to several @DRUG$. DDI-false
The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to @DRUG$, @DRUG$, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed. DDI-false
The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to @DRUG$, cisplatin, @DRUG$ and etoposide   celecoxib following different incubation schedules were analyzed. DDI-false
The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to @DRUG$, cisplatin, doxorubicin and @DRUG$   celecoxib following different incubation schedules were analyzed. DDI-false
The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to @DRUG$, cisplatin, doxorubicin and etoposide   @DRUG$ following different incubation schedules were analyzed. DDI-false
The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, @DRUG$, @DRUG$ and etoposide   celecoxib following different incubation schedules were analyzed. DDI-false
The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, @DRUG$, doxorubicin and @DRUG$   celecoxib following different incubation schedules were analyzed. DDI-false
The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, @DRUG$, doxorubicin and etoposide   @DRUG$ following different incubation schedules were analyzed. DDI-false
The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, @DRUG$ and @DRUG$   celecoxib following different incubation schedules were analyzed. DDI-false
The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, @DRUG$ and etoposide   @DRUG$ following different incubation schedules were analyzed. DDI-false
The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and @DRUG$   @DRUG$ following different incubation schedules were analyzed. DDI-false
We found antagonism between @DRUG$ and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between @DRUG$ and doxorubicin in all cell lines except for two combinations in HCT116 cells. DDI-false
We found antagonism between @DRUG$ and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between celecoxib and @DRUG$ in all cell lines except for two combinations in HCT116 cells. DDI-false
We found antagonism between celecoxib and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between @DRUG$ and @DRUG$ in all cell lines except for two combinations in HCT116 cells. DDI-false
@DRUG$-@DRUG$ interaction and associated gastrointestinal bleeding risk in a case-control study. DDI-false
@DRUG$ users who initiated @DRUG$, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. DDI-int
@DRUG$ users who initiated citalopram, @DRUG$, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. DDI-false
@DRUG$ users who initiated citalopram, fluoxetine, @DRUG$, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. DDI-false
@DRUG$ users who initiated citalopram, fluoxetine, paroxetine, @DRUG$, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. DDI-false
@DRUG$ users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or @DRUG$ had an increased risk of hospitalization for gastrointestinal bleeding. DDI-false
Warfarin users who initiated @DRUG$, @DRUG$, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. DDI-false
Warfarin users who initiated @DRUG$, fluoxetine, @DRUG$, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. DDI-false
Warfarin users who initiated @DRUG$, fluoxetine, paroxetine, @DRUG$, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. DDI-false
Warfarin users who initiated @DRUG$, fluoxetine, paroxetine, amitriptyline, or @DRUG$ had an increased risk of hospitalization for gastrointestinal bleeding. DDI-false
Warfarin users who initiated citalopram, @DRUG$, @DRUG$, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. DDI-false
Warfarin users who initiated citalopram, @DRUG$, paroxetine, @DRUG$, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. DDI-false
Warfarin users who initiated citalopram, @DRUG$, paroxetine, amitriptyline, or @DRUG$ had an increased risk of hospitalization for gastrointestinal bleeding. DDI-false
Warfarin users who initiated citalopram, fluoxetine, @DRUG$, @DRUG$, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. DDI-false
Warfarin users who initiated citalopram, fluoxetine, @DRUG$, amitriptyline, or @DRUG$ had an increased risk of hospitalization for gastrointestinal bleeding. DDI-false
Warfarin users who initiated citalopram, fluoxetine, paroxetine, @DRUG$, or @DRUG$ had an increased risk of hospitalization for gastrointestinal bleeding. DDI-false
We sought to evaluate whether initiation of an @DRUG$ increases the risk of hospitalization for gastrointestinal bleeding in @DRUG$ users. DDI-false
In total, 430,455 @DRUG$ users contributed 407,370 person-years of @DRUG$ use. DDI-false
@DRUG$ users had an increased odds ratio of gastrointestinal bleeding upon initiation of @DRUG$ (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). DDI-false
@DRUG$ users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), @DRUG$ (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). DDI-effect
@DRUG$ users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), @DRUG$ (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). DDI-false
@DRUG$ users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), @DRUG$ (OR   =   1.47 [95% CI, 1.02-2.11]). DDI-false
Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of @DRUG$ (OR   =   1.73 [95% CI, 1.25-2.38]), @DRUG$ (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). DDI-false
Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of @DRUG$ (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), @DRUG$ (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). DDI-false
Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of @DRUG$ (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), @DRUG$ (OR   =   1.47 [95% CI, 1.02-2.11]). DDI-false
Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), @DRUG$ (OR   =   1.63 [95% CI, 1.11-2.38]), @DRUG$ (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). DDI-false
Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), @DRUG$ (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), @DRUG$ (OR   =   1.47 [95% CI, 1.02-2.11]). DDI-false
Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), @DRUG$ (OR   =   1.64 [95% CI, 1.27-2.12]), @DRUG$ (OR   =   1.47 [95% CI, 1.02-2.11]). DDI-false
Also @DRUG$, which is not believed to interact with @DRUG$, increased the risk of GI bleeding (OR   =   1.75 [95% CI, 1.30-2.35]). DDI-false
@DRUG$ enhances the antinociceptive effect of @DRUG$ in mice. DDI-false
The purpose of this study was to evaluate whether the psychostimulant drug @DRUG$ has any effect on @DRUG$-induced antinociception and locomotor inhibitor activity in mice in acute application. DDI-effect
saline + saline, @DRUG$ (10   mg/kg) + saline, saline + @DRUG$ (15     g/kg) and ephedrine (10   mg/kg) + dexmedetomidine (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. DDI-false
saline + saline, @DRUG$ (10   mg/kg) + saline, saline + dexmedetomidine (15     g/kg) and @DRUG$ (10   mg/kg) + dexmedetomidine (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. DDI-false
saline + saline, @DRUG$ (10   mg/kg) + saline, saline + dexmedetomidine (15     g/kg) and ephedrine (10   mg/kg) + @DRUG$ (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. DDI-false
saline + saline, ephedrine (10   mg/kg) + saline, saline + @DRUG$ (15     g/kg) and @DRUG$ (10   mg/kg) + dexmedetomidine (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. DDI-false
saline + saline, ephedrine (10   mg/kg) + saline, saline + @DRUG$ (15     g/kg) and ephedrine (10   mg/kg) + @DRUG$ (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. DDI-false
saline + saline, ephedrine (10   mg/kg) + saline, saline + dexmedetomidine (15     g/kg) and @DRUG$ (10   mg/kg) + @DRUG$ (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. DDI-false
In the hot plate test in mice, co-administration of 15     g/kg @DRUG$ with 10   mg/kg @DRUG$ intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by dexmedetomidine. DDI-false
In the hot plate test in mice, co-administration of 15     g/kg @DRUG$ with 10   mg/kg ephedrine intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by @DRUG$. DDI-effect
In the hot plate test in mice, co-administration of 15     g/kg dexmedetomidine with 10   mg/kg @DRUG$ intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by @DRUG$. DDI-false
At the same time, the locomotor inhibitory effect of @DRUG$ was counteracted by @DRUG$. DDI-false
We concluded that the combined administration of @DRUG$ with @DRUG$ may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans. DDI-effect
We concluded that the combined administration of @DRUG$ with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of @DRUG$ as an analgesic in humans. DDI-effect
We concluded that the combined administration of @DRUG$ with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an @DRUG$ in humans. DDI-false
We concluded that the combined administration of dexmedetomidine with @DRUG$ may have beneficial effects in the treatment of pain without causing sedation, which limits the use of @DRUG$ as an analgesic in humans. DDI-false
We concluded that the combined administration of dexmedetomidine with @DRUG$ may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an @DRUG$ in humans. DDI-false
We concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of @DRUG$ as an @DRUG$ in humans. DDI-false
Interaction study of @DRUG$ and @DRUG$ with co-administered drugs. DDI-false
@DRUG$ and @DRUG$ are fluoroquinolone antibiotics used in treating urinary and respiratory tract infections. DDI-false
@DRUG$ and lomefloxacin are @DRUG$ used in treating urinary and respiratory tract infections. DDI-false
Moxifloxacin and @DRUG$ are @DRUG$ used in treating urinary and respiratory tract infections. DDI-false
Being @DRUG$ and lomefloxacin @DRUG$ the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. DDI-false
Being @DRUG$ and lomefloxacin fluoroquinolones the interaction study of was carried out with @DRUG$, gelusil, erythromycin and multi minerals. DDI-false
Being @DRUG$ and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, @DRUG$, erythromycin and multi minerals. DDI-false
Being @DRUG$ and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, @DRUG$ and multi minerals. DDI-false
Being @DRUG$ and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and @DRUG$. DDI-false
Being moxifloxacin and lomefloxacin @DRUG$ the interaction study of was carried out with @DRUG$, gelusil, erythromycin and multi minerals. DDI-false
Being moxifloxacin and lomefloxacin @DRUG$ the interaction study of was carried out with sucralfate, @DRUG$, erythromycin and multi minerals. DDI-false
Being moxifloxacin and lomefloxacin @DRUG$ the interaction study of was carried out with sucralfate, gelusil, @DRUG$ and multi minerals. DDI-false
Being moxifloxacin and lomefloxacin @DRUG$ the interaction study of was carried out with sucralfate, gelusil, erythromycin and @DRUG$. DDI-false
Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with @DRUG$, @DRUG$, erythromycin and multi minerals. DDI-false
Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with @DRUG$, gelusil, @DRUG$ and multi minerals. DDI-false
Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with @DRUG$, gelusil, erythromycin and @DRUG$. DDI-false
Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, @DRUG$, @DRUG$ and multi minerals. DDI-false
Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, @DRUG$, erythromycin and @DRUG$. DDI-false
Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, @DRUG$ and @DRUG$. DDI-false
The response of @DRUG$ and @DRUG$ after interaction with co-administered drugs at different conditions and temperature were noted using a Shimadzu HPLC system with PDA detector. DDI-false
@DRUG$ and @DRUG$ reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. DDI-false
@DRUG$ and Lomefloxacin reacts faster with @DRUG$ and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. DDI-false
@DRUG$ and Lomefloxacin reacts faster with sucralfate and @DRUG$ in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. DDI-false
@DRUG$ and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with @DRUG$ in basic media and multi-minerals in neutral media. DDI-false
@DRUG$ and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and @DRUG$ in neutral media. DDI-false
Moxifloxacin and @DRUG$ reacts faster with @DRUG$ and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. DDI-false
Moxifloxacin and @DRUG$ reacts faster with sucralfate and @DRUG$ in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. DDI-false
Moxifloxacin and @DRUG$ reacts faster with sucralfate and gelusil in acidic media whereas with @DRUG$ in basic media and multi-minerals in neutral media. DDI-false
Moxifloxacin and @DRUG$ reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and @DRUG$ in neutral media. DDI-false
Moxifloxacin and Lomefloxacin reacts faster with @DRUG$ and @DRUG$ in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. DDI-false
Moxifloxacin and Lomefloxacin reacts faster with @DRUG$ and gelusil in acidic media whereas with @DRUG$ in basic media and multi-minerals in neutral media. DDI-false
Moxifloxacin and Lomefloxacin reacts faster with @DRUG$ and gelusil in acidic media whereas with erythromycin in basic media and @DRUG$ in neutral media. DDI-false
Moxifloxacin and Lomefloxacin reacts faster with sucralfate and @DRUG$ in acidic media whereas with @DRUG$ in basic media and multi-minerals in neutral media. DDI-false
Moxifloxacin and Lomefloxacin reacts faster with sucralfate and @DRUG$ in acidic media whereas with erythromycin in basic media and @DRUG$ in neutral media. DDI-false
Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with @DRUG$ in basic media and @DRUG$ in neutral media. DDI-false
Evaluation of antidepressant like activity of @DRUG$ and its combination with @DRUG$ and imipramine: an acute and chronic study. DDI-false
Evaluation of antidepressant like activity of @DRUG$ and its combination with fluoxetine and @DRUG$: an acute and chronic study. DDI-false
Evaluation of antidepressant like activity of curcumin and its combination with @DRUG$ and @DRUG$: an acute and chronic study. DDI-false
In the present study, the antidepressant like activity of @DRUG$ and its combination with @DRUG$ and imipramine was studied in acute model (three doses 24, 5 and 1 h before test) of forced swimming test (FST) in glass jar and tail suspension test (TST) in mice and in chronic model (14 day study) of FST with water wheel in rats. DDI-false
In the present study, the antidepressant like activity of @DRUG$ and its combination with fluoxetine and @DRUG$ was studied in acute model (three doses 24, 5 and 1 h before test) of forced swimming test (FST) in glass jar and tail suspension test (TST) in mice and in chronic model (14 day study) of FST with water wheel in rats. DDI-false
In the present study, the antidepressant like activity of curcumin and its combination with @DRUG$ and @DRUG$ was studied in acute model (three doses 24, 5 and 1 h before test) of forced swimming test (FST) in glass jar and tail suspension test (TST) in mice and in chronic model (14 day study) of FST with water wheel in rats. DDI-false
All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (@DRUG$ 50 mg/kg), group 3 (@DRUG$ 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). DDI-false
All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (@DRUG$ 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (@DRUG$ 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). DDI-false
All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (@DRUG$ 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (@DRUG$ 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). DDI-false
All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (@DRUG$ 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (@DRUG$ 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). DDI-false
All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (@DRUG$ 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus @DRUG$ 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). DDI-false
All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (@DRUG$ 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (@DRUG$ 100 mg/kg plus imipramine 15 mg/kg). DDI-false
All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (@DRUG$ 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus @DRUG$ 15 mg/kg). DDI-false
All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (@DRUG$ 100 mg/kg), group 4 (@DRUG$ 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). DDI-false
All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (@DRUG$ 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (@DRUG$ 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). DDI-false
All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (@DRUG$ 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (@DRUG$ 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). DDI-false
All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (@DRUG$ 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus @DRUG$ 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). DDI-false
All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (@DRUG$ 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (@DRUG$ 100 mg/kg plus imipramine 15 mg/kg). DDI-false
All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (@DRUG$ 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus @DRUG$ 15 mg/kg). DDI-false
All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (@DRUG$ 20 mg/kg), group 5 (@DRUG$ 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). DDI-false
All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (@DRUG$ 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (@DRUG$ 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). DDI-false
All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (@DRUG$ 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus @DRUG$ 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). DDI-false
All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (@DRUG$ 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (@DRUG$ 100 mg/kg plus imipramine 15 mg/kg). DDI-false
All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (@DRUG$ 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus @DRUG$ 15 mg/kg). DDI-false
All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (@DRUG$ 15 mg/kg), group 6 (@DRUG$ 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). DDI-false
All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (@DRUG$ 15 mg/kg), group 6 (curcumin 100 mg/kg plus @DRUG$ 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). DDI-false
All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (@DRUG$ 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (@DRUG$ 100 mg/kg plus imipramine 15 mg/kg). DDI-false
All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (@DRUG$ 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus @DRUG$ 15 mg/kg). DDI-false
All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (@DRUG$ 100 mg/kg plus @DRUG$ 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). DDI-false
All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (@DRUG$ 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (@DRUG$ 100 mg/kg plus imipramine 15 mg/kg). DDI-false
All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (@DRUG$ 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus @DRUG$ 15 mg/kg). DDI-false
All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus @DRUG$ 20 mg/kg) and group 7 (@DRUG$ 100 mg/kg plus imipramine 15 mg/kg). DDI-false
All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus @DRUG$ 20 mg/kg) and group 7 (curcumin 100 mg/kg plus @DRUG$ 15 mg/kg). DDI-false
All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (@DRUG$ 100 mg/kg plus @DRUG$ 15 mg/kg). DDI-false
The effect of @DRUG$ (100 mg/kg) was similar to that of @DRUG$ and imipramine (p > 0.05) but its addition to fluoxetine and imipramine did not improve their antidepressant activity (p > 0.05). DDI-false
The effect of @DRUG$ (100 mg/kg) was similar to that of fluoxetine and @DRUG$ (p > 0.05) but its addition to fluoxetine and imipramine did not improve their antidepressant activity (p > 0.05). DDI-false
The effect of @DRUG$ (100 mg/kg) was similar to that of fluoxetine and imipramine (p > 0.05) but its addition to @DRUG$ and imipramine did not improve their antidepressant activity (p > 0.05). DDI-false
The effect of @DRUG$ (100 mg/kg) was similar to that of fluoxetine and imipramine (p > 0.05) but its addition to fluoxetine and @DRUG$ did not improve their antidepressant activity (p > 0.05). DDI-false
The effect of curcumin (100 mg/kg) was similar to that of @DRUG$ and @DRUG$ (p > 0.05) but its addition to fluoxetine and imipramine did not improve their antidepressant activity (p > 0.05). DDI-false
The effect of curcumin (100 mg/kg) was similar to that of @DRUG$ and imipramine (p > 0.05) but its addition to @DRUG$ and imipramine did not improve their antidepressant activity (p > 0.05). DDI-false
The effect of curcumin (100 mg/kg) was similar to that of @DRUG$ and imipramine (p > 0.05) but its addition to fluoxetine and @DRUG$ did not improve their antidepressant activity (p > 0.05). DDI-false
The effect of curcumin (100 mg/kg) was similar to that of fluoxetine and @DRUG$ (p > 0.05) but its addition to @DRUG$ and imipramine did not improve their antidepressant activity (p > 0.05). DDI-false
The effect of curcumin (100 mg/kg) was similar to that of fluoxetine and @DRUG$ (p > 0.05) but its addition to fluoxetine and @DRUG$ did not improve their antidepressant activity (p > 0.05). DDI-false
The effect of curcumin (100 mg/kg) was similar to that of fluoxetine and imipramine (p > 0.05) but its addition to @DRUG$ and @DRUG$ did not improve their antidepressant activity (p > 0.05). DDI-false
@DRUG$ can be a useful @DRUG$ especially in cases which respond to drugs having mixed effects on serotonin and catecholamines levels in the brain. DDI-false
